PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA
J	Abdel-Galeel, A; El-Zokaim, A; Hasan-Ali, H; Ibrahim, A; Ibrahim, A; Ghaleb, R				Abdel-Galeel, Ahmed; El-Zokaim, Ahmed; Hasan-Ali, Hosam; Ibrahim, Ahmed; Ibrahim, Ayman; Ghaleb, Ramadan			Low Ankle-Brachial Index is Associated with Microvascular Coronary Obstruction After Primary PCI	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						microvascular coronary obstruction; peripheral arterial disease; myocardial blush grade; ankle-brachial index	ACUTE MYOCARDIAL-INFARCTION; PERIPHERAL ARTERIAL-DISEASE; LEFT-VENTRICULAR FUNCTION; ST-SEGMENT ELEVATION; NO-REFLOW PHENOMENON; ANGIOGRAPHIC ASSESSMENT; MAGNETIC-RESONANCE; PROGNOSTIC-SIGNIFICANCE; CLINICAL-IMPLICATIONS; DISTAL EMBOLIZATION	Introduction: Percutaneous coronary intervention (PCI) has improved recanalization of infarct-related arteries (IRA); however, TIMI-III flow does not always mean an efficient myocardial reperfusion. Myocardial blush grade (MBG) is used as a predictor for coronary microvascular obstruction. We assessed the association between ankle-brachial index (ABI), a widely used method for diagnosis of peripheral arterial disease (PAD), and coronary microvascular obstruction (MVO) as detected by MBG after primary PCI. Patients and Methods: The study included 335 patients with ST-elevation myocardial infarction who had primary PCI. History taking, clinical examination, laboratory assessment, ECG and Echocardiography were done for every participant. MBG was assessed for patients after PCI procedure. ABI for all participating patients was calculated. Results: Two hundred and sixty-one patients fulfilled the inclusion criteria with mean age 58.8 +/- 10.7 years, 84% were males. Sixty-one percent had anterior wall myocardial infarction. After primary PCI, despite achieving TIMI flow III in all study patients, only 37% had normal MBG. There was a statistically significant relationship between MBG and site of infarction, left ventricular ejection fraction and ABI. Low ABI was found to predict poor MBG. Conclusion: Coronary artery disease (CAD) is well linked to PAD. MBG can be used to assess coronary MVO after primary PCI. Poor MBG is associated with low ABI. This could establish a relationship between PAD and coronary MVO after primary PCI.	[Abdel-Galeel, Ahmed; Hasan-Ali, Hosam] Assiut Univ, Assiut Univ Heart Hosp, Cardiovasc Med Dept, Assiut 71526, Egypt; [El-Zokaim, Ahmed; Ibrahim, Ayman; Ghaleb, Ramadan] Aswan Univ, Cardiol Dept, Aswan, Egypt; [Ibrahim, Ahmed] Assiut Univ, Community Med Dept, Assiut, Egypt		Abdel-Galeel, A (通讯作者)，Assiut Univ, Assiut Univ Heart Hosp, Cardiovasc Med Dept, Assiut 71526, Egypt.	ahmed.galeel@aun.edu.eg	Ghaleb, Ramadan/AAK-4824-2021	Hasan-Ali, Hosam/0000-0002-7248-0125; Ibrahim, Ayman/0000-0002-4416-2779; Ibrahim, Ahmed/0000-0002-2286-7188; Abdel-Galeel, Ahmed/0000-0003-3712-5424			Aboyans V, 2012, CIRCULATION, V126, P2890, DOI 10.1161/CIR.0b013e318276fbcb; Al-Qaisi M, 2009, VASC HEALTH RISK MAN, V5, P833; Araszkiewicz A, 2007, INT J CARDIOL, V114, P183, DOI 10.1016/j.ijcard.2006.01.057; Belli G, 2000, CATHETER CARDIO INTE, V50, P362, DOI 10.1002/1522-726X(200007)50:3<362::AID-CCD22>3.3.CO;2-8; Brosh D, 2007, AM J CARDIOL, V99, P442, DOI 10.1016/j.amjcard.2006.08.054; Dieter RS, 2003, VASC MED, V8, P233, DOI 10.1191/1358863x03vm506ra; Fernandes MR, 2012, TEX HEART I J, V39, P342; Fukushima N, 2014, J INTERV CARDIOL, V27, P252, DOI 10.1111/joic.12093; Gibson CM, 2000, CIRCULATION, V101, P125, DOI 10.1161/01.CIR.101.2.125; Gibson CM, 2004, CIRCULATION, V109, P3096, DOI 10.1161/01.CIR.0000134278.50359.CB; Gibson CM, 2002, CIRCULATION, V105, P1909, DOI 10.1161/01.CIR.0000014683.52177.B5; Henriques JPS, 2003, CIRCULATION, V107, P2115, DOI 10.1161/01.CIR.0000065221.06430.ED; Henriques JPS, 2002, EUR HEART J, V23, P1112, DOI 10.1053/euhj.2001.3035; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; Ito H, 1996, CIRCULATION, V93, P223, DOI 10.1161/01.CIR.93.2.223; Karahan Z, 2016, ANGIOLOGY, V67, P151, DOI 10.1177/0003319715583204; Keeley EC, 2007, NEW ENGL J MED, V356, P47, DOI 10.1056/NEJMct063503; KLONER RA, 1974, J CLIN INVEST, V54, P1496, DOI 10.1172/JCI107898; Lee JY, 2013, JACC-CARDIOVASC INTE, V6, P1303, DOI 10.1016/j.jcin.2013.08.008; Manfrini O, 2018, CURR OPIN PHARMACOL, V39, P121, DOI 10.1016/j.coph.2018.04.005; Marra MP, 2010, AM HEART J, V159, P1124, DOI 10.1016/j.ahj.2010.03.007; Md Jafar A, 2018, CARDIOVASC J, V10, P201, DOI [10.3329/cardio.v10i2.36293, DOI 10.3329/CARDIO.V10I2.36293]; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; Papanas N, 2007, INT ANGIOL, V26, P253; Porto I, 2007, AM J CARDIOL, V99, P1671, DOI 10.1016/j.amjcard.2007.01.045; Porto I, 2010, AM HEART J, V160, P1015, DOI 10.1016/j.ahj.2010.08.009; Qu BZ, 2015, CELL BIOCHEM BIOPHYS, V73, P571, DOI 10.1007/s12013-015-0582-z; Sabedotti Marcelo, 2014, Rev. Bras. Cardiol. Invasiva, V22, P359, DOI 10.1590/0104-1843000000060; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Stone GW, 2002, J AM COLL CARDIOL, V39, P591, DOI 10.1016/S0735-1097(01)01779-X; STONE PH, 1988, J AM COLL CARDIOL, V11, P453, DOI 10.1016/0735-1097(88)91517-3; Sukhija R, 2005, CARDIOLOGY, V103, P158, DOI 10.1159/000084586; Svilaas T, 2008, NEW ENGL J MED, V358, P557, DOI 10.1056/NEJMoa0706416; Tarantini G, 2004, AM J CARDIOL, V93, P1081, DOI 10.1016/j.amjcard.2004.01.031; Thygesen K, 2018, GLOB HEART, V13, P305, DOI [10.1093/eurheartj/ehy462, 10.1161/CIR.0000000000000617, 10.1016/j.recesp.2018.11.011, 10.1016/j.jacc.2018.08.1038]; Topol EJ, 2000, CIRCULATION, V101, P570, DOI 10.1161/01.CIR.101.5.570; van't Hof AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302; Vicente J, 2009, CATHETER CARDIO INTE, V74, P1000, DOI 10.1002/ccd.22157; Wu KC, 1998, CIRCULATION, V97, P765, DOI 10.1161/01.CIR.97.8.765; Xu DC, 2010, VASC MED, V15, P361, DOI 10.1177/1358863X10378376; Yamada DM, 2000, AM HEART J, V140, pS90, DOI 10.1067/mhj.2000.111611; Zalewski J, 2004, INT J CARDIOL, V96, P389, DOI 10.1016/j.ijcard.2003.08.009	43	0	0	2	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						23	32		10.2147/VHRM.S291658			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QC3NE	WOS:000614739600001	33564236	Green Published			2022-04-27	
J	Handhle, A; Viljoen, A; Wierzbicki, AS				Handhle, Ahmed; Viljoen, Adie; Wierzbicki, Anthony S.			Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						lipoprotein (a); cardiovascular disease; aortic stenosis; apheresis; genetics; lipoprotein turnover; statin; PCSK9; antisense therapy	CORONARY-HEART-DISEASE; EXTENDED-RELEASE NIACIN; APOLIPOPROTEIN B-100 PARTICLES; LP(A) GLYCOPROTEIN PHENOTYPES; TRANSFER PROTEIN-INHIBITION; CARDIOVASCULAR-DISEASE; OXIDIZED PHOSPHOLIPIDS; TARGETING APOLIPOPROTEIN(A); ISOFORM SIZE; DOUBLE-BLIND	Lipoprotein(a) forms a subfraction of the lipid profile and is characterized by the addition of apolipprotein(a) (apo(a)) to apoB100 derived particles. Its levels are mostly genetically determined inversely related to the number of protein domain (kringle) repeats in apo(a). In epidemiological studies, it shows consistent association with cardiovascular disease (CVD) and most recently with extent of aortic stenosis. Issues with standardizing the measurement of Lp(a) are being resolved and consensus statements favor its measurement in patients at high risk of, or with family histories of CVD events. Major lipid-lowering therapies such as statin, fibrates, and ezetimibe have little effect on Lp(a) levels. Therapies such as niacin or cholesterol ester transfer protein (CETP) inhibitors lower Lp(a) as well as reducing other lipid-related risk factors but have failed to clearly reduce CVD events. Proprotein convertase subtilisin kexin-9 (PCSK9) inhibitors reduce cholesterol and Lp(a) as well as reducing CVD events. New antisense therapies specifically targeting apo(a) and hence Lp(a) have greater and more specific effects and will help clarify the extent to which intervention in Lp(a) levels will reduce CVD events.	[Handhle, Ahmed] Addenbrookes Hosp, Dept Metab Med Chem Pathol, Cambridge, England; [Viljoen, Adie] Lister Hosp, North & East Hertfordshire Hosp Trust, Dept Metab Med Chem Pathol, Stevenage, Herts, England; [Wierzbicki, Anthony S.] Guys & St Thomas Hosp, Dept Metab Med Chem Pathol, London SE1 7EH, England		Wierzbicki, AS (通讯作者)，St Thomas Hosp, Metab Med Chem Pathol, Lambeth Palace Rd, London SE1 7EH, England.	Anthony.Wierzbicki@kcl.ac.Uk					Arsenault BJ, 2018, J CLIN LIPIDOL, V12, P130, DOI 10.1016/j.jacl.2017.10.001; Becker L, 2006, BIOCHEMISTRY-US, V45, P9919, DOI 10.1021/bi060283t; Berliner JA, 2009, J LIPID RES, V50, pS207, DOI 10.1194/jlr.R800074-JLR200; Bittner VA, 2020, J AM COLL CARDIOL, V75, P133, DOI 10.1016/j.jacc.2019.10.057; Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579; Boffa MB, 2016, J LIPID RES, V57, P745, DOI 10.1194/jlr.R060582; Bourgeois Raphaelle, 2021, CJC Open, V3, P450, DOI 10.1016/j.cjco.2020.11.019; Burgess S, 2018, JAMA CARDIOL, V3, P619, DOI 10.1001/jamacardio.2018.1470; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; Capoulade R, 2015, J AM COLL CARDIOL, V66, P1236, DOI 10.1016/j.jacc.2015.07.020; Cegla J, 2019, ATHEROSCLEROSIS, V291, P62, DOI 10.1016/j.atherosclerosis.2019.10.011; Chan DC, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011781; Chretien JP, 2006, J MED GENET, V43, P917, DOI 10.1136/jmg.2006.042119; Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604; Croyal M, 2020, ARTERIOSCL THROM VAS, V40, P819, DOI 10.1161/ATVBAHA.119.313877; Croyal M, 2015, ARTERIOSCL THROM VAS, V35, P2042, DOI 10.1161/ATVBAHA.115.305835; Edelstein C, 2003, J BIOL CHEM, V278, P52841, DOI 10.1074/jbc.M310425200; Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063; Farmakis I, 2021, J CARDIOVASC PHARM, V77, P397, DOI 10.1097/FJC.0000000000000963; Fatica EM, 2020, CLIN BIOCHEM, V86, P45, DOI 10.1016/j.clinbiochem.2020.09.007; Fogacci F, 2019, DRUGS, V79, P751, DOI 10.1007/s40265-019-01114-z; Franchini M, 2016, BLOOD TRANSFUS-ITALY, V14, P413, DOI 10.2450/2015.0163-15; Frischmann ME, 2012, ATHEROSCLEROSIS, V225, P322, DOI 10.1016/j.atherosclerosis.2012.09.031; Garg PK, 2021, J CARDIOVASC COMPUT, V15, P154, DOI 10.1016/j.jcct.2020.06.002; Gencer B, 2017, EUR HEART J, V38, P1553, DOI 10.1093/eurheartj/ehx033; Graham MJ, 2016, J LIPID RES, V57, P340, DOI 10.1194/jlr.R052258; Grundy SM, 2019, CIRCULATION, V139, pE1082, DOI 10.1161/CIR.0000000000000625; Guadagno PA, 2015, CLIN CHIM ACTA, V439, P219, DOI 10.1016/j.cca.2014.10.013; Gurdasani D, 2012, ARTERIOSCL THROM VAS, V32, P3058, DOI 10.1161/ATVBAHA.112.255521; Hoekstra M, 2021, ARTERIOSCL THROM VAS, V41, P458, DOI 10.1161/ATVBAHA.120.314965; Hoppichler F, 1996, ATHEROSCLEROSIS, V122, P127, DOI 10.1016/0021-9150(96)05803-0; Huded CP, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018023; Kamstrup PR, 2008, J CLIN ENDOCR METAB, V93, P3769, DOI 10.1210/jc.2008-0830; Kamstrup PR, 2014, J AM COLL CARDIOL, V63, P470, DOI 10.1016/j.jacc.2013.09.038; Kamstrup PR, 2009, JAMA-J AM MED ASSOC, V301, P2331, DOI 10.1001/jama.2009.801; Khera AV, 2014, CIRCULATION, V129, P635, DOI 10.1161/CIRCULATIONAHA.113.004406; Konerman M, 2012, J CLIN LIPIDOL, V6, P368, DOI 10.1016/j.jacl.2012.01.004; Koschinsky ML, 2004, CURR OPIN LIPIDOL, V15, P167, DOI 10.1097/00041433-200404000-00009; Kostner KM, 2018, ATHEROSCLEROSIS, V274, P16, DOI 10.1016/j.atherosclerosis.2018.04.032; Kronenberg F, 2016, CARDIOVASC DRUG THER, V30, P87, DOI 10.1007/s10557-016-6648-3; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; Lamon-Fava S, 2011, J LIPID RES, V52, P1181, DOI 10.1194/jlr.M012526; Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955; Langsted A, 2019, J AM COLL CARDIOL, V74, P54, DOI 10.1016/j.jacc.2019.03.524; Langsted A, 2016, LANCET DIABETES ENDO, V4, P577, DOI 10.1016/S2213-8587(16)30042-0; Ma L, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13053; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.15829/1560-4071-2020-3826, 10.1093/eurheartj/ehz455]; Mahmood T, 2020, EUR J PREV CARDIOL, V28, P816, DOI [10.1177/ 2047487320915803, DOI 10.1177/2047487320915803]; Marcovina SM, 2016, J LIPID RES, V57, P526, DOI 10.1194/jlr.R061648; McCormick SPA, 2019, PATHOLOGY, V51, P155, DOI 10.1016/j.pathol.2018.11.003; Mefford MT, 2019, J LIPID RES, V60, P1946, DOI 10.1194/jlr.P119000173; Mehta A, 2020, J AM COLL CARDIOL, V76, P781, DOI 10.1016/j.jacc.2020.06.040; Merki E, 2008, CIRCULATION, V118, P743, DOI 10.1161/CIRCULATIONAHA.108.786822; Moriarty PM, 2018, J AM COLL CARDIOL, V71, P1783, DOI 10.1016/S0735-1097(18)32324-6; Moriarty PM, 2017, ARTERIOSCL THROM VAS, V37, P580, DOI 10.1161/ATVBAHA.116.308704; Nandakumar R, 2018, J LIPID RES, V59, P2397, DOI 10.1194/jlr.P082834; Nicholls SJ, 2016, J CLIN LIPIDOL, V10, P519, DOI 10.1016/j.jacl.2015.11.014; Nicholls SJ, 2010, J LIPID RES, V51, P3055, DOI 10.1194/jlr.M008961; Nordestgaard BG, 2020, ATHEROSCLEROSIS, V294, P46, DOI 10.1016/j.atherosclerosis.2019.12.005; Nordestgaard BG, 2016, J LIPID RES, V57, P1953, DOI 10.1194/jlr.R071233; Nordestgaard BG, 2010, EUR HEART J, V31, P2844, DOI 10.1093/eurheartj/ehq386; O'Donoghue ML, 2019, CIRCULATION, V139, P1483, DOI 10.1161/CIRCULATIONAHA.118.037184; Ohira T, 2006, STROKE, V37, P1407, DOI 10.1161/01.STR.0000222666.21482.b6; Paquette M, 2019, CLIN BIOCHEM, V66, P44, DOI 10.1016/j.clinbiochem.2019.02.008; Pare G, 2019, CIRCULATION, V139, P1472, DOI 10.1161/CIRCULATIONAHA.118.034311; Parish S, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.001696; Rabar S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4356; Ray KK, 2018, CIRCULATION, V138, P1304, DOI 10.1161/CIRCULATIONAHA.118.034710; Roeseler E, 2016, ARTERIOSCL THROM VAS, V36, P2019, DOI 10.1161/ATVBAHA.116.307983; Ruscica M, 2020, EUR HEART J SUPPL, V22, pL53, DOI 10.1093/eurheartj/suaa135; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Safarova MS, 2013, ATHEROSCLEROSIS SUPP, V14, P93, DOI 10.1016/j.atherosclerosissup.2012.10.015; Sahebkar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36204-7; Sahebkar A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0787-7; Sahebkar A, 2016, METABOLISM, V65, P1664, DOI 10.1016/j.metabol.2016.08.007; SANDHOLZER C, 1991, HUM GENET, V86, P607; Sandmark J, 2020, J BIOL CHEM, V295, P5136, DOI 10.1074/jbc.RA119.011251; Santos RD, 2015, ARTERIOSCL THROM VAS, V35, P689, DOI 10.1161/ATVBAHA.114.304549; Scanu A M, 1992, Ann Epidemiol, V2, P407, DOI 10.1016/1047-2797(92)90089-9; Scanu AM, 2001, FRONT BIOSCI-LANDMRK, V6, pD546, DOI 10.2741/Scanu; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; Schmidt K, 2016, J LIPID RES, V57, P1339, DOI 10.1194/jlr.R067314; Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174; Schwartz GG, 2018, JAMA CARDIOL, V3, P164, DOI 10.1001/jamacardio.2017.3833; Scipione CA, 2015, J LIPID RES, V56, P2273, DOI 10.1194/jlr.M060210; Seman LJ, 1999, CLIN CHEM, V45, P1039; Shapiro MD, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.010932; Swerdlow D, 2022, CARDIOVASC RES, V118, P1218, DOI 10.1093/cvr/cvab100; Szarek M, 2020, EUR HEART J, V41, P4245, DOI 10.1093/eurheartj/ehaa649; Taylor AJ, 2004, CIRCULATION, V110, P3512, DOI 10.1161/01.CIR.0000148955.19792.8D; Thomas T, 2017, ARTERIOSCL THROM VAS, V37, P1770, DOI 10.1161/ATVBAHA.117.309549; Trinder M, 2021, JAMA CARDIOL, V6, P287, DOI 10.1001/jamacardio.2020.5398; Tsimikas S, 2021, AM HEART ASS SCI SES; Tsimikas S, 2020, EUR HEART J, V41, P2275, DOI 10.1093/eurheartj/ehz310; Tsimikas S, 2020, NEW ENGL J MED, V382, P244, DOI 10.1056/NEJMoa1905239; Tsimikas S, 2019, CIRC RES, V124, P405, DOI 10.1161/CIRCRESAHA.118.313864; Tsimikas S, 2018, J AM COLL CARDIOL, V71, P177, DOI 10.1016/j.jacc.2017.11.014; Tsimikas S, 2017, J AM COLL CARDIOL, V69, P692, DOI 10.1016/j.jacc.2016.11.042; Tsimikas S, 2016, CURR OPIN ENDOCRINOL, V23, P157, DOI 10.1097/MED.0000000000000237; Tsimikas S, 2015, LANCET, V386, P1472, DOI 10.1016/S0140-6736(15)61252-1; Tsimikas S, 2009, CIRCULATION, V119, P1711, DOI 10.1161/CIRCULATIONAHA.108.836940; UTERMANN G, 1983, FEBS LETT, V154, P357, DOI 10.1016/0014-5793(83)80182-3; UTERMANN G, 1988, HUM GENET, V78, P47, DOI 10.1007/BF00291233; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; UTERMANN G, 1988, HUM GENET, V78, P41, DOI 10.1007/BF00291232; van der Valk FM, 2016, CIRCULATION, V134, P611, DOI 10.1161/CIRCULATIONAHA.116.020838; Varvel S, 2016, ARTERIOSCL THROM VAS, V36, P2239, DOI 10.1161/ATVBAHA.116.308011; Viney NJ, 2016, LANCET, V388, P2239, DOI 10.1016/S0140-6736(16)31009-1; Wang XL, 2019, KARDIOL POL, V77, P207, DOI 10.5603/KP.a2019.0013; Wang XY, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105275; Watts GF, 2018, EUR HEART J, V39, P2577, DOI 10.1093/eurheartj/ehy122; Welsh P, 2022, EUR J PREV CARDIOL, V28, P1991, DOI 10.1093/eurjpc/zwaa063; Wierzbicki AS, 2010, CURR OPIN CARDIOL, V25, P379, DOI [10.1097/HCO.0b013e3283393c9b, DOI 10.1097/HCO.0b013e3283393c9b]; Wilson DP, 2019, J CLIN LIPIDOL, V13, P374, DOI 10.1016/j.jacl.2019.04.010; Wong ND, 2021, AM J CARDIOL, V145, P12, DOI 10.1016/j.amjcard.2020.12.075; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; Yeang C, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100053; Yeang C, 2016, J CLIN LIPIDOL, V10, P1389, DOI 10.1016/j.jacl.2016.09.012; Zheng KH, 2019, J AM COLL CARDIOL, V73, P2150, DOI 10.1016/j.jacc.2019.01.070	119	2	2	2	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						527	542		10.2147/VHRM.S266244			16	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UO4LI	WOS:000694666400001	34526771	Green Published, gold			2022-04-27	
J	Lupilov, A; Krause, D; Klaassen-Mielke, R; Trampisch, HJ; Rudolf, H				Lupilov, Alexander; Krause, Dietmar; Klaassen-Mielke, Renate; Trampisch, Hans J.; Rudolf, Henrik			Effects of Three Different Methods Defining Onset of Peripheral Artery Disease on the Assessments of Incidence and Important Predictors - Results from the German Epidemiological Trial on Ankle Brachial Index (getABI)	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						peripheral artery disease; ankle brachial index; risk factors; incidence	RISK-FACTORS; OCCLUSIVE DISEASE; COHORT	Purpose: The common definition of asymptomatic peripheral artery disease (PAD) by a single determination of the ankle brachial index (ABI) has some uncertainty due to measurement errors. This may impact estimates of PAD incidence and assessment of PAD risk factors. To investigate this issue, we used three methods to define asymptomatic PAD and made use of data from the German Epidemiological Trial on Ankle Brachial Index (getABI). Patients and Methods: A total of 6,880 unselected subjects aged >= 65 years, enrolled by 344 trained general practitioners, had ABI assessments at baseline and four visits during follow-up. The first approach defined asymptomatic PAD onset as soon as a single ABI value was below 0.9 (single ABI). The second approach employed a regression method using all available ABI values (regression A), while for the third approach (regression B), an extended regression beyond the last valid ABI value for the observation time of the study was allowed. For each approach, we calculated PAD incidence rates and assessed the effect of important PAD predictors using multivariable Cox proportional hazards regression. Results: The regression method A showed the lowest (25.0 events per 1,000 person years) and the single ABI method the highest incidence rate (41.2). The regression methods assigned greater impact to several risk factors of incident PAD. Using regression A, the hazard ratios (HR) of active smoking (2.36; 95% CI 1.92 to 2.90) and of diabetes (1.33; 95% CI 1.13 to 1.56), using regression B the HR of older age (1.72; 95% CI 1.50 to 1.97) were about twice as high as the corresponding HR of the single ABI approach. Conclusion: Use of the single ABI method leads to higher PAD incidence rates and to lower impact of important PAD predictors compared to regression methods. For an alert risk factor management, multiple ABI determination may be useful.	[Lupilov, Alexander; Krause, Dietmar; Klaassen-Mielke, Renate; Trampisch, Hans J.; Rudolf, Henrik] Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Univ Str 105, D-44789 Bochum, North Rhine Wes, Germany		Rudolf, H (通讯作者)，Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Univ Str 105, D-44789 Bochum, North Rhine Wes, Germany.	henrik.rudolf@rub.de		Rudolf, Henrik/0000-0001-9114-3805; Hans, Trampisch/0000-0001-9136-1079	Open Access Publication Funds of the Ruhr University Bochum	Special thanks go to the participating general practitioners and angiologists as well as all the participants of the getABI trial. We acknowledge support by the Open Access Publication Funds of the Ruhr University Bochum.	Althouse AD, 2014, DIABETES CARE, V37, P1346, DOI 10.2337/dc13-2303; Diehm C, 2002, VASA-J VASCULAR DIS, V31, P241, DOI 10.1024/0301-1526.31.4.241; Diehm C, 2009, CIRCULATION, V120, P2053, DOI 10.1161/CIRCULATIONAHA.109.865600; Holland-Letz T, 2007, VASC MED, V12, P105, DOI 10.1177/1358863X07077281; Hooi JD, 2001, AM J EPIDEMIOL, V153, P666, DOI 10.1093/aje/153.7.666; Krause D, 2016, VASA, V45, P403, DOI 10.1024/0301-1526/a000556; Lawall H, 2015, DEUT MED WOCHENSCHR, V140, P1798, DOI 10.1055/s-0041-107064; Matsushita K, 2017, LANCET DIABETES ENDO, V5, P718, DOI 10.1016/S2213-8587(17)30183-3; Merino J, 2010, WORLD J SURG, V34, P1975, DOI 10.1007/s00268-010-0572-7; Pradhan AD, 2018, CIRCULATION, V138, P141, DOI [10.1161/CIRCULATIONAHA.118.034645, 10.1161/CIRCULATIONAHA.118.035432]; Pujades-Rodriguez M, 2015, INT J EPIDEMIOL, V44, P129, DOI 10.1093/ije/dyu218; Shah AD, 2015, LANCET DIABETES ENDO, V3, P105, DOI 10.1016/S2213-8587(14)70219-0; Song PG, 2019, LANCET GLOB HEALTH, V7, pE1020, DOI 10.1016/S2214-109X(19)30255-4; Alzamora MT, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-015-0170-6; Velescu A, 2016, EUR J VASC ENDOVASC, V51, P696, DOI 10.1016/j.ejvs.2015.12.045; Xu DC, 2013, CAN J CARDIOL, V29, P492, DOI 10.1016/j.cjca.2012.06.014	16	0	0	2	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						421	429		10.2147/VHRM.S307675			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TQ6OO	WOS:000678398500002	34335027	gold, Green Published			2022-04-27	
J	Nigat, AB; Abate, MW; Demelash, AT; Tibebu, NS; Tiruneh, CM; Emiru, TD; Yimam, MA; Nega, AD; Yimer, YS				Nigat, Adane Birhanu; Abate, Moges Wubneh; Demelash, Agimasie Tigabu; Tibebu, Nigusie Selomon; Tiruneh, Chalie Marew; Emiru, Tigabu Desie; Yimam, Mehd Abdu; Nega, Abebe Dires; Yimer, Yohannes Shumet			Knowledge on Stroke Warning Signs and Associated Factors Among Hypertensive Patients, Northwest Ethiopia: An Institution-Based Cross-Sectional Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypertension; knowledge; stroke; warning signs; Ethiopia	RISK-FACTORS; SYMPTOMS	Introduction: Stroke is one of the leading causes of death globally and is a major cause of disability worldwide. It is a preventable and treatable disease by the prevention of modifiable risk factors and early recognition of warning signs, respectively. Objective: To assess knowledge on stroke warning signs and associated factors among hypertensive patients at South Gondar Zone Comprehensive Specialized Hospital, Northwest Ethiopia, 2020. Methods: An institution-based cross-sectional study was conducted in South Gondar Zone Comprehensive Specialized Hospital from June 1-30, 2020. A systematic random sampling technique was used and data were collected through face to face interviews. Data were entered into Epi data version 4.6.0.0 and exported to SPSS version 25 for cleaning and analysis. Bivariate and multivariable logistic regression analysis was used and variables with p <0.05 in the multivariable analysis were considered as statistically significant. Results: Two hundred and fifty-three hypertensive patients completed the questionnaire with a response rate of 100%. Among the total respondents, 15% (95% CI: 10.7, 19.4) of participants had good knowledge of stroke warning signs. Younger age (AOR: 2.82; 95% CI: 1.18, 6.74), urban residence (AOR: 2.9; 95% CI: 1.04, 8.11), being educated (AOR: 2.6; 95% CI: 1.09, 6.23) and having long duration hypertension follow up (AOR: 2.7; 95% CI: 1.25, 5.81) were significantly associated with good knowledge of stroke warning signs. Conclusion: This study revealed that participants had poor knowledge of stroke warning signs. Younger age, urban residence, being educated and having long duration hypertension follow up were predictors of good stroke warning signs knowledge. Health information dissemination needs to be strengthened for hypertensive patients, particularly for older, rural residents, the non-educated and those having short duration of hypertension follow up.	[Nigat, Adane Birhanu; Abate, Moges Wubneh; Demelash, Agimasie Tigabu] Debre Tabor Univ, Coll Hlth Sci, Dept Adult Hlth Nursing, Debre Tabor, Ethiopia; [Tibebu, Nigusie Selomon; Tiruneh, Chalie Marew; Emiru, Tigabu Desie] Debre Tabor Univ, Coll Hlth Sci, Dept Pediat & Child Hlth Nursing, Debre Tabor, Ethiopia; [Yimam, Mehd Abdu] Mizan Tepi Univ, Coll Med & Hlth Sci, Dept Nursing, Mizan Teferi, Ethiopia; [Nega, Abebe Dires] Wollo Univ, Coll Med & Hlth Sci, Dept Comprehens Nursing, Dessie, Ethiopia; [Yimer, Yohannes Shumet] Debre Tabor Univ, Coll Hlth Sci, Dept Pharm, Debre Tabor, Ethiopia		Nigat, AB (通讯作者)，Debre Tabor Univ, Coll Hlth Sci, Dept Adult Hlth Nursing, Debre Tabor, Ethiopia.	adanebirhanu23@gmail.com	Abdu, Mehd/AAW-6969-2021; Desie, Tigabu/AAB-4798-2022; Tiruneh, Chalie Marew/ABD-4861-2021; ABATE, MOGES WUBNEH/AAA-5735-2022; Tibebu, Nigusie Selomon/AAH-6157-2021	Abdu, Mehd/0000-0003-4078-5757; Desie, Tigabu/0000-0001-9535-0190; Tiruneh, Chalie Marew/0000-0002-3647-8415; Tibebu, Nigusie Selomon/0000-0002-5511-5812; Wubneh, Moges/0000-0001-8902-9552; Birhanu, Adane/0000-0001-7158-3256; Dires, Abebe/0000-0002-0186-1123			Abate AT, 2019, NEUROL RES INT, V2019, DOI 10.1155/2019/8570428; Abbott H., 2010, UNIT PUBLIC HLTH ASP, P1; Al-beladi BA, 2018, INT J MED RES PROFES, V4, P2; Amen MR, 2016, J CONTEMP MED SCI, V2, P28; Arisegi SA, 2018, PAN AFR MED J, V29, DOI 10.11604/pamj.2018.29.63.13252; Dar NZ, 2019, CUREUS, V11, DOI 10.7759/cureus.4774; Dasgupta A, 2018, W BENGAL, V5, P262; Ehidiamen OF, 2018, ANN MED HEALTH SCI R, V8, P40; McManus M, 2016, J CLIN NEUROL, V12, P137, DOI 10.3988/jcn.2016.12.2.137; Olin BR, 2018, HYPERTENSION SILENT, P4222; Ozkan S, 2019, STROKE, V8, P651; Soto-Camara R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082557; Sulochana G, 2018, NEUROLOGY, V10, P90; Tibebu NS, 2021, RISK MANAG HEALTHC P, V14, P1681, DOI 10.2147/RMHP.S303876; Walter Johnson a, 2016, OYERE ONUMA B MO C S, P633; Yoon SS, 2001, STROKE, V32, P1926, DOI 10.1161/01.STR.32.8.1926	16	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						721	728		10.2147/VHRM.S333394			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XO1RN	WOS:000729970400002	34848966	gold, Green Published			2022-04-27	
J	Elbaz-Greener, G; Rozen, G; Carasso, S; Kusniec, F; Marai, I; Sud, M; Strauss, B; Smart, FW; Planer, D; Amir, O				Elbaz-Greener, Gabby; Rozen, Guy; Carasso, Shemy; Kusniec, Fabio; Marai, Ibrahim; Sud, Maneesh; Strauss, Bradley; Smart, Frank W.; Planer, David; Amir, Offer			The Relationship Between Body Mass Index and In-Hospital Mortality in the Contemporary Era of an Acute Myocardial Infarction Management	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						body mass index; BMI; acute myocardial infarction; obesity paradox	ACUTE CORONARY SYNDROMES; OBESITY PARADOX; CLINICAL-OUTCOMES; COMORBIDITY INDEX; EXTREME OBESITY; RISK-FACTOR; IMPACT; WEIGHT; TRENDS; PROGNOSIS	Background: The association between body mass index (BMI) and clinical outcomes following an acute myocardial infarction (AMI) remains controversial. Our objective was to investigate the relationship between BMI and AMI presentation, in-hospital clinical course and mortality in the contemporary era of AMI management. Methods: Patients, hospitalized for an AMI between October 2015 and December 2016, were identified in the National Inpatient Sample (NIS) database. Socio-demographic and clinical data, including BMI, were collected and outcomes, including length of stay and mortality, were analyzed. Patients were divided into 6 BMI (kg/m2) subgroups; under-weight (<= 19), normal-weight (20-25), over-weight (26-30), obese I (31-35), obese II (36-39) and extremely obese (>= 40). Multivariable logistic regression model was used to identify predictors of in-hospital mortality. Linear regression model was used to identify predictors of length of stay (LOS). Results: An estimated total of 125,405 hospitalizations for an AMI across the US were analyzed. Compared to the other BMI subgroups, the under-weight, normal-weight and extremely obese groups presented with a non-ST segment elevation AMI (NSTEMI) more frequently and were less likely to undergo coronary revascularization. The data show a J-shaped relationship between BMI and study outcomes with lower mortality in patients with BMI over 25 compared to normal-and low-weight patients. In the multivariate regression model, BMI group was found to be an independent predictor of mortality. Conclusion: J-shaped relationship between BMI and mortality was documented in patients hospitalized for an AMI in the recent years. These findings confirm that the "obesity paradox" persists during the contemporary era of an AMI management.	[Elbaz-Greener, Gabby; Planer, David; Amir, Offer] Hebrew Univ Jerusalem, Hadassah Med Ctr, Fac Med, Dept Cardiol, Room 114, Jerusalem, Israel; [Rozen, Guy] Hillel Yaffe Med Ctr, Cardiol Div, Hadera, Israel; [Rozen, Guy] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Rozen, Guy] Harvard Med Sch, Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02115 USA; [Carasso, Shemy; Kusniec, Fabio; Marai, Ibrahim; Amir, Offer] Baruch Padeh Med Ctr, Div Cardiovasc Med, Poriya, Israel; [Carasso, Shemy; Kusniec, Fabio; Marai, Ibrahim; Amir, Offer] Bar Ilan Univ, Azrieli Fac Med Galilee, Safed, Israel; [Sud, Maneesh; Strauss, Bradley] Univ Toronto, Div Cardiol, Schulich Heart Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Smart, Frank W.] LSU Sch Med, New Orleans, LA USA		Elbaz-Greener, G (通讯作者)，Hebrew Univ Jerusalem, Hadassah Med Ctr, Fac Med, Dept Cardiol, Room 114, Jerusalem, Israel.	Gabbyelbaz@yahoo.com	Carasso, Shemy/AGY-4574-2022; Carasso, Shemy/ABE-3898-2020				Angeras O, 2013, EUR HEART J, V34, P345, DOI 10.1093/eurheartj/ehs217; [Anonymous], Healthcare Cost and Utilization Project (HCUP): 2012-2018; Aronson D, 2010, INT J CARDIOL, V145, P476, DOI 10.1016/j.ijcard.2009.12.029; Berry C, 2000, EUR HEART J, V21, P521, DOI 10.1053/euhj.1999.1882; Buettner HJ, 2007, EUR HEART J, V28, P1694, DOI 10.1093/eurheartj/ehm220; Chu YT, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-140; Coats AJ, 2001, CIRCULATION, V104, P437; Das SR, 2011, J AM COLL CARDIOL, V58, P2642, DOI 10.1016/j.jacc.2011.09.030; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Di Angelantonio E, 2016, LANCET, V388, P776, DOI 10.1016/S0140-6736(16)30175-1; Diercks DB, 2006, AM HEART J, V152, P140, DOI 10.1016/j.ahj.2005.09.024; Eisenstein EL, 2005, AM J MED, V118, P981, DOI 10.1016/j.amjmed.2005.02.017; Elbaz-Greener G, 2020, AM J CARDIOL, V134, P32, DOI 10.1016/j.amjcard.2020.08.019; Habbu A, 2006, AM J CARDIOL, V98, P944, DOI 10.1016/j.amjcard.2006.04.039; HCUP National Inpatient Sample (NIS), HEALTHC COST UT PROJ; Hosseini SM, 2017, EUR HEART J, V38, P2122, DOI 10.1093/eurheartj/ehx100; Kadakia MB, 2011, HEART, V97, P1782, DOI 10.1136/heartjnl-2011-300231; Kalantar-Zadeh K, 2007, CURR OPIN CLIN NUTR, V10, P433, DOI 10.1097/MCO.0b013e3281a30594; Kenchaiah S, 2007, CIRCULATION, V116, P627, DOI 10.1161/CIRCULATIONAHA.106.679779; Khan SS, 2018, JAMA CARDIOL, V3, P280, DOI 10.1001/jamacardio.2018.0022; Kragelund C, 2005, INT J CARDIOL, V98, P123, DOI 10.1016/j.ijcard.2004.03.042; Lamelas P, 2017, AM J CARDIOL, V120, P1453, DOI 10.1016/j.amjcard.2017.07.043; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Lazzeri C, 2013, NUTR METAB CARDIOVAS, V23, P205, DOI 10.1016/j.numecd.2012.05.013; Lopez-Jimenez F, 2004, CHEST, V125, P1205, DOI 10.1378/chest.125.4.1205; Mahaffey KW, 2010, INT J CARDIOL, V139, P123, DOI 10.1016/j.ijcard.2008.10.008; Mehta L, 2007, AM J CARDIOL, V99, P906, DOI 10.1016/j.amjcard.2006.11.038; Mehta RH, 2008, J INTERV CARDIOL, V21, P8, DOI 10.1111/j.1540-8183.2007.00311.x; Muller MJ, 2016, OBESITY FACTS, V9, P193, DOI 10.1159/000445380; Neeland IJ, 2017, EUR HEART J-QUAL CAR, V3, P183, DOI 10.1093/ehjqcco/qcx010; Niedziela J, 2014, EUR J EPIDEMIOL, V29, P801, DOI 10.1007/s10654-014-9961-9; Nigam A, 2006, INT J CARDIOL, V110, P153, DOI 10.1016/j.ijcard.2005.06.040; Oliveros H, 2008, OBESITY, V16, P515, DOI 10.1038/oby.2007.102; Radovanovic D, 2014, HEART, V100, P288, DOI 10.1136/heartjnl-2013-304588; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Uretsky S, 2007, AM J MED, V120, P863, DOI 10.1016/j.amjmed.2007.05.011; World Health Organization, BOD MASS IND BMI	37	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						551	559		10.2147/VHRM.S315248			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XH2QJ	WOS:000725285200001	34531659	Green Published, gold			2022-04-27	
J	Nozewski, J; Grzesk, G; Klopocka, M; Wicinski, M; Nicpon-Nozewska, K; Konieczny, J; Wlodarczyk, A				Nozewski, Jakub; Grzesk, Grzegorz; Klopocka, Maria; Wicinski, Michal; Nicpon-Nozewska, Klara; Konieczny, Jakub; Wlodarczyk, Adam			Management of Patient with Simultaneous Overt Gastrointestinal Bleeding and Myocardial Infarction with ST-Segment Elevation - Priority Endoscopy	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						upper gastrointestinal bleeding; acute coronary syndrome; antiplatelet and anticoagulant therapy; hemorrhage shock; proton pump inhibitors; endoscopy		Background: The current ERC guidelines are the source of many positive changes, reduction of mortality, length of hospitalization and improvement of prognosis of STEMI patients. However, there is a small group of patients whose slight modification in guidelines would further reduce in-hospital mortality and hospitalization costs. These are patients with concomitant STEMI infarction and gastrointestinal bleeding. Methods: Two separate methods of treatment were compared in patients with concomitant gastrointestinal bleeding and ST-segment elevation myocardial infarction. The first - traditional approach, in the line with the ESC guidelines, the second innovative, with priority for endoscopy. Results: Despite the innovative approach, the patient with endoscopy before PCI was discharged without complication. A patient who has undergone coronary intervention and who has been started on typical antiplatelet therapy prior to gastroenterological diagnosis has died due to massive bleeding. Conclusion: For ethical reasons and in connection with the cardiological guidelines of the management of ACS, a study of patients with ASC a high risk of intestinal bleeding, in which endoscopy will have priority, and only later PCI, will probably never be performed. Although, as the described case shows, despite exceeding the 90 minutes time to implement PCI (<120 minutes) in logistic terms such behavior is completely feasible.	[Nozewski, Jakub] Nicolaus Copernicus Univ, Fac Hlth Sci, Emergency Dept, Bydgoszcz, Poland; [Grzesk, Grzegorz] Nicolaus Copernicus Univ, Dept Cardiol & Clin Pharmacol, Fac Hlth Sci, Bydgoszcz, Poland; [Klopocka, Maria] Nicolaus Copernicus Univ, Dept Gastroenterol, Fac Hlth Sci, Bydgoszcz, Poland; [Wicinski, Michal] Nicolaus Copernicus Univ, Fac Med, Dept Pharmacol & Therapy, Bydgoszcz, Poland; [Nicpon-Nozewska, Klara] Nicolaus Copernicus Univ, Fac Hlth Sci, Dept & Clin Geriatr, Bydgoszcz, Poland; [Konieczny, Jakub] Biziels Hosp, Clin Emergency, Bydgoszcz, Poland; [Wlodarczyk, Adam] Med Univ Gdansk, Fac Med, Dept Psychiat, Gdansk, Poland		Nozewski, J (通讯作者)，Nicolaus Copernicus Univ Torun, Fac Hlth Sci, Dept Emergency Med, Coll Med, Jagiellonska 13-15, PL-85067 Bydgoszcz, Poland.	jbnoz@wp.pl	Nozewski, Jakub/ABC-8503-2021; Grześk, Grzegorz/AAS-6549-2021	Nozewski, Jakub/0000-0002-8765-233X; Wlodarczyk, Adam/0000-0001-8549-254X			Adler DG, 2004, GASTROINTEST ENDOSC, V60, P497; AlAssi MT, 1996, ENDOSCOPY, V28, P229, DOI 10.1055/s-2007-1005433; Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; Badar A, 2013, J INVASIVE CARDIOL, V25, P397; Barkun AN, 2010, ANN INTERN MED, V152, P101, DOI 10.7326/0003-4819-152-2-201001190-00009; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; Carrick MM, 2016, J TRAUMA ACUTE CARE, V80, P886, DOI 10.1097/TA.0000000000001044; Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Chassaignon C, 2003, EUR J EMERG MED, V10, P290, DOI 10.1097/00063110-200312000-00010; CHAVEZNEGRETE A, 1991, EUR SURG RES, V23, P123, DOI 10.1159/000129144; Cheung FKY, 2009, GASTROENTEROL CLIN N, V38, P231, DOI 10.1016/j.gtc.2009.03.003; Chua SK, 2011, AM J CRIT CARE, V20, P218, DOI 10.4037/ajcc2011683; Corson JD, 2001, SURGERY; Curdia-Goncalves T, 2016, REV ESP ENFERM DIG, V108, P648, DOI 10.17235/reed.2016.4240/2016; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Ergelen M, 2010, TURK KARDIYOL DERN A, V38, P101; Fallah MA, 2000, MED CLIN N AM, V84, P1183, DOI 10.1016/S0025-7125(05)70282-0; Frattaroli FM, 2009, WORLD J SURG, V33, P2209, DOI 10.1007/s00268-009-0156-6; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; Jairath V, 2015, LANCET, V386, P137, DOI 10.1016/S0140-6736(14)61999-1; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Kwan I, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002245.pub2; Laine L, 2008, GASTROENTEROLOGY, V134, P1836, DOI 10.1053/j.gastro.2008.03.006; Laine L, 2016, NEW ENGL J MED, V374, P2367, DOI 10.1056/NEJMcp1514257; Lam Kelvin L Y, 2015, Curr Treat Options Gastroenterol, V13, P369, DOI 10.1007/s11938-015-0063-x; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; Lau JY, 2007, NEW ENGL J MED, V356, P1631, DOI 10.1056/NEJMoa065703; Leontiadis GI, 2005, BMJ-BRIT MED J, V330, P568, DOI 10.1136/bmj.38356.641134.8F; Leontiadis GI, 2007, MAYO CLIN PROC, V82, P286; Lin S, 2006, DIGEST DIS SCI, V51, P2377, DOI 10.1007/s10620-006-9326-7; Lirio Richard A, 2016, Gastrointest Endosc Clin N Am, V26, P63, DOI 10.1016/j.giec.2015.09.003; Monteiro Sara, 2016, World J Gastrointest Pathophysiol, V7, P86, DOI 10.4291/wjgp.v7.i1.86; Mumtaz K, 2008, EUR J GASTROEN HEPAT, V20, P51, DOI 10.1097/MEG.0b013e3282f16a3a; Odutayo A, 2017, LANCET GASTROENTEROL, V2, P354, DOI 10.1016/S2468-1253(17)30054-7; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Pongprasobchai S, 2009, WORLD J GASTROENTERO, V15, P1099, DOI 10.3748/wjg.15.1099; Schreiber MA, 2015, J TRAUMA ACUTE CARE, V78, P687, DOI 10.1097/TA.0000000000000600; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Stabile BE, 2000, GASTROENTEROL CLIN N, V29, P189, DOI 10.1016/S0889-8553(05)70112-6; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; Straube S, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-41; Sung JJY, 2010, AM J GASTROENTEROL, V105, P84, DOI 10.1038/ajg.2009.507; Sung JJY, 2010, ANN INTERN MED, V152, P1, DOI 10.7326/0003-4819-152-1-201001050-00179; Tanigawa T, 2011, DIGESTION, V83, P153, DOI 10.1159/000321813; Vavlukis M, 2017, EC GASTROENTEROL DIG, V2, P398; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Xia XF, 2018, UNITED EUR GASTROENT, V6, P367, DOI 10.1177/2050640617732651; YAVORSKI RT, 1995, AM J GASTROENTEROL, V90, P568	49	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						123	133		10.2147/VHRM.S292253			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RK0VU	WOS:000638023800001	33833517	Green Published, gold			2022-04-27	
J	Corredor-Orlandelli, D; Sambracos-Parrado, S; Mantilla-Garcia, S; Tovar-Tirado, J; Vega-Ramirez, V; Mendoza-Ayus, SD; Pena, LC; Leal, MF; Rodriguez-Carrillo, J; Leon-Torres, J; Pardo-Oviedo, JM; Abaunza, KP; Bravo, NCC; Ortega-Recalde, O; Mendoza, DJF				Corredor-Orlandelli, David; Sambracos-Parrado, Santiago; Mantilla-Garcia, Santiago; Tovar-Tirado, Josue; Vega-Ramirez, Valentina; Mendoza-Ayus, Santiago David; Pena, Laura Catalina; Leal, Maria Fernanda; Rodriguez-Carrillo, Juliana; Leon-Torres, Juanita; Pardo-Oviedo, Juan Mauricio; Abaunza, Katherine Parra; Bravo, Nora Contreras Contreras; Ortega-Recalde, Oscar; Mendoza, Dora Janeth Fonseca			Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						PON1; genetic risk; cardiovascular disease susceptibility; platelet reactivity; clopidogrel	GENE POLYMORPHISMS; Q192R POLYMORPHISM; SERUM PARAOXONASE; HEART-DISEASE; GLN-ARG192 POLYMORPHISM; CARDIOVASCULAR-DISEASE; FUNCTIONAL GENOMICS; CLINICAL-EFFICACY; PON1; RISK	Background: Paraoxonase-1 (PON1), a glycoprotein associated with serum high-density lipoprotein (HDL), has a central role in metabolizing lipid peroxides, exhibiting antiathero-genic properties. The polymorphism p.Q192R has been previously associated with coronary artery disease (CAD) susceptibility and clopidogrel response. Purpose: We aimed at investigating the association of PON1 p.Q192R with CAD and clopidogrel response in Colombian population. Patients and Methods: The study was conducted among 163 patients diagnosed with CAD and treated with clopidogrel. The allele frequencies for the PON1 192Q and 192R alleles were determined in cases and Latin-American controls obtained from the public database gnomAD (n = 17,711). Response to clopidogrel was determined by assessing the platelet function using the INNOVANCE PFA-200 System. We determined the association between PON1 p.Q192R polymorphism, increased susceptibility to CAD and high on-treatment platelet reactivity (HPR) by using odds ratio (OR) and 95% confidence interval (CI) on four genetic models. Results: The allele frequencies for the PON1 192Q and 192R alleles were 0.60 and 0.40, respectively. The allele distribution was found to be statistically different from the control group and other ethnic groups. The allele 192R was positively associated with decreased susceptibility to CAD under a dominant model (OR, 0.58; 95% CI, 0.42-0.8; P < 0.01). We found no association between the polymorphism and HPR. Conclusion: We propose that PON1 p.Q192R is a potentially useful marker for CAD susceptibility in the Colombian population and lacks association with HPR under clopidogrel treatment.	[Corredor-Orlandelli, David; Sambracos-Parrado, Santiago; Mantilla-Garcia, Santiago; Tovar-Tirado, Josue; Vega-Ramirez, Valentina; Mendoza-Ayus, Santiago David; Pena, Laura Catalina; Leal, Maria Fernanda; Rodriguez-Carrillo, Juliana; Leon-Torres, Juanita; Bravo, Nora Contreras Contreras; Ortega-Recalde, Oscar; Mendoza, Dora Janeth Fonseca] Univ Rosario, Sch Med & Hlth Sci, GENIUROS Res Grp, Ctr Res Genet & Genom CIGGUR, Cra 24 63C69, Bogota 112111, Colombia; [Pardo-Oviedo, Juan Mauricio] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia; [Abaunza, Katherine Parra] Univ Rosario, Hosp Univ Mayor Mederi, Bogota, Colombia		Mendoza, DJF (通讯作者)，Univ Rosario, Sch Med & Hlth Sci, GENIUROS Res Grp, Ctr Res Genet & Genom CIGGUR, Cra 24 63C69, Bogota 112111, Colombia.	dora.fonseca@urosario.edu.co	Pardo-Oviedo, Juan Mauricio/F-9140-2016	Pardo-Oviedo, Juan Mauricio/0000-0003-0084-3449; Corredor-Orlandelli, David/0000-0002-0676-1770; Mendoza-Ayus, Santiago David/0000-0002-5285-1873	Universidad del Rosario [ABN062, IV-FPC015]; Hospital Universitario Mayor - Mederi	This project was supported by Grants ABN062 and IV-FPC015 (Universidad del Rosario) and Hospital Universitario Mayor - Mederi.	Adhikari K, 2016, CURR OPIN GENET DEV, V41, P106, DOI 10.1016/j.gde.2016.09.003; Angulo-Aguado M, 2021, J PERS MED, V11, DOI 10.3390/jpm11050400; Antikainen M, 1996, J CLIN INVEST, V98, P883, DOI 10.1172/JCI118869; Arnett DK, 2007, CIRCULATION, V115, P2878, DOI 10.1161/CIRCULATIONAHA.107.183679; Avena S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034695; Bayrak A, 2012, J ATHEROSCLER THROMB, V19, P376, DOI 10.5551/jat.11320; Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265; Bouman HJ, 2011, NAT MED, V17, P110, DOI 10.1038/nm.2281; Bounafaa A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133719; Camps J, 2011, NAT MED, V17, P1041, DOI 10.1038/nm.2386; Carranza Alva E, 2017, HORIZMED, V17, P22, DOI [10.24265/horizmed.2017.v17n2.04, DOI 10.24265/HORIZMED.2017.V17N2.04]; Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421; de Souza-Nogueira A, 2016, ARCH ENDOCRIN METAB, V60, P426, DOI 10.1590/2359-3997000000184; Moreno-Godinez ME, 2018, ARCH MED RES, V49, P486, DOI 10.1016/j.arcmed.2019.02.002; Falk E, 2013, EUR HEART J, V34, P719, DOI 10.1093/eurheartj/ehs411; Ferre N, 2002, CLIN BIOCHEM, V35, P197, DOI 10.1016/S0009-9120(02)00295-3; Fridman O, 2016, ARCH CARDIOL MEX, V86, P350, DOI 10.1016/j.acmx.2016.08.001; Garcia A., 2015, CARDIOVASC PHARM, V4, P3, DOI [10.4172/2329-6607.1000148, DOI 10.4172/2329-6607.1000148]; Gardemann A, 2000, ATHEROSCLEROSIS, V152, P421, DOI 10.1016/S0021-9150(99)00489-X; Ghouse J, 2018, CLIN GENET, V93, P459, DOI 10.1111/cge.13066; Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P473, DOI 10.1080/10937400903158409; Gonzalez JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025; Gupta N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017805; Hampe Mahesh Harishchandra, 2014, Indian J Hum Genet, V20, P51, DOI 10.4103/0971-6866.132756; Hassan MA, 2013, MOL CELL BIOCHEM, V380, P121, DOI 10.1007/s11010-013-1665-z; Helaly MAH, 2013, INT J DIABETES DEV C, V33, P207, DOI 10.1007/s13410-013-0146-y; Hendricks AE, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007591; Hernandez-Diaz Y, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005298; Hulot JS, 2011, CIRC-CARDIOVASC INTE, V4, P422, DOI 10.1161/CIRCINTERVENTIONS.111.963025; Imai Y, 2000, ATHEROSCLEROSIS, V149, P435, DOI 10.1016/S0021-9150(99)00340-8; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Karlsson H, 2015, HANDB EXP PHARMACOL, V224, P207, DOI 10.1007/978-3-319-09665-0_5; Lewis JP, 2011, CLIN PHARMACOL THER, V90, P568, DOI 10.1038/clpt.2011.194; Li YT, 2021, GENET EPIDEMIOL, V45, P293, DOI 10.1002/gepi.22370; Liu T, 2014, EUR J CLIN NUTR, V68, P1029, DOI 10.1038/ejcn.2014.105; Lusis MJ, 2004, ANNU REV GENOM HUM G, V5, P189, DOI [10.1016/j.tig.2012.03.001, 10.1146/annurev.genom.5.061903.175930]; Luu HN, 2011, ANN EPIDEMIOL, V21, P815, DOI 10.1016/j.annepidem.2011.08.007; Mackness M, 2015, GENE, V567, P12, DOI 10.1016/j.gene.2015.04.088; Marija G, 2008, CROAT CHEM ACTA, V81, P101; Martinez-Quintana E, 2017, CLIN INVEST ARTERIOS, V29, P1, DOI 10.1016/j.arteri.2016.07.005; Munshi R, 2019, CPPM, V16, P219, DOI [10.2174/187569211766, DOI 10.2174/187569211766]; Ombres D, 1998, ARTERIOSCL THROM VAS, V18, P1611, DOI 10.1161/01.ATV.18.10.1611; Orengo-Mercado Carmelo, 2013, J Pharmacogenomics Pharmacoproteomics, V4; Peng WX, 2019, CARDIOVASC THER, V2019, DOI 10.1155/2019/3470145; Ponte-Negretti CI, 2017, INT J CARDIOL, V243, P516, DOI 10.1016/j.ijcard.2017.05.059; Regieli JJ, 2009, J AM COLL CARDIOL, V54, P1238, DOI 10.1016/j.jacc.2009.05.061; Rodriguez F, 2016, J AM COLL CARDIOL, V68, P313, DOI 10.1016/j.jacc.2016.03.599; Roest M, 2007, EUR J CLIN INVEST, V37, P187, DOI 10.1111/j.1365-2362.2007.01769.x; Salzano FM, 2014, GENET MOL BIOL, V37, P151, DOI 10.1590/S1415-47572014000200003; Scacchi R, 2003, HUM BIOL, V75, P365, DOI 10.1353/hub.2003.0049; Sen-Banerjee S, 2000, ARTERIOSCL THROM VAS, V20, P2120, DOI 10.1161/01.ATV.20.9.2120; Senior J, 2013, REV COLOMB CARDIOL, V20, P45; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Siller-Lopez F, 2017, J TOXICOL-US, V2017, DOI 10.1155/2017/6913106; Sugunaraj JP, 2010, AM J THER, V17, P210, DOI 10.1097/MJT.0b013e3181bdc3e4; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F; Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950; World Health Organization, 2019, GLOB HLTH EST LIF EX; Zhao Y, 2012, MOL GENET METAB, V105, P141, DOI 10.1016/j.ymgme.2011.09.018	62	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						689	699		10.2147/VHRM.S330766			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WW0RH	WOS:000717634100001	34764653	Green Published, gold			2022-04-27	
J	Kasim, A; Elbaz-Greener, G; Shalabi, A; Kachel, E; Grosman-Rimon, L; Jerdev, M; Amir, O; Carasso, S				Kasim, Alexandra; Elbaz-Greener, Gabby; Shalabi, Amjad; Kachel, Erez; Grosman-Rimon, Liza; Jerdev, Michael; Amir, Offer; Carasso, Shemy			High Mitral Annulus Calcium Score in Pre-Operative Chest Computerized Tomography and Adverse Outcomes in Mitral Valve Surgery	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						mitral annulus calcification; MACS; mitral valve replacement; MVR	CALCIFICATION; REPAIR	Background: Severe mitral annulus calcification (MAC) is believed to bear high operative and post-operative risk during mitral valve replacement (MVR) surgery, including longer surgery time, post-surgical valvular leaks and increased rate of embolic phenomena. We hypothesized that quantification of mitral calcium in pre-operative chest computerized tomography (CCT), performed to assess aortic root before cross-clamping may help in risk assessment of adverse intraoperative and postoperative outcomes in patients undergoing MVR. Methods: We included patients who underwent MVR between the years 2015 and 2018 at Poriya medical center. Preoperative CCT was performed using Philips iCT 256 and Agatston mitral annulus calcium score (MACS) was retrospectively calculated using Philips Intellispace portal version 8.0. Patients were divided into MACS quintiles; 1-3 quintiles were grouped (Low MACS) and compared to the 4-5 quintiles (High MACS) group for demographic, clinical operative and post-operative parameters. Results: A total of 66 patients had MVR, out of which 61% were males, with mean age of 64 +/- 9. Concomitant coronary or valvular procedures were done in 60% of patients. The median MACS was 43. High MACS (>= 854) was not associated with longer bypass or cross clamp times. No differences in the MVR results were found between the groups. There were 6 post-operative embolic events; 1 mesenteric and 5 cerebral, which were not associated with MACS. Conclusion: MACS did not seem to be related to adverse outcomes in MVR. Due to a low event rate and probable pre-selection of patients without extreme mitral annulus calcifications our results should be confirmed in larger prospective study.	[Kasim, Alexandra] B Padeh Med Ctr, Dept Radiol, Poriya, Israel; [Elbaz-Greener, Gabby; Amir, Offer; Carasso, Shemy] Hadassah Med Ctr, Dept Cardiol, Room 114, Jerusalem, Israel; [Elbaz-Greener, Gabby; Amir, Offer; Carasso, Shemy] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel; [Shalabi, Amjad; Kachel, Erez; Grosman-Rimon, Liza; Jerdev, Michael; Amir, Offer; Carasso, Shemy] B Padeh Med Ctr, Cardiovasc Inst, Poriya, Israel; [Shalabi, Amjad; Kachel, Erez; Grosman-Rimon, Liza; Amir, Offer; Carasso, Shemy] Bar Ilan Univ, Azrieli Fac Med Galilee, Safed, Israel; [Shalabi, Amjad; Kachel, Erez] B Padeh Med Ctr, Dept Cardiac Surg, Poriya, Israel		Elbaz-Greener, G (通讯作者)，Hadassah Med Ctr, Dept Cardiol, Room 114, Jerusalem, Israel.	Gabby@hadassah.org.il	Carasso, Shemy/ABE-3898-2020; Carasso, Shemy/AGY-4574-2022				Abramowitz Y, 2015, J AM COLL CARDIOL, V66, P1934, DOI 10.1016/j.jacc.2015.08.872; Asselbergs FW, 2009, NEPHROL DIAL TRANSPL, V24, P834, DOI 10.1093/ndt/gfn544; Birudaraju D, 2021, EXPERT REV CARDIOVAS, V19, P787, DOI 10.1080/14779072.2021.1964361; Carpentier AF, 1996, J THORAC CARDIOV SUR, V111, P718, DOI 10.1016/S0022-5223(96)70332-X; FERTMAN MH, 1946, AM HEART J, V31, P580, DOI 10.1016/0002-8703(46)90004-X; Foley Paul Wx, 2010, BMC Res Notes, V3, P326, DOI 10.1186/1756-0500-3-326; Fusini L, 2014, AM J CARDIOL, V113, P1867, DOI 10.1016/j.amjcard.2014.03.013; Gaudino M, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012447; Kanjanauthai S, 2010, ATHEROSCLEROSIS, V213, P558, DOI 10.1016/j.atherosclerosis.2010.08.072; Maisano F, 2003, J THORAC CARDIOV SUR, V126, P1987, DOI 10.1016/S0022-5223(03)01291-1; O'Neal WT, 2015, EUROPACE, V17, P358, DOI 10.1093/europace/euu265; Okada Y, 2013, GEN THORAC CARDIOVAS, V61, P619, DOI 10.1007/s11748-013-0207-7; Pekdemir H, 2010, J ELECTROCARDIOL, V43, P339, DOI 10.1016/j.jelectrocard.2010.02.013; Russo A, 2008, J AM COLL CARDIOL, V51, P1203, DOI 10.1016/j.jacc.2007.10.058; Suh YJ, 2019, KOREAN J RADIOL, V20, DOI 10.3348/kjr.2018.0350; Vahanian A, 2021, EUR HEART J, DOI [10.1093/eurheartj/ehab395, 10.1093/ejcts/ezab389]	16	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						801	807		10.2147/VHRM.S338880			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XQ3PF	WOS:000731459400001	34916798	gold, Green Published			2022-04-27	
J	Yagel, O; Shadafny, N; Eliaz, R; Dagan, G; Leibowitz, D; Tahiroglu, I; Planer, D; Amir, O; Greener, GE; Alcalai, R				Yagel, Oren; Shadafny, Naseem; Eliaz, Ran; Dagan, Gil; Leibowitz, David; Tahiroglu, Ilgar; Planer, David; Amir, Offer; Greener, Gabby Elbaz; Alcalai, Ronny			Long-Term Prognosis in Young Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						acute coronary syndrome; ACS; NSTEMI; STEMI; young population; outcomes		Background: Acute coronary syndrome (ACS) at a young age is uncommon. Limited data regarding the long-term follow-up and prognosis in this population are available. Our objectives were to evaluate the long-term clinical outcomes of patients presenting with ACS at a young age and to assess factors that predict long-term prognosis. Methods: A retrospective analysis of consecutive young patients (male below 40 and female below 50 years old) that were admitted with ACS and underwent percutaneous coronary intervention (PCI) between the years 1997 and 2009. Demographics, clinical characteristics, and clinical outcomes including major cardiovascular (CV) events and mortality were analyzed. Multivariable cox proportional hazard model was performed to identify predictors of long-term prognosis. Results: One-hundred sixty-five patients were included with a mean follow-up of 9.1 +/- 4.6 years. Most patients were men (88%), and mean age (years) was 36.8 +/- 4.2. During follow-up, 15 (9.1%) died, 98 (59.4%) patients had at least one major CV event, 22 (13.3%) patients had more than two CV events, and the mean number of recurrent CV events was 1.4 +/- 1.48 events per patient. In multivariate analysis, the strongest predictors of major CV events and/or mortality were coronary intervention without stent insertion (HR1.77; 95% CI 1.09-2.9), LAD artery involvement (HR 1.59; 95% CI 1.04-2.44) and hypertension (HR 1.6; 95% CI 1.0-2.6). Conclusion: Patients with ACS in young age are at high risk for major CV and/or mortality in long-term follow-up with a high rate of recurrent CV events. Close follow-up and risk factor management for secondary prevention have a major role, particularly in this population.	Hadassah Med Ctr, Dept Cardiol, Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel		Greener, GE (通讯作者)，Hadassah Med Ctr, Cardiol Div, Room 114, Jerusalem, Israel.	Gabby@hadassah.org.il					Al-Murayeh MA, 2012, J SAUDI HEART ASSOC, V24, P169, DOI 10.1016/j.jsha.2012.03.001; Arciero TJ, 2004, AM J MED, V117, P228, DOI 10.1016/j.amjmed.2004.04.008; Behar S, 2003, ISR MED ASSOC J, V5, P249; Boles U, 2019, POL ARCH INTERN MED, V129, P833, DOI 10.20452/pamw.14959; Choudhury L, 1999, AM J MED, V107, P254, DOI 10.1016/S0002-9343(99)00218-1; Cole JH, 2003, J AM COLL CARDIOL, V41, P521, DOI 10.1016/S0735-1097(02)02862-0; Doughty M, 2002, AM HEART J, V143, P56, DOI 10.1067/mhj.2002.120300; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; Esteban MR, 2014, OPEN CARDIOVASC MED, V8, P61, DOI 10.2174/1874192401408010061; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; Navas-Nacher EL, 2001, ANN INTERN MED, V134, P433, DOI 10.7326/0003-4819-134-6-200103200-00007; Nowbar AN, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005375; Puricel S, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13816; Rathod KS, 2016, EUR HEART J-ACUTE CA, V5, P23, DOI 10.1177/2048872614567453; Regmi M, 2020, CORONARY ARTERY DIS; Sanchis-Gomar F, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.33; Schoenenberger AW, 2011, INT J CARDIOL, V148, P300, DOI 10.1016/j.ijcard.2009.11.009; Tini G, 2017, HIGH BLOOD PRESS CAR, V24, P77, DOI 10.1007/s40292-017-0183-6; Venkatason P, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030159; WOLFE MW, 1988, CHEST, V94, P926, DOI 10.1378/chest.94.5.926; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zhang YY, 2017, HYPERTENSION, V70, P736, DOI 10.1161/HYPERTENSIONAHA.117.09801; ZIMMERMAN FH, 1995, J AM COLL CARDIOL, V26, P654, DOI 10.1016/0735-1097(95)00254-2	23	3	3	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						153	159		10.2147/VHRM.S298436			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RQ0FN	WOS:000642095800001	33907409	Green Published, gold			2022-04-27	
J	Peper, J; Becker, LM; van Kuijk, JP; Leiner, T; Swaans, MJ				Peper, Joyce; Becker, Leonie M.; van Kuijk, Jan-Peter; Leiner, Tim; Swaans, Martin J.			Fractional Flow Reserve: Patient Selection and Perspectives	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						coronary artery disease; fractional flow reserve; patient selection; revascularisation	PERCUTANEOUS CORONARY INTERVENTION; COMPUTED-TOMOGRAPHY ANGIOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; OPTIMAL MEDICAL THERAPY; ASSOCIATION TASK-FORCE; WAVE-FREE RATIO; BIFURCATION LESIONS; PHYSIOLOGICAL ASSESSMENT; FUNCTIONAL ASSESSMENT; PRACTICE GUIDELINES	The aim of this review was to discuss the current practice and patient selection for invasive FFR, new techniques to estimate invasive FFR and future of coronary physiology tests. We elaborate on the indication and application of FFR and on the contraindications and concerns in certain patient populations.	[Peper, Joyce; Becker, Leonie M.; van Kuijk, Jan-Peter; Swaans, Martin J.] St Antonius Hosp, Dept Cardiol, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands; [Peper, Joyce; Becker, Leonie M.; Leiner, Tim] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands		Peper, J (通讯作者)，St Antonius Hosp, Dept Cardiol, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.	j.peper@antoniusziekenhuis.nl		Becker, Leonie M./0000-0001-9419-7120; Peper, Joyce/0000-0002-4008-1656; Swaans, Martin/0000-0003-1608-2760			Achenbach Stephan, 2017, Interv Cardiol, V12, P97, DOI 10.15420/icr.2017:13:2; Agarwal SK, 2016, JACC-CARDIOVASC INTE, V9, P1022, DOI 10.1016/j.jcin.2016.01.046; Ahn JM, 2012, JACC-CARDIOVASC INTE, V5, P155, DOI 10.1016/j.jcin.2011.10.015; Al-Lamee R, 2018, LANCET, V391, P31, DOI 10.1016/S0140-6736(17)32714-9; Azzalini L, 2019, J INVASIVE CARDIOL, V31, P229; Bech GJW, 2001, CIRCULATION, V103, P2928, DOI 10.1161/01.CIR.103.24.2928; Biscaglia S, 2020, AM HEART J, V229, P100, DOI 10.1016/j.ahj.2020.08.007; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Bruno F, 2020, CATHETER CARDIO INTE, DOI 10.1002/ccd.29427; Celeng C, 2019, JACC-CARDIOVASC IMAG, V12, P1316, DOI 10.1016/j.jcmg.2018.07.022; Changal K, 2020, AM J CARDIOL, V135, P184, DOI 10.1016/j.amjcard.2020.09.002; Chhatriwalla Adnan K, 2006, J Invasive Cardiol, V18, P544; Coenen A, 2015, RADIOLOGY, V274, P674, DOI 10.1148/radiol.14140992; Collet C, 2018, EUR HEART J, V39, P3314, DOI 10.1093/eurheartj/ehy445; Collet JP, 2021, EUR HEART J, V42, P1289, DOI [10.1093/eurheartj/ehaa575, 10.15829/1560-4071-2021-4418]; Collison D, 2021, EUR HEART J, V42, P4656, DOI 10.1093/eurheartj/ehab449; Davies JE, 2017, NEW ENGL J MED, V376, P1824, DOI 10.1056/NEJMoa1700445; De Bruyne B, 2014, NEW ENGL J MED, V371, P1208, DOI 10.1056/NEJMoa1408758; de Waard GA, 2017, EUROINTERVENTION, V13, P450, DOI 10.4244/EIJ-D-16-00456; de Waard GA, 2016, JACC-CARDIOVASC INTE, V9, P602, DOI 10.1016/j.jcin.2016.01.001; Demir OM, 2021, INT J CARDIOL, V330, P12, DOI 10.1016/j.ijcard.2021.02.008; Di Gioia G, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.120.009157; Di Gioia G, 2020, EUR HEART J, V41, P1665, DOI 10.1093/eurheartj/ehz571; Di Gioia G, 2016, AM J CARDIOL, V117, P1511, DOI 10.1016/j.amjcard.2016.02.023; Ding DX, 2021, EUR HEART J, V42, P2695, DOI 10.1093/eurheartj/ehab186; Dominguez-Franco AJ, 2008, REV ESP CARDIOL, V61, P352, DOI 10.1016/S1885-5857(08)60144-9; Donnelly PM, 2018, AM J CARDIOL, V121, P9, DOI 10.1016/j.amjcard.2017.09.018; Engstrom T, 2015, LANCET, V386, P665, DOI 10.1016/S0140-6736(15)60648-1; Escaned J, 2003, J AM COLL CARDIOL, V42, P226, DOI 10.1016/S0735-1097(03)00588-6; Fournier S, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017729; Fournier S, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.117.006368; Gaur S, 2013, J CARDIOVASC COMPUT, V7, P279, DOI 10.1016/j.jcct.2013.09.003; Gershlick AH, 2015, J AM COLL CARDIOL, V65, P963, DOI 10.1016/j.jacc.2014.12.038; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; Gotberg M, 2017, NEW ENGL J MED, V376, P1813, DOI 10.1056/NEJMoa1616540; Hakeem A, 2010, CATHETER CARDIO INTE, V75, P229, DOI 10.1002/ccd.22237; Hamilos M, 2009, CIRCULATION, V120, P1505, DOI 10.1161/CIRCULATIONAHA.109.850073; Huang AL, 2020, CAN ASSOC RADIOL J, V71, P201, DOI 10.1177/0846537119893752; Ihdayhid AR, 2018, EUR HEART J-CARD IMG, V19, P1234, DOI 10.1093/ehjci/jey114; Jin XJ, 2016, CIRC J, V80, P1583, DOI 10.1253/circj.CJ-15-1402; Johnson NP, 2019, EUR HEART J, V40, P2585, DOI 10.1093/eurheartj/ehz230; Kandaswamy E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020424; Kang SJ, 2014, CATHETER CARDIO INTE, V83, P545, DOI 10.1002/ccd.25057; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Ko BS, 2017, JACC-CARDIOVASC IMAG, V10, P663, DOI 10.1016/j.jcmg.2016.07.005; Kobayashi Y, 2016, J AM COLL CARDIOL, V67, P1701, DOI 10.1016/j.jacc.2016.01.056; Kobayashi Y, 2016, INT J CARDIOL, V204, P206, DOI 10.1016/j.ijcard.2015.11.169; Koo BK, 2005, J AM COLL CARDIOL, V46, P633, DOI 10.1016/j.jacc.2005.04.054; Koo BK, 2008, EUR HEART J, V29, P726, DOI 10.1093/eurheartj/ehn045; Koo BK, 2011, J AM COLL CARDIOL, V58, P1989, DOI 10.1016/j.jacc.2011.06.066; Koo BK, 2010, CIRC-CARDIOVASC INTE, V3, P113, DOI 10.1161/CIRCINTERVENTIONS.109.887406; Koo BK, 2009, J INTERV CARDIOL, V22, P110, DOI 10.1111/j.1540-8183.2009.00437.x; Lee JM, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.120.009232; Lee JM, 2019, JAMA CARDIOL, V4, P857, DOI 10.1001/jamacardio.2019.2298; Leone AM, 2013, CIRC-CARDIOVASC INTE, V6, P29, DOI 10.1161/CIRCINTERVENTIONS.112.971101; Levine GN, 2011, J AM COLL CARDIOL, V58, pE44, DOI 10.1016/j.jacc.2011.08.007; Li Y, 2020, J INT MED RES, V48, DOI 10.1177/0300060520955060; Li Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042558, 10.1371/journal.pone.0043023]; Lim HS, 2014, INT J CARDIOL, V177, P66, DOI 10.1016/j.ijcard.2014.09.010; Lindstaedt M, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.03.026; Lotfi A, 2014, CATHETER CARDIO INTE, V83, P509, DOI 10.1002/ccd.25222; Lukkarinen H, 2006, NURS RES, V55, P26, DOI 10.1097/00006199-200601000-00004; Mancini GBJ, 2014, JACC-CARDIOVASC INTE, V7, P195, DOI 10.1016/j.jcin.2013.10.017; Maron DJ, 2020, NEW ENGL J MED, V382, P1395, DOI 10.1056/NEJMoa1915922; Masdjedi K, 2020, EUROINTERVENTION, V16, P591, DOI 10.4244/EIJ-D-19-00466; McClish JC, 2004, AM J CARDIOL, V93, P1102, DOI 10.1016/j.amjcard.2004.01.035; Mehta SR, 2019, NEW ENGL J MED, V381, P1411, DOI 10.1056/NEJMoa1907775; Mejia-Renteria H, 2020, EUROINTERVENTION, V16, pE285, DOI 10.4244/EIJ-D-19-01001; Morris PD, 2013, JACC-CARDIOVASC INTE, V6, P149, DOI 10.1016/j.jcin.2012.08.024; Nakazato R, 2013, CIRC-CARDIOVASC IMAG, V6, P881, DOI 10.1161/CIRCIMAGING.113.000297; Neale T., FUTURE RESULTS CONFI; Nederland Z., FARMACOTHERAPEUTISCH; Ntalianis A, 2010, JACC-CARDIOVASC INTE, V3, P1274, DOI 10.1016/j.jcin.2010.08.025; Okutucu S, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-021-01521-3; Papafaklis MI, 2014, EUROINTERVENTION, V10, P574, DOI 10.4244/EIJY14M07_01; Pargaonkar VS, 2021, EUROINTERVENTION, V16, DOI 10.4244/EIJ-D-20-00779; Peper J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86245-8; Pesarini G, 2016, CIRC-CARDIOVASC INTE, V9, DOI 10.1161/CIRCINTERVENTIONS.116.004088; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Renker M, 2014, AM J CARDIOL, V114, P1303, DOI 10.1016/j.amjcard.2014.07.064; Sabbah M, 2020, EUROINTERVENTION, V16, P584, DOI 10.4244/EIJ-D-19-00577; Sahinarslan A, 2009, CORONARY ARTERY DIS, V20, P317, DOI 10.1097/MCA.0b013e32832c8ca3; Seike F, 2016, AM J CARDIOL, V118, P1158, DOI 10.1016/j.amjcard.2016.07.026; Sen S, 2012, J AM COLL CARDIOL, V59, P1392, DOI 10.1016/j.jacc.2011.11.003; Smits PC, 2017, NEW ENGL J MED, V376, P1234, DOI 10.1056/NEJMoa1701067; Soares A, 2020, INT J CARDIOL, V302, P34, DOI 10.1016/j.ijcard.2019.12.040; Svanerud J, 2018, EUROINTERVENTION, V14, P806, DOI 10.4244/EIJ-D-18-00342; Thim T, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05252-6; Timbadia D, 2020, J CARDIAC SURG, V35, P2785, DOI 10.1111/jocs.14880; Tonino PAL, 2009, NEW ENGL J MED, V360, P213, DOI 10.1056/NEJMoa0807611; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Toth GG, 2016, JACC-CARDIOVASC INTE, V9, P453, DOI 10.1016/j.jcin.2015.11.021; Trobs M, 2016, AM J CARDIOL, V117, P29, DOI 10.1016/j.amjcard.2015.10.008; Tsujita K, 2008, AM J CARDIOL, V102, P1608, DOI 10.1016/j.amjcard.2008.07.054; Tu SX, 2016, JACC-CARDIOVASC INTE, V9, P2024, DOI 10.1016/j.jcin.2016.07.013; Tu SX, 2014, JACC-CARDIOVASC INTE, V7, P768, DOI 10.1016/j.jcin.2014.03.004; van Hamersvelt Robbert W, 2019, Radiol Cardiothorac Imaging, V1, pe190036, DOI 10.1148/ryct.2019190036; van't Veer M, 2017, J AM COLL CARDIOL, V70, P3088, DOI 10.1016/j.jacc.2017.10.066; Vendrik J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015133; Verdoia M, 2021, ANGIOLOGY, V72, P62, DOI 10.1177/0003319720947578; Wald DS, 2013, NEW ENGL J MED, V369, P1115, DOI 10.1056/NEJMoa1305520; Wermers J, FUTURE TRIAL DOES NO; Westra J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009603; Westra J, 2018, CIRC-CARDIOVASC IMAG, V11, DOI 10.1161/CIRCIMAGING.117.007107; Williams B, 2018, J HYPERTENS, V36, P2284, DOI [10.1097/HJH.0000000000001961, 10.1080/08037051.2018.1527177]; Xaplanteris P, 2018, NEW ENGL J MED, V379, P250, DOI 10.1056/NEJMoa1803538; Xie XZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064564; Xu B, 2017, J AM COLL CARDIOL, V70, P3077, DOI 10.1016/j.jacc.2017.10.035; Yanagisawa H, 2004, CIRC J, V68, P993, DOI 10.1253/circj.68.993; Yang L, 2019, CLIN RADIOL, V74, DOI 10.1016/j.crad.2019.08.007; Zimmermann FM, 2015, EUR HEART J, V36, P3182, DOI 10.1093/eurheartj/ehv452	111	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						817	831		10.2147/VHRM.S286916			15	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	YI6YG	WOS:000743991700002	34934324	Green Published			2022-04-27	
J	Wang, MQ; Gu, MX; Liu, L; Liu, Y; Tian, L				Wang, Mingqiang; Gu, Mingxia; Liu, Ling; Liu, Yu; Tian, Lei			Single-Cell RNA Sequencing (scRNA-seq) in Cardiac Tissue: Applications and Limitations	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						cardiovascular diseases; clustering; trajectory inference; RNA velocity; cell-cell communication; spatial genomics	GENE-EXPRESSION; REVEALS; HEART; HETEROGENEITY; RECONSTRUCTION; PLATFORM; ATLAS; MAPS	Cardiovascular diseases (CVDs) are a group of disorders of the blood vessels and heart, which are considered as the leading causes of death worldwide. The pathology of CVDs could be related to the functional abnormalities of multiple cell types in the heart. Single-cell RNA sequencing (scRNA-seq) technology is a powerful method for characterizing individual cells and elucidating the molecular mechanisms by providing a high resolution of transcriptomic changes at the single-cell level. Specifically, scRNA-seq has provided novel insights into CVDs by identifying rare cardiac cell types, inferring the trajectory tree, estimating RNA velocity, elucidating the cell-cell communication, and comparing healthy and pathological heart samples. In this review, we summarize the different scRNAseq platforms and published single-cell datasets in the cardiovascular field, and describe the utilities and limitations of this technology. Lastly, we discuss the future perspective of the application of scRNA-seq technology into cardiovascular research.	[Wang, Mingqiang; Liu, Yu; Tian, Lei] Stanford Univ, Sch Med, Stanford Cardiovasc Inst, 1291 Welch Rd,Biomed Innovat Bldg, Stanford, CA 94305 USA; [Gu, Mingxia] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Div Pulm Biol, Cincinnati, OH 45229 USA; [Gu, Mingxia] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Ctr Stem Cell & Organoid Med, CuSTOM, Cincinnati, OH 45229 USA; [Liu, Ling] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Wang, MQ; Tian, L (通讯作者)，Stanford Univ, Sch Med, Stanford Cardiovasc Inst, 1291 Welch Rd,Biomed Innovat Bldg, Stanford, CA 94305 USA.	timwang5@stanford.edu; tianlei@stanford.edu		Liu, Yu/0000-0001-7110-127X	American Heart AssociationAmerican Heart Association [20POST35210924]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R00HL135258]	We are grateful for funding support from the American Heart Association Postdoctoral Fellowship 20POST35210924 (Dr Tian) and the National Heart, Lung, and Blood Institute R00HL135258 (Dr Gu).	Almanzar N, 2020, NATURE, V583, P590, DOI 10.1038/s41586-020-2496-1; Andrews TS, 2021, NAT PROTOC, V16, P1, DOI 10.1038/s41596-020-00409-w; Asp M, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900221; Asp M, 2019, CELL, V179, P1647, DOI 10.1016/j.cell.2019.11.025; Bagnoli JW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05347-6; Bergen V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0591-3; Cabello-Aguilar S, 2020, NUCLEIC ACIDS RES, V48, DOI 10.1093/nar/gkaa183; Cao JY, 2020, SCIENCE, V370, P808, DOI 10.1126/science.aba7721; Chaudhry F, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00173; Chestnut B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16515-y; Churko JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07333-4; Cui YX, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab236; Cui YL, 2019, CELL REP, V26, P1934, DOI 10.1016/j.celrep.2019.01.079; de Soysa TY, 2019, NATURE, V572, P120, DOI 10.1038/s41586-019-1414-x; DeLaughter DM, 2016, DEV CELL, V39, P480, DOI 10.1016/j.devcel.2016.10.001; Deng QL, 2014, SCIENCE, V343, P193, DOI 10.1126/science.1245316; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dong J, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1416-2; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Farbehi N, 2019, ELIFE, V8, DOI 10.7554/eLife.43882; Friedman CE, 2018, CELL STEM CELL, V23, P586, DOI 10.1016/j.stem.2018.09.009; Galow AM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051144; Gambardella L, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.174441; Gelali E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09616-w; Gelali E, 2018, METHODS MOL BIOL, V1766, P303, DOI 10.1007/978-1-4939-7768-0_17; Gierahn TM, 2017, NAT METHODS, V14, P395, DOI 10.1038/nmeth.4179; Gladka MM, 2018, CIRCULATION, V138, P166, DOI 10.1161/CIRCULATIONAHA.117.030742; Goldstein LD, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3893-1; Goodyer WR, 2019, CIRC RES, V125, P379, DOI 10.1161/CIRCRESAHA.118.314578; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Han X, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.176198; Hashimshony T, 2012, CELL REP, V2, P666, DOI 10.1016/j.celrep.2012.08.003; Holowiecki A, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.185652; Honkoop H, 2019, ELIFE, V8, DOI 10.7554/eLife.50163; Hu P, 2018, GENE DEV, V32, P1344, DOI 10.1101/gad.316802.118; Hu Z, 2021, ARTERIOSCL THROM VAS, V41, P1408, DOI 10.1161/ATVBAHA.120.315373; Hulin A, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.173047; Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050; Islam S, 2014, NAT METHODS, V11, P163, DOI [10.1038/NMETH.2772, 10.1038/nmeth.2772]; Jaitin DA, 2014, SCIENCE, V343, P776, DOI 10.1126/science.1247651; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kamdar F, 2020, J AM COLL CARDIOL, V75, P1159, DOI 10.1016/j.jacc.2019.12.066; King KR, 2017, NAT MED, V23, P1481, DOI 10.1038/nm.4428; Kiselev VY, 2019, NAT REV GENET, V20, P273, DOI 10.1038/s41576-018-0088-9; Kiselev VY, 2017, NAT METHODS, V14, P483, DOI [10.1038/NMETH.4236, 10.1038/nmeth.4236]; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kretzschmar K, 2018, P NATL ACAD SCI USA, V115, pE12245, DOI 10.1073/pnas.1805829115; Kulkarni A, 2019, CURR OPIN BIOTECH, V58, P129, DOI 10.1016/j.copbio.2019.03.001; Kuppe C., 2020, SPATIAL MULTIOMIC HU, DOI [10.1101/2020.12.08.411686, DOI 10.1101/2020.12.08.411686]; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Lacar B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11022; Lahnemann D, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1926-6; Lareau CA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14667-5; Leon-Mimila P, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00091; Leopold JA, 2018, CIRC RES, V122, P1302, DOI 10.1161/CIRCRESAHA.117.310782; Lescroart F, 2018, SCIENCE, V359, P1177, DOI 10.1126/science.aao4174; Li G, 2016, DEV CELL, V39, P491, DOI 10.1016/j.devcel.2016.10.014; Li ZW, 2019, EUR HEART J, V40, P2507, DOI 10.1093/eurheartj/ehz305; Linnarsson S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0960-x; Linscheid N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10709-9; Litvinukova M, 2020, NATURE, V588, P466, DOI 10.1038/s41586-020-2797-4; Liu SJ, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0932-1; Liu XY, 2019, CELL REP, V28, P1346, DOI 10.1016/j.celrep.2019.06.092; Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746; Ma S, 2021, CELL RES, V31, P415, DOI 10.1038/s41422-020-00412-6; Ma YG, 2018, TRANSL RES, V191, P15, DOI 10.1016/j.trsl.2017.10.001; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; McCormick ME, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003170; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Miao YF, 2020, CELL STEM CELL, V27, P574, DOI 10.1016/j.stem.2020.07.015; Moffitt JR, 2016, METHOD ENZYMOL, V572, P1, DOI 10.1016/bs.mie.2016.03.020; Mohenska M., 2019, 3D CARDIOMICS SPATIA, DOI [10.1101/792002, DOI 10.1101/792002]; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nayak R, 2021, GENOMICS, V113, P606, DOI 10.1016/j.ygeno.2021.01.007; Neeland IJ, 2018, CIRCULATION, V137, P1391, DOI 10.1161/CIRCULATIONAHA.117.029617; Nomura S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06639-7; Paik DT, 2020, CIRCULATION, V142, P1848, DOI 10.1161/CIRCULATIONAHA.119.041433; Phansalkar RS, 2021, BIORXIV, V2, P584; Picelli S, 2019, METHODS MOL BIOL, V1979, P25, DOI 10.1007/978-1-4939-9240-9_3; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/NMETH.2639, 10.1038/nmeth.2639]; Pollen AA, 2014, NAT BIOTECHNOL, V32, P1053, DOI 10.1038/nbt.2967; Potter SS, 2018, NAT REV NEPHROL, V14, P479, DOI 10.1038/s41581-018-0021-7; Ren ZN, 2020, CIRCULATION, V141, P1704, DOI 10.1161/CIRCULATIONAHA.119.043053; Rosenberg AB, 2018, SCIENCE, V360, P176, DOI 10.1126/science.aam8999; Roth R, 2020, BMB REP, V53, P393, DOI 10.5483/BMBRep.2020.53.8.130; Rozenblatt-Rosen O, 2017, NATURE, V550, P451, DOI 10.1038/550451a; Ruan H, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0709-6; Saelens W, 2019, NAT BIOTECHNOL, V37, P547, DOI 10.1038/s41587-019-0071-9; Sahara M, 2019, DEV CELL, V48, P475, DOI 10.1016/j.devcel.2019.01.005; Salomon R, 2019, LAB CHIP, V19, P1706, DOI 10.1039/c8lc01239c; Santoro Federica, 2021, STAR Protoc, V2, P100339, DOI 10.1016/j.xpro.2021.100339; Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586-018-0590-4; See K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00319-8; Sheng KW, 2017, NAT METHODS, V14, P267, DOI [10.1038/NMETH.4145, 10.1038/nmeth.4145]; Singh M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11049-4; Song DY, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02341-y; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sun WF, 2020, NATURE, V587, P98, DOI 10.1038/s41586-020-2856-x; Suryawanshi H, 2020, CARDIOVASC RES, V116, P1446, DOI 10.1093/cvr/cvz257; Svensson V, 2018, NAT PROTOC, V13, P599, DOI 10.1038/nprot.2017.149; Thomas H, 2018, GLOB HEART, V13, P143, DOI 10.1016/j.gheart.2018.09.511; Vu TN, 2019, BIOINFORMATICS, V35, P4679, DOI 10.1093/bioinformatics/btz288; Tucker NR, 2020, CIRCULATION, V142, P466, DOI 10.1161/CIRCULATIONAHA.119.045401; Vidal R, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131092; Wagner DE, 2020, NAT REV GENET, V21, P410, DOI 10.1038/s41576-020-0223-2; Wang B, 2017, NAT METHODS, V14, P414, DOI 10.1038/nmeth.4207; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang L, 2020, NAT CELL BIOL, V22, P108, DOI 10.1038/s41556-019-0446-7; Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16204-w; Waylen LN, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01341-1; Weinberger M, 2020, DEV CELL, V52, P574, DOI 10.1016/j.devcel.2020.01.023; Wolfien M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020318; Xin YR, 2016, P NATL ACAD SCI USA, V113, P3293, DOI 10.1073/pnas.1602306113; Xiong HQ, 2019, CIRC RES, V125, P398, DOI 10.1161/CIRCRESAHA.119.315243; Xu D, 2020, SINGLE CELL TRANSCRI, V8, P103; Yamada S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218345; Yekelchyk M, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0744-z; Zhang QQ, 2021, CIRC RES, V129, P474, DOI 10.1161/CIRCRESAHA.121.318943; Zhang WQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15997-0; Zhang YQ, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0095-9; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou Y, 2019, CELL STEM CELL, V25, P149, DOI 10.1016/j.stem.2019.05.020; Ziegenhain C, 2017, MOL CELL, V65, P631, DOI 10.1016/j.molcel.2017.01.023	124	0	0	2	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						641	657		10.2147/VHRM.S288090			17	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WC8OF	WOS:000704511200001	34629873	gold, Green Published			2022-04-27	
J	Hung, DQ; Minh, NT; Vo, HL; Hien, NS; Tuan, NQ				Doan Quoc Hung; Nguyen Thai Minh; Hoang-Long Vo; Nguyen Sinh Hien; Nguyen Quang Tuan			Impact of Pre-, Intra-and Post-Operative Parameters on In-Hospital Mortality in Patients Undergoing Emergency Coronary Artery Bypass Grafting: A Scarce Single-Center Experience in Resource-Scare Setting	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						emergency coronary artery bypass grafting; early mortality; in-hospital mortality; risk factor; Vietnam	ACUTE MYOCARDIAL-INFARCTION; CARDIOGENIC-SHOCK; OUTCOMES; SURGERY; REVASCULARIZATION; MANAGEMENT; TRENDS	Background: In-hospital mortality after emergency coronary artery bypass grafting (CABG) remains an important issue that has needed considerable attention in recent years as the mortality rate is still high and prevention factors are not yet optimal. Our study presents the first largest cohort of emergency CABG from one large institution in Vietnam with the primary aim of comparing a large variety of pre-, intra-and postoperative parameters between in-hospital mortality patients and in-hospital survival patients and investigate risk factors of in-hospital mortality in patients undergoing emergency CABG. Methods: We conducted a retrospective evaluation of prospectively collected data in patients undergoing emergency CABG at the Hanoi Heart Hospital (Hanoi, Vietnam) from January 1, 2017, to December 31, 2019. Primary outcome variable was in-hospital mortality. Results: A total of 71 patients were included in final analysis. The mean age of the cohort was 68.68 years (+/- 9.28, range 38-86). The mean weight, height and body mass index were 54.35 kg (+/- 9.17, range 37-77), 158.96 (+/- 7.64, range 145-179) and 21.48 kg/m(2) (+/- 3.08, range 13.59-30.08), respectively. In-hospital mortality rate was 9.86%. Preoperative risk factors for in-hospital mortality included diabetes, decreased ejection fraction (EF), EF below 30%, cardiogenic shock, elevated systolic pulmonary artery pressure (PAP), elevated NT-ProBNP, and Euroscore II. Without grafting with left internal thoracic artery, and prolonged cardiopulmonary bypass (CPB) time were increased intraoperative factors for inhospital mortality risk. In-hospital mortality's postoperative risk factors were found to be postextubation respiratory failure requiring mechanical ventilation, ventricular fibrillation, dialysis-requiring acute renal failure, pneumonia, bacterial sepsis, gastrointestinal bleeding, and prolonged mechanical ventilation time. Significant predictors determining in-hospital mortality were known as prolonged CPB time in surgery and postoperative ventricular fibrillation. Conclusion: Our hospital mortality rate after emergency CABG was relatively high. An optimal preventive strategy in emergency CABG management should target significant factors combined with other previously identified risk factors to reduce in-hospital mortality.	[Doan Quoc Hung; Hoang-Long Vo; Nguyen Quang Tuan] Hanoi Med Univ, Hanoi 100000, Vietnam; [Doan Quoc Hung] Viet Duc Univ Hosp, Dept Cardiovasc & Thorac Surg, Hanoi 100000, Vietnam; [Nguyen Thai Minh; Nguyen Sinh Hien] Hanoi Heart Hosp, Hanoi 100000, Vietnam; [Nguyen Quang Tuan] Bach Mai Hosp, Hanoi 100000, Vietnam		Hung, DQ; Vo, HL (通讯作者)，Hanoi Med Univ, Hanoi 100000, Vietnam.; Hung, DQ (通讯作者)，Viet Duc Univ Hosp, Dept Cardiovasc & Thorac Surg, Hanoi 100000, Vietnam.	hung.doanquoc@gmail.com; vohoanglonghmu@gmail.com	Vo, Hoang-Long/R-1975-2019	Vo, Hoang-Long/0000-0001-5992-875X			Antunes PE, 2008, EUR J CARDIO-THORAC, V34, P370, DOI 10.1016/j.ejcts.2008.05.008; Axelsson TA, 2016, EUR J CARDIO-THORAC, V49, P1451, DOI 10.1093/ejcts/ezv388; Babaev A, 2005, JAMA-J AM MED ASSOC, V294, P448, DOI 10.1001/jama.294.4.448; Biancari F, 2015, J CARDIOTHOR VASC AN, V29, P275, DOI 10.1053/j.jvca.2014.10.019; Bouchart F, 2001, EUR J CARDIO-THORAC, V20, P1157, DOI 10.1016/S1010-7940(01)00982-4; CHRISTAKIS GT, 1992, J THORAC CARDIOV SUR, V103, P1083; Christiansen S, 2010, ANN THORAC CARDIOVAS, V16, P168; Davierwala PM, 2016, CIRCULATION, V134, P1224, DOI 10.1161/CIRCULATIONAHA.115.021092; Glance LG, 2007, J THORAC CARDIOV SUR, V134, P53, DOI 10.1016/j.jtcvs.2007.02.037; Hochman JS, 2000, J AM COLL CARDIOL, V36, P1063, DOI 10.1016/S0735-1097(00)00879-2; Khaladj N, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-167; Leavitt BJ, 2004, CIRCULATION, V110, pII41, DOI 10.1161/10.CIR.0000138197.07051.e7; Mehta RH, 2008, CIRCULATION, V117, P876, DOI 10.1161/CIRCULATIONAHA.107.728147; Nashef SAM, 2012, EUR J CARDIO-THORAC, V41, P734, DOI 10.1093/ejcts/ezs043; Neglia D, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.114.002179; Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193; Santarpino G, 2015, AM J CARDIOL, V116, P1193, DOI 10.1016/j.amjcard.2015.07.034; Schumer EM, 2016, TEX HEART I J, V43, P214, DOI 10.14503/THIJ-14-4978; SCOTT SM, 1994, CIRCULATION, V90, P120; Sezai A, 2012, ANN THORAC CARDIOVAS, V18, P338, DOI 10.5761/atcs.oa.11.01821; Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI [10.1016/j.jacc.2012.08.001, 10.1038/nrcardio.2012.122]; Trachiotis GD, 1998, ANN THORAC SURG, V66, P1632, DOI 10.1016/S0003-4975(98)00773-5; Wang WH, 2012, ANN THORAC SURG, V93, P796, DOI 10.1016/j.athoracsur.2011.11.007	23	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						211	226		10.2147/VHRM.S303726			16	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SD1EX	WOS:000651111500001	34040381	gold, Green Published			2022-04-27	
J	Alwani, M; Yassin, A; Talib, R; Al-Qudimat, A; Aboumarzouk, O; Al-Zoubi, RM; Saad, F; Haider, KS; Al Ansari, A				Alwani, Mustafa; Yassin, Aksam; Talib, Raidh; Al-Qudimat, Ahmad; Aboumarzouk, Omar; Al-Zoubi, Raed M.; Saad, Farid; Haider, Karim S.; Al Ansari, Abdulla			Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						functional hypogonadism; testosterone therapy; erectile function; cardiovascular disease	ANDROGEN DEPRIVATION THERAPY; REPLACEMENT THERAPY; METABOLIC SYNDROME; INCREASED RISK; TRANSDERMAL TESTOSTERONE; MYOCARDIAL-ISCHEMIA; INTERNATIONAL INDEX; SERUM TESTOSTERONE; VISCERAL ADIPOSITY; SEXUAL DYSFUNCTION	Purpose: Erectile dysfunction (ED) is associated with testosterone deficiency and is a symptom of functional hypogonadism. A correlation between ED and cardiovascular disease (CVD) has been recognized, and ED has been proposed as an early marker of CVD. However, the relationship between ED and CVD risk in hypogonadism requires clarification and whether testosterone therapy (TTh) can be a beneficial treatment strategy, but long-term data are limited. This study investigates long-term TTh in men with hypogonadism and ED with a history of CVD. Methods: Seventy-seven patients with a history of CVD and diagnosed with functional hypogonadism and erectile dysfunction (erectile function domain score <21 on the International Index of Erectile Function questionnaire (IIEF questions 1-5)) were enrolled and TTh effects on anthropometric and metabolic parameters investigated for a maximum duration of 12 years. All men received long-acting injections of testosterone undecanoate at 3-monthly intervals. Eight-year data were analysed. Data collection registry started in November 2004 till January 2015. Results: In hypogonadal men receiving TTh, IIEF increased by 5.4 (p<0.001). Total weight loss was 23.6 +/- 0.6 kg after 8 years. HbA1c had declined by an average of 2.0% (P<0.0001). Total cholesterol levels significantly declined following TTh after only 1 year (P<0.0001), and HDL increased from 1.6 +/- 0.5 at baseline to 2 +/- 0.5 mmol/L following 8 years of TTh (P<0.0001). SBP decreased from 164 +/- 14 at baseline to 133 +/- 9 mmHg, signifying a reduction of 33 +/- 1 mmHg (P<0.0001). Conclusion: In hypogonadal men with a history of CVD, TTh improves and preserves erectile function over prolonged periods with concurrent sustained improvements in cardio-metabolic risk factors. Measuring ED and testosterone status may serve as an important male health indicator predicting subsequent CVD-related events and mortality and TTh may be an effective add-on treatment in secondary prevention of cardiovascular events in hypogonadal men with a history of CVD.	[Alwani, Mustafa] Jordan Univ Sci & Technol, Sch Med, Irbid, Jordan; [Alwani, Mustafa; Yassin, Aksam; Talib, Raidh; Al-Qudimat, Ahmad; Aboumarzouk, Omar; Al-Zoubi, Raed M.; Al Ansari, Abdulla] Hamad Med Corp, Dept Surg, Div Urol Androl, Doha, Qatar; [Alwani, Mustafa; Yassin, Aksam; Talib, Raidh; Al-Qudimat, Ahmad; Aboumarzouk, Omar; Al-Zoubi, Raed M.; Al Ansari, Abdulla] Hamad Med Corp, Dept Surg, Sect Surg Res, Doha, Qatar; [Yassin, Aksam] Weill Cornell Med Coll, New York, NY USA; [Yassin, Aksam] Weill Cornell Med Coll, Doha, Qatar; [Al-Zoubi, Raed M.] Jordan Univ Sci & Technol, Dept Chem, Irbid, Jordan; [Saad, Farid] Dresden Int Univ, Ctr Med & Hlth Sci, Dresden, Germany; [Haider, Karim S.] Klinikum Bremen Mitte, Dept Urol, Bremen, Germany		Yassin, A (通讯作者)，Rathausallee 94 A, D-22846 Norderstedt Hamburg, Germany.	yassin@t-online.de	ALWANI, MUSTAFA/AAM-5986-2021	Al-Qudimat, Ahmad R./0000-0003-1161-7244			Almehmadi Y, 2015, AGING MALE, V18, P186, DOI 10.3109/13685538.2015.1046044; Bosco C, 2015, EUR UROL, V68, P386, DOI 10.1016/j.eururo.2014.11.039; Cappelleri JC, 1999, UROLOGY, V54, P346, DOI 10.1016/S0090-4295(99)00099-0; Cornoldi A, 2010, INT J CARDIOL, V142, P50, DOI 10.1016/j.ijcard.2008.12.107; Corona G, 2014, ANDROLOGY-US, V2, P741, DOI 10.1111/j.2047-2927.2014.00241.x; Corona G, 2014, EXPERT OPIN DRUG SAF, V13, P1327, DOI 10.1517/14740338.2014.950653; Corona G, 2011, J SEX MED, V8, P2098, DOI 10.1111/j.1743-6109.2011.02292.x; Corona G, 2010, J SEX MED, V7, P1557, DOI 10.1111/j.1743-6109.2009.01690.x; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Feldman HA, 2000, PREV MED, V30, P328, DOI 10.1006/pmed.2000.0643; Gandaglia G, 2014, EUR UROL, V65, P968, DOI 10.1016/j.eururo.2013.08.023; Gazzaruso C, 2004, CIRCULATION, V110, P22, DOI 10.1161/01.CIR.0000133278.81226.C9; Giltay EJ, 2010, J SEX MED, V7, P2572, DOI 10.1111/j.1743-6109.2010.01859.x; Hackett G, 2020, WORLD J MENS HEALTH, V38, P68, DOI 10.5534/wjmh.180052M; Hackett G, 2013, J SEX MED, V10, P1612, DOI 10.1111/jsm.12146; Heufelder AE, 2009, J ANDROL, V30, P726, DOI 10.2164/jandrol.108.007005; Hodges LD, 2007, INT J CLIN PRACT, V61, P2019, DOI 10.1111/j.1742-1241.2007.01629.x; Hougaku H, 2006, AM J PHYSIOL-ENDOC M, V290, pE234, DOI 10.1152/ajpendo.00059.2005; Hoyos CM, 2012, EUR J ENDOCRINOL, V167, P531, DOI 10.1530/EJE-12-0525; Inman BA, 2009, MAYO CLIN PROC, V84, P108, DOI 10.4065/84.2.108; Isidori AM, 2014, EUR UROL, V65, P99, DOI 10.1016/j.eururo.2013.08.048; Jones TH, 2007, BRIT J HOSP MED, V68, P547, DOI 10.12968/hmed.2007.68.10.27326; Jones TH, 2010, TRENDS ENDOCRIN MET, V21, P496, DOI 10.1016/j.tem.2010.03.002; Jones TH, 2009, ATHEROSCLEROSIS, V207, P318, DOI 10.1016/j.atherosclerosis.2009.04.016; Kalinchenko SY, 2010, CLIN ENDOCRINOL, V73, P602, DOI 10.1111/j.1365-2265.2010.03845.x; Kapoor D, 2007, INT J ANDROL, V30, P500, DOI 10.1111/j.1365-2605.2007.00744.x; Kapoor D, 2006, EUR J ENDOCRINOL, V154, P899, DOI 10.1530/eje.1.02166; Kelly DM, 2013, J ENDOCRINOL, V217, pR47, DOI 10.1530/JOE-12-0582; Livingston M, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12995; Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069; Malkin CJ, 2004, HEART, V90, P871, DOI 10.1136/hrt.2003.021121; Mathur A, 2009, EUR J ENDOCRINOL, V161, P443, DOI 10.1530/EJE-09-0092; Mazzola CR, 2012, ASIAN J ANDROL, V14, P198, DOI 10.1038/aja.2011.106; Montorsi F, 2003, EUR UROL, V44, P360, DOI 10.1016/S0302-2838(03)00305-1; Montorsi P, 2006, EUR HEART J, V27, P2632, DOI 10.1093/eurheartj/ehl142; Montorsi P, 2006, EUR UROL, V50, P721, DOI 10.1016/j.eururo.2006.07.015; Muraleedharan V, 2013, EUR J ENDOCRINOL, V169, P725, DOI 10.1530/EJE-13-0321; Permpongkosol S, 2016, J SEX MED, V13, P1199, DOI 10.1016/j.jsxm.2016.06.003; Ponholzer A, 2005, EUR UROL, V48, P512, DOI 10.1016/j.eururo.2005.05.014; Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857; Saad F, 2016, INT J OBESITY, V40, P162, DOI 10.1038/ijo.2015.139; Saad F, 2008, J ANDROL, V29, P102, DOI 10.2164/jandrol.107.002774; Saad F, 2020, AGING MALE, V23, P81, DOI 10.1080/13685538.2019.1575354; Saad F, 2013, OBESITY, V21, P1975, DOI 10.1002/oby.20407; Sai Ravi Shanker A, 2013, Indian Heart J, V65, P180, DOI 10.1016/j.ihj.2013.02.013; Sesti F, 2020, ANDROLOGY-US, V8, P1614, DOI 10.1111/andr.12876; Shores MM, 2006, ARCH INTERN MED, V166, P1660, DOI 10.1001/archinte.166.15.1660; Solomon H, 2003, HEART, V89, P251, DOI 10.1136/heart.89.3.251; Svartberg J, 2004, EUR J ENDOCRINOL, V150, P65, DOI 10.1530/eje.0.1500065; Traish AM, 2017, J CARDIOVASC PHARM T, V22, P414, DOI 10.1177/1074248417691136; Wu FCW, 2010, NEW ENGL J MED, V363, P123, DOI 10.1056/NEJMoa0911101; Yassin A, 2016, AGING MALE, V19, P64, DOI 10.3109/13685538.2015.1126573; Yassin A, 2016, CLIN ENDOCRINOL, V84, P107, DOI 10.1111/cen.12936; Yassin AA, 2015, ARAB J UROL, V13, P162, DOI 10.1016/j.aju.2015.06.003; Zarotsky V, 2014, ANDROLOGY-US, V2, P819, DOI 10.1111/andr.274	56	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						497	508		10.2147/VHRM.5309714			12	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UE7GA	WOS:000688051100001	34465997				2022-04-27	
J	Bruce, C; Achan, V; Rathore, S				Bruce, Charo; Achan, Vinod; Rathore, Sudhir			Yoga-Based Cardiac Rehabilitation: Current Perspectives from Randomized Controlled Trials in Coronary Artery Disease	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						yoga; cardiac rehabilitation; coronary artery disease		Coronary artery disease carries a high morbidity and mortality worldwide, and exercise-based cardiac rehabilitation programmes play a large role in secondary prevention. Exercise-based rehabilitation programmes are expensive, and in certain subgroups uptake is poor. Yoga has been suggested to show improvements in cardiovascular health which would support its use in cardiac rehabilitation programmes. We carried out a review of current randomized controlled trials to determine if yoga-based cardiac rehabilitation leads to reduced cardiac risk factors, and improved physiological and psychological outcomes in patients with coronary artery disease compared to standard care. Six randomized controlled studies were identified after a medical database search, and meta-analysis was carried out for the different outcomes. Overall, the addition of yoga to standard care resulted in improved subjective feeling of cardiac health and quality of life. There was also a trend towards improvement in left ventricular systolic function. Improvement in cardiac risk factors, MACE and psychological health in this cohort has still to be proven, but was not inferior to standard or enhanced care, and the benefits became more pronounced at longer follow-up. Future studies with longer follow-up and larger patient numbers would aid in accurately assessing the long-term benefit of yoga-based rehabilitation.	[Bruce, Charo; Achan, Vinod; Rathore, Sudhir] Frimley Pk Hosp, Dept Cardiol, Frimley GU16 7UJ, Surrey, England		Rathore, S (通讯作者)，Frimley Pk Hosp, Dept Cardiol, Frimley GU16 7UJ, Surrey, England.	Sudhir.rathore@nhs.net					BHF, 2020, HEART CIRC DIS STAT; Christa Edmin, 2019, Int J Yoga Therap, V29, P43, DOI 10.17761/2019-00019; Chu P, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002737; Cramer H, 2014, INT J CARDIOL, V173, P170, DOI 10.1016/j.ijcard.2014.02.017; Cramer H, 2013, DEPRESS ANXIETY, V30, P1068, DOI 10.1002/da.22166; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Germano G, 2012, EUR HEART J, V33, P137; Gomes-Neto M, 2014, ARQ BRAS CARDIOL, V103, P433, DOI 10.5935/abc.20140149; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub2, 10.1002/14651858.CD001800.pub3]; Nagarathna R, 2020, INT J YOGA, V13, P89, DOI 10.4103/ijoy.IJOY_22_20; Organisation WH, 2021, CARD DIS KEY FACTS; Prabhakaran D, 2020, J AM COLL CARDIOL, V75, P1551, DOI 10.1016/j.jacc.2020.01.050; Raghuram Nagarathna, 2014, Indian Heart J, V66, P490, DOI 10.1016/j.ihj.2014.08.007; Ragupathi L, 2017, GLOB HEART, V12, P323, DOI 10.1016/j.gheart.2016.09.004; Ranjita R, 2016, J AYURVEDA INTEGR ME, V7, P158, DOI 10.1016/j.jaim.2015.12.001; Sharma KNS, 2020, J ALTERN COMPLEM MED, V26, P918, DOI 10.1089/acm.2019.0250; Supervia M, 2019, ECLINICALMEDICINE, V13, P46, DOI 10.1016/j.eclinm.2019.06.006; Thomas RJ, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/HCQ.0000000000000037; Tillin T, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030119; Yadav Raj Kumar, 2015, Int J Yoga, V8, P68	20	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						779	789		10.2147/VHRM.S286928			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XN6KR	WOS:000729612000002	34880621	Green Published, gold			2022-04-27	
J	Gedamu, DK; Sisay, W				Gedamu, Demlie Kassa; Sisay, Wullo			Prevalence of Hypertension and Associated Factors Among Public Servants in North Wollo Zone, Amhara Region, Ethiopia, 2020	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						prevalence of hypertension; high blood pressure	HIGH BLOOD-PRESSURE; GENDER; ADULTS; GHANA	Background: The leading preventable risk factor for premature death and disability worldwide is hypertension. Globally, 31.1% of adults (1.39 billion people) have hypertension and 9.4 million deaths are recorded annually, accounting for 13% of overall mortality. Objective: The objective of this study is to assess the prevalence of hypertension and associated factors among public servants in North Wollo Zone, Amhara Region, Ethiopia. Materials and Methods: An institutional-based cross-sectional study was conducted among 627 public servants. To classify candidate variables for multivariable logistic regression, a binary logistic regression model was applied. In order to analyze factors associated with hypertension among participants, all variables with a P-value<0.2 were entered into the multivariable logistic regression model. In order to determine statistical significance, a p value of less than 0.05 was taken. The assumptions of Chi square and multi-collinearity were verified. For model fitness, the Hosmer-Lemeshow goodness-of-fit was checked. Results: The total hypertension rate was 27.6% (95% CI: 24.1-31.3). The prevalence was higher in males 129 (32.5%) than in females 444 (19.1%). History of diabetes mellitus (AOR= 9.64, 95% CI: 3.20-29.30), age >35 years (AOR= 2.94, 95% CI: 1.91-4.51) and body mass index 25 kg/m(2) and above (AOR= 3.44, 95% CI: 2.21-5.34) have been found to be separately associated with hypertension. Conclusion and Recommendation: Among public servants in the study setting (study area), hypertension has become a major public health issue. Half of the newly reported cases is hypertensive. The conclusion of this study calls for a more holistic approach to hypertension in terms of hypertension prevention, screening, and proper management.	[Gedamu, Demlie Kassa] Amhara Reg Hlth Bur, Dept Publ Hlth Emergency Management, Woldia, Ethiopia; [Sisay, Wullo] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, POB 196, Gondar, Ethiopia		Sisay, W (通讯作者)，Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, POB 196, Gondar, Ethiopia.	wsisay2733@gmail.com					Abebe SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125210; Agyemang C, 2006, PUBLIC HEALTH, V120, P525, DOI 10.1016/j.puhe.2006.02.002; Amoah AGB, 2003, ETHNIC DIS, V13, P310; Angaw K, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0062-9; Asresahegn Henok, 2017, BMC Res Notes, V10, P629, DOI 10.1186/s13104-017-2966-1; Astrup A, 2001, Public Health Nutr, V4, P499; Astuti A, 2015, J HYPERTENS, V33, pE18, DOI 10.1097/01.hjh.0000469780.63844.0f; Awoke A, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-113; Bell K., 2015, ALABAMA PHARM ASS, V334, P4222; Bissa S, 2014, WORLD J MED MEDICAL, V2, P01; Chan M, 2013, GLOBAL BRIEF HYPERTE; Cheung BMY, 2012, CURR ATHEROSCLER REP, V14, P160, DOI 10.1007/s11883-012-0227-2; Demisse AG, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4646-4; Doumas M, 2013, CURR HYPERTENS REP, V15, P321, DOI 10.1007/s11906-013-0359-y; Fava C, 2013, HYPERTENSION, V61, P319, DOI 10.1161/HYPERTENSIONAHA.112.202655; Garland T, 2011, J EXP BIOL, V214, P206, DOI 10.1242/jeb.048397; Gebreselassie KZ, 2015, INT J HYPERTENS, V2015, DOI 10.1155/2015/959256; Gebrihet TA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176904; Helelo TP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112790; Karstad MH, 2008, PERCEPTIONS HLTH EAT; Kayima J, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-54; Li YC, 2011, ADDICTION, V106, P1946, DOI 10.1111/j.1360-0443.2011.03514.x; Mensah GA, 2008, HEART, V94, P697, DOI 10.1136/hrt.2007.127753; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Mittal BV, 2010, AM J KIDNEY DIS, V55, P590, DOI 10.1053/j.ajkd.2009.06.044; Nielsen GA, 2003, PREV MED, V36, P229, DOI 10.1016/S0091-7435(02)00017-8; Noubiap JJ, 2019, HEART, V105, P98, DOI 10.1136/heartjnl-2018-313599; Ogah OS, 2006, ETHNIC DIS, V16, P765; PEARSON AC, 1994, AM HEART J, V128, P344, DOI 10.1016/0002-8703(94)90488-X; Siani A, 2002, AM J HYPERTENS, V15, P780, DOI 10.1016/S0895-7061(02)02976-X; Siu AL, 2015, ANN INTERN MED, V163, P778, DOI 10.7326/M15-2223; Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585; Undavalli VK, 2018, INT J COMMUNITY MED, V5, P1366, DOI DOI 10.18203/2394-6040.IJCMPH20180974; Warren TY, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110170	34	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						363	370		10.2147/VHRM.S298138			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD6WU	WOS:000669465400001	34188478	Green Published, gold			2022-04-27	
J	Al-Zoubi, NA; Shatnawi, NJ; Bakkar, L; Al-Sabah, M				Al-Zoubi, Nabil A.; Shatnawi, Nawaf J.; Bakkar, Lujain; Al-Sabah, Mohammad			Endovascular Treatment for Critical Limb Ischemia in Type II Diabetes Mellitus Involving Femoropopliteal and Infrapopliteal Segments: Revascularization Strategy	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						femoropopliteal; crural vessels; endovascular therapy	VASCULAR-DISEASE; ARTERY; ANGIOPLASTY; OUTCOMES	Purpose: To determine if further endovascular infrapopliteal angioplasty in combination with femoropopliteal revascularization improves the clinical outcomes regarding major amputation rate, rate of secondary interventions, and mortality in diabetic type-II patients presented with critical lower limb ischemia (CLI). Patients and Methods: This is a retrospective study in which all type-II diabetic patients with CLI at King Abdullah University Hospital between October 2015 and September 2019 were identified. Patients with concomitant femoropopliteal and infrapopliteal vessels athero-sclerotic lesions (total occlusion or more than 50% stenosis) who received successful endovascular treatment were included. Patients were divided into 2 groups. Group-I included patients treated for femoropopliteal segment alone, while Group-II included patients treated for both femoropopliteal and infrapopliteal segments. The outcomes of the two groups were compared regarding major amputation rate, rate of secondary interventions, and mortality. In addition, demographic data, atherosclerotic lesions distributions and cardiovascular risk factors were also collected and analyzed. Results: In all, 90 patients (65 males and 25 females) with a mean age of 67.5 +/- 12 years were included. In Group-I; 44 patients (48.9%) were included (36 males and 8 females) with a mean age of 67 +/- 12 years. In group-II; 46 patients (51.1%) were included (29 males and 17 females) with a mean age of 68 +/- 13 years. The major amputation rate was higher and statistically significant in Group-I (38.6% vs 17.4%, p-value = 0.034). However, the second-ary interventions and the mortality rates showed no statistically significant differences (56.8% vs 39.1%, p-value = 0.139) and (22.7% vs 28.3%, p-value = 0.632), respectively. Conclusion: Endovascular infrapopliteal angioplasty in combination with femoropopliteal revascularization in diabetic type-II patients with CLI improves the clinical outcome regard-ing major amputation rate. However, there were no significant differences regarding the rate of secondary interventions and the mortality rate.	[Al-Zoubi, Nabil A.; Shatnawi, Nawaf J.; Bakkar, Lujain; Al-Sabah, Mohammad] Jordan Univ Sci & Technol, Dept Surg, Vasc Surg, Irbid 22110, Jordan		Al-Zoubi, NA (通讯作者)，Jordan Univ Sci & Technol, Dept Surg, Vasc Surg, Irbid 22110, Jordan.	dr_nabeil_z3bi@yahoo.com		Alsabah, Mohamed/0000-0003-0397-7936			Aiello A, 2014, NUTR METAB CARDIOVAS, V24, P355, DOI 10.1016/j.numecd.2013.12.007; Biagioni RB, 2018, EUR J VASC ENDOVASC, V55, P518, DOI 10.1016/j.ejvs.2017.12.022; Brooke BS, 2014, ANN VASC SURG, V28, P1719, DOI 10.1016/j.avsg.2014.05.009; Conte MS., 2019, J VASC SURG, V6, P125; Darling JD, 2018, J VASC SURG, V67, P1159, DOI 10.1016/j.jvs.2017.06.119; Faglia E, 2005, EUR J VASC ENDOVASC, V29, P620, DOI 10.1016/j.ejvs.2005.02.035; Freisinger E, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0524-8; Gamal WM, 2015, GLOB SURG, V1, P37, DOI [10.15761/GOS.1000114, DOI 10.15761/GOS.1000114]; Giannopoulos S, 2020, EXPERT REV CARDIOVAS, V18, P131, DOI 10.1080/14779072.2020.1736562; Gutierrez M, 2020, VASC DIS MANAGE, V17, P150; Huizing E, 2019, J VASC INTERV RADIOL, V30, P1361, DOI 10.1016/j.jvir.2019.05.001; Jongsma H, 2017, J VASC SURG, V65, P1208, DOI 10.1016/j.jvs.2016.10.100; Katsanos K, 2014, CARDIOVASC INTER RAD, V37, P592, DOI 10.1007/s00270-014-0876-3; Kim J, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e178; Lofberg AM, 2001, J VASC SURG, V34, P114, DOI 10.1067/mva.2001.113486; Luscher TF, 2003, CIRCULATION, V108, P1655, DOI 10.1161/01.CIR.0000089189.70578.E2; Morris-Stiff G, 2011, ANN ROY COLL SURG, V93, P250, DOI 10.1308/147870811X566394; Morris-Stiff G, 2011, ANN ROY COLL SURG, V93, P306, DOI 10.1308/003588411X571999; Motsumi MJ, 2017, S AFR J SURG, V55, P48; Mustapha JA., 2015, INTERV CARDIOL, V7, DOI [10.2217/ ica.15.33, DOI 10.2217/ICA.15.33]; Ozkan U, 2009, J VASC INTERV RADIOL, V20, P437, DOI 10.1016/j.jvir.2009.01.010; Shaker M., 2019, OPEN J CLIN MED CASE, V5, P1572; Soares RD, 2016, J VASC SURG, V64, P1344, DOI 10.1016/j.jvs.2016.04.020; Sobieszczyk P, 2013, CIRCULATION, V128, P749, DOI 10.1161/CIRCULATIONAHA.113.001560; Thiruvoipati T, 2015, WORLD J DIABETES, V6, P961, DOI 10.4239/wjd.v6.i7.961; Uccioli L, 2018, VASC HEALTH RISK MAN, V14, P63, DOI 10.2147/VHRM.S125065	26	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						69	76		10.2147/VHRM.S298435			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	YZ0JW	WOS:000755170700001	33692625	gold, Green Published			2022-04-27	
J	Chaulin, A				Chaulin, Aleksey			The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis (vol 17, pg 601, 2021)	VASCULAR HEALTH AND RISK MANAGEMENT			English	Correction													Chaulin, Aleksey M./F-1229-2019	Chaulin, Aleksey M./0000-0002-2712-0227			Chauin A, 2021, VASC HEALTH RISK MAN, V17, P601, DOI 10.2147/VHRM.S327661	1	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						659	659		10.2147/VHRM.S342979			1	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WM8NB	WOS:000711334700001		Green Published			2022-04-27	
J	Ahmed, HM; Ameen, EE; Awad, MS; Botrous, OE				Ahmed, Heba Mostafa; Ameen, Emad El-Deen; Awad, Mohammad Shafiq; Botrous, Osama Ezzat			Assessment of Carotid Intima Media Thickness and Left Ventricular Mass Index in Children with Idiopathic Nephrotic Syndrome	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						nephrotic syndrome; children; left ventricular hypertrophy; carotid intima media thickness; dyslipidemia	ENDOTHELIAL DYSFUNCTION; RISK-FACTORS; ATHEROSCLEROSIS; INFLAMMATION; DILATATION	Background: Children with nephrotic syndrome (NS) are at a greater risk of atherosclerosis due to recurrent exposures to hyperlipidemia, hypertension, and immunosuppressive medications. CIMT (carotid intima media thickness) is a reliable marker for assessment of atherosclerosis of large and medium-sized blood vessels; endothelial dysfunction and increased CIMT usually precede the development of cardiovascular diseases. Some manifestations of NS, like proteinuria and hyperlipidemia, are associated with an increased risk of cardiac morbidity and mortality. The aim of the current study was to evaluate the carotid intima media thickness and LVM (left ventricular mass) thickness in children with nephrotic syndrome. Subjects and Methods: Eighty-one children with nephrotic syndrome and 100 healthy children as controls were enrolled in the study. The inclusion criteria were: disease duration of minimum of 12 months, glomerular filtration rate >60mL/min/1.73m(2) and children aged two years or more at the time of study. CIMT and left ventricular mass index, lipid profile, protein/creatinine ratio in urine and kidney function tests were done for cases and controls after approval of internal ethical committee. Results: The mean CIMT (mm) was significantly higher in NS (0.51 +/- 0.12) compared to controls (0.42 +/- 0.09) (P <0.001). LVM and LVM Index were significantly higher in NS than controls (p< 0.001, for both). Subsequently, CIMT was significantly correlated to duration of the disease (p< 0.001), LVM index was significantly correlated with duration of the disease, body mass index (BMI), blood pressures and triglycerides level (p< 0.05). Conclusion: Children with NS are at increasing risk to develop atherosclerosis as measured by CIMT. LVM was significantly higher in NS and positively correlated to BP, disease duration, triglyceride levels and BMI.	[Ahmed, Heba Mostafa; Ameen, Emad El-Deen; Botrous, Osama Ezzat] Beni Suef Univ, Fac Med, Dept Pediat, Bani Suwayf, Egypt; [Awad, Mohammad Shafiq] Beni Suef Univ, Fac Med, Dept Cardiol, Bani Suwayf, Egypt		Ahmed, HM (通讯作者)，Beni Suef Univ, Fac Med, Dept Pediat, Bani Suwayf, Egypt.	heba_most@yahoo.com	Ahmed, Heba Mostafa/T-1277-2018	Ahmed, Heba Mostafa/0000-0002-8086-3759; Shafiq, Mohammad/0000-0003-1506-9185			Adhikari MC, 2012, SEMIN ARTHRITIS RHEU, V41, P669, DOI 10.1016/j.semarthrit.2011.08.003; Birjmohun RS, 2007, ARTERIOSCL THROM VAS, V27, P1153, DOI 10.1161/ATVBAHA.106.136325; Candan C, 2014, PEDIATR NEPHROL, V29, P95, DOI 10.1007/s00467-013-2608-3; Chaubey S, 2017, J PEDIAT REV, V4, P91; Serra JD, 2009, AN PEDIATR, V70, P349, DOI 10.1016/j.anpedi.2008.11.017; Dogra GK, 2002, NEPHROL DIAL TRANSPL, V17, P2220, DOI 10.1093/ndt/17.12.2220; El-Mashad GM, 2016, J PEDIAT RIO J, V16, P237; Frishberg Y, 2006, J AM SOC NEPHROL, V17, P227, DOI 10.1681/ASN.2005060653; Hooman N, 2013, NEFROLOGIA, V33, P650, DOI 10.3265/Nefrologia.pre2013.May.12036; Ishikura K, 2015, CLIN EXP NEPHROL, V19, P6, DOI 10.1007/s10157-014-1030-x; Kniazewska MH, 2009, PEDIATR NEPHROL, V24, P549, DOI 10.1007/s00467-008-1029-1; Kuzma-Mroczkowska Elzbieta, 2016, Dev Period Med, V20, P16; Mehta Anita, 2019, Sudan J Paediatr, V19, P110, DOI 10.24911/SJP.106-1535804613; Mitsnefes M, 2010, J AM SOC NEPHROL, V21, P137, DOI 10.1681/ASN.2009060609; Nakamura A, 2010, CLIN EXP NEPHROL, V14, P457, DOI 10.1007/s10157-010-0317-9; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Rahul I, 2015, CLIN EXP NEPHROL, V19, P125, DOI 10.1007/s10157-014-0958-1; Safaei A, 2009, Indian J Nephrol, V19, P87, DOI 10.4103/0971-4065.57103; Schillaci G, 2001, J HYPERTENS, V19, P2265, DOI 10.1097/00004872-200112000-00021; Srivastava RN, 2005, NEPHROTIC SYNDROME, P161; Szeto CC, 2007, J AM SOC NEPHROL, V18, P1966, DOI 10.1681/ASN.2006101184; Tkaczyk M, 2008, AM J NEPHROL, V28, P197, DOI 10.1159/000110088; Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145; Valavi E, 2020, J PEDIAT-BRAZIL, V96, P117, DOI [10.1016/j.jped.2018.07.014, 10.1016/j.ped.2018.07.014]; Vaziri ND, 2001, AM J PHYSIOL-RENAL, V280, pF823, DOI 10.1152/ajprenal.2001.280.5.F823; Yousser DM, 2018, IRAN J KIDNEY DIS, V12, P331; Zhang QY, 2012, NEPHROLOGY, V17, P338, DOI 10.1111/j.1440-1797.2012.01575.x	27	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						349	356		10.2147/VHRM.S295868			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD6RN	WOS:000669451700001	34140775	gold, Green Published			2022-04-27	
J	Nurcahyo, WI; Arifin, A; Primatika, AD; Muttaqin, Z; Boom, CE; Harahap, MS; Mochamat, M; Nugroho, TE; Wicaksono, SA				Nurcahyo, Widya Istanto; Arifin, Anshoril; Primatika, Aria Dian; Muttaqin, Zainal; Boom, Cindy Elfira; Harahap, M. Sofyan; Mochamat, Mochamat; Nugroho, Taufik Eko; Wicaksono, Satrio Adi			An Association Between C-Reactive Protein Levels and the Occurrence of Cognitive Dysfunction After Heart Valve Replacement	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						C-reactive protein; cardiac surgical procedure; cognition disorders; cognitive dysfunction; heart valves; postoperative complication	CARDIAC-SURGERY; NEUROINFLAMMATION; DECLINE	Background: Postoperative cognitive dysfunction (POCD) is defined as cognitive dysfunction related to inflammation after surgical procedures, which is common following cardiac surgery. Cognitive deficits are thought to result from a systemic inflammatory response. C-reactive protein (CRP) and other proinflammatory cytokines, which are released in response to inflammation, disrupt the blood-brain barrier and neurotransmission, resulting in POCD. This study aimed to determine the correlation between POCD and increased levels of CRP in patients who had undergone heart valve replacement. Methods: This study comprised 32 patients with normal cognitive function undergoing heart valve replacement. The CRP levels were measured before surgery and on the second postoperative day, and cognitive function was examined via the Indonesian-adapted Montreal Cognitive Assessment (MOCA-INA) on the third postoperative day. Data were analyzed using Spearman correlation test. Results: Of the 32 patients, 28 (87.5%) experienced POCD. The median level of CRP was 6.6 mg/dL (interquartile range: 4.0, 8.3 g/dL). According to Spearman correlation test, increased levels of CRP were significantly related to POCD following heart valve replacement (p = 0.003, r = 0.501). The receiver operating characteristic curve indicated that the CRP cutoff level was 3.345 mg/dL, and the sensitivity and specificity were 89.3% and 75%, respectively. Conclusion: High expression level of CRP was correlated with POCD following heart valve replacement.	[Nurcahyo, Widya Istanto; Arifin, Anshoril; Primatika, Aria Dian; Harahap, M. Sofyan; Mochamat, Mochamat; Nugroho, Taufik Eko; Wicaksono, Satrio Adi] Diponegoro Univ, Dept Anesthesiol & Intens Care, Fac Med, Dr Kariadi Gen Hosp, Semarang City, Central Java Pr, Indonesia; [Muttaqin, Zainal] Diponegoro Univ, Fac Med, Dept Neurosurg, Dr Kariadi Gen Hosp, Semarang City, Central Java Pr, Indonesia; [Boom, Cindy Elfira] Harapan Kita Hosp, Cardiovasc Ctr, Dept Anesthesiol & Intens Care, Jakarta, Indonesia		Nurcahyo, WI (通讯作者)，Diponegoro Univ, Dept Anesthesiol & Intens Care, Fac Med, Dr Kariadi Gen Hosp, Semarang City, Central Java Pr, Indonesia.	widya_istanto2@yahoo.com		Muttaqin, Zainal/0000-0002-9054-1809			Akbar Novita Linda, 2019, Open Access Maced J Med Sci, V7, P1762, DOI 10.3889/oamjms.2019.461; Amiri M, 2017, RES CARDIOVASC MED, V6, P5, DOI [10.5812/cardiovascmed.37284, DOI 10.5812/CARDIOVASCMED.37284]; Androsova G, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00112; Chung E, 2015, CARDIOVASC PSYCHIAT, V2015, P1, DOI 10.1155/2015/370612; Czyz-Szypenbejl K, 2019, PSYCHIATR POL, V53, P145, DOI 10.12740/PP/90648; Dong YH, 2010, J NEUROL SCI, V299, P15, DOI 10.1016/j.jns.2010.08.051; Feinkohl I, 2017, DTSCH ARZTEBL INT, V114, P110, DOI 10.3238/arztebl.2017.0110; Glumac S, 2019, MED SCI MONITOR, V25, P3262, DOI 10.12659/MSM.914435; Glumac S, 2017, EUR J ANAESTH, V34, P776, DOI 10.1097/EJA.0000000000000647; Hovens IB, 2016, BRAIN BEHAV IMMUN, V54, P178, DOI 10.1016/j.bbi.2016.02.003; Hudetz JA, 2011, J ANESTH, V25, P1, DOI 10.1007/s00540-010-1042-y; Husein N., 2010, NEURONA, V27, P15; Knipp SC, 2017, INTERACT CARDIOV TH, V24, P534, DOI 10.1093/icvts/ivw421; Li X, 2013, HEPATOB PANCREAT DIS, V12, P370, DOI 10.1016/S1499-3872(13)60058-2; Liu XB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207705; Medrzycka-Dabrowska W, 2016, NEUROL NEUROCHIR POL, V50, P163, DOI 10.1016/j.pjnns.2016.02.004; Neumaier M, 2006, ACTA ORTHOP, V77, P788, DOI 10.1080/17453670610013006; Oldham MA, 2018, J AM GERIATR SOC, V66, P2327, DOI 10.1111/jgs.15601; Oliveira FR, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0481-0; Ozturk S, 2016, ANATOL J CARDIOL, V16, P875, DOI 10.14744/AnatolJCardiol.2015.6572; Pappa Maria, 2017, Electron Physician, V9, P3768, DOI 10.19082/3768; Rundshagen I, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0119; Safavynia SA, 2019, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00752; Scott David A, 2014, J Extra Corpor Technol, V46, P15; Sun YT, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20190719; Tan AMY, 2013, BJA EDUC, V13, P218, DOI 10.1093/bjaceaccp/mkt022; Tao H, 2014, MED SCI MONITOR, V20, P1902, DOI [10.12659/MSM.892271, 10.12659/MSM.892485]; Toner AJ, 2017, ANESTHESIOLOGY, V126, P234, DOI 10.1097/ALN.0000000000001466; van Harten AE, 2012, ANAESTHESIA, V67, P280, DOI 10.1111/j.1365-2044.2011.07008.x; Vide S, 2018, PRESSE MED, V47, pE65, DOI 10.1016/j.lpm.2018.03.010; World Health Organization, 2014, VMNIS, P1; Xu T, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-204; Yang GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078355; Zhang Y, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-018-0676-4; Zimpfer D, 2002, ANN THORAC SURG, V74, P407, DOI 10.1016/S0003-4975(02)03651-2	35	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						713	720		10.2147/VHRM.S334982			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XO1RN	WOS:000729970400001	34824534	Green Published, gold			2022-04-27	
J	Al Smady, MN; Zaki, MN; Alataywi, E; Jegaden, O				Al Smady, Montaser Nabeeh; Zaki, Mohammed Nagdi; Alataywi, Eman; Jegaden, Olivier			Impact of Bilateral versus Single Internal Thoracic Artery Grafting on the Long-Term Survival in Adults: A Systematic Review	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						coronary artery bypass grafting; coronary artery disease; internal thoracic artery; arterial revascularization; multiple arterial grafts	MULTIPLE-ARTERIAL; RANDOMIZED-TRIAL	Objective: To analyse the survival of patients who had undergone bilateral internal thoracic artery grafting versus those with single internal thoracic artery grafting from the available literature. Moreover, this study will review the available literature regarding which of the two techniques seems to be the safest with long-term survival and reduced mortality rates. Methods: A literature search of the databases was conducted to retrieve studies that fall under the study design of cohort and randomized controlled clinical trials in English from January 2015 to July 2021. Finally, seven studies were selected: four cohort studies and three other from a randomized trial. Results: The cohort studies revealed that bilateral internal thoracic artery grafting is associated with lower mortality rates and better long-term survival outcomes than single internal thoracic artery grafting, while the ART randomized controlled clinical trials showed that there is no significant difference in mortality rates between both the coronary artery bypass grafting techniques. However, all studies concluded that bilateral internal thoracic artery grafting is associated with a higher frequency of deep sternal wound infections. Conclusion: The discrepancy in results between the cohort studies and randomized controlled clinical trial remains persistent. However, the stated advantages of bilateral internal thoracic artery grafting are not strong enough to convince surgeons to alter their practice and the wide magnitude of expectations from the ART study was reckoned as inadequate. This may well be due to the presence of limited criteria for bilateral internal thoracic artery grafting in identifying the impact on survival of extended arterial revascularization, and there is a new colossal expectation from the ongoing randomized trial based on multiple arterial grafting versus single arterial grafting.	[Al Smady, Montaser Nabeeh; Zaki, Mohammed Nagdi; Alataywi, Eman] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates; [Jegaden, Olivier] Airport Rd Hosp, Mediclin, Cardiothorac Surg Dept, Abu Dhabi, U Arab Emirates		Al Smady, MN (通讯作者)，Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.; Jegaden, O (通讯作者)，Airport Rd Hosp, Mediclin, Cardiothorac Surg Dept, Abu Dhabi, U Arab Emirates.	Montaseralsmadi@gmail.com; olivier.jegaden@mediclinic.ae		Zaki, Mohammed/0000-0001-9705-2584; Al Smady, Montaser/0000-0003-0101-6007			Cuminetti G, 2017, NETH HEART J, V25, P4, DOI 10.1007/s12471-016-0919-2; DeSimone JP, 2018, ANN THORAC SURG, V106, P466, DOI 10.1016/j.athoracsur.2018.01.089; Ejiofor JI, 2018, SEMIN THORAC CARDIOV, V30, P398, DOI 10.1053/j.semtcvs.2018.05.004; Gaudino M, 2018, NEW ENGL J MED, V378, P2069, DOI 10.1056/NEJMoa1716026; Gaudino M, 2017, EUR J CARDIO-THORAC, V52, P1031, DOI 10.1093/ejcts/ezx358; Jegaden OJL, 2021, J CARDIOTHORAC SURG, V16, DOI 10.1186/s13019-020-01384-9; Kurlansky PA, 2015, ANN THORAC SURG, V100, P1374, DOI 10.1016/j.athoracsur.2015.04.019; Lu JCY, 2003, EUR J CARDIO-THORAC, V23, P943, DOI 10.1016/S1010-7940(03)00137-4; Marasco S., 2016, OPERATIVE TECH THORA, V21, P20, DOI [10.1053/j.optechstcvs.20 16.08.002, DOI 10.1053/J.OPTECHSTCVS.2016.08.002]; Melly L, 2018, J THORAC DIS, V10, P1960, DOI 10.21037/jtd.2018.02.43; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Pevni D, 2017, ANN THORAC SURG, V103, P551, DOI 10.1016/j.athoracsur.2016.06.044; Puskas JD, 2012, ANN THORAC SURG, V94, P710, DOI 10.1016/j.athoracsur.2012.03.082; Rubino AS, 2018, ANN THORAC SURG, V105, P1717, DOI 10.1016/j.athoracsur.2017.11.079; Samadashvili Z, 2019, J AM COLL CARDIOL, V74, P1275, DOI 10.1016/j.jacc.2019.06.067; Schwann TA, 2018, ANN THORAC SURG, V105, P1109, DOI 10.1016/j.athoracsur.2017.10.058; Shi WY, 2015, J THORAC CARDIOV SUR, V150, P1526, DOI 10.1016/j.jtcvs.2015.05.074; Squiers JJ, 2018, ANN CARDIOTHORAC SUR, V7, P516, DOI 10.21037/acs.2018.05.13; Taggart David P, 2022, J Thorac Cardiovasc Surg, V163, P1002, DOI 10.1016/j.jtcvs.2020.03.013; Taggart DP, 2019, NEW ENGL J MED, V380, P437, DOI 10.1056/NEJMoa1808783; Taggart DP, 2016, NEW ENGL J MED, V375, P2540, DOI 10.1056/NEJMoa1610021; Taggart DP, 2010, EUR HEART J, V31, P2470, DOI 10.1093/eurheartj/ehq318	22	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						509	518		10.2147/VHRM.S32848			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UF3BK	WOS:000688451900001	34471357				2022-04-27	
J	Chowdhury, S; Alrawaji, F; Leenen, LPH				Chowdhury, Sharfuddin; Alrawaji, Fatmah; Leenen, Luke P. H.			Incidence and Nature of Lower-Limb Deep Vein Thrombosis in Patients with Polytrauma on Thromboprophylaxis: A Prospective Cohort Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						venous thromboembolism; deep vein thrombosis; pulmonary embolism; wounds and injuries; doppler ultrasonography; heparin	MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; ANTITHROMBOTIC THERAPY; TRAUMA PATIENTS; AMERICAN-COLLEGE; PREVENTION; INJURY; PROPHYLAXIS; GUIDELINES	Purpose: Deep vein thrombosis (DVT) is common among the severely injured and may lead to pulmonary embolism (PE), which can be life threatening. Thromboprophylaxis may reduce the incidence of venous thromboembolism (VTE); it does not guarantee complete protection. This study's primary aim was to determine the incidence and nature of lower-limb DVT in polytrauma patients taking prophylaxis. The secondary objective was to assess the incidence of DVT-related complications, including the development of PE and death. Patients and Methods: This prospective observational study included patients age 18 years or older who presented with polytrauma directly from the scene and were admitted into the trauma unit between March 1, 2020 and August 31, 2020. All patients underwent lowerlimb ultrasound during their hospital course to diagnose DVT. Results: A total of 169 patients underwent extremity Doppler ultrasound to detect DVT. Of these, 69 patients (40.8%) were considered at the highest-risk for VTE development. For VTE prophylaxis, 115 patients (68%) received pharmacologic agents, and 54 patients (32%) had intermittent pneumatic compression on admission. Three patients (1.8%) developed DVT despite prophylaxis. Four patients (2.4%) developed PE during the index presentation and were diagnosed between days 3 and 13 after injury. Early DVT was not detected in any patients with diagnosed PE. Overall, nine patients (5.33%) died, but no in-hospital deaths were related to DVT and/or PE. Conclusion: The incidence of DVT in polytrauma patients remains low in our small series, perhaps because of the mandatory VTE risk assessment for all hospitalized patients and the early initiation of prophylaxis. Using a trauma center registry to measure DVT and PE incidence regularly is recommended to improve trauma care quality.	[Chowdhury, Sharfuddin] King Saud Med City, Trauma Ctr, Riyadh, Saudi Arabia; [Alrawaji, Fatmah] King Saud Med City, Dept Gen Surg, Riyadh, Saudi Arabia; [Leenen, Luke P. H.] Univ Med Ctr Utrecht, Dept Trauma, Utrecht, Netherlands		Chowdhury, S (通讯作者)，King Saud Med City, Trauma Ctr, Riyadh, Saudi Arabia.	dr_smahmud@yahoo.com	Chowdhury, Sharfuddin/B-7324-2018	Chowdhury, Sharfuddin/0000-0002-3794-4158; Leenen, Luke/0000-0001-8385-1801			Al-Hameed FM, 2016, SAUDI MED J, V37, P1279, DOI 10.15537/smj.2016.11.15268; Allen CJ, 2016, J AM COLL SURGEONS, V222, P65, DOI 10.1016/j.jamcollsurg.2015.10.014; Barrera LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008303.pub2; Brakenridge SC, 2013, J TRAUMA ACUTE CARE, V74, P1231, DOI 10.1097/TA.0b013e31828cc9a0; Brakenridge SC, 2011, AM J SURG, V201, P209, DOI 10.1016/j.amjsurg.2009.12.005; Brill JB, 2017, J TRAUMA ACUTE CARE, V83, P413, DOI 10.1097/TA.0000000000001618; Chowdhury S, 2019, SAUDI MED J, V40, P266, DOI 10.15537/smj.2019.3.24005; Cipolle MD, 2002, J TRAUMA, V52, P453, DOI 10.1097/00005373-200203000-00007; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; DeYoung E, 2016, SEMIN INTERVENT RAD, V33, P65, DOI 10.1055/s-0036-1581088; Engelman DT, 1996, WORLD J SURG, V20, P5, DOI 10.1007/s002689900001; FITTS WT, 1964, SURGERY, V56, P663; FREEARK RJ, 1967, ARCH SURG-CHICAGO, V95, P567; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Gelbard RB, 2016, AM J SURG, V212, P769, DOI 10.1016/j.amjsurg.2015.08.027; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Giordano S, 2017, INTERN EMERG MED, V12, P981, DOI 10.1007/s11739-017-1674-0; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Hak D J, 2001, Curr Opin Pulm Med, V7, P338, DOI 10.1097/00063198-200109000-00015; Haut ER, 2011, J TRAUMA, V70, P27, DOI 10.1097/TA.0b013e3182077d55; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Kitagawa Kazuo, 2009, Rinsho Shinkeigaku, V49, P798; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Lu JP, 2009, J AM COLL SURGEONS, V209, P589, DOI 10.1016/j.jamcollsurg.2009.08.001; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Mismetti P, 2001, BRIT J SURG, V88, P913, DOI 10.1046/j.0007-1323.2001.01800.x; Netto FS, 2012, INJURY, V43, P1502, DOI 10.1016/j.injury.2010.12.028; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Rappold JF, 2021, TRAUMA SURG ACUTE CA, V6, DOI 10.1136/tsaco-2020-000643; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Shahan CP, 2016, J TRAUMA ACUTE CARE, V81, P173, DOI 10.1097/TA.0000000000001058; Shuster R, 2018, INJURY, V49, P1, DOI 10.1016/j.injury.2017.08.024; Tadlock MD, 2015, AM J SURG, V209, P959, DOI 10.1016/j.amjsurg.2014.09.027; Thorson CM, 2012, CRIT CARE MED, V40, P2967, DOI 10.1097/CCM.0b013e31825bcb60; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Zhang LD, 2012, CHINESE MED J-PEKING, V125, P3133, DOI 10.3760/cma.j.issn.0366-6999.2012.17.030	39	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						395	405		10.2147/VHRM.S314951			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TE3EV	WOS:000669897900002	34262284	gold, Green Published			2022-04-27	
J	Pengpid, S; Peltzer, K				Pengpid, Supa; Peltzer, Karl			Ideal Cardiovascular Health Behaviours in Nationally Representative School-Based Samples of Adolescents in the Caribbean	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						cardiovascular health behaviour; adolescents; Caribbean	RISK; PREVALENCE; ASSOCIATIONS; ADULTHOOD; OUTCOMES; CHILDREN	Background: Ideal cardiovascular health behaviour (CVHB) measures four ideal health behaviours (non-smoking, body mass index <85th Percentile, healthy diet, and physical activity). This study aimed to determine the prevalence, distribution, and correlates of ideal CVHB among adolescents in the Caribbean. Methods: Nationally representative cross-sectional data of 2016 or 2017 with complete CVHB measurements were analysed from 7556 school adolescents from four Caribbean countries. Results: The prevalence of 0-1 ideal metrics CVHB was 20.4%, 2 ideal metrics 48.7%, and 3-4 ideal metrics 30.8%. Only 5.0% had all 4 ideal CVHB metrics, 41.0% intermediate CVH (>1 metric in the intermediate category and none in the poor category), and 54.0% had poor CVH (>1 metric in poor category). In adjusted logistic regression analysis, compared to students from Dominican Republic, students from Jamaica (Adjusted Odds Ratio-AOR: 1.36, 95% confidence interval-CI: 1.01-1.85), students from Trinidad and Tobago (AOR: 1.46, 95% CI: 1.17-1.82) and male sex (AOR: 1.35, 95% CI: 1.11-1.64) were positively associated with meeting 3-4 ideal CVHB metrics. In addition, in unadjusted analysis, rarely or sometimes experiencing hunger was negatively and high peer and parent support were positively associated with meeting 3-4 ideal CVHB metrics. Conclusion: The proportion of meeting 3-4 ideal CVHB metrics was low among adolescents in four Caribbean countries. Both high-risk and school-wide intervention programmes should be implemented in aiding to improve CVHB in Caribbean countries. Several factors associated with ideal CVHB were identified, which can be targeted in school health interventions.	[Pengpid, Supa] Mahidol Univ, ASEAN Inst Hlth Dev, Salaya, Nakhon Pathom, Thailand; [Pengpid, Supa] Univ Limpopo, Dept Res Adm & Dev, Turfloop, South Africa; [Peltzer, Karl] Univ Free State, Dept Psychol, Bloemfontein, South Africa		Peltzer, K (通讯作者)，Univ Free State, Dept Psychol, Bloemfontein, South Africa.	kfpeltzer@gmail.com	Peltzer, Karl/Q-7334-2019	Peltzer, Karl/0000-0002-5980-0876			Aatola H, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000532; Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Agostinis-Sobrinho C, 2021, REV PAUL PEDIATR, V39, DOI 10.1590/1984-0462/2021/39/2019343; Aguilar-Farias N, 2018, INT J EPIDEMIOL, V47, P976, DOI 10.1093/ije/dyy033; Allen NB, 2020, JAMA CARDIOL, V5, P557, DOI 10.1001/jamacardio.2020.0140; Caleyachetty R, 2018, AM J CLIN NUTR, V108, P414, DOI 10.1093/ajcn/nqy105; Chen F F, 2018, Zhonghua Yu Fang Yi Xue Za Zhi, V52, P1124, DOI 10.3760/cma.j.issn.0253-9624.2018.11.006; Dong CH, 2012, CIRCULATION, V125, P2975, DOI 10.1161/CIRCULATIONAHA.111.081083; Dong HB, 2017, INT J CARDIOL, V231, P264, DOI 10.1016/j.ijcard.2016.12.027; Gande N, 2021, NUTR METAB CARDIOVAS, V31, P1286, DOI 10.1016/j.numecd.2020.11.002; Gooding HC, 2016, J ADOLESCENT HEALTH, V58, P119, DOI 10.1016/j.jadohealth.2015.09.011; Henriksson P, 2017, INT J CARDIOL, V240, P428, DOI 10.1016/j.ijcard.2017.03.022; Huffman MD, 2012, CIRCULATION, V125, P2595, DOI 10.1161/CIRCULATIONAHA.111.070722; Koebnick C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218203; Komulainen K, 2019, EUR J PREV CARDIOL, V26, P1605, DOI 10.1177/2047487319850959; Laitinen TT, 2012, CIRCULATION, V125, P1971, DOI 10.1161/CIRCULATIONAHA.111.073585; Lenhart CM, 2014, CARDIOL YOUNG, V24, P748, DOI 10.1017/S1047951113001121; Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703; Maclagan LC, 2014, CAN MED ASSOC J, V186, P180, DOI 10.1503/cmaj.131358; Onuoha C.A., 2017, IJHSR, V7, P353; Pacor JM, 2016, PROG PEDIATR CARDIOL, V43, P141, DOI 10.1016/j.ppedcard.2016.09.002; Pengpid S, 2019, INT J GEN MED, V12, P387, DOI 10.2147/IJGM.S226633; Pengpid S, 2018, J PSYCHOL AFR, V28, P212, DOI 10.1080/14330237.2017.1409481; Pengpid S, 2016, ASR CHIANG MAI UNIV, V3, P115, DOI 10.12982/CMUJASR.2016.0007; Perez A, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/1479-5868-12-S1-S2; Razzaghi H, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.37; Republic of Trinidad and Tobago Ministry of Education Curriculum Development Division, 2006, PRIMARY HLTH FAMILY; World Health Organization (WHO), 2019, GLOB SCH BAS STUD HL; Yan YK, 2019, ANN MED, V51, P88, DOI 10.1080/07853890.2019.1580383; Younus A, 2016, MAYO CLIN PROC, V91, P649, DOI 10.1016/j.mayocp.2016.01.019	30	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						187	194		10.2147/VHRM.S302168			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RZ2JD	WOS:000648421800001	33976549	gold, Green Published			2022-04-27	
J	Alawneh, KZ; Raffee, LA; Alshehabat, MAM; Haddad, H; Jaradat, SA				Alawneh, Khaled Z.; Raffee, Liqaa A.; Alshehabat, Musa Ahmed Mohammed; Haddad, Hazem; Jaradat, Saied A.			Characterizing and Profiling microRNAs in Dogs Undergoing Induced Ischemic Brain Stroke After Middle Cerebral Artery Occlusion Under Fluoroscopic Guidance	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						dogs; fluoroscopic induced ischemic brain; microRNAs; middle cerebral artery stroke	TRANSIENT FOCAL ISCHEMIA; ANIMAL-MODELS; EXPRESSION; BLOOD; RISK; RATS	Purpose: Ischemic stroke of the brain is still considered one of the most common causes of disability and death in developed and developing countries in human beings despite advances in medicine and technology. This study was conducted to characterize and profile tens of induced biomarkers (microRNAs) after experimentally inducing regional ischemic stroke of the brain by occluding the middle cerebral artery under fluoroscopic guidance using an autologous blood clot. Patient and Methods: A total of six healthy dogs were recruited for this study. The microRNAs were profiled in the blood and urine before and after occluding the middle cerebral artery using genetic techniques. Results: The very highly expressed genes were comprised within cluster A, followed by cluster D in both 24 and 48-hour brain samples. Clusters B and C revealed down-regulated genes, while miRNAs remained up-regulated in the 24-hour samples merely in cluster F. Upregulated genes at 48 hours of reperfusion were included in cluster E. On the other hand, changes were observed after a day on the cluster G genes. Exclusive upregulation was notified after 2 days due to the changes in mIR-138. The normalized gene expression in the test sample is witnessed through Fold-Change, which divides the control sample's normalized gene expression. Moreover, fold-change has emerged as a significant approach for representing fold-regulation. Conclusion: The microRNAs expression in blood and urine may have a potential role in the diagnosis, prognosis, and assessment of therapy associated with cerebral artery occlusion under fluoroscopic guidance.	[Alawneh, Khaled Z.] Jordan Univ Sci & Technol, Fac Med, Dept Diagnost Radiol & Nucl Med, Irbid, Jordan; [Raffee, Liqaa A.] Jordan Univ Sci & Technol, Dept Accid & Emergency Med, Fac Med, Irbid, Jordan; [Alshehabat, Musa Ahmed Mohammed] Jordan Univ Sci & Technol, Dept Clin Vet Med Sci, Fac Vet Med, Irbid, Jordan; [Haddad, Hazem] Jordan Univ Sci & Technol, Haya Biotechnol Ctr, Irbid 22110, Jordan; [Jaradat, Saied A.] Jordan Univ Sci & Technol, Princess Haya Biotechnol Ctr, Irbid 22110, Jordan		Raffee, LA (通讯作者)，Jordan Univ Sci & Technol, Dept Accid & Emergency Med, Fac Med, Irbid, Jordan.	laraffee5@just.edu.jo		haddad, hazem/0000-0002-5534-1529; Raffee, Liqaa/0000-0001-8020-8677	Deanship of research at Jordan University of Science and Technology	This research is funded by the Deanship of research at Jordan University of Science and Technology. The authors declare no competing interest.	Bacigaluppi Marco, 2010, Open Neurol J, V4, P26, DOI 10.2174/1874205X01004020026; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beuvink I, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1118; Chen H B, 2016, Zhonghua Nei Ke Za Zhi, V55, P366, DOI 10.3760/cma.j.issn.0578-1426.2016.05.007; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Fluri F, 2015, DRUG DES DEV THER, V9, P3445, DOI 10.2147/DDDT.S56071; Howells DW, 2010, J CEREBR BLOOD F MET, V30, P1412, DOI 10.1038/jcbfm.2010.66; Jeon JH, 2015, J VET SCI, V16, P75, DOI [10.4142/jvs.2015.16.1.75, 10.4142/jvs.2015.16.1.67]; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Jickling GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099283; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Navi BB, 2016, THROMB RES, V140, pS169, DOI 10.1016/S0049-3848(16)30119-0; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sonderer J, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14138; Song HS, 2008, J CLIN NEUROL, V4, P75, DOI 10.3988/jcn.2008.4.2.75; Tan JR, 2013, INT J MOL SCI, V14, P2072, DOI 10.3390/ijms14012072; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Tibaek M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003158; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhou JQ, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20150206	24	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						543	550		10.2147/VHRM.S317861			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UR6VN	WOS:000696884600001	34526772	gold, Green Published			2022-04-27	
J	Blacher, J; Femery, V; Comm, VM				Blacher, Jacques; Femery, Virginie; Comm, V. I. V. O. P. T. I. M. Med			Updating the VIVOPTIM Program for the Assessment of Cardiovascular Risk	VASCULAR HEALTH AND RISK MANAGEMENT			English	Letter									[Blacher, Jacques] Univ Paris, Hotel Dieu Hosp, AP HP, Diag & Therapeut Ctr, Paris, France; [Femery, Virginie] VIVOPTIM Solut, Dept Execut Management, Paris, France		Blacher, J (通讯作者)，Univ Paris, Hop Hotel Dieu, Assistance Publ Hop Paris, Unite HTA Prevent & Therapeut Cardiovasc,Ctr Diag, Pl Parvis Notre Dame, F-75004 Paris, France.	jacques.blacher@aphp.fr			VIVOPTIM program	The MGEN supported all expenses of the VIVOPTIM program.	Blacher J, 2020, ARCH CARDIOVASC DIS, V113, P590, DOI 10.1016/j.acvd.2020.02.005; Boulat T., 2019, Bulletin Epidemiologique Hebdomadaire, P576; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Dibie A, 2018, Ann Cardiol Angeiol (Paris), V67, P293, DOI 10.1016/j.ancard.2018.09.002; Zins M, 2015, EUR J EPIDEMIOL, V30, P1317, DOI 10.1007/s10654-015-0096-4	6	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						675	678		10.2147/VHRM.S333542			4	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WR8RY	WOS:000714763400001	34737571	gold, Green Published			2022-04-27	
J	Fernberg, U; Fernstrom, M; Hurtig-Wennlof, A				Fernberg, Ulrika; Fernstrom, Maria; Hurtig-Wennlof, Anita			Higher Total Physical Activity is Associated with Lower Arterial Stiffness in Swedish, Young Adults: The Cross-Sectional Lifestyle, Biomarkers, and Atherosclerosis Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						accelerometry; atherosclerosis; healthy population; pulse wave analysis; pulse wave velocity	PULSE-WAVE VELOCITY; SEDENTARY BEHAVIORS; UNITED-STATES; RISK-FACTORS; TIME SPENT; ALL-CAUSE; ADOLESCENTS; PREDICTION; INACTIVITY; MORTALITY	Purpose: Arterial stiffness describes the rigidity of the arterial walls and is associated with risk factors for cardiovascular disease (CVD). Arterial stiffness predicts future events and mortality, and the predictive value is stronger in younger versus older subjects. The aims of the present study were, firstly, to present data on physical activity (PA) and time spent sedentary, in the population of Swedish, young adults. Secondly, to explore the association between PA and arterial stiffness. Material and Methods: Self-reported healthy, non-smoking, Swedish, young adults, 18-25 years old, participated in the cross-sectional Lifestyle, Biomarkers and Atherosclerosis (LBA) study. The daily PA was objectively measured with an accelerometer for 1 week. Of the 834 participants, 658 individuals had valid registrations. The arterial stiffness measures, pulse wave velocity (PWV) and augmentation index (AIx) were measured with applanation tonometry. Results: Women were on overall more physically active than men, they spent 214 min/day in light PA (LPA) compared to men who spent 202 min/day. Women took significantly more steps per day than men, 7796 vs 7336 steps/day, and spent less time sedentary, 523 min/day, compared to men who spent 547 min/day sedentary. In total, 76% of the individuals spent on average at least 30 minutes per day in the recommended moderate and vigorous PA (MVPA). Lower arterial stiffness was associated with more MVPA and total PA in the total population. Conclusion: We conclude that in this age group of young, self-reported healthy adults 18-25 years, it is important to highlight the health-enhancing possibilities of time spent in physical activity on the vascular function, measured as PWV and AIx. It is of high relevance in a public health perspective to expand preventive efforts beyond the high-risk groups and encourage young adults to be physically active.	[Fernberg, Ulrika; Hurtig-Wennlof, Anita] Orebro Univ, Fac Med & Hlth, Cardiovasc Res Ctr, Fak Gatan 1, SE-70182 Orebro, Sweden; [Fernstrom, Maria] GIH, Dept Phys Act & Hlth, Swedish Sch Sport & Hlth Sci, S-11433 Stockholm, Sweden; [Hurtig-Wennlof, Anita] Jonkoping Univ, Sch Hlth & Welf, Dept Nat Sci & Biomed, Biomed Platform, S-55111 Jonkoping, Sweden		Fernberg, U (通讯作者)，Orebro Univ, Fac Med & Hlth, Cardiovasc Res Ctr, Fak Gatan 1, SE-70182 Orebro, Sweden.	ulrika.fernberg@oru.se		Hurtig-Wennlof, Anita/0000-0003-1067-8627; Fernberg, Ulrika/0000-0002-6520-9265	Asset Management Arm (AFA) life insurance [130275]; AFA	Funding was provided by Asset Management Arm (AFA) life insurance nr: 130275. AFA contributed with financial support, but study design, data collection, analysis of data, and writing the manuscript were done by the authors.	Andersson C, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001528; Ben-Shlomo Y, 2014, J AM COLL CARDIOL, V63, P636, DOI 10.1016/j.jacc.2013.09.063; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bergman P, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01026-7; Edwards NM, 2012, METABOLISM, V61, P869, DOI 10.1016/j.metabol.2011.10.016; Ekblom-Bak E, 2019, SCAND J MED SCI SPOR, V29, P232, DOI 10.1111/sms.13328; Ekblom-Bak E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126336; Ekelund U, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4570; Fernberg U, 2019, 102019 OR U SCH MED; Fernberg U, 2017, EUR J PREV CARDIOL, V24, P1809, DOI 10.1177/2047487317720796; Fernstrom M, 2017, VASC HEALTH RISK MAN, V13, P91, DOI 10.2147/VHRM.S125966; Ferreira I, 2012, HYPERTENSION, V59, P54, DOI 10.1161/HYPERTENSIONAHA.110.156109; Gabriel KKP, 2012, J PHYS ACT HEALTH, V9, pS11, DOI 10.1123/jpah.9.s1.s11; Gepner AD, 2014, STROKE, V45, P48, DOI 10.1161/STROKEAHA.113.002649; Germano-Soares AH, 2018, ATHEROSCLEROSIS, V269, P211, DOI 10.1016/j.atherosclerosis.2018.01.009; Hagstromer M, 2007, MED SCI SPORT EXER, V39, P1502, DOI 10.1249/mss.0b013e3180a76de5; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1161/CIRCULATIONAHA.107.185649; Hawkins M, 2014, VASC MED, V19, P257, DOI 10.1177/1358863X14536630; Horta BL, 2015, ATHEROSCLEROSIS, V243, P148, DOI 10.1016/j.atherosclerosis.2015.09.005; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Mackenzie IS, 2002, QJM-INT J MED, V95, P67, DOI 10.1093/qjmed/95.2.67; Matthews CE, 2008, AM J EPIDEMIOL, V167, P875, DOI 10.1093/aje/kwm390; Matthews CE, 2012, MED SCI SPORT EXER, V44, pS68, DOI 10.1249/MSS.0b013e3182399e5b; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McGill HC, 2000, AM J CLIN NUTR, V72, p1307S, DOI 10.1093/ajcn/72.5.1307s; Mitchell GF, 2004, HYPERTENSION, V43, P1239, DOI 10.1161/01.HYP.0000128420.01881.aa; Nichols WW, 2011, MCDONALD'S BLOOD FLOW IN ARTERIES: THEORETICAL, EXPERIMENTAL AND CLINICAL PRINCIPLES, 6TH EDITION, P1; Nocon M, 2008, EUR J CARDIOV PREV R, V15, P239, DOI 10.1097/HJR.0b013e3282f55e09; Office of Disease Prevention and Health promotion, 2018, PHYS ACT GUID AM; Palmefors H, 2014, ATHEROSCLEROSIS, V235, P150, DOI 10.1016/j.atherosclerosis.2014.04.026; Pauca AL, 2001, HYPERTENSION, V38, P932, DOI 10.1161/hy1001.096106; Ried-Larsen M, 2013, SCAND J MED SCI SPOR, V23, pe168, DOI 10.1111/sms.12046; Seals DR, 2008, J APPL PHYSIOL, V105, P1323, DOI 10.1152/japplphysiol.90553.2008; Shea JL, 2012, NUTR METAB CARDIOVAS, V22, P741, DOI 10.1016/j.numecd.2010.11.009; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Trost SG, 2005, MED SCI SPORT EXER, V37, pS531, DOI 10.1249/01.mss.0000185657.86065.98; van de Laar RJ, 2010, HYPERTENSION, V55, P33, DOI 10.1161/HYPERTENSIONAHA.109.138289; Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061; Weber T, 2009, J HYPERTENS, V27, P1624, DOI 10.1097/HJH.0b013e32832cb04e; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617; Yrkesforeningar for fysisk aktivitet (YFA) och Svenska Lakaresallskapet, 2011, REK FYS AKT VUXN	44	1	1	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						175	185		10.2147/VHRM.S283211			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RW0OH	WOS:000646223600001	33953561	Green Published, gold			2022-04-27	
J	Los-Stegienta, A; Katarzynska, J; Borkowska, A; Marcinek, A; Cypryk, K; Gebicki, J				Los-Stegienta, Agnieszka; Katarzynska, Joanna; Borkowska, Anna; Marcinek, Andrzej; Cypryk, Katarzyna; Gebicki, Jerzy			Differentiation of Diabetic Foot Ulcers Based on Stimulation of Myogenic Oscillations by Transient Ischemia	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						vascular complications; microcirculation; hypoxia; diabetic foot; flowmotion; NADH fluorescence; FMSF technique		Purpose: Diabetic foot ulceration is a chronic complication characterized by impaired wound healing. There is a great demand for a diagnostic tool that is able to monitor and predict wound healing. Patients and Methods: Oscillations in the microcirculation, known as flowmotion, can be monitored very distinctly and precisely using the Flow Mediated Skin Fluorescence (FMSF) technique. The flowmotion response to hypoxia was measured quantitatively in 42 patients with diabetic foot ulcers. Results: The flowmotion response to hypoxia parameters FM(R) and HS were used to differentiate the diabetic foot ulcers and correlate them with clinical status. In some cases, FMSF measurements were continued over the period of a year in order to monitor disease progress. The clinical status of the quarter of patients with the highest HS values (group A, HS = 50.2 +/- 18.3) was compared to the quarter with the lowest HS values (group B, HS = 4.3 +/- 1.7). The patients in the group B were identified as having low prognosis for healing and were characterized by higher incidences of hypertension, hyperlipidemia, prevalent CVD, neuropathy and nephropathy. Conclusion: Impaired flowmotion responses to hypoxia induced by transient ischemia can be used for differentiation of diabetic foot ulcers and identification of cases with low prognosis for healing.	[Los-Stegienta, Agnieszka; Borkowska, Anna; Cypryk, Katarzyna] Med Univ Lodz, Dept Internal Dis & Diabetol, Lodz, Poland; [Katarzynska, Joanna; Marcinek, Andrzej; Gebicki, Jerzy] Angionica Ltd, Lodz, Poland; [Marcinek, Andrzej; Gebicki, Jerzy] Lodz Univ Technol, Inst Appl Radiat Chem, PL-90924 Lodz, Poland		Gebicki, J (通讯作者)，Lodz Univ Technol, Inst Appl Radiat Chem, PL-90924 Lodz, Poland.	jerzy.gebicki@p.lodz.pl	; Marcinek, Andrzej/M-1775-2018	Gebicki, Jerzy/0000-0003-2304-5036; Marcinek, Andrzej/0000-0002-9852-7593; Borkowska, Anna/0000-0002-8971-9868; Los-Stegienta, Agnieszka/0000-0001-6101-5212; Cypryk, Katarzyna/0000-0003-0877-9111	European UnionEuropean Commission [POIR. 01.01.01-00-0540/15-00]	This work was supported by the European Union from the resources of the European Regional Development Fund under the Smart Growth Operational Program, Grant No. POIR. 01.01.01-00-0540/15-00.	Aalkjaer C, 2011, ACTA PHYSIOL, V202, P253, DOI 10.1111/j.1748-1716.2011.02320.x; Armstrong DG, 2017, NEW ENGL J MED, V376, P2367, DOI 10.1056/NEJMra1615439; Botusan IR, 2008, P NATL ACAD SCI USA, V105, P19426, DOI 10.1073/pnas.0805230105; Brownrigg JRW, 2012, DIABETOLOGIA, V55, P2906, DOI 10.1007/s00125-012-2673-3; Catrina SB, 2021, DIABETOLOGIA, V64, P709, DOI 10.1007/s00125-021-05380-z; Catrina SB, 2016, DIABETES-METAB RES, V32, P179, DOI 10.1002/dmrr.2742; Cole WC, 2019, ADV EXP MED BIOL, V1124, P297, DOI 10.1007/978-981-13-5895-1_12; Gebicki J, 2021, VASC HEALTH RISK MAN, V17, P33, DOI 10.2147/VHRM.S292087; Hwang DJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175270; Katarzynska J, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00702; Katarzynska Joanna, 2020, J Diabetes Sci Technol, V14, P693, DOI 10.1177/1932296819895544; Katarzynska J, 2019, REV SCI INSTRUM, V90, DOI 10.1063/1.5092218; Katarzynska J, 2019, MICROVASC RES, V124, P19, DOI 10.1016/j.mvr.2019.02.005; Lin CJ, 2017, BIOMED RES-INDIA, V28, P8121; Nilsson Holger, 2003, Mol Interv, V3, P79, DOI 10.1124/mi.3.2.79; Piotrowski L, 2016, REV SCI INSTRUM, V87, DOI 10.1063/1.4945044; Rossi M, 2006, BIOMED PHARMACOTHER, V60, P437, DOI 10.1016/j.biopha.2006.07.012; Stang D., 2018, DIABETIC FOOT J, V21, P100; Thangarajah H, 2010, CELL CYCLE, V9, P75, DOI 10.4161/cc.9.1.10371; Thangarajah H, 2009, P NATL ACAD SCI USA, V106, P13505, DOI 10.1073/pnas.0906670106	20	2	2	1	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						145	152		10.2147/VHRM.S307366			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RQ0EX	WOS:000642094200001	33907408	gold, Green Published			2022-04-27	
J	Kang, NL				Kang, Nam Lyong			Association Between Obesity and Blood Pressure in Common Korean People	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypertension; pulse pressure; waist-to-height ratio; body mass index; lump mean value	BODY-MASS INDEX; TO-HEIGHT RATIO; WAIST CIRCUMFERENCE; PULSE PRESSURE; RISK-FACTORS; ABDOMINAL OBESITY; METABOLIC SYNDROME; HYPERTENSION; MORTALITY; PREDICTOR	Purpose: The aim of this study was to investigate the associations of high blood pressure (BP) and wide pulse pressure (PP) with obesity among common Korean people. Materials and Methods: This study analyzed data from the Seventh Korean National Health and Nutrition Examination Survey (2017). The associations of BP with body mass index (BMI) and waist-to-height ratio (WHT2R) were investigated using their lump mean values. Results: The BPs of males and females increased with BMI, the PP of females increased with BMI and then decreased, and the PP of males is nearly independent of BMI. The BPs of males and females increased to their maximum values with WHT2R and then decreased. The PPs of males and females increased with WHT2R. Conclusion: BMI can be used as a useful predictor for high BP, and WHT2R can be used as a useful predictor for wide PP.	[Kang, Nam Lyong] Pusan Natl Univ, Dept Nanomechatron Engn, Miryang 50463, South Korea		Kang, NL (通讯作者)，Pusan Natl Univ, Dept Nanomechatron Engn, 1268-50 Samnangjin Ro, Miryang Si 50463, Gyeonsangnam Do, South Korea.	nlkang@pusan.ac.kr		Kang, Nam Lyong/0000-0003-3615-0492			[Anonymous], 2021, VASC HEALTH RISK MAN, P17; Ashwell M, 2012, OBES REV, V13, P275, DOI 10.1111/j.1467-789X.2011.00952.x; Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410; Carr DB, 2004, DIABETES, V53, P2087, DOI 10.2337/diabetes.53.8.2087; Coutinho T, 2013, J AM COLL CARDIOL, V61, P553, DOI 10.1016/j.jacc.2012.10.035; Czernichow S, 2011, OBES REV, V12, P680, DOI 10.1111/j.1467-789X.2011.00879.x; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; Ghandehari H, 2009, INT J OBESITY, V33, P239, DOI 10.1038/ijo.2008.252; Hsieh SD, 2003, INT J OBESITY, V27, P610, DOI 10.1038/sj.ijo.0802259; Hu G, 2004, HYPERTENSION, V43, P25, DOI 10.1161/01.HYP.0000107400.72456.19; Hwang S, 2020, MED HYPOTHESES, V135, DOI 10.1016/j.mehy.2019.109471; James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Kawai VK, 2019, OBESITY, V27, P1184, DOI 10.1002/oby.22505; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; Langenberg C, 2005, AM J PUBLIC HEALTH, V95, P628, DOI 10.2105/2004.046219; Lee CMY, 2008, J CLIN EPIDEMIOL, V61, P646, DOI 10.1016/j.jclinepi.2007.08.012; Lee SC, 2017, J EPIDEMIOL, V27, P130, DOI 10.1016/j.je.2016.10.006; Li C, 2007, OBESITY, V15, P216, DOI 10.1038/oby.2007.505; Linderman GC, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1271; Michard F, 2000, AM J RESP CRIT CARE, V162, P134, DOI 10.1164/ajrccm.162.1.9903035; Mitchell GF, 1997, CIRCULATION, V96, P4254; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mule G, 2007, AM J HYPERTENS, V20, P197, DOI 10.1016/j.amjhyper.2006.07.016; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Nevill AM, 2017, SCAND J MED SCI SPOR, V27, P1470, DOI 10.1111/sms.12780; Nichols W., 2005, MCDONALDS BLOOD FLOW, V5th ed.; Park J, 2016, ENDOCRINOL METAB, V31, P559, DOI 10.3803/EnM.2016.31.4.559; Petursson H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026621; Protogerou AD, 2007, AM J HYPERTENS, V20, P127, DOI 10.1016/j.amjhyper.2006.06.014; Rahmouni K, 2014, HYPERTENSION, V64, P215, DOI 10.1161/HYPERTENSIONAHA.114.00920; Segers P, 2008, P I MECH ENG H, V222, P417, DOI 10.1243/09544119JEIM287; Seidell JC, 2010, EUR J CLIN NUTR, V64, P35, DOI 10.1038/ejcn.2009.71; Seo DC, 2017, PREV MED, V97, P100, DOI 10.1016/j.ypmed.2017.01.012; Shen SW, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43046; Shuger SL, 2008, AM J HYPERTENS, V21, P613, DOI 10.1038/ajh.2008.169; Stergiopulos N, 1999, AM J PHYSIOL-HEART C, V276, pH81; Taylor RW, 1998, AM J CLIN NUTR, V67, P44, DOI 10.1093/ajcn/67.1.44; Thaikruea L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37100; Vasque F, 2019, PEDIATR RES, V85, P269, DOI 10.1038/s41390-018-0257-8; Westerhof N, 2009, MED BIOL ENG COMPUT, V47, P131, DOI 10.1007/s11517-008-0359-2; WHELTON PK, 1992, J HYPERTENS, V10, pS77; Zahedi Edmond, 2007, Cardiovasc Eng, V7, P172, DOI 10.1007/s10558-007-9037-5; Zhu SK, 2002, AM J CLIN NUTR, V76, P743, DOI 10.1093/ajcn/76.4.743	45	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						371	377		10.2147/VHRM.S316108			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD8DZ	WOS:000669551700001	34234445	Green Published, gold, Green Submitted			2022-04-27	
J	Pirozzi, N; Mancianti, N; Scrivano, J; Fazzari, L; Pirozzi, R; Tozzi, M				Pirozzi, Nicola; Mancianti, Nicoletta; Scrivano, Jacopo; Fazzari, Loredana; Pirozzi, Roberto; Tozzi, Matteo			Monitoring the Patient Following Radio-Cephalic Arteriovenous Fistula Creation: Current Perspectives	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						arteriovenous fistula maturation; hemodialysis; early failure; rule of six; vascular access		Autogenous radial-cephalic direct wrist arteriovenous fistula (RC-AVF) in the non-dominant arm is the gold standard for dialysis vascular access. However, the RC-AVF non-maturation rate is significant (similar or equal to 40%) due to an increasingly elderly and comorbid population incidence. A detailed identification of the biological cascade underlying arteriovenous fistula (AVF) maturation could be the key to clinical research aimed at identify the group of patients at risk of primary AVF failure. Currently, careful post-operative monitoring remains the most crucial aspect to overcome the problem of impaired maturation. Up to 80% of patients with immature RC-AVF have problems potentially solvable with early endovascular or surgical correction. Physical examination by experienced practitioners in conjunction with duplex ultrasound examination (DUS) can identify physical signs of non-maturation, understand the underlying cause, and drive for a tailored early planning to treat the complication. New approaches for the early assessment of AVF maturation are under study. Techniques to promote RC-AVF maturation performed through the administration of pre-or peri-operative drugs have missed up to now to prove an efficacy in improving fistula success. The new techniques tested after surgery appear to hold future promise for improving fistula maturation.	[Pirozzi, Nicola; Scrivano, Jacopo; Fazzari, Loredana; Pirozzi, Roberto] CdC Nuova ITOR, Intervent Nephrol Unit, Nephrol & Dialysis Dept, Via Pietralata 162, I-00158 Rome, Italy; [Mancianti, Nicoletta] Univ Hosp Siena, Nephrol Dialysis & Transplant Unit, Siena, Italy; [Tozzi, Matteo] Univ Insubria, Vasc Surg, Asst Settelaghi Varese, Varese, Italy		Pirozzi, N (通讯作者)，CdC Nuova ITOR, Intervent Nephrol Unit, Nephrol & Dialysis Dept, Via Pietralata 162, I-00158 Rome, Italy.	nicola.pirozzi1@gmail.com					Access BV, 2018, CLIN PRACTICE RECOMM; Andreucci VE, 2004, AM J KIDNEY DIS, V44, pS61, DOI 10.1053/j.ajkd.2004.08.013; Astor BC, 2000, AM J KIDNEY DIS, V36, P1126, DOI 10.1053/ajkd.2000.19816; Beathard GA, 2003, KIDNEY INT, V64, P1487, DOI 10.1046/j.1523-1755.2003.00210.x; Beathard GA, 2016, MATURATION EVALUATIO; Berman SS, 2008, J VASC ACCESS, V9, P241, DOI 10.1177/112972980800900404; Bleyer AJ, 2019, J VASC SURG, V69, P507, DOI 10.1016/j.jvs.2018.04.068; Bourquelot P, 2012, J VASC SURG, V56, P440, DOI 10.1016/j.jvs.2012.01.068; Bourquelot P, 2009, J VASC SURG, V50, P369, DOI 10.1016/j.jvs.2009.03.009; Brimble KS, 2002, CLIN NEPHROL, V58, P122; Bronder CM, 2008, J AM COLL SURGEONS, V206, P1076, DOI 10.1016/j.jamcollsurg.2007.12.030; Browne LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145795; Chan CY, 2007, J VASC SURG, V45, P804, DOI 10.1016/j.jvs.2006.12.063; Chemla E, 2014, J VASC ACCESS, V15, P38, DOI 10.5301/jva.5000169; Chen FA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166362; Chen YW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060833; Conte MS, 2011, J VASC SURG, V54, P1383, DOI 10.1016/j.jvs.2011.05.005; Conte MS, 2009, J VASC SURG, V50, P1359, DOI 10.1016/j.jvs.2009.07.108; Corpataux JM, 2002, NEPHROL DIAL TRANSPL, V17, P1057, DOI 10.1093/ndt/17.6.1057; Ene-Iordache B, 2013, NEPHROL DIAL TRANSPL, V28, P997, DOI 10.1093/ndt/gfs298; Fekih-Mrissa N, 2016, THER APHER DIAL, V20, P107, DOI 10.1111/1744-9987.12379; Fitts Michelle K, 2014, Open Urol Nephrol J, V7, P33; Fontsere N, 2016, HEMODIAL INT, V20, P306, DOI 10.1111/hdi.12376; Gallieni M, 2019, NEPHROL DIAL TRANSPL, V34, P1, DOI 10.1093/ndt/gfz072; Gameiro J, 2020, J VASC ACCESS, V21, P134, DOI 10.1177/1129729819845562; Hadimeri U, 2017, CLIN HEMORHEOL MICRO, V66, P211, DOI 10.3233/CH-170254; Hammes M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/171674; Idrees M, 2020, J VASC ACCESS, V21, P554, DOI 10.1177/1129729819867817; Inston N, 2017, J VASC ACCESS, V18, P3, DOI 10.5301/jva.5000621; Johansson M, 2010, ATHEROSCLEROSIS, V211, P159, DOI 10.1016/j.atherosclerosis.2010.01.031; Karam L, 2018, J VASC SURG, V67, P236, DOI 10.1016/j.jvs.2017.05.120; Karydis N, 2020, AM J KIDNEY DIS, V75, P45, DOI 10.1053/j.ajkd.2019.05.023; Kosa SD, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007013.pub2; Ladenheim ED, 2016, J VASC ACCESS, V17, P307, DOI 10.5301/jva.5000544; Lazarides MK, 2007, J VASC SURG, V45, P420, DOI 10.1016/j.jvs.2006.10.035; Lee T, 2011, CLIN J AM SOC NEPHRO, V6, P575, DOI 10.2215/CJN.06630810; Leon C, 2008, SEMIN DIALYSIS, V21, P85, DOI 10.1111/j.1525-139X.2007.00382.x; Leon C, 2008, SEMIN DIALYSIS, V21, P557, DOI 10.1111/j.1525-139X.2008.00477.x; Li HZ, 2018, QUANT IMAG MED SURG, V8, P444, DOI 10.21037/qims.2018.01.03; Lok CE, 2020, AM J KIDNEY DIS, V75, pS1, DOI 10.1053/j.ajkd.2019.12.001; Mendes RR, 2002, J VASC SURG, V36, P460, DOI 10.1067/mva.2002.126544; Cases SM, 2016, NEFROLOGIA, V36, P410, DOI 10.1016/j.nefro.2015.10.016; Nassar GM, 2008, TECH VASC INTERV RAD, V11, P175, DOI 10.1053/j.tvir.2008.09.004; Nath KA, 2016, J AM SOC NEPHROL, V27, P3508, DOI 10.1681/ASN.2016050569; Nikam M, 2015, J VASC SURG, V61, P1020, DOI 10.1016/j.jvs.2014.11.082; Nordyke RJ, 2019, AM J NEPHROL, V50, P320, DOI 10.1159/000502507; Pham XBD, 2017, J VASC SURG, V65, P444, DOI 10.1016/j.jvs.2016.09.037; Pirozzi N, 2015, J VASC ACCESS, V16, P364, DOI 10.5301/jva.5000443; Pirozzi N, 2010, NEPHROL DIAL TRANSPL, V25, P520, DOI 10.1093/ndt/gfp452; Remuzzi A, 2017, CARDIOVASC ENG TECHN, V8, P273, DOI 10.1007/s13239-017-0323-0; Remuzzi A, 2017, J VASC ACCESS, V18, pS10, DOI 10.5301/jva.5000686; Robbin ML, 2016, RADIOLOGY, V279, P620, DOI 10.1148/radiol.2015150385; Robbin ML, 2002, RADIOLOGY, V225, P59, DOI 10.1148/radiol.2251011367; Rooijens PPGM, 2004, EUR J VASC ENDOVASC, V28, P583, DOI 10.1016/j.ejvs.2004.08.014; Rosales LM, 2019, BLOOD PURIFICAT, V47, P240, DOI 10.1159/000494742; Rotondi S, 2020, CLIN KIDNEY J, V13, P184, DOI 10.1093/ckj/sfz064; Salimi F, 2013, J VASC ACCESS, V14, P239, DOI 10.5301/jva.5000123; Epifanio APS, 2018, NUTR HOSP, V35, P176, DOI 10.20960/nh.1319; Schmidli J, 2018, EUR J VASC ENDOVASC; Shahverdyan R, 2021, J VASC ACCESS, V22, P166, DOI 10.1177/1129729820904599; Siddiqui MA, 2018, KIDNEY RES CLIN PRAC, V37, P277, DOI 10.23876/j.krcp.2018.37.3.277; Smith GE, 2016, J VASC ACCESS, V17, P1, DOI 10.5301/jva.5000484; Srivastava A, 2015, INDIAN J UROL, V31, P240, DOI 10.4103/0970-1591.159650; Thimmisetty RK, 2017, KIDNEY INT REP, V2, P76, DOI 10.1016/j.ekir.2016.08.013; Tong XY, 2017, AM J PATHOL, V187, P2095, DOI 10.1016/j.ajpath.2017.05.006; Tordoir JHM, 2018, EUR J VASC ENDOVASC, V55, P240, DOI 10.1016/j.ejvs.2017.12.001; Tordoir JHM, 2009, J VASC SURG, V50, P953, DOI 10.1016/j.jvs.2009.06.058; Turmel-Rodrigues LA, 2014, J VASC ACCESS, V15, pS55, DOI 10.5301/jva.5000232; Viecelli AK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213274; Viecelli AK, 2018, SEMIN DIALYSIS, V31, P244, DOI 10.1111/sdi.12658; Wan QS, 2017, RENAL FAILURE, V39, P613, DOI 10.1080/0886022X.2017.1361835; Wang RR, 2016, ALTERN THER HEALTH M, V22, P18; Weyde W, 2002, KIDNEY INT, V61, P1170, DOI 10.1046/j.1523-1755.2002.00202.x; Zavacka M, 2020, INT ANGIOL, V39, P525, DOI 10.23736/S0392-9590.20.04401-6; Zhao JJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004891	75	2	2	0	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						111	121		10.2147/VHRM.S205130			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RK0UW	WOS:000638021400001	33854321	gold, Green Published			2022-04-27	
J	Zuraini, NZA; Sekar, M; Wu, YS; Gan, SH; Bonam, SR; Rani, NNIM; Begum, MY; Lum, PT; Subramaniyan, V; Fuloria, NK; Fuloria, S				Zuraini, Nur Zulaikha Azwa; Sekar, Mahendran; Wu, Yuan Seng; Gan, Siew Hua; Bonam, Srinivasa Reddy; Rani, Nur Najihah Izzati Mat; Begum, M. Yasmin; Lum, Pei Teng; Subramaniyan, Vetriselvan; Fuloria, Neeraj Kumar; Fuloria, Shivkanya			Promising Nutritional Fruits Against Cardiovascular Diseases: An Overview of Experimental Evidence and Understanding Their Mechanisms of Action	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						nutritional fruits; cardiovascular diseases; heart disease; antioxidant; hypertension; nutraceuticals	ISCHEMIA-REPERFUSION INJURY; RANDOMIZED CONTROLLED-TRIAL; LOW-DENSITY-LIPOPROTEIN; CARICA-PAPAYA L.; HIGH-FAT DIET; BLOOD-PRESSURE; SEED EXTRACT; GRAPE SEED; PLASMA-LIPIDS; RISK-FACTORS	Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortality in both developed and developing countries, affecting millions of individuals each year. Despite the fact that successful therapeutic drugs for the management and treatment of CVDs are available on the market, nutritional fruits appear to offer the greatest benefits to the heart and have been proved to alleviate CVDs. Experimental studies have also demonstrated that nutritional fruits have potential protective effects against CVDs. The aim of the review was to provide a comprehensive summary of scientific evidence on the effect of 10 of the most commonly available nutritional fruits reported against CVDs and describe the associated mechanisms of action. Relevant literatures were searched and collected from several scientific databases including PubMed, ScienceDirect, Google Scholar and Scopus. In the context of CVDs, 10 commonly consumed nutritious fruits including apple, avocado, grapes, mango, orange, kiwi, pomegranate, papaya, pineapple, and watermelon were analysed and addressed. The cardioprotective mechanisms of the 10 nutritional fruits were also compiled and highlighted. Overall, the present review found that the nutritious fruits and their constituents have significant benefits for the management and treatment of CVDs such as myocardial infarction, hypertension, peripheral artery disease, coronary artery disease, cardiomyopathies, dyslipidemias, ischemic stroke, aortic aneurysm, atherosclerosis, cardiac hypertrophy and heart failure, diabetic cardiovascular complications, drug-induced cardiotoxicity and cardiomyopathy. Among the 10 nutritional fruits, pomegranate and grapes have been well explored, and the mechanisms of action are well documented against CVDs. All of the nutritional fruits mentioned are edible and readily accessible on the market. Consuming these fruits, which may contain varying amounts of active constituents depending on the food source and season, the development of nutritious fruits-based health supplements would be more realistic for consistent CVD protection.	[Zuraini, Nur Zulaikha Azwa; Sekar, Mahendran; Lum, Pei Teng] Univ Kuala Lumpur, Fac Pharm & Hlth Sci, Dept Pharmaceut Chem, Royal Coll Med Perak, Ipoh 30450, Perak, Malaysia; [Wu, Yuan Seng] Sunway Univ, Ctr Virus & Vaccine Res, Sch Med & Life Sci, Subang Jaya 47500, Selangor, Malaysia; [Wu, Yuan Seng] Sunway Univ, Sch Med & Life Sci, Dept Biol Sci, Subang Jaya 47500, Selangor, Malaysia; [Gan, Siew Hua] Monash Univ Malaysia, Sch Pharm, Bandar Sunway 47500, Selangor Darul, Malaysia; [Bonam, Srinivasa Reddy] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, Inst Natl Sante & Rech Med, Paris, France; [Rani, Nur Najihah Izzati Mat] Univ Kuala Lumpur, Fac Pharm & Hlth Sci, Royal Coll Med Perak, Ipoh 30450, Perak, Malaysia; [Begum, M. Yasmin] King Khalid Univ KKU, Coll Pharm, Dept Pharmaceut, Asir Abha 61421, Saudi Arabia; [Subramaniyan, Vetriselvan] MAHSA Univ, Fac Med Biosci & Nursing, Jenjarom 42610, Selangor, Malaysia; [Fuloria, Neeraj Kumar; Fuloria, Shivkanya] AIMST Univ, Fac Pharm, Bedong 08100, Kedah, Malaysia; [Fuloria, Neeraj Kumar; Fuloria, Shivkanya] AIMST Univ, Ctr Excellence Biomat Engn, Bedong 08100, Kedah, Malaysia		Sekar, M (通讯作者)，Univ Kuala Lumpur, Fac Pharm & Hlth Sci, Dept Pharmaceut Chem, Royal Coll Med Perak, Ipoh 30450, Perak, Malaysia.	mahendransekar@unikl.edu.my	, mahendransekar/J-2397-2019; Wu, Yuan-Seng/S-9490-2019; BONAM, SRINIVASA REDDY/I-1342-2016; Sekar, Mahendran/J-6945-2016; gan, siew hua/A-6266-2011	, mahendransekar/0000-0002-3022-6137; Wu, Yuan-Seng/0000-0001-5574-8049; BONAM, SRINIVASA REDDY/0000-0002-2888-2418; Sekar, Mahendran/0000-0002-3022-6137; gan, siew hua/0000-0001-6470-3651; fuloria, Neeraj Kumar/0000-0002-8970-5212			Abbasi AM, 2015, INT J MOL SCI, V16, P13507, DOI 10.3390/ijms160613507; Ademosun AO, 2017, ORIENTAL PHARM EXP M, V17, P269, DOI 10.1007/s13596-017-0279-5; Al Heriri M, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00397; Al-Jarallah A, 2013, ATHEROSCLEROSIS, V228, P80, DOI 10.1016/j.atherosclerosis.2013.02.025; Alissa EM, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/569486; Anand SS, 2015, J AM COLL CARDIOL, V66, P1590, DOI 10.1016/j.jacc.2015.07.050; Ansari MN, 2007, HUM EXP TOXICOL, V26, P933, DOI 10.1177/0960327107085835; Aptekmann NP, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-119; Asgary S, 2013, ARYA ATHEROSCLER, V9, P98; Aune D, 2017, INT J EPIDEMIOL, V46, P1029, DOI 10.1093/ije/dyw319; Balasuriya N, 2012, FOOD CHEM, V135, P2320, DOI 10.1016/j.foodchem.2012.07.023; Bashir I., 2016, INT CURR PHARM J, V5, P69, DOI DOI 10.3329/ICPJ.V5I8.28875; Bondonno NP, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700674; Bonferoni MC, 2017, SEMIN CANCER BIOL, V46, P205, DOI 10.1016/j.semcancer.2017.06.010; Borde P, 2011, NAT PROD RES, V25, P1549, DOI 10.1080/14786410903335190; Brasil GA, 2014, PLANTA MED, V80, P1580, DOI 10.1055/s-0034-1383122; Brown BG, 2006, CURR OPIN LIPIDOL, V17, P631, DOI 10.1097/MOL.0b013e32800ff750; Cao K, 2015, SCI REP-UK, V5, DOI 10.1038/srep14014; Carapetis JR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.84; Carvajal-Zarrabal O, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/386425; Castello F, 2020, ARCH BIOCHEM BIOPHYS, V695, DOI 10.1016/j.abb.2020.108627; Cerda B, 2003, EUR J NUTR, V42, P18, DOI 10.1007/s00394-003-0396-4; Chen CY, 2005, J NUTR, V135, P1366, DOI 10.1093/jn/135.6.1366; Cocchi C, 2021, FUTUR CARDIOL, V17, P487, DOI 10.2217/fca-2021-0011; Connolly M, 2019, Curr Develop Nutri, V3, DOI 10.1093/cdn/nzz031.P06-102-19; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; D'Angelo S, 2012, J MED FOOD, V15, P1024, DOI 10.1089/jmf.2012.0076; Dabas D, 2013, CURR PHARM DESIGN, V19, P6133, DOI 10.2174/1381612811319340007; Davatgaran-Taghipour Y, 2017, INT J NANOMED, V12, P2689, DOI 10.2147/IJN.S131973; Del Rio D, 2013, ANTIOXID REDOX SIGN, V18, P1818, DOI 10.1089/ars.2012.4581; Dohadwala MM, 2009, J NUTR, V139, p1788S, DOI 10.3945/jn.109.107474; Drummond L, 2013, ADV FOOD NUTR RES, V68, P33, DOI 10.1016/B978-0-12-394294-4.00003-1; Duttaroy AK, 2004, PLATELETS, V15, P287, DOI 10.1080/09537100410001710290; Maldonado-Celis ME, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01073; Elkordy AA, 2021, J DRUG DELIV SCI TEC, V63, DOI 10.1016/j.jddst.2021.102459; Eno AE, 2000, PHYTOTHER RES, V14, P235, DOI 10.1002/1099-1573(200006)14:4&lt;235::AID-PTR574&gt;3.0.CO;2-G; Escudero-Lopez B, 2013, J AGR FOOD CHEM, V61, P8773, DOI 10.1021/jf401240p; Everson-Rose SA, 2005, ANNU REV PUBL HEALTH, V26, P469, DOI 10.1146/annurev.publhealth.26.021304.144542; Fidrianny I, 2013, INT J PHARM PHARM SC, V5, P189, DOI DOI 10.3923/rjmp.2013.130.140; Fraccarollo D, 2012, CARDIOVASC RES, V94, P293, DOI 10.1093/cvr/cvs109; Gammon CS, 2013, BRIT J NUTR, V109, P2208, DOI 10.1017/S0007114512004400; Gargallo Fernandez Manuel, 2012, Endocrinol Nutr, V59, P429; Gattuso G, 2007, MOLECULES, V12, P1641, DOI 10.3390/12081641; Gayer BA, 2019, CURR DEV NUTR, V3, DOI 10.1093/cdn/nzz109; Gayosso-Garcia Sancho L. E., 2010, American Journal of Agricultural and Biological Sciences, V5, P194; Glaser D, 2006, PLATELETS, V17, P37, DOI 10.1080/09537100500197489; Go AS, 2013, CIRCULATION, V127, pE841, DOI 10.1161/CIR.0b013e31829ae08c; Godse S, 2010, PHARM BIOL, V48, P494, DOI 10.3109/13880200903188526; Gonzalez J, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/918384; Gouegni EF., 2013, NIGER FOOD J, V31, P64, DOI [10.1016/S0189-7241(15)30057, DOI 10.1016/S0189-7241(15)30057]; Rodriguez-Sanchez DG, 2015, FOOD FUNCT, V6, P193, DOI 10.1039/c4fo00610k; Guo DC, 2006, ANN NY ACAD SCI, V1085, P339, DOI 10.1196/annals.1383.013; Haghighian MK, 2016, EUR J INTEGR MED, V8, P676, DOI 10.1016/j.eujim.2016.06.010; Hajipour Somayeh, 2014, Pak J Biol Sci, V17, P991, DOI 10.3923/pjbs.2014.991.998; Haq S, 2001, CIRCULATION, V103, P670; Hattori Y, 2010, DIABETOLOGIA, V53, P2256, DOI 10.1007/s00125-010-1831-8; HEINICKE R. M., 1957, ECON BOT, V11, P225, DOI 10.1007/BF02860437; Hering NA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.610164; Hiraga Y, 2021, BIOSCI BIOTECH BIOCH, V85, P1194, DOI 10.1093/bbb/zbab014; Hodgson JM, 2016, BRIT J NUTR, V115, P860, DOI 10.1017/S0007114515005231; Hsieh CL, 2016, J FOOD SCI, V81, pH2059, DOI 10.1111/1750-3841.13390; Hughson RL, 2018, NAT REV CARDIOL, V15, P167, DOI 10.1038/nrcardio.2017.157; Humphries KH, 2017, FRONT NEUROENDOCRIN, V46, P46, DOI 10.1016/j.yfrne.2017.04.001; Iwasawa H, 2011, BIOL PHARM BULL, V34, P128, DOI 10.1248/bpb.34.128; Izem-Meziane M, 2012, AM J PHYSIOL-HEART C, V302, pH665, DOI 10.1152/ajpheart.00467.2011; Jadeja RN, 2010, CARDIOVASC TOXICOL, V10, P174, DOI 10.1007/s12012-010-9076-9; Juhasz B, 2008, AM J PHYSIOL-HEART C, V294, pH1365, DOI 10.1152/ajpheart.01005.2007; Jumde A, 2015, INT J SCI ENG TECHNO, V4, P2395; Jung KA, 2005, BIOL PHARM BULL, V28, P1782, DOI 10.1248/bpb.28.1782; Kadoya K, 2018, INT SYM MED INFORM, P186; Kalani A, 2015, METAB BRAIN DIS, V30, P427, DOI 10.1007/s11011-014-9537-0; Karlsen A, 2013, J HUM HYPERTENS, V27, P126, DOI 10.1038/jhh.2011.116; Koutsos A, 2015, NUTRIENTS, V7, P3959, DOI 10.3390/nu7063959; Kumar RK, 2013, INDIAN J MED RES, V137, P643; Kuriakose D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207609; Lagoa R, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.04.004; Leibowitz A, 2014, EUR J NUTR, V53, P973, DOI 10.1007/s00394-013-0601-z; Leifert WR, 2008, NUTR RES, V28, P729, DOI [10.1016/j.nutres.2008.08.007, 10.1016/j.nutres.2008.09.001]; Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4; Li H, 2014, MOL CELL ENDOCRINOL, V382, P998, DOI 10.1016/j.mce.2013.11.012; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lin JS, 2018, JAMA-J AM MED ASSOC, V320, P281, DOI 10.1001/jama.2018.4242; Liu RH, 2013, ADV NUTR, V4, p384S, DOI 10.3945/an.112.003517; Livio M, 1978, DRUGS EXP CLIN RES, V4, P49; Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902; Luzak B, 2014, ADV MED SCI-POLAND, V59, P178, DOI 10.1016/j.advms.2014.02.005; Mahmassani HA, 2018, AM J CLIN NUTR, V107, P523, DOI 10.1093/ajcn/nqx078; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Maoto MM, 2019, INT J FOOD PROP, V22, P355, DOI 10.1080/10942912.2019.1584212; Markus H., 2008, MEDICINE, V36, P586, DOI [10.1016/j.mpmed.2008.08.009, DOI 10.1016/J.MPMED.2008.08.009, 10.1016/j.mpmed.2016.06.006]; Mattioli AV, 2018, CLIN NUTR ESPEN, V27, P110, DOI 10.1016/j.clnesp.2018.05.010; Mc Namara K, 2019, INTEGR PHARM RES PRA, V8, P1, DOI 10.2147/IPRP.S133088; Mesotten L, 1998, J Nucl Med Technol, V26, P4; Mohan M, 2010, PHYTOTHER RES, V24, pS196, DOI 10.1002/ptr.3090; Mosterd A, 2007, HEART, V93, P1137, DOI 10.1136/hrt.2003.025270; Muthulakshmi S, 2013, MOL CELL BIOCHEM, V377, P23, DOI 10.1007/s11010-013-1566-1; Ndisang JF, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/506948; Neboh E.E., 2015, J EXP RES, V3, P92; Nerbonne JM, 2005, PHYSIOL REV, V85, P1205, DOI 10.1152/physrev.00002.2005; Neumayer C, 2006, J SURG RES, V133, P150, DOI 10.1016/j.jss.2005.12.005; Ng SW, 2009, SOC SCI MED, V68, P1305, DOI 10.1016/j.socscimed.2009.01.035; Niemann B, 2011, J AM COLL CARDIOL, V57, P577, DOI 10.1016/j.jacc.2010.09.040; Norred CL, 2001, ALTERN THER HEALTH M, V7, P58; Null G, 2017, J EVID-BASED INTEGR, V22, P68, DOI 10.1177/2156587216637539; Padmanabhan P., 2016, ENCY FOOD HLTH, P490, DOI [10.1016/B978-0-12-384947-2.00409-8, DOI 10.1016/B978-0-12-384947-2.00409-8]; Pala R, 2020, INT J NANOMED, V15, P3741, DOI 10.2147/IJN.S250872; Park E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091287; Pascall E, 2018, FUTUR CARDIOL, V14, P343, DOI 10.2217/fca-2017-0065; Pistollato F, 2016, TARGET ONCOL, V11, P1, DOI 10.1007/s11523-015-0378-5; Prabhu S., 2006, Indian Journal of Experimental Biology, V44, P209; Quinones M, 2013, FOOD RES INT, V51, P587, DOI 10.1016/j.foodres.2013.01.023; Quintieri AM, 2013, J NUTR BIOCHEM, V24, P1221, DOI 10.1016/j.jnutbio.2012.09.006; Rahimi HR, 2016, AVICENNA J PHYTOMEDI, V6, P383; Ravn-Haren G, 2013, EUR J NUTR, V52, P1875, DOI 10.1007/s00394-012-0489-z; Razavi SM, 2013, J MED FOOD, V16, P255, DOI 10.1089/jmf.2012.2408; Resende AC, 2013, J NUTR BIOCHEM, V24, P2119, DOI 10.1016/j.jnutbio.2013.08.003; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Safwen K, 2015, INT J STROKE, V10, P415, DOI 10.1111/ijs.12391; Sandoval-Ramirez BA, 2020, CRIT REV FOOD SCI, V60, P3862, DOI 10.1080/10408398.2019.1709801; Santana LF, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071608; Saxena P, 2014, J ACUTE DIS, V3, P228, DOI 10.1016/S2221-6189(14)60051-2; Sear, 2004, CONTIN ED ANAESTH CR, V4, P71, DOI DOI 10.1093/BJACEACCP/MKH020; Seenak P, 2021, NUTR METAB, V18, DOI 10.1186/s12986-021-00566-z; Serra AT, 2012, FOOD CHEM, V135, P2378, DOI 10.1016/j.foodchem.2012.07.067; Shanely RA, 2020, NUTR RES, V76, P9, DOI 10.1016/j.nutres.2020.02.005; Shanmuganayagam D, 2012, J AGR FOOD CHEM, V60, P5787, DOI 10.1021/jf203487g; Shao D, 2014, CELL METAB, V19, P232, DOI 10.1016/j.cmet.2013.12.013; Sharifi-Rad J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072326; Siddiqui IA, 2016, MOL NUTR FOOD RES, V60, P1330, DOI 10.1002/mnfr.201600035; Sikuten I, 2020, MOLECULES, V25, DOI 10.3390/molecules25235604; Singh M, 2014, J FOOD SCI TECH MYS, V51, P2070, DOI 10.1007/s13197-014-1267-0; Sousa FH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67577-3; Stonehouse W, 2013, CAN J PHYSIOL PHARM, V91, P442, DOI 10.1139/cjpp-2012-0303; Sun WY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34246; Svendsen M, 2015, BLOOD PRESSURE, V24, P48, DOI 10.3109/08037051.2014.976979; Tantry US, 2018, EXPERT OPIN PHARMACO, V19, P653, DOI 10.1080/14656566.2018.1457649; Terauchi M, 2014, MENOPAUSE, V21, P990, DOI [10.1097/GME.0000000000000200, 10.1097/gme.0000000000000200]; Thandapilly SJ, 2012, AM J HYPERTENS, V25, P1070, DOI 10.1038/ajh.2012.98; Tian J, 2018, CLIN EXP HYPERTENS, V40, P65, DOI 10.1080/10641963.2017.1313851; Wali N, 2019, NONVITAMIN AND NONMINERAL NUTRITIONAL SUPPLEMENTS, P367, DOI 10.1016/B978-0-12-812491-8.00050-3; Wang S, 2014, J NUTR BIOCHEM, V25, P363, DOI 10.1016/j.jnutbio.2013.10.002; Weinhaus AJ, 2009, HANDBOOK OF CARDIAC ANATOMY, PHYSIOLOGY, AND DEVICES, SECOND EDITION, P59, DOI 10.1007/978-1-60327-372-5_5; WHO, 2003, WHO TECH REP SER, V916, P1; WHO, 2014, INCR FRUITS VEG CONS; Wightman JD, 2015, J SCI FOOD AGR, V95, P1584, DOI 10.1002/jsfa.6890; Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055; Wilson RK, 2002, LIFE SCI, V71, P497, DOI 10.1016/S0024-3205(02)01708-3; Xu SW, 2019, PHARMACOL THERAPEUT, V196, P15, DOI 10.1016/j.pharmthera.2018.11.003; Xu SW, 2018, TRENDS ENDOCRIN MET, V29, P739, DOI 10.1016/j.tem.2018.04.007; Zhao CN, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060598; Zingg JM, 2013, BIOFACTORS, V39, P101, DOI 10.1002/biof.1072; Zino S, 1997, BMJ-BRIT MED J, V314, P1787, DOI 10.1136/bmj.314.7097.1787	154	2	2	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						739	769		10.2147/VHRM.S328096			31	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XH6VV	WOS:000725570800001	34858028	gold, Green Published			2022-04-27	
J	Mattioli, AV; Coppi, F; Manenti, A; Farinetti, A				Mattioli, Anna Vittoria; Coppi, Francesca; Manenti, Antonio; Farinetti, Alberto			Subclinical Vascular Damage: Current Insights and Future Potential	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						prevention; risk factors; women; lifestyle; microbiota; pandemic	PERIPHERAL ARTERIAL-DISEASE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ENDOTHELIAL FUNCTION; SEX-DIFFERENCES; GUT MICROBIOTA; WEIGHT-LOSS; INFLAMMATION; OBESITY; IMPACT	The cardiovascular risk assessment must be carried out during all the different phases of life because the cardiovascular risk and the related prevention actions are dynamic and constantly evolving. As patients age, they change their exposure to various risk factors and accumulate comorbidities by changing their subjective cardiovascular risk, so it is necessary to undertake personalized early and preventive diagnostic actions. The main approach to asymptomatic vascular disease is based on primary prevention with the adoption of a healthy lifestyle. Indeed, lifestyle influences most of the traditional risk factors. In recent years, important differences between the sexes regarding cardiovascular risk factors have emerged and in particular, risk factors specific for female sex have been identified. Women are more likely to be categorized into lower risk categories for cardiovascular disease and, as a result, receive less lifestyle counseling than men, as well as less intensive prevention. This narrative review aims to analyze CVD risk prevention in asymptomatic atherosclerosis with a look at new emerging factors. In the end, we quickly analyzed the effects of the recent pandemic on lifestyle and cardiovascular risk and the potential negative effects in the long term.	[Mattioli, Anna Vittoria; Manenti, Antonio] Univ Modena & Reggio Emilia, Surg Med & Dent Dept Morphol Sci Related Transpla, Via Pozzo 71, I-41100 Modena, Italy; [Coppi, Francesca] Policlin Modena, Cardiol Div, Modena, Italy; [Farinetti, Alberto] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy		Mattioli, AV (通讯作者)，Univ Modena & Reggio Emilia, Surg Med & Dent Dept Morphol Sci Related Transpla, Via Pozzo 71, I-41100 Modena, Italy.	annavittoria.mattioli@unimore.it	Mattioli, Anna Vittoria/G-6001-2012	Mattioli, Anna Vittoria/0000-0003-1487-9530; manenti, antonio/0000-0003-0523-9515			Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095; Ahmadi A, 2019, J AM COLL CARDIOL, V74, P1608, DOI 10.1016/j.jacc.2019.08.012; Andrade BS, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040700; [Anonymous], 2010, J PHYS ACT HEALTH, V7, pS370; Bakaloudi DR, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051514; Bendall CL, 2018, CRIT REV FOOD SCI, V58, P3070, DOI 10.1080/10408398.2017.1351917; Benjamin EJ, 2004, CIRCULATION, V109, P613, DOI 10.1161/01.CIR.0000112565.60887.1E; Berger JS, 2009, JAMA-J AM MED ASSOC, V302, P874, DOI 10.1001/jama.2009.1227; Betageri O, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-021-01577-1; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]; Bucciarelli V, 2022, TRENDS CARDIOVAS MED, V32, P12, DOI 10.1016/j.tcm.2021.09.009; Carrero JJ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012638; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P1468, DOI 10.1016/0735-1097(94)90141-4; Chait A, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00022; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; Cocchi C, 2021, FUTUR CARDIOL, V17, P487, DOI 10.2217/fca-2021-0011; COLLINS S. D., 1932, Public Health Reports, V47, P2159, DOI 10.2307/4580606; Coppi F, 2021, PROG NUTR, V23, DOI 10.23751/pn.v23i2.11755; Coromilas EJ, 2021, CIRC-ARRHYTHMIA ELEC, V14, P285, DOI 10.1161/CIRCEP.120.009458; Costa D, 2019, BIOGERONTOLOGY, V20, P605, DOI 10.1007/s10522-019-09824-3; Cotillard A, 2013, NATURE, V500, P585, DOI 10.1038/nature12480; D'Ascenzi F, 2021, EUR J PREV CARDIOL, V28, P361, DOI 10.1177/2047487319893832; Despres JP, 2021, J AM COLL CARDIOL, V78, P513, DOI 10.1016/j.jacc.2021.05.035; Ding QY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.530160; Dinu M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062007; Dinu M, 2020, ADV NUTR, V11, P815, DOI 10.1093/advances/nmaa006; Fisher EA, 2012, ARTERIOSCL THROM VAS, V32, P2813, DOI 10.1161/ATVBAHA.112.300133; Forsythe LKS, 2008, NUTR RES REV, V21, P117, DOI 10.1017/S0954422408138732; Garcia M, 2016, CIRC RES, V118, P1273, DOI 10.1161/CIRCRESAHA.116.307547; Garrett S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X561249; Goossens GH, 2021, NAT REV ENDOCRINOL, V17, P47, DOI 10.1038/s41574-020-00431-8; Goossens GH, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00055; Guo DQ, 2017, ONCOTARGET, V8, P77020, DOI 10.18632/oncotarget.20331; Han SH, 2008, EUR HEART J, V29, P1359, DOI 10.1093/eurheartj/ehn142; Hardin SJ, 2019, REV CARDIOVASC MED, V20, P121, DOI 10.31083/j.rcm.2019.03.518; Hughes WE, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0802-6; Jiao N, 2018, PHYSIOL GENOMICS, V50, P244, DOI 10.1152/physiolgenomics.00114.2017; Jie ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00900-1; Jones AC, 2021, CURR ATHEROSCLER REP, V23, DOI 10.1007/s11883-021-00965-w; Juonala M, 2008, EUR HEART J, V29, P1198, DOI 10.1093/eurheartj/ehm556; Kirichenko TV, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586189; Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401; Kotseva K, 2010, EUR J CARDIOV PREV R, V17, P530, DOI 10.1097/HJR.0b013e3283383f30; Kurilshikov A, 2019, CIRC RES, V124, P1808, DOI 10.1161/CIRCRESAHA.118.314642; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Li D, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.673839; Louvardi M, 2020, PALLIAT SUPPORT CARE, V18, P394, DOI 10.1017/S1478951520000528; Madsen EL, 2008, EUR J ENDOCRINOL, V158, P179, DOI 10.1530/EJE-07-0721; Magriplis E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030853; Matthews KA, 2009, J AM COLL CARDIOL, V54, P2366, DOI 10.1016/j.jacc.2009.10.009; Mattioli AV, 2017, NUTR METAB CARDIOVAS, V27, P985, DOI 10.1016/j.numecd.2017.09.011; Mattioli AV, 2018, J CARDIOVASC MED, V19, P183, DOI 10.2459/JCM.0000000000000626; Mattioli AV, 2021, AM J LIFESTYLE MED, V15, P356, DOI 10.1177/1559827620981014; Mattioli Anna Vittoria, 2020, Obes Med, V20, P100263, DOI 10.1016/j.obmed.2020.100263; Mattioli AV, 2020, FUTUR CARDIOL, V16, P539, DOI 10.2217/fca-2020-0055; Mattioli AV, 2019, J CARDIOVASC MED, V20, P575, DOI 10.2459/JCM.0000000000000831; Meadows JL, 2020, CIRC-CARDIOVASC IMAG, V13, DOI 10.1161/CIRCIMAGING.120.011054; Napoli C, 2020, AM HEART J, V224, P113, DOI 10.1016/j.ahj.2020.03.007; Napoli C, 2012, CIRCULATION, V125, P2363, DOI 10.1161/CIRCULATIONAHA.111.085787; Napoli C, 2011, CARDIOVASC RES, V92, P367, DOI 10.1093/cvr/cvr201; Nasi M, 2020, MOL CELL NEUROSCI, V108, DOI 10.1016/j.mcn.2020.103538; Nasi M, 2019, J CARDIOVASC MED, V20, P631, DOI 10.2459/JCM.0000000000000855; Paolisso P, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01606; Pelliccia A, 2021, EUR HEART J, V42, P17, DOI [10.1093/eurheartj/ehaa605, 10.15829/1560-4071-2021-4488]; PIEPOLI MF, EUR HEART J, V42, P3227, DOI DOI 10.1093/EURHEARTJ/EHAB484; Rosengren A, 2004, EUR HEART J, V25, P663, DOI 10.1016/j.ehj.2004.02.023; Schiano C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236951; Sciomer S, 2019, EUR J PREV CARDIOL, V26, P609, DOI 10.1177/2047487318810560; Selvin E, 2007, ARCH INTERN MED, V167, P31, DOI 10.1001/archinte.167.1.31; Shaya Gabriel E, 2022, Trends Cardiovasc Med, V32, P181, DOI 10.1016/j.tcm.2021.04.002; Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87; Siti HN, 2015, VASC PHARMACOL, V71, P40, DOI 10.1016/j.vph.2015.03.005; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; Stanhewicz AE, 2018, AM J PHYSIOL-HEART C, V315, pH1569, DOI 10.1152/ajpheart.00396.2018; Su HY, 2019, CLIN CARDIOL, V42, P39, DOI 10.1002/clc.23095; Sun XL, 2016, BIOCHEM BIOPH RES CO, V481, P63, DOI 10.1016/j.bbrc.2016.11.017; Wolf G, 2006, NUTR REV, V64, P47, DOI [10.1301/nr.2006.jan.47-50, 10.1111/j.1753-4887.2006.tb00173.x]; Woodward M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071165; Yoshikawa T, 2021, CIRC J, V85, P1365, DOI 10.1253/circj.CJ-20-0751; Yu SJ, 2019, EXP CELL RES, V379, P191, DOI 10.1016/j.yexcr.2019.04.002; Ziv-Baran T, 2017, CLIN CHIM ACTA, V471, P185, DOI 10.1016/j.cca.2017.06.008	82	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						729	738		10.2147/VHRM.S242636			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XO1RN	WOS:000729970400003	34866906	Green Published, gold			2022-04-27	
J	Murakami, K; Inayama, E; Itoh, Y; Tuchiya, S; Iwasaki, M; Tamura, N; Suzuki, T; Iwai, N; Utino, J; Masai, M; Nagayama, D; Shirai, K				Murakami, Kouichi; Inayama, Emi; Itoh, Yukiko; Tuchiya, Shoji; Iwasaki, Masashi; Tamura, Nobuko; Suzuki, Toshihiko; Iwai, Noriko; Utino, Junji; Masai, Motoyuki; Nagayama, Daiji; Shirai, Kohji			The Role of Cardio-Ankle Vascular Index as a Predictor of Mortality in Patients on Maintenance Hemodialysis	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hemodialysis patient; mortality; cardio-ankle vascular index; phosphorus	PULSE-WAVE VELOCITY; ARTERIAL STIFFNESS; CARDIOVASCULAR EVENTS; HEART-FAILURE; ASSOCIATION; DISEASE; CAVI	Aim: Mortality rate of maintenance hemodialysis patients is known to be high. Cardio-ankle vascular index (CAVI) is an index reflecting the proper stiffness of the arterial tree from the origin of the aorta to the ankle. We aimed to clarify the utility of CAVI as a predictor of mortality in hemodialysis patients. The roles of age and nutritional conditions on survival were also examined. Methods: We followed 242 patients undergoing hemodialysis for 6 consecutive years. Data from 209 patients (mean age was 60 +/- 11 years) excluding those with ankle-brachial index <0.90 were then analyzed. CAVI and heart to ankle pulse wave velocity (haPWV) were measured using Vasera 1500. Results: Thirty-eight hemodialysis patients who died during the 6-year period had higher age, cardiothoracic ratio (CTR), CAVI, and haPWV, and lower diastolic blood pressure, albumin, phosphate, and calcium phosphate product. The Kaplan-Meier curves for cumulative survival among the tertile groups showed that the mortality rate was higher in the highest tertile (T3) compared to T1/T2 for both CAVI and haPWV. Receiver operating characteristic (ROC) analysis revealed that CAVI had better discriminatory power for all-cause mortality compared to haPWV. In the Cox-proportional hazards analyses, 1 SD increase in both parameters contributed independently to all-cause mortality [CAVI: HR 1.595 (95% CI 1.108-2.297), haPWV: HR 1.695 (95% CI 1.185-2.425)], as well as age and CTR. Both parameters above the cut-offs estimated in the ROC analysis (CAVI >= 9.2, haPWV >= 8.9) also had independent contributions to mortality. Conclusion: Through the 6 consecutive years of follow-up in 209 HD patients, increased CAVI might represent a major modifiable risk factor for all-cause mortality. Further research is needed to examine whether CAVI-lowering interventions contribute to improved prognosis.	[Murakami, Kouichi; Inayama, Emi; Itoh, Yukiko; Tuchiya, Shoji; Tamura, Nobuko; Iwai, Noriko] Seijinaki Mihama Narita Clin, Narita City, Chiba 2860041, Japan; [Iwasaki, Masashi] Seijinkai Mihama Katori Clin, Katori City, Chiba 2870041, Japan; [Suzuki, Toshihiko] Seijinkai Mihama Sakura Clin, Sakura, Chiba 2850841, Japan; [Utino, Junji; Masai, Motoyuki; Shirai, Kohji] Seijinkai Mihama Hosp, Sakura, Chiba 2610013, Japan; [Nagayama, Daiji] Nagayama Clin, 2-12-22 Tenjin Cho, Oyama City, Tochigi 3230032, Japan; [Nagayama, Daiji; Shirai, Kohji] Toho Univ, Sakura Hosp, Sch Med, Sakura, Chiba 2858741, Japan		Nagayama, D (通讯作者)，Nagayama Clin, 2-12-22 Tenjin Cho, Oyama City, Tochigi 3230032, Japan.	deverlast96071@gmail.com					Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022; El Ghoul B, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2543262; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hanlon P, 2018, LANCET PUBLIC HEALTH, V3, pE323, DOI 10.1016/S2468-2667(18)30091-4; HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8; Hayashida H, 2013, ATHEROSCLEROSIS, V229, P186, DOI 10.1016/j.atherosclerosis.2013.04.002; Ichihara A, 2008, AM J KIDNEY DIS, V52, P947, DOI 10.1053/j.ajkd.2008.06.007; Imanishi R, 2004, HYPERTENS RES, V27, P71, DOI 10.1291/hypres.27.71; Itano S, 2020, AM J HYPERTENS, V33, P1003, DOI 10.1093/ajh/hpaa097; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kato A, 2012, THER APHER DIAL, V16, P232, DOI 10.1111/j.1744-9987.2012.01058.x; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; Kirigaya J, 2020, J ATHEROSCLER THROMB, V27, P657, DOI 10.5551/jat.51409; Kirkham FA, 2019, J AM GERIATR SOC, V67, P317, DOI 10.1111/jgs.15648; Kubozono T, 2009, J ATHEROSCLER THROMB, V16, P840; Lopes MB, 2020, NEPHROL DIAL TRANSPL, V35, P1794, DOI 10.1093/ndt/gfaa054; Ma LJ, 2017, INT J CARDIOL, V238, P151, DOI 10.1016/j.ijcard.2017.02.095; Morita N, 2017, J ATHEROSCLER THROMB, V24, P819, DOI 10.5551/jat.36517; Nakamura K, 2009, J ATHEROSCLER THROMB, V16, P371, DOI 10.5551/jat.No687; Nitta K, 2020, RENAL REPLACE THER, V6, DOI 10.1186/s41100-020-00286-9; Noike H, 2010, J ATHEROSCLER THROMB, V17, P517, DOI 10.5551/jat.3707; Ogawa A, 2020, INT HEART J, V61, P769, DOI 10.1536/ihj.20-058; Okute Y, 2017, J ATHEROSCLER THROMB, V24, P412, DOI 10.5551/jat.36426; Saiki A, 2020, J ATHEROSCLER THROMB, V27, P732, DOI 10.5551/jat.RV17043; Sato Y, 2016, J ATHEROSCLER THROMB, V23, P596, DOI 10.5551/jat.31385; Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101, DOI 10.5551/jat.13.101; Shirai K, 2019, J ATHEROSCLER THROMB, V26, P603, DOI 10.5551/jat.48314; Shirai K, 2011, J ATHEROSCLER THROMB, V18, P49, DOI 10.5551/jat.3582; Tomita Y, 2020, REV CARDIOVASC MED, V21, P353, DOI 10.31083/j.rcm.2020.03.67; Ueyama K, 2009, HYPERTENS RES, V32, P716, DOI 10.1038/hr.2009.83; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zhang CM, 2013, INT HEART J, V54, P216, DOI 10.1536/ihj.54.216	32	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						791	798		10.2147/VHRM.S339769			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XN6KR	WOS:000729612000003	34880622	Green Published, gold			2022-04-27	
J	Rabben, T; Mansoor, SM; Bay, D; Sundhagen, JO; Guevara, C; Jorgensen, JJ				Rabben, Toril; Mansoor, Saira Mauland; Bay, Dag; Sundhagen, Jon Otto; Guevara, Cecilia; Jorgensen, Jorgen Joakim			Screening for Abdominal Aortic Aneurysms and Risk Factors in 65-Year-Old Men in Oslo, Norway	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						prevalence; sub-aneurysmal aorta; ultrasonography; men; smoking; diabetes	EDITORS CHOICE; PREVALENCE; MORTALITY; ASSOCIATION; PROGRAM; DISEASE; REPAIR; ULTRASONOGRAPHY; GUIDELINES; SOCIETY	Purpose: To investigate the prevalence of and risk factors for abdominal aortic aneurysm (AAA) in 65-year-old men in Oslo, Norway. Materials and Methods: From May 2011, until September 2019, the annual population of 65 -year-old men living in Oslo were invited to an ultrasonographic screening of the abdominal aorta. Candidates received a one-time invitation by mail, including a questionnaire on possible risk factors and comorbidities. Abdominal aortic outer-to-outer diameter and ankle-brachial index were measured by the screening team. Participants were allocated into three groups: non-, sub-and aneurysmal aorta. Written information on recommended follow-up regime was given to participants with an aortic diameter >= 25 mm. Univariate and multivariate analyses of potential risk factors were performed, in addition to descriptive analyses and significance testing. Results: In total, 19,328 were invited, 13,215 men were screened, of which 12,822 accepted inclusion in the study. Aortic diameter was registered for 12,810 participants and 330 men had aortic diameter >= 30 mm, giving a prevalence of AAA of 2.6% (95% confidence interval (CI) 2.31-2.86). We identified 4 independent risk factors for AAA: smoking (OR = 3.64, 95% CI 2.90-4.58), hypertension (OR = 1.87, 95% CI 1.49-2.35), BMI >30 (OR = 1.02, 95% CI 1.00-1.03), and diabetes mellitus (OR = 0.52, 95% CI 0.35-0.79), the latter showing an inverse association with AAA growth. A subgroup of 862 men with aortic diameters 25-29 mm had a significantly higher prevalence of BMI >25, smoking and family history of AAA, compared to participants with aortic diameter <25 mm. Conclusion: Among the participants in this study, the prevalence of abdominal aortic aneurysms was 2.6%. Participants with AAA more frequently reported cardiovascular risk factors, and less frequently diabetes mellitus.	[Rabben, Toril; Mansoor, Saira Mauland; Sundhagen, Jon Otto; Guevara, Cecilia; Jorgensen, Jorgen Joakim] Oslo Univ Hosp, Dept Vasc Surg, POB 4950 Nydalen, N-0424 Oslo, Norway; [Bay, Dag] Oslo Univ Hosp, Dept Radiol & Intervent Radiol, Oslo, Norway; [Jorgensen, Jorgen Joakim] Oslo Univ Hosp, Dept Traumatol, Oslo, Norway; [Jorgensen, Jorgen Joakim] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway		Rabben, T (通讯作者)，Oslo Univ Hosp, Dept Vasc Surg, POB 4950 Nydalen, N-0424 Oslo, Norway.	torabb@ous-hf.no					Aboyans V, 2018, EUR J VASC ENDOVASC, V55, P305, DOI 10.1016/j.ejvs.2017.07.018; Ali MU, 2018, J VASC SURG, V68, P612, DOI 10.1016/j.jvs.2018.03.411; Ali MU, 2016, J VASC SURG, V64, P1855, DOI 10.1016/j.jvs.2016.05.101; Ammar AD, 2019, AM SURGEON, V85, P1341; [Anonymous], 2021, PERCENTAGE DAILY SMO; Ashton H, 2001, J MED SCREEN, V8, P46; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Aune D, 2018, J DIABETES COMPLICAT, V32, P1169, DOI 10.1016/j.jdiacomp.2018.09.009; Beck AW, 2009, J VASC SURG, V49, P838, DOI 10.1016/j.jvs.2008.10.067; Benson RA, 2016, J VASC SURG, V63, P301, DOI 10.1016/j.jvs.2015.08.091; Briggs CS, 2018, J VASC SURG, V68, P408, DOI 10.1016/j.jvs.2017.12.037; Budtz-Lilly J, 2018, EUR J VASC ENDOVASC, V56, P181, DOI 10.1016/j.ejvs.2018.01.014; Chabok M, 2016, BRIT J SURG, V103, P1132, DOI 10.1002/bjs.10179; Chaikof EL, 2018, J VASC SURG, V67, P2, DOI 10.1016/j.jvs.2017.10.044; Chun KC, 2019, J VASC SURG, V70, P1123, DOI 10.1016/j.jvs.2019.01.053; COLLIN J, 1988, LANCET, V2, P613; Cornuz J, 2004, EUR J PUBLIC HEALTH, V14, P343, DOI 10.1093/eurpub/14.4.343; Cosford PA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002945.pub2; Cronin O, 2013, ATHEROSCLEROSIS, V226, P321, DOI 10.1016/j.atherosclerosis.2012.10.041; Dattani N, 2018, DIABETES VASC DIS RE, V15, P367, DOI 10.1177/1479164118780799; Davis M, 2013, J VASC SURG, V57, P1440, DOI 10.1016/j.jvs.2012.10.114; Dias-Neto M, 2020, EUR J VASC ENDOVASC, V60, P27, DOI 10.1016/j.ejvs.2020.02.024; Fleming C, 2005, ANN INTERN MED, V142, P203, DOI 10.7326/0003-4819-142-3-200502010-00012; Forsdahl SH, 2009, CIRCULATION, V119, P2202, DOI 10.1161/CIRCULATIONAHA.108.817619; Golledge J, 2017, BRIT J SURG, V104, P1486, DOI 10.1002/bjs.10587; Guirguis-Blake JM, 2019, JAMA-J AM MED ASSOC, V322, P2219, DOI 10.1001/jama.2019.17021; Guirguis-Blake JM, 2014, ANN INTERN MED, V160, P321, DOI 10.7326/M13-1844; Hernesniemi JA, 2015, J VASC SURG, V62, P232, DOI 10.1016/j.jvs.2015.02.037; Hjellestad ID, 2016, J DIABETES COMPLICAT, V30, P438, DOI 10.1016/j.jdiacomp.2015.12.015; Kent KC, 2010, J VASC SURG, V52, P539, DOI 10.1016/j.jvs.2010.05.090; Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR; Kobeissi E, 2019, EUR J EPIDEMIOL, V34, P547, DOI 10.1007/s10654-019-00510-9; Koshty A, 2021, THORAC CARDIOV SURG, V69, P57, DOI 10.1055/s-0038-1676336; KROHN CD, 1992, EUR J SURG, V158, P527; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lin YT, 2019, ANGIOLOGY, V70, P41, DOI 10.1177/0003319718757615; Lindholt JS, 2005, BMJ-BRIT MED J, V330, P750, DOI 10.1136/bmj.38369.620162.82; Newman AB, 2001, ANN INTERN MED, V134, P182, DOI 10.7326/0003-4819-134-3-200102060-00008; Norman PE, 2004, BRIT MED J, V329, P1259, DOI 10.1136/bmj.38272.478438.55; Oliver-Williams C, 2018, BRIT J SURG, V105, P68, DOI 10.1002/bjs.10715; Owens DK, 2019, JAMA-J AM MED ASSOC, V322, P2211, DOI 10.1001/jama.2019.18928; Powell JT, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7661; Qadura M, 2013, J VASC SURG, V57, P1676, DOI 10.1016/j.jvs.2013.02.013; Reutersberg B, 2020, VASA, V49, P375, DOI 10.1024/0301-1526/a000881; Roosendaal LC, 2020, EUR J VASC ENDOVASC, V59, P16, DOI 10.1016/j.ejvs.2019.07.014; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; Singh K, 2001, AM J EPIDEMIOL, V154, P236, DOI 10.1093/aje/154.3.236; Stackelberg O, 2013, BRIT J SURG, V100, P360, DOI 10.1002/bjs.8983; Svensjo S, 2014, EUR J VASC ENDOVASC, V47, P37, DOI 10.1016/j.ejvs.2013.10.007; Takagi H, 2017, ANN VASC SURG, V39, P74, DOI 10.1016/j.avsg.2016.04.019; Takagi H, 2016, J VASC SURG, V64, P506, DOI 10.1016/j.jvs.2016.01.059; Takagi H, 2016, ANGIOLOGY, V67, P513, DOI 10.1177/0003319715602414; Takagi H, 2010, J VASC SURG, V52, P1103, DOI 10.1016/j.jvs.2010.02.283; Thompson SG, 2012, BRIT J SURG, V99, P1649, DOI 10.1002/bjs.8897; van Lindert NHA, 2009, EUR J NEUROL, V16, P602, DOI 10.1111/j.1468-1331.2009.02550.x; Vanni V, 2021, SCAND J SURG, V110, P395, DOI 10.1177/1457496920917269; Wanhainen A, 2019, EUR J VASC ENDOVASC, V57, P8, DOI 10.1016/j.ejvs.2018.09.020; Wanhainen A, 2016, CIRCULATION, V134, P1141, DOI 10.1161/CIRCULATIONAHA.116.022305; Watson JDB, 2020, SEMIN VASC SURG, V33, P54, DOI 10.1053/j.semvascsurg.2020.05.002	59	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						561	570		10.2147/VHRM.S310358			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XH2QJ	WOS:000725285200002	34531660	Green Published, gold			2022-04-27	
J	Taengsakul, N; Saiwongse, T; Sakornwattananon, O; Kreesaeng, P; Kantathavorn, N				Taengsakul, Nawaphan; Saiwongse, Thaweechai; Sakornwattananon, Orattha; Kreesaeng, Pattraporn; Kantathavorn, Nuttavut			Incidence and Risk Factors for Venous Thromboembolism Following 2462 Major Abdomino-Pelvic Surgeries in Tertiary Hospital	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						postoperative venous thromboembolism; deep vein thrombosis; thromboprophylaxis; abdomino-pelvic surgery; Thailand	DEEP-VEIN THROMBOSIS; BLEEDING COMPLICATIONS; CANCER; ERYTHROCYTES; EPIDEMIOLOGY; PROPHYLAXIS; PREDICTORS; RECURRENCE; PREVENTION; MORTALITY	Purpose: To determine the incidence and risk factor of postoperative venous thromboembolism (VTE) in Thai populations and to evaluate morbidity, mortality, bleeding complications and the benefit of thromboprophylaxis in real-world practice. Patients and Methods: We performed a retrospective, single-center, cohort study of patients from all age groups who underwent elective open or laparoscopic major abdominopelvic surgery between January 2008 and December 2018 at Chulabhorn Hospital, Bangkok, Thailand. We collected general medical information and specific data based on items from the Caprini risk scoring system. Results: A total of 2462 major abdomino-pelvic surgeries were included. The study population consisted of 742 males (30.1%) and 1720 females (69.9%) aged 54.59 +/- 13.27 years. The incidence of VTE in Thai patients that underwent major abdominal surgery was 0.48%. The most frequent influencing factor for VTE was a history of pulmonary embolism, which increased the risk of VTE 98.28-fold, whereas a history of deep vein thrombosis increased the risk of VTE by 12.34-fold. Other factors influencing VTE development were obesity, anticoagulant use, postoperative chemotherapy, preoperative chemotherapy, endometrium cancer, tumor-node-metastasis (TNM) stage 4 and American College of Chest Physicians (ACCP) class 4. Protective factors included no history of VTE, laparoscopic surgery, TNM stage 0 and benign disease and BMI<30. VTE significantly increased mortality whereas following ACCP guideline reduced mortality. Conclusion: Post-operative VTE incidence in Thai patients undergoing major abdominopelvic surgery was lower compared with Western patients. Factors influencing for VTE were history of VTE, anticoagulant use, postoperative chemotherapy, preoperative chemotherapy, endometrium cancer, TNM stage 4 and ACCP class 4. Following ACCP guideline reduced the incidence of mortality.	[Taengsakul, Nawaphan; Saiwongse, Thaweechai; Sakornwattananon, Orattha; Kreesaeng, Pattraporn] Chulabhorn Royal Acad, Chulabhorn Hosp, HRH Princess Chulabhorn Coll Med Sci, Dept Surg, 906 Kamphaeng Phet 6 Rd, Bangkok 10210, Thailand; [Kantathavorn, Nuttavut] Chulabhorn Royal Acad, Chulabhorn Hosp, HRH Princess Chulabhorn Coll Med Sci, Dept Obstet & Gynecol, Bangkok, Thailand; [Kantathavorn, Nuttavut] Chulabhorn Royal Acad, HRH Princess Chulabhorn Coll Med Sci, Fac Med & Publ Hlth, Bangkok, Thailand		Taengsakul, N (通讯作者)，Chulabhorn Royal Acad, Chulabhorn Hosp, HRH Princess Chulabhorn Coll Med Sci, Dept Surg, 906 Kamphaeng Phet 6 Rd, Bangkok 10210, Thailand.	nawaphan.tan@pccms.ac.th			Chulabhorn Hospital Research Grant	This study was supported by Chulabhorn Hospital Research Grant. The authors would like to extend our special thanks to all patients and staff of Chulabhorn Hospital for their kind assistance and support towards the success and accomplishment of this study.	Ageno W, 2008, CIRCULATION, V117, P93, DOI 10.1161/CIRCULATIONAHA.107.709204; Angchaisuksiri P, 2007, INT J HEMATOL, V86, P397, DOI 10.1532/IJH97.A20715; Angchaisuksiri P, 2011, THROMB HAEMOSTASIS, V106, P585, DOI 10.1160/TH11-03-0184; Bahl V, 2010, ANN SURG, V251, P344, DOI 10.1097/SLA.0b013e3181b7fca6; Braekkan SK, 2010, HAEMATOL-HEMATOL J, V95, P270, DOI 10.3324/haematol.2009.008417; Cohen AT, 2017, THROMB HAEMOSTASIS, V117, P57, DOI 10.1160/TH15-08-0686; Connolly GC, 2010, THROMB RES, V126, P113, DOI 10.1016/j.thromres.2010.05.012; Di Nisio M, 2016, LANCET, V388, P3060, DOI 10.1016/S0140-6736(16)30514-1; Graul A, 2017, INT J GYNECOL CANCER, V27, P581, DOI 10.1097/IGC.0000000000000912; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Heit JA, 2000, ARCH INTERN MED, V160, P761, DOI 10.1001/archinte.160.6.761; Ho KM, 2012, J THROMB HAEMOST, V10, P1768, DOI 10.1111/j.1538-7836.2012.04846.x; Kakkar AK, 2006, HEMOSTASIS THROMBOSI, P1361; Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301; Kim IG, 2004, J KOREAN SOC VASC SU, V20, P237; Kim JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061968; Kroger K, 2006, ANN ONCOL, V17, P297, DOI 10.1093/annonc/mdj068; Lee CH, 2010, J THROMB HAEMOST, V8, P1515, DOI 10.1111/j.1538-7836.2010.03873.x; Leonardi MJ, 2006, ARCH SURG-CHICAGO, V141, P790, DOI 10.1001/archsurg.141.8.790; Liew NC, 2017, INT ANGIOL, V36, P1, DOI 10.23736/S0392-9590.16.03765-2; Louzada ML, 2012, CIRCULATION, V126, P448, DOI 10.1161/CIRCULATIONAHA.111.051920; Matsuo K, 2013, GYNECOL ONCOL, V128, P544, DOI 10.1016/j.ygyno.2012.12.014; Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669; Mutirangura P, 2004, INT J ANGIOL, V13, P81; Nicolaides AN, 2001, INT ANGIOL, V20, P1; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Prandoni P, 2021, SEMIN THROMB HEMOST, V47, P914, DOI 10.1055/s-0040-1718927; Rauh-Hain JA, 2015, OBSTET GYNECOL, V125, P1362, DOI 10.1097/AOG.0000000000000866; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; Shapiro R, 2011, DIS COLON RECTUM, V54, P1496, DOI 10.1097/DCR.0b013e31823302a1; Shaw JR, 2019, J THROMB HAEMOST, V17, P1171, DOI 10.1111/jth.14468; Sugimachi K, 2012, J SURG RES, V178, P657, DOI 10.1016/j.jss.2012.06.002; 양신석, 2012, Vascular specialist international, V28, P37; Tsai AW, 2002, AM J MED, V113, P636, DOI 10.1016/S0002-9343(02)01345-1; Vachirasrisirikul Sitthichai, 2016, Journal of the Medical Association of Thailand, V99, P665; VALLES J, 1991, BLOOD, V78, P154; Wu PK, 2014, THROMB RES, V133, P719, DOI 10.1016/j.thromres.2014.01.039; Yeo DXW, 2015, WORLD J SURG, V39, P150, DOI 10.1007/s00268-014-2763-0; Yhim HY, 2014, J THROMB HAEMOST, V12, P1035, DOI 10.1111/jth.12611	39	1	1	0	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						135	143		10.2147/VHRM.S304187			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RK0WO	WOS:000638025800001	33854322	Green Published			2022-04-27	
J	Zatonska, K; Basiak-Rasala, A; Poltyn-Zaradna, K; Rozanska, D; Karczewski, M; Wolyniec, M; Szuba, A				Zatonska, Katarzyna; Basiak-Rasala, Alicja; Poltyn-Zaradna, Katarzyna; Rozanska, Dorota; Karczewski, Maciej; Wolyniec, Maria; Szuba, Andrzej			Characteristic of FINDRISC Score and Association with Diabetes Development in 6-Year Follow-Up in PURE Poland Cohort Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						diabetes; preventive medicine; epidemiology	RISK SCORE; INSULIN-RESISTANCE; PROSPECTIVE URBAN; TYPE-2; QUESTIONNAIRE; PREVALENCE; GUIDELINES; POSITION; DISEASES; TOOL	Purpose: The aim of the study was to assess if FINDRISC score was associated with diabetes development after 6 years of observation. Methods: Polish cohort is a part of global PURE study. Hereby analysis presents data from baseline (2007-2010) and 6-year follow-up (2013-2016) and was conducted on 1090 participants (702 women) from urban and rural areas in Lower Silesia region (Poland) without diabetes at the baseline and with complete data throughout course of the study. Results: At the baseline, women had significantly higher FINDRISC score than men (10.43 vs 8.91; p'0.000) and participants from rural areas had higher score than from urban areas (10.97 vs 9.33; p=0.000). At the baseline, 25.87% of the participants had low risk of diabetes according to FINDRISC score, 38.90% had slightly elevated risk, 16.79% moderate risk, 16.42% high risk and 2.02% very high risk. Participants, who were healthy at baseline, but developed diabetes after 6 years of observation had significantly higher FINDRISC, than those who did not (13.39 vs 9.36; p=0.000). In 6-year follow-up, diabetes was diagnosed in 2.8% of participants, who were ascer-tained to "low risk" according to FINDRISC score in baseline; in 9.9% of participants of "slightly elevated risk", 17.5% of participants of "moderate risk", 26.8% in participants of "high risk" and 50.0% of participants of "very high risk". Conclusions: Results of PURE Poland cohort study indicates that higher FINDRISC score at the baseline was associated with higher risk of diabetes development during 6 years of observation.	[Zatonska, Katarzyna; Basiak-Rasala, Alicja; Poltyn-Zaradna, Katarzyna; Wolyniec, Maria] Wroclaw Med Univ, Dept Social Med, 0 Bujwida 44 St, PL-50345 Wroclaw, Poland; [Rozanska, Dorota] Wroclaw Med Univ, Dept Dietet, Wroclaw, Poland; [Karczewski, Maciej] Wroclaw Univ Environm & Life Sci, Fac Environm Engn & Geodesy, Dept Math, Wroclaw, Poland; [Szuba, Andrzej] Wroclaw Med Univ, Dept Angiol Hypertens & Diabetol, Wroclaw, Poland		Basiak-Rasala, A (通讯作者)，Wroclaw Med Univ, Dept Social Med, 0 Bujwida 44 St, PL-50345 Wroclaw, Poland.	alicja.basiak-rasala@umed.wroc.pl	Różańska, Dorota/ABD-3220-2021; Zatońska, Katarzyna/ABD-4236-2021; Połtyn-Zaradna, Katarzyna/ABD-4071-2021; Basiak-Rasała, Alicja/ABD-4068-2021; Rozanska, Dorota/S-5239-2018	Połtyn-Zaradna, Katarzyna/0000-0002-5094-219X; Basiak-Rasała, Alicja/0000-0002-0313-021X; Szuba, Andrzej/0000-0002-7555-6201; Rozanska, Dorota/0000-0002-0561-2749; Zatonska, Katarzyna/0000-0002-3772-5588; Wolyniec, Maria/0000-0003-2054-1691	Population Health Research Institute; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of OntarioHeart & Stroke Foundation of Ontario; Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [290/W-PURE/2008/0]	The main PURE study and its components are funded by the Population Health Research Institute, the Canadian Institutesof Health Research, Heart and Stroke Foundation of Ontario and through unrestricted grants from several pharmaceutical companies, Poland cohort study is funded by Polish Ministry of Science and Higher Education (grant no. 290/W-PURE/2008/0) . Additionally, presented research results, were con-ducted within the framework of the topic: "Analiza rozpows-zechnienia czynnikow ryzyka chorob cywilizacyjnych w populacji osob dorosych oraz dzieci w wieku szkolnym z uwzgldnieniem miejsca zamieszkania (miasto-wies) " (eng., Study of prevalence of risk factors of noncommunicable dis-eases in adults and school-aged children considering the place of residence (urban-rural) ") as per records in SIMPLE system number SUB. C. 300.20.033. We declare that funding body had no role in the design of the study, collection, analysis, or interpretation of data and no role in writing the manuscript.	Agardh E, 2011, INT J EPIDEMIOL, V40, P804, DOI 10.1093/ije/dyr029; [Anonymous], 2020, R LANG ENV STAT COMP; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dehghan M, 2012, J HUM NUTR DIET, V25, P225, DOI 10.1111/j.1365-277X.2012.01240.x; Espelt A, 2008, DIABETOLOGIA, V51, P1971, DOI 10.1007/s00125-008-1146-1; Fano V, 2013, EUR J PUBLIC HEALTH, V23, P991, DOI 10.1093/eurpub/cks168; Hwang CK, 2012, DIABETES RES CLIN PR, V96, P271, DOI 10.1016/j.diabres.2011.12.001; IDF, 2019, DIABETES ATLAS; Janghorbani M, 2013, DIABETES RES CLIN PR, V102, P202, DOI 10.1016/j.diabres.2013.10.018; Jarosz M., 2017, NUTR GUIDELINES POLI; Jolle A, 2019, BMJ OPEN DIAB RES CA, V7, DOI 10.1136/bmjdrc-2019-000769; Jolle A, 2016, BMJ OPEN DIAB RES CA, V4, DOI 10.1136/bmjdrc-2016-000217; Kalbarczyk WP., 2018, RAPORT INSTYTUTU OCH; Kengne AP, 2014, LANCET DIABETES ENDO, V2, P19, DOI 10.1016/S2213-8587(13)70103-7; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kulkarni M, 2017, DIABETES OBES METAB, V19, P1260, DOI 10.1111/dom.12949; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Lindstrom J, 2003, DIABETES CARE, V26, P725, DOI 10.2337/diacare.26.3.725; Mavrogianni C, 2019, DIABETES RES CLIN PR, V150, P99, DOI 10.1016/j.diabres.2019.02.017; Meijnikman AS, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0310-0; O'Connor A, 2012, PUBLIC HEALTH, V126, P813, DOI 10.1016/j.puhe.2012.05.029; Rawshani A, 2017, NEW ENGL J MED, V376, P1407, DOI 10.1056/NEJMoa1608664; Ryden L, 2013, EUR HEART J, V34, P3035, DOI 10.1093/eurheartj/eht108; Schwarz PEH, 2009, J CLIN ENDOCR METAB, V94, P920, DOI 10.1210/jc.2007-2427; Su Y, 2008, AM J CARDIOL, V102, P497, DOI 10.1016/j.amjcard.2008.03.087; Tan C, 2016, ENVIRON HEALTH PREV, V21, P470, DOI 10.1007/s12199-016-0568-5; Tankova T, 2011, DIABETES RES CLIN PR, V92, P46, DOI 10.1016/j.diabres.2010.12.020; Teo K, 2009, AM HEART J, V158, P1, DOI 10.1016/j.ahj.2009.04.019; US Department of Health and Human Services and US Department of Agriculture, 2015, 2015 2020 DIET GUID, DOI [10.1097/ NT.0b013-31826c50af, DOI 10.1097/NT.0B013-31826C50AF]; Zatonska K, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08970-5; Zozulinska-Ziolkiewicz D, 2019, CLIN DIABETOL, V8, P1	31	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						631	639		10.2147/VHRM.S321700			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WK4QQ	WOS:000709712300002	34611406	Green Published, gold			2022-04-27	
J	Dorogova, IV; Panina, ES				Dorogova, Inna V.; Panina, Elena S.			撤稿声明: Comparison of the BPLab (R) Sphygmomanometer for Ambulatory Blood Pressure Monitoring with Mercury Sphygmomanometry in Pregnant Women: Validation Study According to the British Hypertension Society Protocol (Retraction of Vol 11, Pg 245, 2015)	VASCULAR HEALTH AND RISK MANAGEMENT			English	Retraction																	Dorogova IV, 2015, VASC HEALTH RISK MAN, V11, P245, DOI 10.2147/VHRM.S82381	1	0	0	3	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						799	799		10.2147/VHRM.S352187			1	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XN6KR	WOS:000729612000004		Green Published, gold			2022-04-27	
J	Reynolds, TM; Pottle, A; Quoraishi, SH				Reynolds, Timothy Mark; Pottle, Alison; Quoraishi, Sadat H.			Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						cholesterol; lipid management; guidelines; recommendations; cost effectiveness	CHOLESTEROL; METAANALYSIS; MANAGEMENT	Despite widespread evidence of the effectiveness of lipid modification for the reduction of cardiovascular disease (CVD) risk, lipid modification goals are commonly underachieved in the United Kingdom (UK). In order to understand current UK lipid management guidance and the corresponding attainment of recommended lipid lowering goals relating to treatment with statins and ezetimibe, a literature review was conducted using PubMed focusing on publications between January 2017 and February 2020 in order to capture the most up-to-date literature. Identified publications were reviewed against key clinical guidelines for lipid management in relation to CVD risk from the National Institute for Health and Care Excellence (NICE, CG181), the Scottish Intercollegiate Guidelines Network (SIGN, 149) and European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS). Cholesterol lowering goals are central to current lipid lowering therapy guidance, although specific goals vary depending on the guideline and patients' individual risk profile. Current guidance by NICE and SIGN specifies that treatment should achieve a greater than 40% reduction in non-high-density lipoprotein cholesterol (non-HDL-C) at 3 months of treatment, while the ESC/EAS place emphasis on the lowering of low-density lipoprotein (LDL-C) and total cholesterol. Yet, despite widespread availability of guidance and consistent messaging that lipid lowering goals should be ambitious, current evidence suggests a significant proportion of UK patients have sub-optimal reductions in cholesterol/non-HDL-C/LDL-C. The reasons for this are reported to be multifactorial, including a lack of compliance with guidelines, particularly regarding high-intensity statin prescribing, patient adherence, statin intolerance and statin reluctance as well as wider genetic factors. A number of possible strategies to improve current lipid management and attainment of lipid-lowering goals were identified, including improving the patient-healthcare professional partnership, conducting audits of local prescribing versus guidance, implementing plans for the refinement of current services and considering alternative options such as cost-effective single pill combinations for improving adherence.	[Reynolds, Timothy Mark] Univ Hosp Derby & Burton, Burton Upon Trent, England; [Pottle, Alison] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Quoraishi, Sadat H.] Daiichi Sankyo UK Ltd, Uxbridge, Middx, England		Reynolds, TM (通讯作者)，Queens Hosp, Pathol Dept, Belvedere Rd, Burton Upon Trent DE13 0RB, Staffs, England.	Timothy.Reynolds2@NHS.net		Quoraishi, Sadat/0000-0003-0937-8723	Alexion Pharma UK Ltd; AmGen LtdAmgen; Boehringer Ingelheim GmbHBoehringer Ingelheim; Dalcor Pharmaceuticals; Sanofi-GenzymeSanofi-AventisGenzyme Corporation; Shire Pharmaceuticals Ltd; Takeda LtdTakeda Pharmaceutical Company Ltd	The development of this manuscript was initiated and funded by Daiichi Sankyo UK, who were involved in the design of the literature review and the review and approval of the manuscript. TR has received funding to attend conferences from Sanofi-Genzyme and for research projects (investigatorled and multicentre trials) from Alexion Pharma UK Ltd, AmGen Ltd, Boehringer Ingelheim GmbH, Dalcor Pharmaceuticals, Sanofi-Genzyme, Shire Pharmaceuticals Ltd, Takeda Ltd. He has no direct stock holdings in any pharmaceutical company or any patents.. AP has received funding to attend conferences from Sanofi.	Akyea RK, 2019, HEART, V105, P975, DOI 10.1136/heartjnl-2018-314253; Alkhalil M, 2020, ATHEROSCLEROSIS, V293, P75, DOI 10.1016/j.atherosclerosis.2019.12.006; [Anonymous], FAMILIAL HYPERCHOLES; Aubiniere-Robb L, 2019, BR J CARDIOL, V26, P141, DOI [10.5837/bjc.2019.041., DOI 10.5837/BJC.2019.041]; Banach M, 2018, CARDIOL CLIN, V36, P225, DOI 10.1016/j.ccl.2017.12.004; Catapano Alberico L, 2017, Rev Esp Cardiol (Engl Ed), V70, P115, DOI 10.1016/j.rec.2017.01.002; Cohen JD, 2017, J CLIN LIPIDOL, V11, P891, DOI [10.1016/j.jac1.2017.04.120, 10.1016/j.jacl.2017.04.120]; Connolly SB, 2017, HEART, V103, P840, DOI 10.1136/heartjnl-2016-310477; Danese MD, 2021, EUR J PREV CARDIOL, V28, P335, DOI 10.1177/2047487319899212; Danese MD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013851; De Backer G, 2019, ATHEROSCLEROSIS, V285, P135, DOI 10.1016/j.atherosclerosis.2019.03.014; Drexel H, EUR HEART J CARDIOVA; Elamin AFM, 2019, POSTGRAD MED J, V95, P61, DOI 10.1136/postgradmedj-2018-136171; European Medicines Agency, 2020, LEQV; Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144; Ferrieres J, 2018, EUR J PREV CARDIOL, V25, P1966, DOI 10.1177/2047487318806359; Finnikin S, 2017, BRIT J GEN PRACT, V67, pE881, DOI 10.3399/bjgp17X693485; Fulcher J, 2019, LANCET, V393, P407, DOI 10.1016/S0140-6736(18)31942-1; Giugliano RP, 2017, LANCET, V390, P1962, DOI 10.1016/S0140-6736(17)32290-0; Graham I, 2018, EUR HEART J-CARD PHA, V4, P119, DOI 10.1093/ehjcvp/pvx031; Karlson BW, 2017, ATHEROSCLEROSIS, V265, P54, DOI 10.1016/j.atherosclerosis.2017.08.014; Leeds Teaching Hospitals NHS Trust, INN MED OPT CLIM PCS; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.15829/1560-4071-2020-3826, 10.1093/eurheartj/ehz455]; Matthews A, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3283; National Institute for Health and Care Excellence, BRIT NATL FORMULARY; National Institute for Health and Care Excellence (NICE), CARD DIS PREV OV; NICE, CARD DIS RISK ASS RE; Nordstrom Beth L, 2015, BR J CARDIOL, V22, P147; Overview, EZ TREAT PRIM HET FA; Overview, EVOLOCUMAB TREATING; Overview, AL TREAT PRIM HYP MI; Patient decision aid, CARD DIS RISK ASS RE; Preiss D, 2015, ANN CLIN BIOCHEM, V52, P629, DOI 10.1177/0004563215594818; Rosenson RS, 2017, J AM COLL CARDIOL, V70, P1290, DOI 10.1016/j.jacc.2017.07.752; Royal Brompton & Harefield NHS Foundation Trust, NEW OPP TREATM HYP I; Saratzis A, 2019, BRIT J SURG, V106, P1168, DOI 10.1002/bjs.11214; Scottish Intercollegiate Guidelines Network (SIGN), 2017, SIGN 149 RISK EST PR; Soran H, 2017, CURR OPIN LIPIDOL, V28, P291, DOI 10.1097/MOL.0000000000000433; Soran H, 2017, CLIN RES CARDIOL, V106, P237, DOI 10.1007/s00392-016-1069-7; Toth Peter P, 2019, Methodist Debakey Cardiovasc J, V15, P23, DOI 10.14797/mdcj-15-1-23; Vallejo-Vaz AJ, 2017, CIRCULATION, V136, P1878, DOI 10.1161/CIRCULATIONAHA.117.027966; Waters DD, 2017, CAN J CARDIOL, V33, P343, DOI 10.1016/j.cjca.2016.10.019; Williams B, 2020, CARDIOL THER, V9, P19, DOI 10.1007/s40119-019-00159-1; Wood FA, 2020, NEW ENGL J MED, V383, P2182, DOI 10.1056/NEJMc2031173	44	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						227	237		10.2147/VHRM.S269879			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7MM	WOS:000655714600001	34054297	gold, Green Published			2022-04-27	
J	Tanmit, P; Angkasith, P; Teeratakulpisarn, P; Thanapaisal, C; Wongkonkitsin, N; Prasertcharoensuk, S; Panich, C				Tanmit, Parichat; Angkasith, Phati; Teeratakulpisarn, Panu; Thanapaisal, Chaiyut; Wongkonkitsin, Narongchai; Prasertcharoensuk, Supatcha; Panich, Chaiwat			Treatment Outcome of Traumatic Subclavian Artery Injuries	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						traumatic subclavian artery injury; blunt trauma; penetrating trauma; pseudoaneurysms; stent graft; endovascular treatment; bypass	MANAGEMENT	Background: Traumatic subclavian artery injuries are associated with high morbidity and mortality. Thoracic cage and clavicle provide a well protection of the underlying subclavian vessels and nerves and also cause a very limited operation space during open surgery. The endovascular modality is less invasive and alternative to conventional open surgical reconstruction. Purpose: The purpose of this study was to analyze the different therapeutic effects on limb salvage. Methods: A retrospective review of patients who presented with blunt or penetrating injuries to the subclavian arteries between March 2012 and March 2021. Results: Endovascular and open repairs were both effective for traumatic subclavian artery injury. There was no statistical difference in the limb salvage, mortality, procedure-related complication, reintervention rate and in-hospital medical complications. Intraoperative blood loss, red blood cell transfusion requirement and length of hospital stay were significantly lower in the endovascular intervention group. Conclusion: Endovascular treatment represents an attractive alternative to the traditional surgical approach for the treatment of traumatic injuries in the subclavian.	[Tanmit, Parichat; Angkasith, Phati; Teeratakulpisarn, Panu; Thanapaisal, Chaiyut; Wongkonkitsin, Narongchai; Prasertcharoensuk, Supatcha; Panich, Chaiwat] Khon Kaen Univ, Fac Med, Dept Surg, 123 Moo 16 Mittraphap Rd, Khon Kaen 40002, Thailand		Tanmit, P (通讯作者)，Khon Kaen Univ, Fac Med, Dept Surg, 123 Moo 16 Mittraphap Rd, Khon Kaen 40002, Thailand.	pari.tanmit@gmail.com		Panich, Chaiwat/0000-0003-2940-4546; Teeratakulpisarn, Panu/0000-0002-7190-2461; Angkasith, Phati/0000-0002-3489-1759; tanmit, parichat/0000-0002-3676-2424			ABOULJOUD MS, 1993, AM SURGEON, V59, P590; Chemelli AP, 2010, J VASC INTERV RADIOL, V21, P470, DOI 10.1016/j.jvir.2009.12.392; Committee American College of Surgeon, 2010, ADV SURG SKILLS EXP; Corvino A, 2020, J ULTRASOUND, V23, P563, DOI 10.1007/s40477-020-00475-6; Corvino F, 2018, RADIOL MED, V123, P369, DOI 10.1007/s11547-017-0844-5; DEGIANNIS E, 1995, AUST NZ J SURG, V65, P327, DOI 10.1111/j.1445-2197.1995.tb00647.x; Demetriades D, 2001, SURG CLIN N AM, V81, P1357, DOI 10.1016/S0039-6109(01)80012-8; Jacks R, 2014, SCAND J SURG, V103, P149, DOI 10.1177/1457496914532248; Klocker J, 2010, EUR J VASC ENDOVASC, V39, P160, DOI 10.1016/j.ejvs.2009.11.019; Leonardou P, 2012, ULUS TRAVMA ACIL CER, V18, P527, DOI 10.5505/tjtes.2012.50374; Martin MJ, 2013, EUR J TRAUMA EMERG S, V39, P569, DOI 10.1007/s00068-013-0336-9; MCCREADY RA, 1986, J VASC SURG, V3, P24, DOI 10.1067/mva.1986.avs0030024; PERRY MO, 1971, ANN SURG, V173, P403, DOI 10.1097/00000658-197103000-00011; Schaff HV, 1977, J TRAUMA, V17, P981, DOI [10.1097/00005373-197712000-00022, DOI 10.1097/00005373-197712000-00022]; Sciarretta JD, 2013, EMERG MED OPEN ACCES, V3, P143; Tadayon N, 2020, J CARDIOVASC THORAC, V12, P145, DOI 10.34172/jcvtr.2020.24; Tian X, 2020, CHIN J TRAUMATOL, V23, P25, DOI 10.1016/j.cjtee.2019.11.007	17	2	2	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						481	487		10.2147/VHRM.S322127			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UB0JU	WOS:000685540200002	34429608	gold, Green Published			2022-04-27	
J	Chandra, R; Saini, H; Cerejo, R; Tayal, A; Malhotra, K				Chandra, Rahul; Saini, Harneel; Cerejo, Russell; Tayal, Ashis; Malhotra, Konark			Ticagrelor Use in Stroke Patients: Past, Present, and Future	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						Ticagrelor; stroke; clopidogrel; platelet inhibition	ACUTE ISCHEMIC-STROKE; ASPIRIN; CLOPIDOGREL; PREVENTION; EFFICACY; ATTACK	Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardio-vascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discussed the pharmacology of ticagrelor, published literature in cardiology and stroke trials, use of ticagrelor among patients with ischemic strokes, and compared its efficacy, limitations and side-effects with other antiplatelet medications.	[Chandra, Rahul; Saini, Harneel; Cerejo, Russell; Tayal, Ashis; Malhotra, Konark] Allegheny Hlth Network, Dept Neurol, Pittsburgh, PA 15224 USA		Malhotra, K (通讯作者)，Allegheny Hlth Network, Dept Neurol, Pittsburgh, PA 15224 USA.	konark.malhotra@yahoo.com					Amarenco P, 2020, STROKE, V51, P3504, DOI 10.1161/STROKEAHA.120.032239; [Anonymous], Ticagrelol versus aspirin inischemic stroke; Bonaca MP, 2016, CIRCULATION, V134, P861, DOI 10.1161/CIRCULATIONAHA.116.024637; Charpentier T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232768; Cowper PA, 2015, J AM COLL CARDIOL, V65, P465, DOI 10.1016/j.jacc.2014.11.034; Dobesh PP, 2014, PHARMACOTHERAPY, V34, P1077, DOI 10.1002/phar.1477; Hiatt WR, 2017, NEW ENGL J MED, V376, P32, DOI 10.1056/NEJMoa1611688; Johnston SC, 2020, NEW ENGL J MED, V383, P207, DOI 10.1056/NEJMoa1916870; Johnston SC, 2016, NEW ENGL J MED, V375, P35, DOI 10.1056/NEJMoa1603060; Karan Vivek, 2019, Neurointervention, V14, P125, DOI 10.5469/neuroint.2019.00087; Mahaffey KW, 2011, CIRCULATION, V124, P544, DOI 10.1161/CIRCULATIONAHA.111.047498; Malhotra K, 2018, J NEUROL SCI, V390, P212, DOI 10.1016/j.jns.2018.05.001; Nylander S, 2013, J THROMB HAEMOST, V11, P1867, DOI 10.1111/jth.12360; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Verdoia M, 2019, ATHEROSCLEROSIS, V284, P136, DOI 10.1016/j.atherosclerosis.2019.02.011; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wang YL, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2211; Wong KSL, 2018, STROKE, V49, P1678, DOI 10.1161/STROKEAHA.118.020553	18	0	0	2	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						357	362		10.2147/VHRM.S266968			6	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD8EA	WOS:000669551800001	34163168	gold, Green Published			2022-04-27	
J	Garg, PK; Bartz, TM; Burke, G; Gottdiener, JS; Herrington, D; Heckbert, SR; Kizer, JR; Sotoodehnia, N; Mukamal, KJ				Garg, Parveen K.; Bartz, Traci M.; Burke, Gregory; Gottdiener, John S.; Herrington, David; Heckbert, Susan R.; Kizer, Jorge R.; Sotoodehnia, Nona; Mukamal, Kenneth J.			Brachial Flow-Mediated Dilation and Risk of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						atrial fibrillation; arrhythmia; endothelium; flow-mediated dilation; subclinical disease	ENDOTHELIAL DYSFUNCTION; PULSE PRESSURE; VASODILATION; AGE; ATHEROSCLEROSIS; INFLAMMATION; STRESS	Background: Endothelial dysfunction is associated with common risk factors for AF and has been implicated in the pathophysiology of atrial fibrillation (AF) through a variety of mechanisms. We determined the prospective association of brachial flow-mediated dilation (FMD) with incident AF among older adults. Methods: We included 2027 Cardiovascular Health Study participants (mean age=78.3 years, male=39%, Black=17%) who underwent brachial FMD measurement at the 1997 to 1998 clinic visit. Incident AF was ascertained by study electrocardiograms, hospital discharge diagnosis coding and Medicare claims data. Cox regression models were used to examine the association between FMD and incident AF. Results: We identified 754 incident of AF cases (37%) over a median follow-up of 11.0 years. After adjusting for age, sex, race, height, weight, cardiovascular disease, cigarette smoking, hypertension, diabetes, kidney function, c-reactive protein, physical activity, alcohol consumption, and statins, the risk of AF did not differ according to brachial FMD response (4th vs 1st quartile hazard ratio (HR)=1.01, 95% confidence interval (CI): 0.81, 1.26; per FMD unit increment HR=1.01, 95% CI: 0.97, 1.05). Conclusion: We found no relationship between brachial FMD and the risk of developing AF in this elderly cohort. Our findings suggest that the utility of brachial FMD as a risk marker for AF in older individuals is minimal.	[Garg, Parveen K.] Univ Southern Calif, Keck Sch Med, Div Cardiol, 1510 San Pablo St,Suite 322, Los Angeles, CA 90033 USA; [Bartz, Traci M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Burke, Gregory] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27101 USA; [Gottdiener, John S.] Univ Maryland, Sch Med, Dept Med, Cardiol Div, Baltimore, MD 21201 USA; [Herrington, David] Wake Forest Univ, Dept Cardiol, Winston Salem, NC 27101 USA; [Herrington, David] Wake Forest Univ, Dept Epidemiol & Prevent, Winston Salem, NC 27101 USA; [Heckbert, Susan R.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Kizer, Jorge R.] San Francisco Vet Affairs Hlth Care Syst, Cardiol Sect, San Francisco, CA USA; [Kizer, Jorge R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Kizer, Jorge R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA; [Sotoodehnia, Nona] Univ Washington, Div Cardiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA		Garg, PK (通讯作者)，Univ Southern Calif, Keck Sch Med, Div Cardiol, 1510 San Pablo St,Suite 322, Los Angeles, CA 90033 USA.	parveeng@med.usc.edu		Garg, Parveen/0000-0002-6482-2711	National Heart, Lung, and Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HHSN268201200036C, HHSN268200800007C, HHSN2682 01800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295, U01HL130114]; National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023629]	This research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN2682 01800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional sup-port was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.	Andrade J, 2014, CIRC RES, V114, P1453, DOI 10.1161/CIRCRESAHA.114.303211; Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F; Beigel R, 2010, VASC MED, V15, P299, DOI 10.1177/1358863X10373300; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Boriani G, 2006, EUR HEART J, V27, P893, DOI 10.1093/eurheartj/ehi651; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0; Ceravolo R, 2003, J AM COLL CARDIOL, V41, P1753, DOI 10.1016/S0735-1097(03)00295-X; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Garg PK, 2020, ALZ DIS ASSOC DIS, V34, P272, DOI 10.1097/WAD.0000000000000394; Garg PK, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008424; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Heeringa J, 2007, ARCH INTERN MED, V167, P382, DOI 10.1001/archinte.167.4.382; Herrington DM, 2001, ARTERIOSCL THROM VAS, V21, P1955, DOI 10.1161/hq1201.100241; Herrington DM, 2001, J CARDIOVASC RISK, V8, P319, DOI 10.1097/00043798-200110000-00012; Kim YM, 2005, CIRC RES, V97, P629, DOI 10.1161/01.RES.0000183735.09871.61; Lin YK, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-20; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Nakamura A, 2019, J MED ULTRASON, V46, P503, DOI 10.1007/s10396-019-00946-2; O'Neal WT, 2014, ARTERIOSCL THROM VAS, V34, P2717, DOI 10.1161/ATVBAHA.114.304560; Paniagua OA, 2001, CIRCULATION, V103, P1752, DOI 10.1161/01.CIR.103.13.1752; Parker BA, 2006, AM J PHYSIOL-HEART C, V291, pH3043, DOI 10.1152/ajpheart.00190.2006; Psaty BM, 1997, CIRCULATION, V96, P2455; Shaikh AY, 2016, HYPERTENSION, V68, P590, DOI 10.1161/HYPERTENSIONAHA.116.07650; Soga J, 2008, HYPERTENS RES, V31, P1293, DOI 10.1291/hypres.31.1293; Weiner SD, 2014, HEART, V100, P862, DOI 10.1136/heartjnl-2013-304893; Yeboah J, 2007, CIRCULATION, V115, P2390, DOI 10.1161/CIRCULATIONAHA.106.678276	28	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						95	102		10.2147/VHRM.S297720			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QY9QK	WOS:000630370300001	33737810	gold, Green Published			2022-04-27	
J	Park, JK; Jung, WB; Yoon, JH				Park, Jong Kwon; Jung, Won Beom; Yoon, Jung-Hee			Distribution Pattern of Atherosclerosis in the Abdomen and Lower Extremities and Its Association with Clinical and Hematological Factors	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						atherosclerosis; elastic arteries; muscular arteries; risk factors	SMOOTH-MUSCLE-CELLS; PROLIFERATION; DISEASE	Purpose: Abdominal arteries differ from the arteries located at the extremities in histological composition and clinical features. This study investigated the distributional pattern of atherosclerosis in arteries of the abdomen and lower extremities and its association with clinical and hematologic factors.\ Patients and Methods: This retrospective study included 227 patients with atherosclerosis who underwent computed tomography angiography (CTA) of the abdomen and lower extremities. The distributional pattern of atherosclerosis was categorized into type 1 (suprainguinal elastic), type 2 (infrainguinal muscular), and type 3 (both arterial involvement). Chi-square tests, Mann Whitney U-tests, and logistic regression analysis were used to investigate the data. Results: Of the 227 patients, 132 (58%) had type 1 and 95 (42%) had type 3 atherosclerosis. None had type 2. Older age, heavier smoking, and higher levels of HbA 1 c and homocysteine were the significant risk factors for type 3 atherosclerosis (odds ratio: 1.076, 1.023, 1.426, and 1.130, respectively). Patients with type 3 showed significantly lower right and left ankle and toe brachial indices compared to type 1 (P: 0.029, 0.023, 0.003, and <0.001, respectively). Conclusion: In arteries of the abdomen and lower extremities, atherosclerosis may occur initially at suprainguinal elastic arteries. In addition, the significant risk factors for type 3 atherosclerosis may contribute to the development of atherosclerosis at infrainguinal muscular arteries and deteriorate the peripheral arterial circulation. Therefore, if atherosclerotic lesions are found at the suprainguinal elastic arteries on CTA, to prevent atherosclerosis at infrainguinal muscular arteries and subsequent peripheral arterial ischemic disease, cessation of smoking and control of blood glucose and homocysteine may be recommended, especially in elderly patients.	[Park, Jong Kwon; Jung, Won Beom] Inje Univ, Haeundae Paik Hosp, Coll Med, Dept Surg, Busan, South Korea; [Yoon, Jung-Hee] Inje Univ, Haeundae Paik Hosp, Coll Med, Dept Radiol, Busan, South Korea		Park, JK (通讯作者)，Inje Univ, Haeundae Paik Hosp, Coll Med, Dept Surg, Busan, South Korea.	jparkvk@gmail.com					Asanuma Y, 2003, NEW ENGL J MED, V349, P2407, DOI 10.1056/NEJMoa035611; Basu P, 2010, VASC HEALTH RISK MAN, V6, P215; Chappell J, 2016, CIRC RES, V119, P1313, DOI 10.1161/CIRCRESAHA.116.309799; Chung J, 2017, ANN VASC SURG, V40, P198, DOI 10.1016/j.avsg.2016.11.003; Etienne P, 1998, DIFFERENTIATION, V63, P225, DOI 10.1111/j.1432-0436.1998.00225.x; Faglia E, 1998, DIABETES CARE, V21, P625, DOI 10.2337/diacare.21.4.625; Fhayll W, 2019, MATRIX BIOL, V84, P41, DOI 10.1016/j.matbio.2019.08.005; Gayral S, 2014, CARDIOVASC RES, V102, P118, DOI 10.1093/cvr/cvt336; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE726, DOI 10.1161/CIR.0000000000000471; Gray BH, 2010, ANN VASC SURG, V24, P349, DOI 10.1016/j.avsg.2009.07.034; Greenwald SE, 2007, J PATHOL, V211, P157, DOI 10.1002/path.2101; Jara LJ, 2003, CLIN REV ALLERG IMMU, V25, P79, DOI 10.1385/CRIAI:25:1:79; Knibb G, 2018, ALCOHOL CLIN EXP RES, V42, P1228, DOI 10.1111/acer.13767; Lin H, 2018, INT J CARDIOL, V269, P242, DOI 10.1016/j.ijcard.2018.07.043; Majesky MW, 2016, ARTERIOSCL THROM VAS, V36, pe82, DOI 10.1161/ATVBAHA.116.308261; Maurice P, 2013, TRENDS CARDIOVAS MED, V23, P211, DOI 10.1016/j.tcm.2012.12.004; Siasos G, 2014, CURR MED CHEM, V21, P3936, DOI 10.2174/092986732134141015161539; Steed MM, 2011, ANTIOXID REDOX SIGN, V15, P1927, DOI 10.1089/ars.2010.3721; Tesauro M, 2017, J INTERN MED, V281, P471, DOI 10.1111/joim.12605; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; Tucker WD, 2020, ANATOMY BLOOD VESSEL; Wang ZY, 2019, ATHEROSCLEROSIS, V284, P1, DOI 10.1016/j.atherosclerosis.2019.02.008; Xu T, 2021, ACTA DIABETOL, V58, P301, DOI 10.1007/s00592-020-01608-3	23	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						13	21		10.2147/VHRM.S287194			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	PS9SV	WOS:000608264400001	33488084	Green Published, gold			2022-04-27	
J	Poschinger-Figueiredo, D; Virgini-Magalhaes, CE; Porto, LC; Amorim, CS; Gomes, CFD; Riguetti-Pinto, CR; Mayall, MR; de Castro, LS; Fagundes, FB				Poschinger-Figueiredo, Douglas; Virgini-Magalhaes, Carlos Eduardo; Porto, Luis Cristovao; Amorim, Claudia Salvador; Gomes, Cristiane Ferreira de Araujo; Riguetti-Pinto, Cristina Ribeiro; Mayall, Monica Rochedo; de Castro, Leonardo Silveira; Fagundes, Felipe Borges			Radiofrequency Ablation for Axial Reflux Associated with Foam Sclerotherapy for Varicosities in One-Step Approach: A Prospective Cohort Study Comprising Large Diameters Saphenous Veins	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						saphenous vein; varicose veins; varicose ulcer; quality of life; catheter ablation; sclerotherapy	CLINICAL-PRACTICE-GUIDELINES; ENDOVENOUS ABLATION; VASCULAR-SURGERY; MANAGEMENT; SOCIETY; ADJUNCT; TRIAL	Objective: This study assessed the outcomes and impact on the quality of life following one-step outpatient radiofrequency ablation (RFA) and ultrasound guided foam sclerotherapy (USGFS) for large reflux with varicosities in the great saphenous vein (GSV). Design: Prospective, single-centre, analytical cohort. Materials and Methods: Thirty symptomatic patients having reflux in the GSV and varicosities (CEAP C3 to C6) were treated with RFA and USGFS simultaneously, in a singlestep procedure, from March 2016 to December 2016. They were followed up at 1 week, 6 months, 1 and 3 years. Clinical outcomes, changes in the Quality of Life (QOL) questionnaires SF-36TM, VCSS and AVVQ, evolutive vein occlusion rates were assessed by duplex ultrasound, and ulcer closure was checked. Results: The sample was divided into two groups: (Group 1) GSV diameter >13.0 mm (median 19.0 [14-24]), 17 subjects, and (Group 2) GSV diameter <= 12.9 mm (median 10.3 [10-12]), 16 subjects. No major adverse event was observed, and the postoperative minor adverse event rates were similar between the two groups. A significant improvement was observed in VCSS and AVVQ from the preoperative levels to the sixth month and the third-year follow-up. Twelve of 13 ulcers had healed at 1 year and remained closed until 3 years. The entire sample had a significant increase in all short form 36 domains, except for mental health in the Group 2 (GSV > 13.0 mm). Overall first week occlusion rate for the whole sample was 90.9% and 69.7% at the 3-year follow-up. No difference in occlusion rate was observed between the two groups at any time. Conclusion: Exclusively outpatient combined techniques were safe and feasible in this study with no major adverse events, despite the large diameters of the GSV or ulcer presence. Within 3 years, both diameter groups showed equivalent improvement in all QOL parameters, satisfactory axial occlusion, and maintained ulcer closure.	[Poschinger-Figueiredo, Douglas; Virgini-Magalhaes, Carlos Eduardo; Amorim, Claudia Salvador; Gomes, Cristiane Ferreira de Araujo; Riguetti-Pinto, Cristina Ribeiro; Mayall, Monica Rochedo; de Castro, Leonardo Silveira; Fagundes, Felipe Borges] Rio de Janeiro State Univ UERJ, Pedro Ernesto Univ Hosp HUPE, Teaching & Hlth Care Unit, Vasc & Endovasc Surg Med Staff, Blvd Vinte Oito Setembro 77,4th Floor, BR-20551030 Rio De Janeiro, Brazil; [Virgini-Magalhaes, Carlos Eduardo; Riguetti-Pinto, Cristina Ribeiro] Rio de Janeiro State Univ UERJ, Med Sci Coll FCM, Rio De Janeiro, Brazil; [Porto, Luis Cristovao] Rio de Janeiro State Univ UERJ, Histocompatibil & Cryopreservat Lab HLA, Rio De Janeiro, Brazil; [Porto, Luis Cristovao] Rio de Janeiro State Univ UERJ, Roberto Alcantara Gomes Biol Inst IBRAG, Rio De Janeiro, Brazil		Poschinger-Figueiredo, D (通讯作者)，Rio de Janeiro State Univ UERJ, Pedro Ernesto Univ Hosp HUPE, Teaching & Hlth Care Unit, Vasc & Endovasc Surg Med Staff, Blvd Vinte Oito Setembro 77,4th Floor, BR-20551030 Rio De Janeiro, Brazil.	dpvasc@icloud.com	Porto, Luis Cristovao/I-2984-2013	Porto, Luis Cristovao/0000-0003-1499-1821; Poschinger Figueiredo, Douglas/0000-0002-4533-603X			Aherne TM, 2020, EUR J VASC ENDOVASC, V60, P430, DOI 10.1016/j.ejvs.2020.05.028; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; BOND MR, 1966, J PSYCHOSOM RES, V10, P203, DOI 10.1016/0022-3999(66)90064-X; Brittenden J, 2019, NEW ENGL J MED, V381, P912, DOI 10.1056/NEJMoa1805186; Fernandez MC, 2017, J VASC SURG-VENOUS L, V5, P810, DOI 10.1016/j.jvsv.2017.05.021; Ceccarino R, 2019, ANN PLAS SURG, V83, P384, DOI 10.1097/SAP.0000000000001798; De Cassai A, 2019, KOREAN J ANESTHESIOL, V72, P53, DOI 10.4097/kja.d.18.00224; Durkin MT, 2001, EUR J VASC ENDOVASC, V21, P545, DOI 10.1053/ejvs.2001.1364; Eklof B, 2005, VASA-J VASCULAR DIS, V34, P157, DOI 10.1024/0301-1526.34.3.157; Garcia-Madrid C, 2012, ANN VASC SURG, V26, DOI 10.1016/j.avsg.2011.01.014; Garratt A M, 1993, Qual Health Care, V2, P5, DOI 10.1136/qshc.2.1.5; Gloviczki P, 2012, PHLEBOLOGY, V27, P2, DOI [10.1258/phleb.2012.012S28, 10.1258/phleb.2012.012s28]; Gloviczki P, 2011, J VASC SURG, V53, p2S, DOI 10.1016/j.jvs.2011.01.079; Gohel MS, 2018, NEW ENGL J MED, V378, P2105, DOI 10.1056/NEJMoa1801214; GOLDMAN MP, 1995, DERMATOL SURG, V21, P19, DOI 10.1111/j.1524-4725.1995.tb00107.x; Hamel-Desnos CM, 2019, EUR J VASC ENDOVASC, V58, P96, DOI 10.1016/j.ejvs.2018.09.011; Hollander M., 1973, NONPARAMETRIC STAT M; Jarjous Farah, 2015, J Clin Med Res, V7, P681, DOI 10.14740/jocmr2205w; Klein JA., 1987, AM J COSMET SURG, V4, P263, DOI DOI 10.1177/074880688700400403; Laios K, 2018, SURG INNOV, V25, P536, DOI 10.1177/1553350618781618; Lane TRA, 2017, BRIT J SURG, V104, P1648, DOI 10.1002/bjs.10598; MacKenzie RK, 2002, J VASC SURG, V35, P1197, DOI 10.1067/mva.2002.121985; NEMENYI P, 1963, DISTRIBUTIONFREE MUL; Nesbitt C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005624.pub3; O'Donnell TF, 2016, J VASC SURG-VENOUS L, V4, P97, DOI 10.1016/j.jvsv.2014.11.004; Onida Sarah, 2013, Nurs Times, V109, P16; Pihlaja T, 2020, EUR J VASC ENDOVASC, V59, P73, DOI 10.1016/j.ejvs.2019.08.020; Proebstle TM, 2008, J VASC SURG, V47, P151, DOI 10.1016/j.jvs.2007.08.056; Rabe E, 2014, PHLEBOLOGY, V29, P338, DOI 10.1177/0268355513483280; Rasmussen LH, 2011, BRIT J SURG, V98, P1079, DOI 10.1002/bjs.7555; Rasmussen Lars, 2013, J Vasc Surg Venous Lymphat Disord, V1, P349, DOI 10.1016/j.jvsv.2013.04.008; Rutherford RB, 2000, J VASC SURG, V31, P1307, DOI 10.1067/mva.2000.107094; Stanish WM, P 9 ANN SAS USERS GR; Tan MKH, 2019, EUR J VASC ENDOVASC, V57, P851, DOI 10.1016/j.ejvs.2019.01.024; Tessari L, 2001, DERMATOL SURG, V27, P58, DOI 10.1111/j.1524-4725.2001.00192.x; Toniolo J, 2018, J VASC SURG-VENOUS L, V6, P707, DOI 10.1016/j.jvsv.2018.05.029; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Wittens C, 2015, EUR J VASC ENDOVASC, V49, P678, DOI 10.1016/j.ejvs.2015.02.007; Zimmet S, 2011, PHLEBOLOGY, V26, P89, DOI 10.1258/phleb.2011.011e03	39	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						379	387		10.2147/VHRM.S313282			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD7CU	WOS:000669481000001	34239304	Green Published, gold			2022-04-27	
J	Radchenko, GD; Sirenko, YM				Radchenko, Ganna D.; Sirenko, Yuriy M.			Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						idiopathic pulmonary arterial hypertension; systemic arterial stiffness; pulse wave velocity; cardio-ankle vascular index; survival	PULSE-WAVE VELOCITY; ENDOTHELIAL DYSFUNCTION; AORTIC STIFFNESS; 6-MINUTE WALK; SURVIVAL; MANAGEMENT; REGISTRY; DISEASE; IMATINIB; RECOMMENDATIONS	Background: In a previous study, the cardio-ankle vascular index (CAVI) was increased significantly in idiopathic pulmonary arterial hypertension (IPAH) patients compared to the healthy group and did not much differ from one in systemic hypertensives. In this study the relations between survival and CAVI was evaluated in patients with IPAH. Patients and Methods: We included 89 patients with new-diagnosed IPAH without concomitant diseases. Standard examinations, including right heart catheterization (RHC) and systemic arterial stiffness evaluation, were performed. All patients were divided according to CAVI value: the group with CAVI >= 8 (n = 18) and the group with CAVI < 8 (n = 71). The mean follow-up was 33.8 +/- 23.7 months. Kaplan-Meier and Cox regression analysis were performed for the evaluation of our cohort survival and the predictors of death. Results: The group with CAVI >= 8 was older and more severe compared to the group with CAVI< 8. Patients with CAVI >= 8 had significantly reduced end-diastolic (73.79 +/- 18.94 vs 87.35 +/- 16.69 mL, P<0.009) and end-systolic (25.71 +/- 9.56 vs 33.55 +/- 10.33 mL, P<0.01) volumes of the left ventricle, the higher right ventricle thickness (0.77 +/- 0.12 vs 0.62 +/- 0.20 mm, P < 0.006), and the lower TAPSE (13.38 +/- 2.15 vs 15.98 +/- 4.4 mm, P<0.018). RHC data did not differ significantly between groups, except the higher level of the right atrial pressure in patients with CAVI >= 8-11.38 +/- 7.1 vs 8.76 +/- 4.7 mmHg, P<0.08. The estimated overall survival rate was 61.2%. The CAVI=8 increased the risk of mortality 2.34 times (CI 1.04-5.28, P = 0.041). The estimated Kaplan-Meier survival in the patients with CAVI >= 8 was only 46.7 +/- 7.18% compared to patients with CAVI < 8 - 65.6 +/- 4.2%, P = 0.035. At multifactorial regression analysis, the CAVI reduced but saved its relevance as death predictor - OR = 1.13, CI 1.001-1.871. Summary: We suggested the CAVI could be a new independent predictor of death in the IPAH population and could be used to better risk stratify this patient population if CAVI is validated as a marker in a larger multicenter trial.	[Radchenko, Ganna D.; Sirenko, Yuriy M.] Natl Acad Med Sci, MD Strazhesko Inst Cardiol, Natl Sci Ctr, Dept Symptomat Hypertens, 5 Narodnogo Opolchenia Str, UA-03680 Kiev, Ukraine		Radchenko, GD (通讯作者)，Natl Acad Med Sci, MD Strazhesko Inst Cardiol, Natl Sci Ctr, Dept Symptomat Hypertens, 5 Narodnogo Opolchenia Str, UA-03680 Kiev, Ukraine.	rganna@bigmir.net	Sirenko, Yuriy/C-8012-2019	Sirenko, Yuriy/0000-0002-4091-4910; Radchenko, Ganna/0000-0002-3651-3014			Anand V, 2016, JAMA CARDIOL, V1, P1021, DOI 10.1001/jamacardio.2016.3591; Anwar A, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0396-6; Arnold N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06175-2; Austin ED, 2012, CIRC-CARDIOVASC GENE, V5, P336, DOI 10.1161/CIRCGENETICS.111.961888; Benza RL, 2015, J HEART LUNG TRANSPL, V34, P356, DOI 10.1016/j.healun.2014.09.016; Benza RL, 2012, CHEST, V141, P354, DOI 10.1378/chest.11-0676; Benza RL, 2010, CIRCULATION, V122, P164, DOI 10.1161/CIRCULATIONAHA.109.898122; Boucly A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00889-2017; Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022; Caillon A, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-016-0628-7; Chamorro N, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA2452; Chen TH, 2009, AM J MED, V122, P53, DOI 10.1016/j.amjmed.2008.08.023; Cracowski JL, 2014, EUR RESPIR J, V43, P915, DOI 10.1183/09031936.00151313; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Desjardins MP, 2018, J AM SOC HYPERTENS, V12, P5, DOI 10.1016/j.jash.2017.09.013; Di Benedetto P, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02218-8; Du B, 2015, AM J PHYSIOL-HEART C, V308, pH1382, DOI 10.1152/ajpheart.00712.2014; Farber HW, 2004, NEW ENGL J MED, V351, P1655, DOI 10.1056/NEJMra035488; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Ghofrani HA, 2005, NEW ENGL J MED, V353, P1412, DOI 10.1056/NEJMc051946; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8; Heresi GA, 2014, EUR RESPIR J, V43, P912, DOI 10.1183/09031936.00164713; Hoeper MM, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00629-2018; Hoeper MM, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00740-2017; Hoeper MM, 2016, INT J CARDIOL, V203, P612, DOI 10.1016/j.ijcard.2015.11.001; Hoeper MM, 2013, CIRCULATION, V127, P1128, DOI 10.1161/CIRCULATIONAHA.112.000765; Horinaka S, 2014, ATHEROSCLEROSIS, V235, P239, DOI 10.1016/j.atherosclerosis.2014.04.034; Hu Y, 2013, NETH HEART J, V21, P222, DOI 10.1007/s12471-012-0353-z; Hughes R, 2005, CHEST, V128, p617S, DOI 10.1378/chest.128.6_suppl.617S; Humbert M, 2006, AM J RESP CRIT CARE, V173, P1023, DOI 10.1164/rccm.200510-1668OC; Humbert M, 2010, EUR RESPIR J, V36, P549, DOI 10.1183/09031936.00057010; Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818; Kim HL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005783; Kubozono T, 2007, CIRC J, V71, P89, DOI 10.1253/circj.71.89; Kylhammar D, 2018, EUR HEART J, V39, P4175, DOI 10.1093/eurheartj/ehx257; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Li JH, 2007, CHEST, V132, P793, DOI 10.1378/chest.07-0366; Luk KS, 2017, J GERIATR CARDIOL, V14, P766, DOI 10.11909/j.issn.1671-5411.2017.12.007; Mahmud A, 2005, HYPERTENSION, V46, P1118, DOI 10.1161/01.HYP.0000185463.27209.b0; Malenfant S, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006126; McMaster WG, 2015, CIRC RES, V116, P1022, DOI 10.1161/CIRCRESAHA.116.303697; Miyoshi T, 2016, PULSE, V4, P11, DOI 10.1159/000445214; Mozos I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01058; Nickel NP, 2020, AM J RESP CRIT CARE, V201, P148, DOI 10.1164/rccm.201903-0656CI; Nickel NP, 2019, PULM CIRC, V9, DOI 10.1177/2045894018824564; Nold-Petry CA, 2014, J IMMUNOL, V192, P589, DOI 10.4049/jimmunol.1202802; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Olsson KM, 2014, CIRCULATION, V129, P57, DOI 10.1161/CIRCULATIONAHA.113.004526; Peled N, 2009, J RHEUMATOL, V36, P970, DOI 10.3899/jrheum.081088; Perros F, 2005, SEMIN RESP CRIT CARE, V26, P355, DOI 10.1055/s-2005-916149; Perros F, 2012, AM J RESP CRIT CARE, V185, P311, DOI 10.1164/rccm.201105-0927OC; Preston IR, 2015, CIRCULATION, V132, P2403, DOI 10.1161/CIRCULATIONAHA.115.018435; Radchenko GD, 2020, VASC HEALTH RISK MAN, V16, P29, DOI 10.2147/VHRM.S230041; Radegran G, 2016, SCAND CARDIOVASC J, V50, P243, DOI 10.1080/14017431.2016.1185532; Reiss A.B., 2017, CLIN LIPIDOL, V12, P14; Rhodes CJ, 2015, AM J RESP CRIT CARE, V192, P356, DOI 10.1164/rccm.201408-1528OC; Riccieri V, 2013, RHEUMATOLOGY, V52, P1525, DOI 10.1093/rheumatology/ket168; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; Rodriguez-Iturbe B, 2014, NAT REV NEPHROL, V10, P56, DOI 10.1038/nrneph.2013.248; Schillaci G, 2007, HYPERTENSION, V49, P317, DOI 10.1161/01.HYP.0000255790.98391.9b; Schillaci G, 2015, HYPERTENS RES, V38, P68, DOI 10.1038/hr.2014.138; Shimony A, 2011, AM J CARDIOL, V108, P460, DOI 10.1016/j.amjcard.2011.03.066; Simonneau G, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01913-2018; Soon E, 2010, CIRCULATION, V122, P921, DOI 10.1161/CIRCULATIONAHA.109.933762; Soubrier F, 2013, J AM COLL CARDIOL, V62, pD13, DOI 10.1016/j.jacc.2013.10.035; Speich R, 2014, INT J CLIN PHARM-NET, V36, P256, DOI 10.1007/s11096-013-9881-x; Stacher E, 2012, AM J RESP CRIT CARE, V186, P261, DOI 10.1164/rccm.201201-0164OC; Sun CK, 2013, INTEGR BLOOD PRESS C, V6, P27, DOI 10.2147/IBPC.S34423; Sznajder M, 2020, CARDIOL J, V27, P742, DOI 10.5603/CJ.a2018.0109; Takaki A, 2007, CIRC J, V71, P1710, DOI 10.1253/circj.71.1710; Thenappan T, 2010, EUR RESPIR J, V35, P1079, DOI 10.1183/09031936.00072709; Thenappan T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5492; Thenappan T, 2012, CHEST, V141, P642, DOI 10.1378/chest.11-0969; Tomiyama H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005729; Townsend RR, 2015, HYPERTENSION, V66, P698, DOI 10.1161/HYP.0000000000000033; Udovcic Maja, 2017, Methodist Debakey Cardiovasc J, V13, P55, DOI 10.14797/mdcj-13-2-55; Vakilian Farveh, 2016, Res Cardiovasc Med, V5, pe29361, DOI 10.5812/cardiovascmed.29361; Versari D, 2009, BRIT J PHARMACOL, V157, P527, DOI 10.1111/j.1476-5381.2009.00240.x; Voelkel NF, 2012, EUR RESPIR J, V40, P1555, DOI 10.1183/09031936.00046612; Weatherald J, 2018, CIRCULATION, V137, P693, DOI 10.1161/CIRCULATIONAHA.117.029254; Wensel R, 2013, INT J CARDIOL, V167, P1193, DOI 10.1016/j.ijcard.2012.03.135; Williams B, 2018, J HYPERTENS, V36, P2284, DOI [10.1097/HJH.0000000000001961, 10.1080/08037051.2018.1527177]; Yambe T, 2004, BIOMED PHARMACOTHER, V58, pS95, DOI 10.1016/S0753-3322(04)80015-5; Zamanian RT, 2009, EUR RESPIR J, V33, P318, DOI 10.1183/09031936.00000508	86	2	2	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						77	93		10.2147/VHRM.S294767			17	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QY9QH	WOS:000630370000001	33731998	gold, Green Published			2022-04-27	
J	Tigabe, M; Fentahun, A; Getawa, S; Gelaye, KA; Gebreyohannes, EA				Tigabe, Masho; Fentahun, Abaynesh; Getawa, Solomon; Gelaye, Kassahun Alemu; Gebreyohannes, Eyob Alemayehu			Clinical Characteristics and In-Hospital Outcome of Acute Heart Failure Patients Admitted to the Medical Ward of University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						heart failure; clinical characteristics; in-hospital mortality; Ethiopia	PROGNOSTIC IMPACT; SLEEP-APNEA; MANAGEMENT; REGISTRY; MORTALITY; PREDICTORS; OXYGEN	Background: Despite the growing burden of heart failure in developing countries, data describing the clinical characteristics and in-hospital outcomes of acute heart failures are limited. Therefore, this study aimed at describing the clinical characteristics and in-hospital outcomes of acute heart failure patients admitted to the medical ward of University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. Methods: A prospective observational hospital-based cross-sectional study was conducted on 226 patients with acute heart failure at the University of Gondar Comprehensive Specialized Hospital from November 2019 to October 2020. Data were collected by using a pretested data abstraction format and analyzed with Statistical Package for Social Sciences version 21. Bivariable and multivariable binary logistic regression model were fitted to identify factors associated with in-hospital outcome and reported with 95% confidence interval (CI). P-value <0.05 was considered as statistically significant. Results: The mean (+/- standard deviation) age of the study participant was 51.17 +/- 19.03 years and 59.3% were females. Majority, 60.6% of patients were admitted with new onset heart failure. Dyspnea (88.05%) and peripheral edema (80.5%) were the most frequent clinical findings. The in-hospital mortality was 10.6% (95% CI: 7.1-14.7). Atrial fibrillation (AOR=9.46; 95% CI: 1.49-60.29), concurrent ischemic heart disease (AOR=8.23; 95% CI: 1.15-58.89), being admitted with reduced left ventricular ejection fraction (AOR=5.36; 95% CI: 2.81-35.52), presence of orthopnea (AOR=6.63; 95% CI: 2.94-46.76), and using intranasal oxygen therapy (AOR=9.41; 95% CI: 1.35-65.82) were significantly associated with in-hospital mortality in patients with acute heart failure. Conclusion: The in-hospital mortality of acute heart failure patients was relatively higher in the study area. Therefore, specific preventative and therapeutic strategies focusing on heart failure patients with reduced left ventricular ejection fraction, atrial fibrillation, ischemic heart disease, orthopnea, and intranasal oxygen therapy are required to reduce the mortality rate.	[Tigabe, Masho; Fentahun, Abaynesh; Gebreyohannes, Eyob Alemayehu] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Clin Pharm, Gondar, Ethiopia; [Getawa, Solomon] Univ Gondar, Coll Med & Hlth Sci, Sch Biomed & Lab Sci, Dept Hematol & Immunohematol, POB 196, Gondar, Ethiopia; [Gelaye, Kassahun Alemu] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia; [Gebreyohannes, Eyob Alemayehu] Univ Western Australia, Sch Allied Hlth, Div Pharm, Nedlands, WA, Australia		Getawa, S (通讯作者)，Univ Gondar, Coll Med & Hlth Sci, Sch Biomed & Lab Sci, Dept Hematol & Immunohematol, POB 196, Gondar, Ethiopia.	solomon2525geta@gmail.com	Getawa, Solomon/AAV-2057-2021; Gebreyohannes, Eyob/E-5608-2018	Getawa, Solomon/0000-0003-2670-9547; Gebreyohannes, Eyob/0000-0002-0075-4553			Abraham WT, 2008, J AM COLL CARDIOL, V52, P347, DOI 10.1016/j.jacc.2008.04.028; Asfaw E, 2020, ETHIOP MED J, V58; Bekele K, 2019, J PHARM PHARM, V6, P65; Boombhi J, 2017, OALIB, V04, P1; Bradley TD, 2005, NEW ENGL J MED, V353, P2025, DOI 10.1056/NEJMoa051001; Damasceno A, 2012, ARCH INTERN MED, V172, P1386, DOI 10.1001/archinternmed.2012.3310; Damy T, 2012, EUR J HEART FAIL, V14, P1009, DOI 10.1093/eurjhf/hfs085; Eren M, 2016, TURK KARDIYOL DERN A, V44, P637, DOI 10.5543/tkda.2016.07572; Fonarow GC, 2008, ARCH INTERN MED, V168, P847, DOI 10.1001/archinte.168.8.847; Hamaguchi S, 2013, J CARDIOL, V62, P95, DOI 10.1016/j.jjcc.2013.03.009; Jilek C, 2011, EUR J HEART FAIL, V13, P68, DOI 10.1093/eurjhf/hfq183; Kapoor JR, 2016, JACC-HEART FAIL, V4, P464, DOI 10.1016/j.jchf.2016.02.017; Kasai T, 2008, CHEST, V133, P690, DOI 10.1378/chest.07-1901; Lee SE, 2017, KOREAN CIRC J, V47, P341, DOI 10.4070/kcj.2016.0419; Logeart D, 2013, EUR J HEART FAIL, V15, P465, DOI 10.1093/eurjhf/hfs189; Mebazaa A, 2011, INTENS CARE MED, V37, P290, DOI 10.1007/s00134-010-2073-4; Medicine I., 2010, CARDIOVASCULAR DISAB; Nkoke C, 2019, J XIANGYA MED; Okello S, 2014, INT J CARDIOL, V176, P1233, DOI 10.1016/j.ijcard.2014.07.212; Oliva F, 2012, EUR J HEART FAIL, V14, P1208, DOI 10.1093/eurjhf/hfs117; Panduranga Prashanth, 2016, Oman Med J, V31, P188, DOI 10.5001/omj.2016.37; Park JH, 2010, HEART, V96, P533, DOI 10.1136/hrt.2009.175257; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Rivero-Ayerza M, 2008, EUR HEART J, V29, P1618, DOI 10.1093/eurheartj/ehn217; Sepehrvand N, 2016, JACC-HEART FAIL, V4, P783, DOI 10.1016/j.jchf.2016.03.026; Sika-Paotonu D, 2017, S PYOGENES; Sinan UY, 2019, ANATOL J CARDIOL, V21, P25, DOI 10.14744/AnatolJCardiol.2018.50880; Spinar J, 2011, CRIT CARE, V15, DOI 10.1186/cc10584; Sulaiman K, 2015, EUR J HEART FAIL, V17, P374, DOI 10.1002/ejhf.245; Szymanski PZ, 2018, SAMJ S AFR MED J, V108, P94, DOI [10.7196/SAMJ.2017.v108i2.12519, 10.7196/SAMJ.2018.v108i2.12519, 10.7196/samj.2018.v108i2.12519]; Tirfe M, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-019-01318-x; Wajner A, 2017, ARQ BRAS CARDIOL, V109, P321, DOI 10.5935/abc.20170136; World Health Organiztion, 2017, HEM CONC DIAGN AN AS; Yaku H, 2018, CIRC J, V82, P2811, DOI 10.1253/circj.CJ-17-1386; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Zeru M.A., 2018, J PUBLIC HLTH EPIDEM, V10, P326, DOI [10.5897/jphe2018.1046, DOI 10.5897/JPHE2018.1046]; Zhang YH, 2017, J CARD FAIL, V23, P868, DOI 10.1016/j.cardfail.2017.09.014	37	0	0	3	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						581	590		10.2147/VHRM.S322493			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UX7PW	WOS:000701033600002	34556989	gold, Green Published			2022-04-27	
J	Williams, KJ; Moore, HM; Ellis, M; Davies, AH				Williams, Katherine J.; Moore, Hayley M.; Ellis, Mary; Davies, Alun H.			Pilot Trial of Neuromuscular Stimulation in Human Subjects with Chronic Venous Disease	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						neuromuscular; electrical; stimulation; venous disease; venous insufficiency	DEEP-VEIN THROMBOSIS; INTERMITTENT PNEUMATIC COMPRESSION; ELECTRICAL-STIMULATION; EPIDEMIOLOGY; LEG; INSUFFICIENCY; EXERCISE	Introduction: Neuromuscular stimulation (NMES) has been shown to improve peripheral blood flow in healthy people. We investigated the effect of bilateral leg NMES on the symptoms of chronic venous disease. Methods: Forty subjects were recruited from four groups: healthy, superficial insufficiency, deep insufficiency, and deep obstruction. Haemodynamic venous measurements were taken from the right femoral vein with ultrasound, laser Doppler fluximetry from the left hand and foot. Devices were then worn for 4-6 hours per day, for 6 weeks. Haemodynamic measurements were repeated at week 6. Quality of life questionnaires were taken at week 0, 6 and 8. Results: The mean age was 48.7, HMI 28.6kg/m2, and maximum calf circumference 39.0 cm. Twenty-four subjects were men. NMES increased femoral vein peak velocity, TAMV and volume flow by 55%, 20%, 36% at 20 minutes (all p<0.05), which was enhanced at week 6 (PV and TAMV p<0.05). Mean increases in arm and leg fluximetry were 71% and 194% (both p<0.01). Leg swelling was reduced by mean 252.7 mL (13%, p<0.05) overall; 338.9 mL (16%, p<0.05) in venous disease. For those with venous pathology, scores for disease specific and generic quality of life questionnaires improved. Those with C4-6 disease benefitted the most, with improvements in VDS score of 1, AVVQ of 6, and SF-12 of 10. Conclusion: NMES improves venous haemodynamic parameters in chronic venous disease, which is enhanced by regular use. NMES reduces leg oedema, improves blood supply to the skin of the foot, and may positively affect quality of life.	[Williams, Katherine J.; Moore, Hayley M.; Ellis, Mary; Davies, Alun H.] Imperial Coll London, Acad Sect Vasc Surg, London, England		Davies, AH (通讯作者)，Charing Cross Hosp, Acad Dept Vasc Surg, 4th Floor,Fulham Palace Rd, London W6 8RF, England.	a.h.davies@ic.ac.uk		Williams, Katherine/0000-0002-3572-8777	National Institute for Health Research (NIHR) Biomedical Research Centre, based at Imperial College Healthcare NHS Trust and Imperial College LondonNational Institute for Health Research (NIHR); European Venous Forum; Royal Society of MedicineRoyal Society of London; Graham-Dixon Charitable Trust; Royal College of Surgeons of England; Firstkind Ltd.	This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre, based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS,NIHR, or Department of Health. The research was funded by the European Venous Forum, Royal Society of Medicine, the Graham-Dixon Charitable Trust, and the Royal College of Surgeons of England. Ultrasound equip-ment and NMES devices were supplied through an unrest-ricted academic grant from Firstkind Ltd. The authors had sole control over analysis, manuscript preparation, and publication of the results.	Anderson SI, 2004, EUR J VASC ENDOVASC, V27, P201, DOI 10.1016/j.ejvs.2003.10.003; BAKER SR, 1991, BRIT J SURG, V78, P864, DOI 10.1002/bjs.1800780729; Baldwin MJ, 2013, J THROMB HAEMOST, V11, P795, DOI 10.1111/jth.12180; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; CALLAM MJ, 1994, BRIT J SURG, V81, P167, DOI 10.1002/bjs.1800810204; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Comerota A, 2009, VASCULAR, V17, pS82; Comerota AJ, 2011, J VASC SURG, V53, P1121, DOI 10.1016/j.jvs.2010.08.059; Delis KT, 2001, J VASC SURG, V33, P773, DOI 10.1067/mva.2001.112707; Goldhaber SZ, 2004, CIRCULATION, V110, pE445, DOI 10.1161/01.CIR.0000145141.70264.C5; Kan YM, 2001, ARCH SURG-CHICAGO, V136, P1364, DOI 10.1001/archsurg.136.12.1364; Maruish ME, 2004, USE PSYCHOL TESTING, P363, DOI 10.1037/t29280-000; Maurins U, 2008, J VASC SURG, V48, P680, DOI 10.1016/j.jvs.2008.04.029; Morris JK, 2012, ORTHOPEDICS, V35, pE1716, DOI 10.3928/01477447-20121120-15; Nelson EA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001899.pub3; NICOLAIDES AN, 1971, BRIT J RADIOL, V44, P653, DOI 10.1259/0007-1285-44-525-653; Padberg FT, 2004, J VASC SURG, V39, P79, DOI 10.1016/j.jvs.2003.09.036; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Ravikumar R, 2015, BRIT J SURG, V102, P45; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; SUKUL DMKSK, 1993, J BIOMED ENG, V15, P477, DOI 10.1016/0141-5425(93)90062-4; Tucker AT, 2010, INT J ANGIOL, V19, pE31, DOI 10.1055/s-0031-1278361; Vasquez MA, 2012, PHLEBOLOGY, V27, P119, DOI [10.1258/phleb.2012.012S16, 10.1258/phleb.2012.012s16]; Vowden K, 2001, Br J Nurs, V10, P491; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Williams KJ, 2015, PHLEBOLOGY, V30, P365, DOI 10.1177/0268355514531255; Williams KJ, 2015, BRIT J SURG, V102, P9; Williams KJ, 2014, J VASC SURG-VENOUS L, V2, P329, DOI 10.1016/j.jvsv.2013.10.053; Williams KJ, 2014, INT J CASE REP IMAGE, V5, P744, DOI [10.5348/ ijcri- 201462- CS- 10048, DOI 10.5348/IJCRI-201462-CS-10048]	29	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						771	778		10.2147/VHRM.S320883			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	XN6KR	WOS:000729612000001	34880620	Green Published			2022-04-27	
J	Chauin, A				Chauin, Aleksey			The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						diagnostics; differential diagnosis; causes of increased concentration; mechanisms of increase; cardiac troponins; troponin T; troponin I; acute myocardial infarction; physical activity; psycho-emotional stress; myocarditis; endocarditis; pericarditis; sepsis; pulmonary embolism; chronic renal failure	NECROSIS-FACTOR-ALPHA; PROGNOSTIC VALUE; T ISOFORMS; I LEVELS; DIAGNOSIS; EXPRESSION; EXERCISE; SERUM; DYSFUNCTION; ELEVATION	The causes and mechanisms of increased cardiac troponin T and I (cTnT and cTnI) concentrations are numerous and are not limited to acute myocardial infarction (AMI) (ischemic necrosis of cardiac myocytes). Any type of reversible or irreversible cardiomyocyte injury can result in elevated serum cTnT and cTnI levels. Researchers and practitioners involved in the diagnosis and treatment of cardiovascular disease, including AMI, should know the key causes and mechanisms of elevated serum cTnT and cTnI levels. This will allow to reduce or completely avoid diagnostic errors and help to choose the most correct tactics for further patient management. The purpose of this article is to discuss the main causes and mechanisms of increase in cardiac troponins concentrations in frequently occurring physiological (physical exertion, psycho-emotional stress) and pathological conditions (inflammatory heart disease, pulmonary embolism, chronic renal failure and sepsis (systemic inflammatory response)) not related to myocardial infarction.	[Chauin, Aleksey] Samara State Med Univ, Dept Cardiol & Cardiovasc Surg, Samara 443099, Russia; [Chauin, Aleksey] Samara State Med Univ, Dept Histol & Embryol, Samara 443099, Russia		Chauin, A (通讯作者)，Samara State Med Univ, Dept Histol & Embryol, Dept Cardiol & Cardiovasc Surg, 89 Chapaevskaya St, Samara 443099, Samara Region, Russia.	alekseymichailovich22976@gmail.com	Chaulin, Aleksey M./F-1229-2019	Chaulin, Aleksey M./0000-0002-2712-0227			Aberegg SK, 2019, ANN AM THORAC SOC, V16, P1335, DOI 10.1513/AnnalsATS.201905-412LE; Abrar S, 2016, J CLIN DIAGN RES, V10, pSC12, DOI 10.7860/JCDR/2016/19856.7967; Aimo A, 2019, INT J CARDIOL, V277, P166, DOI 10.1016/j.ijcard.2018.10.079; Aimo A, 2018, CIRCULATION, V137, P286, DOI 10.1161/CIRCULATIONAHA.117.031560; Ali Syed Affan, 2019, J Ayub Med Coll Abbottabad, V31, P364; Apple FS, 1998, EUR HEART J, V19, pN30; Arroyo D, 2012, TRANSPL P, V44, P2545, DOI 10.1016/j.transproceed.2012.09.073; Becattini C, 2007, CIRCULATION, V116, P427, DOI 10.1161/CIRCULATIONAHA.106.680421; Bessiere F, 2013, INTENS CARE MED, V39, P1181, DOI 10.1007/s00134-013-2902-3; Body R, 2018, EMERG MED J, V35, P120, DOI 10.1136/emermed-2017-206812; Bohner J, 1996, CLIN CHEM, V42, P2046; Brandt RR, 2001, AM J CARDIOL, V87, P1326, DOI 10.1016/S0002-9149(01)01536-3; Broz P, 2018, J MED BIOCHEM, V37, P364, DOI 10.1515/jomb-2017-0055; Bunin V. A., 2017, KOMPLEKSNYE PROBLEMY, V6, P13; Chang YJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214087; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P91, DOI 10.15829/1728-8800-2021-2539; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P93, DOI 10.15829/1728-8800-2021-2590; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P82, DOI 10.15829/1728-8800-2021-2639; [Чаулин А.М. Chaulin A.M.], 2020, [Комплексные проблемы сердечно-сосудистых заболеваний, Kompleksnye problemy serdechno-sosudistykh zabolevanii], V9, P69, DOI 10.17802/2306-1278-2020-9-3-69-80; [Чаулин А.М. Chaulin A.M.], 2019, [Комплексные проблемы сердечно-сосудистых заболеваний, Kompleksnye problemy serdechno-sosudistykh zabolevanii], V8, P103, DOI 10.17802/2306-1278-2019-8-4-103-115; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P172, DOI 10.15829/1560-4071-2020-3923; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P17, DOI 10.15829/1560-4071-2020-3814; [Чаулин А.М. Chaulin A.M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology, Rossiiskii kardiologicheskii zhurnal], V25, P62, DOI 10.15829/1560-4071-2020-4061; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P55, DOI 10.15829/1560-4071-2020-4140; Chaulin AM, 2019, KARDIOLOGIYA, V59, P66, DOI 10.18087/cardio.2019.11.n414; Chaulin A.M., 2021, RIV ITAL MED LAB, V17, P99, DOI [DOI 10.23736/S1825-859X.21.00107-9, 10.23736/S1825-859X.21.00107-9]; Chaulin A, 2021, VASC HEALTH RISK MAN, V17, P431, DOI 10.2147/VHRM.S315376; Chaulin A, 2021, VASC HEALTH RISK MAN, V17, P299, DOI 10.2147/VHRM.S300002; Chaulin AM, 2021, INT J BIOMED, V11, P250, DOI 10.21103/Article11(3)_RA2; Chaulin AM, 2021, COR VASA, V63, P486, DOI 10.33678/cor.2021.041; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2020, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V11, P70, DOI 10.17816/clinpract48893; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2020, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V11, P75, DOI 10.17816/clinpract34284; Chaulin AM, 2020, RUSS OPEN MED J, V9, DOI 10.15275/rusomj.2020.0305; Chaulin AM, 2020, INT J BIOMED, V10, P198, DOI 10.21103/Article10(3)_RA3; Chaulin AM, 2021, J CLIN DIAGN RES, V15, pBE01, DOI 10.7860/JCDR/2021/47764.15025; Chaulin AM, 2021, SIGNA VITAE, V17, P79, DOI 10.22514/sv.2021.050; Chaulin AM, 2019, SIBERIAN MED REV, V6, P5, DOI [10.20333/2500136-2019-6-5-14, DOI 10.20333/2500136-2019-6-5-14]; Chaulin AM, 2021, MODERN PROB SCI ED, DOI [10.17513/spno.30462, DOI 10.17513/SPNO.30462]; Chen JY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123917; Cotugno M, 2017, MED CLIN-BARCELONA, V148, P339, DOI [10.1016/j.medcli.2016.11.023, 10.1016/j.medcle.2017.04.007]; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; Dancea A B, 2001, Paediatr Child Health, V6, P543; de Lavallaz JD, 2018, J AM COLL CARDIOL, V72, P2936, DOI 10.1016/j.jacc.2018.09.050; deFilippi CR, 2017, CLIN CHEM, V63, P59, DOI 10.1373/clinchem.2016.254748; Dubin RF, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-229; Friden V, 2017, CLIN BIOCHEM, V50, P468, DOI 10.1016/j.clinbiochem.2017.02.007; Gamaza-Chulian S, 2014, J CARDIOVASC MED, V15, P68, DOI 10.2459/JCM.0b013e3283641161; Garcia-Osuna A, 2018, CLIN CHIM ACTA, V486, P224, DOI 10.1016/j.cca.2018.08.015; Giannitsis E, 2000, CIRCULATION, V102, P211, DOI 10.1161/01.CIR.102.2.211; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; Haller C, 1998, CLIN CHEM, V44, P930; Hammerer-Lercher A, 2001, CLIN CHEM, V47, P451; Hickman PE, 2010, CLIN CHIM ACTA, V411, P318, DOI 10.1016/j.cca.2009.12.009; Imazio M, 2003, J AM COLL CARDIOL, V42, P2144, DOI 10.1016/j.jacc.2003.02.001; Jarolim P, 2015, CLIN CHEM LAB MED, V53, P635, DOI 10.1515/cclm-2014-0565; Jozwiak M, 2011, SEMIN RESP CRIT CARE, V32, P206, DOI 10.1055/s-0031-1275533; Kanderian AS, 2006, KIDNEY INT, V69, P1112, DOI 10.1038/sj.ki.5000174; Kaplan A, 2015, TURK J EMERG MED, V15, P47, DOI 10.5505/1304.7361.2014.00378; Katrukha IA, 2017, CLIN CHEM, V63, P1094, DOI 10.1373/clinchem.2016.266635; KATUS HA, 1992, CLIN CHEM, V38, P386; Khan NA, 2005, CIRCULATION, V112, P3088, DOI 10.1161/CIRCULATIONAHA.105.560128; Kilinc G, 2012, J THORAC DIS, V4, P588, DOI 10.3978/j.issn.2072-1439.2012.10.13; Kim JY, 2019, KOREAN J INTERN MED, V34, P1263, DOI 10.3904/kjim.2018.153; Kolwicz SC, 2013, CIRC RES, V113, P603, DOI 10.1161/CIRCRESAHA.113.302095; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; Kumar A, 2007, CRIT CARE MED, V35, P358, DOI 10.1097/01.CCM.0000254341.87098.A4; La Gerche A, 2004, INT J SPORTS MED, V25, P45; Lankeit M, 2010, EUR HEART J, V31, P1836, DOI 10.1093/eurheartj/ehq234; Lauer B, 1997, J AM COLL CARDIOL, V30, P1354, DOI 10.1016/S0735-1097(97)00317-3; Lavie CJ, 2015, CURR SPORT MED REP, V14, P104, DOI 10.1249/JSR.0000000000000134; Lazzarino AI, 2013, J AM COLL CARDIOL, V62, P1694, DOI 10.1016/j.jacc.2013.05.070; Li FF, 2017, J EXERC SCI FIT, V15, P49, DOI 10.1016/j.jesf.2017.08.001; Li SF, 2005, AM J EMERG MED, V23, P860, DOI 10.1016/j.ajem.2005.05.008; Lindner G, 2014, INTERN EMERG MED, V9, P335, DOI 10.1007/s11739-013-1030-y; Lippi G, 2019, SEMIN THROMB HEMOST, V45, P784, DOI 10.1055/s-0039-1698762; Lippi G, 2011, BIOCHEM MEDICA, V21, P55, DOI 10.11613/BM.2011.012; Long B, 2020, AM J EMERG MED, V38, P998, DOI 10.1016/j.ajem.2019.12.007; Mair J, 2018, EUR HEART J-ACUTE CA, V7, P553, DOI 10.1177/2048872617748553; Manjunath L, 2018, CARDIOL THER, V7, P197, DOI 10.1007/s40119-018-0120-3; Matsumori A., 2011, CVD PREV CONTROL, V6, P41, DOI [10.1016/j.cvdpc.2011.02.004, DOI 10.1016/J.CVDPC.2011.02.004]; Messner B, 2000, AM J CLIN PATHOL, V114, P544, DOI 10.1309/8KCL-UQRF-6EEL-36XK; Meyer T, 2000, J AM COLL CARDIOL, V36, P1632, DOI 10.1016/S0735-1097(00)00905-0; Mingels A, 2009, CLIN CHEM, V55, P101, DOI 10.1373/clinchem.2008.106427; Mirzaii-Dizgah I, 2013, INDIAN J MED RES, V138, P861; Muller-Bardorff M, 2002, CLIN CHEM, V48, P673; Muslimovic A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63744-8; Norlund H, 2017, UGESKR LAEGER, V179; Nussinovitch U, 2010, HEART, V96, P1518, DOI 10.1136/hrt.2010.195255; O'Hanlon R, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-38; Ooi DS, 2000, CLIN CHEM, V46, P338; Pervan P., 2017, Signa Vitae, V13, P62; Picano E, 2014, EUR HEART J, V35, P1033, DOI 10.1093/eurheartj/eht350; Punukollu G, 2005, INT J CARDIOL, V99, P207, DOI 10.1016/j.ijcard.2004.01.012; Purcell JB, 2008, AM J CARDIOL, V101, P1479, DOI 10.1016/j.amjcard.2008.01.031; Putschoegl A, 2020, PEDIATR CLIN N AM, V67, P855, DOI 10.1016/j.pcl.2020.06.013; Rahimtoola A, 2005, CURR PROB CARDIOLOGY, V30, P61, DOI 10.1016/j.cpcardiol.2004.06.001; Razin VA, 2012, ULYANOVSK MEDICO BIO, P13; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; Richardson AJ, 2018, J SCI MED SPORT, V21, P880, DOI 10.1016/j.jsams.2018.02.005; Rifai N, 1999, AM J CARDIOL, V83, P1085, DOI 10.1016/S0002-9149(99)00020-X; Rocco E, 2019, J CARDIOVASC MED, V20, P504, DOI 10.2459/JCM.0000000000000811; Rosano GMC, 2008, CURR PHARM DESIGN, V14, P2551, DOI 10.2174/138161208786071317; Rosjo H, 2011, INTENS CARE MED, V37, P77, DOI 10.1007/s00134-010-2051-x; Samaha E, 2019, CLIN BIOCHEM, V63, P18, DOI 10.1016/j.clinbiochem.2018.11.013; Scherr J, 2011, MED SCI SPORT EXER, V43, P1819, DOI 10.1249/MSS.0b013e31821b12eb; Schmid J, 2018, J AM COLL CARDIOL, V71, P1540, DOI 10.1016/j.jacc.2018.01.070; SCHWARTZ P, 1984, AM J PATHOL, V115, P349; Shave RE, 2002, INT J SPORTS MED, V23, P489, DOI 10.1055/s-2002-35069; Sheyin O, 2014, HEART LUNG, V44, P75, DOI 10.1016/j.hrtlng.2014.10.002; Sicari R, 2008, EUR J ECHOCARDIOGR, V9, P415, DOI 10.1093/ejechocard/jen175; Sicari R, 2017, CARDIOVASC ULTRASOUN, V15, DOI 10.1186/s12947-017-0099-2; Smith SC, 1997, CIRCULATION, V95, P163, DOI 10.1161/01.CIR.95.1.163; Soongswang J, 2005, PEDIATR CARDIOL, V26, P45, DOI 10.1007/s00246-004-0677-6; Soongswang J, 2002, PEDIATR CARDIOL, V23, P531, DOI 10.1007/PL00021005; Streng AS, 2016, BIOCHEM BIOPH RES CO, V481, P165, DOI 10.1016/j.bbrc.2016.10.149; Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310; Tsenovoy P, 2009, CARDIOLOGY, V112, P202, DOI 10.1159/000149573; Tulloh L, 2006, BRIT J SPORT MED, V40, P605, DOI 10.1136/bjsm.2005.022319; Ukena C, 2014, CLIN RES CARDIOL, V103, P743, DOI 10.1007/s00392-014-0709-z; Watkin RW, 2004, AM J CARDIOL, V94, P1198, DOI 10.1016/j.amjcard.2004.07.096; Wilhelm J, 2014, CLIN RES CARDIOL, V103, P561, DOI 10.1007/s00392-014-0684-4; Yozgat CY, 2020, INDIAN J PEDIATR, V87, P1076, DOI 10.1007/s12098-020-03272-5; Ziebig R, 2003, CLIN CHEM, V49, P1191, DOI 10.1373/49.7.1191	124	4	4	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						601	617		10.2147/VHRM.S327661			17	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	US6MJ	WOS:000697540600001	34584417	gold, Green Published			2022-04-27	
J	Chang, JC				Chang, Jae C.			COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						acute respiratory distress syndrome; ARDS; ADAMTS13; endotheliopathy; macrothrombosis; microthrombosis; multiorgan dysfunction syndrome; MODS	VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; RESPIRATORY-DISTRESS-SYNDROME; ACUTE MYOCARDIAL-INFARCTION; N-ACETYLCYSTEINE; FACTOR STRINGS; PERIPHERAL GANGRENE; ADAMTS13 ACTIVITY; DOUBLE-BLIND; D-DIMER	COVID-19 sepsis is characterized by acute respiratory distress syndrome (ARDS) as a consequence of pulmonary tropism of the virus and endothelial heterogeneity of the host. ARDS is a phenotype among patients with multiorgan dysfunction syndrome (MODS) due to disseminated vascular microthrombotic disease (VMTD). In response to the viral septicemia, the host activates the complement system which produces terminal complement complex C5b-9 to neutralize pathogen. C5b-9 causes pore formation on the membrane of host endothelial cells (ECs) if CD59 is underexpressed. Also, viral S protein attraction to endothelial ACE2 receptor damages ECs. Both affect ECs and provoke endotheliopathy. Disseminated endotheliopathy activates two molecular pathways: inflammatory and microthrombotic. The former releases inflammatory cytokines from ECs, which lead to inflammation. The latter initiates endothelial exocytosis of unusually large von Willebrand factor (ULVWF) multimers and FVIII from Weibel-Palade bodies. If ADAMTS13 is insufficient, ULVWF multimers activate intravascular hemostasis of ULVWF path. In activated ULVWF path, ULVWF multimers anchored to damaged endothelial cells recruit circulating platelets and trigger microthrombogenesis. This process produces "microthrombi strings" composed of platelet-ULVWF complexes, leading to endotheliopathy-associated VMTD (EA-VMTD). In COVID-19, microthrombosis initially affects the lungs per tropism causing ARDS, but EA-VMTD may orchestrate more complex clinical phenotypes, including thrombotic thrombocytopenic purpura (TTP)-like syndrome, hepatic coagulopathy, MODS and combined micro-macrothrombotic syndrome. In this pandemic, ARDS and pulmonary thromboembolism (PTE) have often coexisted. The analysis based on two hemostatic theories supports ARDS caused by activated ULVWF path is EA-VMTD and PTE caused by activated ULVWF and TF paths is macrothrombosis. The thrombotic disorder of COVID-19 sepsis is consistent with the notion that ARDS is virus-induced disseminated EAVMTD and PTE is in-hospital vascular injury-related macrothrombosis which is not directly related to viral pathogenesis. The pathogenesis-based therapeutic approach is discussed for the treatment of EA-VMTD with antimicrothrombotic regimen and the potential need of anticoagulation therapy for coinciding macrothrombosis in comprehensive COVID-19 care.	[Chang, Jae C.] Univ Calif Irvine, Sch Med, Dept Med, Irvine, CA 92717 USA		Chang, JC (通讯作者)，6 Via Castilla Unit B, Laguna Woods, CA 92637 USA.	jaec@uci.edu		Chang, Jae/0000-0002-9401-7684			Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Adeli SH, 2020, POL ARCH INTERN MED, V130, P455, DOI 10.20452/pamw.15340; Al Saiegh F, 2020, J NEUROL NEUROSUR PS, V91, P846, DOI 10.1136/jnnp-2020-323522; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564; Ali A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71188-3; Annane D, 2020, ECLINICALMEDICINE, V28, DOI 10.1016/j.eclinm.2020.100590; Azfar MF, 2017, CLIN INVEST MED, V40, pE49, DOI 10.25011/cim.v40i2.28195; Bazzan M, 2020, INTERN EMERG MED, V15, P861, DOI 10.1007/s11739-020-02394-0; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bernardo A, 2005, J THROMB HAEMOST, V3, P562, DOI 10.1111/j.1538-7836.2005.01122.x; Bois MC, 2021, CIRCULATION, V143, P230, DOI 10.1161/CIRCULATIONAHA.120.050754; Bolsen T, 2020, SCI COMMUN, V42, P562, DOI 10.1177/1075547020953603; Bompard F, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01365-2020; Boonyawat K, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00248-5; Borczuk AC, 2020, MODERN PATHOL, V33, P2156, DOI 10.1038/s41379-020-00661-1; Cabanillas G, 2016, AM J THER, V23, pE1277, DOI 10.1097/MJT.0000000000000386; Capecchi M, 2020, HAEMATOLOGICA, V105, pE540, DOI 10.3324/haematol.2020.262345; Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5; Chakraborty U, POSTGRAD MED J, V2021; Chang JC, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00231-0; Chang JC, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620913634; Chang JC, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619887437; Chang JC, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0198-4; Chang JC, 2018, BLOOD COAGUL FIBRIN, V29, P585, DOI 10.1097/MBC.0000000000000769; Chang JC, 2018, THROMB J, V16, DOI 10.1186/s12959-018-0174-4; Chang JC, 2018, BLOOD COAGUL FIBRIN, V29, P573, DOI 10.1097/MBC.0000000000000765; Chang JC, 2004, THER APHER DIAL, V8, P413, DOI 10.1111/j.1526-0968.2004.00184.x; Chauhan AK, 2007, J THROMB HAEMOST, V5, P583, DOI 10.1111/j.1538-7836.2007.02361.x; Chemla D, 2009, CHEST, V135, P760, DOI 10.1378/chest.08-0904; Chen JM, 2011, J CLIN INVEST, V121, P593, DOI 10.1172/JCI41062; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chen X, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00772; Cipolloni L, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080575; Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006; Davis MDP, 2007, J AM ACAD DERMATOL, V57, P944, DOI 10.1016/j.jaad.2007.07.039; De Ceunynck K, 2013, BLOOD, V121, P270, DOI 10.1182/blood-2012-07-442285; de Nooijer AH, 2021, J INFECT DIS, V223, P214, DOI 10.1093/infdis/jiaa646; Del Giudice P, 2020, J EUR ACAD DERMATOL, V34, pE679, DOI 10.1111/jdv.16763; Denorme F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179258; Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875; Divatia JV, 2011, INDIAN J ANAESTH, V55, P470, DOI 10.4103/0019-5049.89872; Dogan L, 2020, BRAIN BEHAV IMMUN, V87, P155, DOI 10.1016/j.bbi.2020.05.022; Domenighetti G, 1997, J CRIT CARE, V12, P177, DOI 10.1016/S0883-9441(97)90029-0; DONG ZG, 1994, J BIOL CHEM, V269, P6753; Eerenberg ES, 2016, CARDIOVASC RES, V111, P194, DOI 10.1093/cvr/cvw097; Elsoukkary SS, 2021, PATHOBIOLOGY, V88, P56, DOI 10.1159/000511325; Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014; Faqihi F, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04454-4; Farkas I, 2002, J PHYSIOL-LONDON, V539, P537, DOI 10.1113/jphysiol.2001.013381; Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448; FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034; Fletcher-Sandersjoo A, 2020, THROMB RES, V194, P36, DOI 10.1016/j.thromres.2020.06.027; Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749; Franchini M, 2020, DIAGNOSIS, V7, P357, DOI 10.1515/dx-2020-0078; GAFFNEY PJ, 1975, CLIN CHIM ACTA, V65, P109, DOI 10.1016/0009-8981(75)90341-1; Gavriilaki E, 2020, BRIT J HAEMATOL, V189, pE227, DOI 10.1111/bjh.16783; Geerts W, 2003, CHEST, V124, p357S, DOI 10.1378/chest.124.6_suppl.357S; Goebel PJ, 2010, WEST J EMERG MED, V11, P173; Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7; Guglielmetti G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03060-9; Hajra A, 2020, DRUGS, V80, P1553, DOI 10.1007/s40265-020-01377-x; Hamada SR, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0315-0; Hardy M, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00230-1; Hindilerden F, 2020, THROMB RES, V195, P136, DOI 10.1016/j.thromres.2020.07.005; Horii M, 2008, HEART VESSELS, V23, P301, DOI 10.1007/s00380-008-1053-x; Huang J, 2009, BLOOD, V113, P1589, DOI 10.1182/blood-2008-05-158584; Huisman A, 2020, INT J LAB HEMATOL, V42, pE211, DOI 10.1111/ijlh.13244; Java A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140711; Jhaveri KD, 2020, KIDNEY INT, V98, P509, DOI 10.1016/j.kint.2020.05.025; Jih Thomas Kuen-Shan, 2005, J Chin Med Assoc, V68, P1; Joly BS, 2020, INTENS CARE MED, V46, P1603, DOI 10.1007/s00134-020-06088-1; Kamran SM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0244853; Kanitakis J, 2020, J AM ACAD DERMATOL, V83, P870, DOI 10.1016/j.jaad.2020.05.145; Keith P, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20933473; Khamis F, 2020, INT J INFECT DIS, V99, P214, DOI 10.1016/j.ijid.2020.06.064; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Kroll Michael H, 2012, Pulm Circ, V2, P291, DOI 10.4103/2045-8932.101398; Kumar A, 2020, MED HYPOTHESES, V145, DOI 10.1016/j.mehy.2020.110320; Ladikou EE, 2020, CLIN MED, V20, pE178, DOI 10.7861/clinmed.2020-0346; Lax SF, 2020, ANN INTERN MED, V173, P350, DOI 10.7326/M20-2566; Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706; Levi M, 2018, J THROMB HAEMOST, V16, P646, DOI 10.1111/jth.13953; Levitt MH, 2020, NEW DEV NMR, V22, P3; Li JY, 2020, BRIT J HAEMATOL, V190, P24, DOI 10.1111/bjh.16797; Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327; Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Mackey K, 2020, J GEN INTERN MED, V17, P1; Madeeva DV, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142917; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Mancini I, 2021, J THROMB HAEMOST, V19, P513, DOI 10.1111/jth.15191; Marchandot B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061651; Marietta M, 2020, INTERN EMERG MED, V15, P1375, DOI 10.1007/s11739-020-02432-x; Martinelli N, 2020, THROMB RES, V193, P170, DOI 10.1016/j.thromres.2020.07.034; Marzano AV, 2020, BRIT J DERMATOL, V183, P431, DOI 10.1111/bjd.19264; Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450; McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1; Merrill JT, 2020, NAT REV RHEUMATOL, V16, P581, DOI 10.1038/s41584-020-0474-5; Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149; Minet C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1003-9; Mokhtari T, 2020, J MOL HISTOL, V51, P613, DOI 10.1007/s10735-020-09915-3; Mondal S, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00483-y; Moradi M, 2009, RESP MED, V103, P434, DOI 10.1016/j.rmed.2008.09.013; Morens DM, 2020, AM J TROP MED HYG, V103, P955, DOI 10.4269/ajtmh.20-0849; Mourik MJ, 2013, J THROMB HAEMOST, V11, P2009, DOI 10.1111/jth.12401; NIH, INF RES COR; Novara E, 2020, EUR REV MED PHARMACO, V24, P5769, DOI 10.26355/eurrev_202005_21369; Ortega-Paz L, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019650; Pagliari MT, 2021, THROMB RES, V197, P132, DOI 10.1016/j.thromres.2020.10.037; Palumbo D, 2020, J VASC INTERV RADIOL, V31, P1494, DOI 10.1016/j.jvir.2020.06.010; Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850; Peetermans M, 2020, J THROMB HAEMOST, V18, P722, DOI 10.1111/jth.14686; Pourdowlat G, 2020, CLIN CASE REP, V8, P2768, DOI 10.1002/ccr3.3276; Qian SZ, 2020, J CARDIOTHOR VASC AN, V34, P2846, DOI 10.1053/j.jvca.2020.03.063; Rapkiewicz AV, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100434; Rauch A, 2020, J THROMB HAEMOST, V18, P2942, DOI 10.1111/jth.15067; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; Robba C, 2020, EXPERT REV RESP MED, V14, P865, DOI 10.1080/17476348.2020.1778470; Romagnoli S, 2020, PHYSIOL REV, V100, P1455, DOI 10.1152/physrev.00020.2020; Rottenstreich A, 2016, J THROMB THROMBOLYS, V41, P678, DOI 10.1007/s11239-015-1259-6; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Schiviz A, 2012, BLOOD, V119, P6128, DOI 10.1182/blood-2011-09-380535; Schultz K, 2020, J HAND SURG-AM, V45, P518, DOI 10.1016/j.jhsa.2020.04.024; Shi H, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105974; Shi ZC, 2020, THER CLIN RISK MANAG, V16, P1047, DOI 10.2147/TCRM.S273700; Shimbo K, 2015, CASE REP PLAST SURG, V2, P53, DOI 10.3109/23320885.2015.1041529; Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262; Simpson JM, 2020, CIRCULATION, V142, P437, DOI 10.1161/CIRCULATIONAHA.120.048726; Sonneveld MAH, 2015, BLOOD, V126, P2739, DOI [10.1182/blood-2015-05643338, 10.1182/blood-2015-05-643338]; Spieth PM, 2012, CRIT CARE MED, V40, P3320, DOI 10.1097/CCM.0b013e318270e3a2; Stahel PF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01661; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Suarez-Valle A, 2020, J EUR ACAD DERMATOL, V34, pE455, DOI 10.1111/jdv.16592; SUTER PM, 1994, CHEST, V105, P190, DOI 10.1378/chest.105.1.190; Tersteeg C, 2017, BLOOD, V129, P1030, DOI 10.1182/blood-2016-09-738856; Thachil J, 2020, SEMIN THROMB HEMOST, V46, P831, DOI 10.1055/s-0040-1714274; Tsai HM, 2010, INT J HEMATOL, V91, P1, DOI 10.1007/s12185-009-0476-1; Tsutsumi T, 2021, HEPATOL RES, V51, P227, DOI 10.1111/hepr.13577; Turner NA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140740; Valdivia-Mazeyra MF, 2021, VIRCHOWS ARCH, V478, P487, DOI 10.1007/s00428-020-02926-1; Valga F, 2020, CLIN KIDNEY J, V13, P477, DOI 10.1093/ckj/sfaa095; Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828; Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R; Wang L, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00078; Warkentin TE, 2019, HAMOSTASEOLOGIE, V39, P6, DOI 10.1055/s-0038-1676823; Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wu YQ, 2020, CLIN CHIM ACTA, V509, P220, DOI 10.1016/j.cca.2020.06.026; Yeh HC, 2010, J THROMB HAEMOST, V8, P2778, DOI 10.1111/j.1538-7836.2010.04094.x; Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618; Zhang CL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015833; Zhang R, 2021, J VASC SURG-VENOUS L, V9, P289, DOI 10.1016/j.jvsv.2020.11.023; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575; Zhang Y, 2017, EXP THER MED, V14, P2863, DOI 10.3892/etm.2017.4891; Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598	157	4	4	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						273	298		10.2147/VHRM.S299357			26	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD7NF	WOS:000669508100001	34103921	Green Published, gold			2022-04-27	
J	Chaulin, A				Chaulin, Aleksey			Clinical and Diagnostic Value of Highly Sensitive Cardiac Troponins in Arterial Hypertension	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						CVD; hs-Tn; acute myocardial infarction; arterial hypertension; hypertensive crisis; noninvasive diagnostics; oral fluid; urine	LEFT-VENTRICULAR DYSFUNCTION; CREATINE-KINASE-MB; ADRENERGIC REGULATION; PLATELET ACTIVATION; SKELETAL-MUSCLE; DIURNAL RHYTHM; BLOOD-PRESSURE; I DEGRADATION; T ISOFORMS; EXPRESSION	In modem laboratory diagnostics of cardiovascular diseases (CVD), there is a clear tendency toward an increase in the sensitivity of methods for determining key CVD biomarkers, among which highly sensitive cardiac troponins (hs-Tn) deserve special attention. The introduction of the latter into clinical practice made it possible not only to improve the early diagnosis of acute myocardial infarction but also to open up a number of additional valuable opportunities for the use of hs-Tn, including the assessment of the risk of developing CVD in a healthy population, detection and monitoring of early myocardial injuries in the early stages of CVD development (for example, with ischemic heart disease and arterial hypertension), with noncardiac pathologies (for example, sepsis, chronic obstructive pulmonary disease, chronic renal failure, stroke, cancer, etc), and diagnostics of CVD by using biological fluids that can be obtained by noninvasive methods. This article discusses in detail the diagnostic value of hs-Tn in serum and urine in cases of arterial hypertension. Also, the paper pays considerable attention to the consideration of the mechanisms underlying the increase in hs-Tn in serum and urine in cases of arterial hypertension.	[Chaulin, Aleksey] Samara State Med Univ, Dept Cardiol & Cardiovasc Surg, Samara 443099, Russia; [Chaulin, Aleksey] Samara State Med Univ, Dept Histol & Embryol, Samara 443099, Russia		Chaulin, A (通讯作者)，Samara State Med Univ, Dept Histol & Embryol, Dept Cardiol & Cardiovasc Surg, 89 Chapaevskaya St, Samara 443099, Russia.	alekseymichailovich22976@gmail.com	Chaulin, Aleksey M./F-1229-2019	Chaulin, Aleksey M./0000-0002-2712-0227			Acosta G, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.6787; Afonso L, 2011, J CLIN HYPERTENS, V13, P551, DOI 10.1111/j.1751-7176.2011.00476.x; [Anonymous], 2008, LANCET, V371, P1513, DOI [10.1016/S0140- 6736(08)60655-8, DOI 10.1016/S0140-6736(08)60655-8]; [Anonymous], HIGH SENSITIVITY CAR; Apple FS, 1999, CLIN CHIM ACTA, V284, P151, DOI 10.1016/S0009-8981(99)00077-7; Apple FS, 1998, EUR HEART J, V19, pN30; Bleier J, 1998, CLIN CHEM, V44, P1912; Bohn MK, 2019, CLIN CHEM, V65, P589, DOI 10.1373/clinchem.2018.299156; Brinkmann C, 2018, HERZ, V43, P681, DOI 10.1007/s00059-018-4763-6; Caligiuri SPB, 2017, AM J HYPERTENS, V30, P236, DOI 10.1093/ajh/hpw136; Chaudary Nauman, 2014, J Miss State Med Assoc, V55, P40; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P93, DOI 10.15829/1728-8800-2021-2590; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P82, DOI 10.15829/1728-8800-2021-2639; [Чаулин А.М. Chaulin A.M.], 2020, [Комплексные проблемы сердечно-сосудистых заболеваний, Kompleksnye problemy serdechno-sosudistykh zabolevanii], V9, P69, DOI 10.17802/2306-1278-2020-9-3-69-80; [Чаулин А.М. Chaulin A.M.], 2019, [Комплексные проблемы сердечно-сосудистых заболеваний, Kompleksnye problemy serdechno-sosudistykh zabolevanii], V8, P103, DOI 10.17802/2306-1278-2019-8-4-103-115; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P17, DOI 10.15829/1560-4071-2020-3814; [Чаулин А.М. Chaulin A.M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology, Rossiiskii kardiologicheskii zhurnal], V25, P62, DOI 10.15829/1560-4071-2020-4061; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P55, DOI 10.15829/1560-4071-2020-4140; Chaulin AM, 2019, KARDIOLOGIYA, V59, P66, DOI 10.18087/cardio.2019.11.n414; Chaulin A, 2021, VASC HEALTH RISK MAN, V17, P299, DOI 10.2147/VHRM.S300002; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2021, [Гигиена и санитария, Hygiene and Sanitation, Gigiena i sanitariya], V100, P223, DOI 10.47470/0016-9900-2021-100-3-223-228; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2019, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V10, P81, DOI 10.17816/clinpract16309; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2020, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V11, P75, DOI 10.17816/clinpract34284; Chaulin AM, 2020, RUSS OPEN MED J, V9, DOI 10.15275/rusomj.2020.0305; Chaulin AM, 2021, SIGNA VITAE, V17, P79, DOI 10.22514/sv.2021.050; Chaulin AM, 2019, KARDIOLOGIYA NOVOSTI, V7, P13, DOI [10.24411/2309-1908-2019-12002.(inRussian), 10.24411/2309-1908-2019-12002, DOI 10.24411/2309-1908-2019-12002]; Chaulin AM, 2019, KARDIOLOGIYA, V7, P24, DOI [10.24411/2309-1908-2019-12003, DOI 10.24411/2309-1908-2019-12003, 10.24411/2309-1908-2019-12003.(inRussian)]; CHAULIN AM, 2021, CARDIOVASCULAR THERA, V20, P2539, DOI DOI 10.15829/1728-8800-2021-2539; Chaulin AM, 2020, MODERN PROBLEMS SCI, V6, DOI [10.17513/spno.30302, DOI 10.17513/SPNO.30302]; Chaulin AM, 2020, RUSSIAN J CARDIOLOGY, V25, P3923, DOI [10.15829/1560-4071-2020-3923, DOI 10.15829/1560-4071-2020-3923]; Chen JY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123917; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Clerico A, 2021, CLIN CHEM LAB MED, V59, P641, DOI 10.1515/cclm-2020-1433; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; Dalal S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196626; de Lemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503, DOI 10.1001/jama.2010.1768; deFilippi C, 2012, CLIN CHEM, V58, P1342, DOI 10.1373/clinchem.2012.185322; Derhaschnig U, 2013, J HUM HYPERTENS, V27, P368, DOI 10.1038/jhh.2012.53; Di Lullo Luca, 2015, G Ital Nefrol, V32; Diris JHC, 2004, CIRCULATION, V109, P23, DOI 10.1161/01.CIR.0000109483.45211.8F; Dubin RF, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-229; Duplyakov DV, 2019, CARDIOLOGY NEWS OPIN, V7, P8, DOI 10.24411/2309-1908-2019-13001; Feng J, 2001, CIRCULATION, V103, P2035; Garcia-Osuna A, 2018, CLIN CHIM ACTA, V486, P224, DOI 10.1016/j.cca.2018.08.015; Gommans DHF, 2021, AM J CARDIOL, V152, P120, DOI 10.1016/j.amjcard.2021.04.040; Gore MO, 2014, J AM COLL CARDIOL, V63, P1441, DOI 10.1016/j.jacc.2013.12.032; Harvell B, 2016, AM J EMERG MED, V34, P145, DOI 10.1016/j.ajem.2015.09.037; Hessel MHM, 2008, PFLUG ARCH EUR J PHY, V455, P979, DOI 10.1007/s00424-007-0354-8; Horwich TB, 2003, CIRCULATION, V108, P833, DOI 10.1161/01.CIR.0000084543.79097.34; Jaffe AS, 2011, J AM COLL CARDIOL, V58, P1819, DOI 10.1016/j.jacc.2011.08.026; Jeremias A, 2005, ANN INTERN MED, V142, P786, DOI 10.7326/0003-4819-142-9-200505030-00015; Joharimoghadam A, 2017, KARDIOL POL, V75, P71, DOI 10.5603/KP.a2016.0097; Kandasamy AD, 2010, CARDIOVASC RES, V85, P413, DOI 10.1093/cvr/cvp268; Katrukha IA, 2017, CLIN CHEM, V63, P1094, DOI 10.1373/clinchem.2016.266635; KATUS HA, 1992, CLIN CHEM, V38, P386; Klinkenberg LJJ, 2016, CLIN CHEM, V62, P1602, DOI 10.1373/clinchem.2016.257485; Kobayashi T, 2008, PFLUG ARCH EUR J PHY, V457, P37, DOI 10.1007/s00424-008-0511-8; Kostyukevich OI, 2011, RUSSIAN MED J, V19, P338; Kozinski M, 2017, CRIT REV CL LAB SCI, V54, P143, DOI 10.1080/10408363.2017.1285268; Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8; Lazzarino AI, 2013, J AM COLL CARDIOL, V62, P1694, DOI 10.1016/j.jacc.2013.05.070; Li FF, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.651851; Lindner G, 2014, INTERN EMERG MED, V9, P335, DOI 10.1007/s11739-013-1030-y; LOFBERG M, 1995, ARCH NEUROL-CHICAGO, V52, P1210, DOI 10.1001/archneur.1995.00540360090020; Long B, 2020, AM J EMERG MED, V38, P998, DOI 10.1016/j.ajem.2019.12.007; Maekawa A, 2003, J MOL CELL CARDIOL, V35, P1277, DOI 10.1016/S0022-2828(03)00238-4; Marques MD, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00429; Maruta T, 2012, CRIT CARE MED, V40, P1, DOI [10.1097/01.ccm.0000424470.26633.42, DOI 10.1097/01.ccm.0000424470.26633.42]; Masri W, 2017, ANN BIOL CLIN-PARIS, V75, P411, DOI 10.1684/abc.2017.1262; McEvoy JW, 2015, CIRCULATION, V132, P825, DOI 10.1161/CIRCULATIONAHA.114.014364; McLaurin MD, 1997, CLIN CHEM, V43, P976; Messner B, 2000, AM J CLIN PATHOL, V114, P544, DOI 10.1309/8KCL-UQRF-6EEL-36XK; Monneret D, 2018, CLIN CHEM LAB MED, V56, P818, DOI 10.1515/cclm-2017-0256; Morrow David A, 2007, Circulation, V115, pe356; MullerBardorff M, 1997, CLIN CHEM, V43, P458; Muslimovic A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63744-8; Omondi A, 2017, J AM COLL CARDIOL, V69, P1803, DOI 10.1016/S0735-1097(17)35192-6; Papadopoulos DP, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0515-z; Pattanshetty DJ, 2012, J HYPERTENS, V30, P2410, DOI 10.1097/HJH.0b013e3283599b4f; Pervan P., 2017, Signa Vitae, V13, P62; Postigo A, 2021, EUR HEART J-ACUTE CA, V10, P356, DOI 10.1093/ehjacc/zuab008; Potkonjak AM, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110252; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; Richardson AJ, 2018, J SCI MED SPORT, V21, P880, DOI 10.1016/j.jsams.2018.02.005; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Samaha E, 2019, CLIN BIOCHEM, V63, P18, DOI 10.1016/j.clinbiochem.2018.11.013; Schmid J, 2018, J AM COLL CARDIOL, V71, P1540, DOI 10.1016/j.jacc.2018.01.070; Shah ASV, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7873; Shah ASV, 2014, CIRCULATION, V130, P1607, DOI 10.1161/CIRCULATIONAHA.114.011085; SIEGEL AJ, 1995, CARDIOLOGY, V86, P451, DOI 10.1159/000176922; Sigurdardottir FD, 2018, AM J CARDIOL, V121, P949, DOI 10.1016/j.amjcard.2018.01.004; Singh K, 2001, J CELL PHYSIOL, V189, P257, DOI 10.1002/jcp.10024; Singh K, 2000, CARDIOVASC RES, V45, P713, DOI 10.1016/S0008-6363(99)00370-3; Stabouli S, 2009, PEDIATR NEPHROL, V24, P1545, DOI 10.1007/s00467-009-1165-2; Talha AM, 2019, CIRCULATION, V140; Thygesen K, 2018, GLOB HEART, V13, P305, DOI [10.1093/eurheartj/ehy462, 10.1161/CIR.0000000000000617, 10.1016/j.recesp.2018.11.011, 10.1016/j.jacc.2018.08.1038]; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Ucar H, 2014, BLOOD PRESSURE, V23, P240, DOI 10.3109/08037051.2013.840429; van den Born BJH, 2011, J HYPERTENS, V29, P922, DOI 10.1097/HJH.0b013e328345023d; van der Linden N, 2016, INT J CARDIOL, V221, P287, DOI 10.1016/j.ijcard.2016.06.268; van der Wees CGC, 2006, PFLUG ARCH EUR J PHY, V451, P588, DOI 10.1007/s00424-005-1402-x; Wang K, 2020, KIDNEY INT REP, V5, P2002, DOI 10.1016/j.ekir.2020.08.028; Wang WJ, 2002, CIRCULATION, V106, P1543, DOI 10.1161/01.CIR.0000028818.33488.7B; Weckbach LT, 2021, CIRC-CARDIOVASC IMAG, V14, DOI 10.1161/CIRCIMAGING.120.011713; Weil BR, 2018, J AM COLL CARDIOL, V71, P2906, DOI 10.1016/j.jacc.2018.04.029; Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006; Widera C, 2019, INT J CARDIOL, V275, P13, DOI 10.1016/j.ijcard.2018.10.027; World Health Organisation, 2013, GLOBAL BRIEF HYPERTE; Yotti R, 2019, ANNU REV GENOM HUM G, V20, P129, DOI 10.1146/annurev-genom-083118-015306; Zhao H, 2021, NANOSCALE, V13, P3275, DOI 10.1039/d0nr08008j; Ziebig R, 2003, CLIN CHEM, V49, P1191, DOI 10.1373/49.7.1191	111	10	10	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						431	443		10.2147/VHRM.S315376			13	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TT5DD	WOS:000680367600001	34366667	gold, Green Published			2022-04-27	
J	Gebicki, J; Marcinek, A; Zielinski, J				Gebicki, Jerzy; Marcinek, Andrzej; Zielinski, Jacek			Assessment of Microcirculatory Status Based on Stimulation of Myogenic Oscillations by Transient Ischemia: From Health to Disease	VASCULAR HEALTH AND RISK MANAGEMENT			English	Editorial Material									[Gebicki, Jerzy; Marcinek, Andrzej] Lodz Univ Technol, Inst Appl Radiat Chem, PL-90924 Lodz, Poland; [Gebicki, Jerzy; Marcinek, Andrzej] Angionica Ltd, Lodz, Poland; [Zielinski, Jacek] Poznan Univ Phys Educ, Dept Athlet Strength & Conditioning, Poznan, Poland		Gebicki, J (通讯作者)，Lodz Univ Technol, Inst Appl Radiat Chem, PL-90924 Lodz, Poland.	jerzy.gebicki@p.lodz.pl	Zieliński, Jacek/B-8680-2019; Marcinek, Andrzej/M-1775-2018	Zieliński, Jacek/0000-0002-2782-9973; Marcinek, Andrzej/0000-0002-9852-7593; Gebicki, Jerzy/0000-0003-2304-5036	European UnionEuropean Commission [POIR. 01.01.01-00-0540/15-00]	This work was supported by the European Union from the resources of the European Regional Development Fund under the Smart Growth Operational Program, Grant No. POIR. 01.01.01-00-0540/15-00.	Bugaj O, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00600; Gebicki J, 2020, RESP PHYSIOL NEUROBI, V280, DOI 10.1016/j.resp.2020.103478; Hellmann M, 2017, MICROVASC RES, V113, P60, DOI 10.1016/j.mvr.2017.05.004; Katarzynska J, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00702; Katarzynska Joanna, 2020, J Diabetes Sci Technol, V14, P693, DOI 10.1177/1932296819895544; Katarzynska J, 2019, REV SCI INSTRUM, V90, DOI 10.1063/1.5092218; Katarzynska J, 2019, MICROVASC RES, V124, P19, DOI 10.1016/j.mvr.2019.02.005; Majewski S, 2020, MICROVASC RES, V127, DOI 10.1016/j.mvr.2019.103914; Rossi M, 2006, BIOMED PHARMACOTHER, V60, P437, DOI 10.1016/j.biopha.2006.07.012	9	2	2	2	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						33	36		10.2147/VHRM.S292087			4	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QM5XE	WOS:000621851200001	33603387	Green Published, gold			2022-04-27	
J	Kumboyono, K; Nurwidyaningtyas, W; Chomsy, IN; Wihastuti, TA				Kumboyono, Kumboyono; Nurwidyaningtyas, Wiwit; Chomsy, Indah Nur; Wihastuti, Titin Andri			Early Detection of Negative Smoking Impacts: Vascular Adaptation Deviation Based on Quantification of Circulated Endothelial Activation Markers	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						endothelial injury; cardiovascular disease; atherosclerosis; peripheral blood mononuclear cells; smoker	E-SELECTIN; PLATELETS; INFLAMMATION; CELLS; MICROPARTICLES; DYSFUNCTION; ATHEROSCLEROSIS; MECHANISMS; LIGANDS; DISEASE	Introduction: Smoking can cause vascular damage in the form of an inflammatory reaction characterized by endothelial activation. Endothelial activation forms a pathological adaptation pattern so that it can induce the atherogenesis process. Several markers, such as E-selectin, platelet-derived micro particles (PMPs) and hematopoietic stem cell (HSC) can identify the activation of endothelial in circulating blood. Therefore, the deviation of vascular adaptation due to smoking can be detected early through the feedback mechanism between E-selectin, PMPs, and HSC. Purpose: This study aims to analyze the initial picture of the negative impact of smoking on vascular adaptation by measuring E-selectin, PMPs, and HSC in the peripheral blood circulation. Participant criteria and methods: Peripheral blood samples (5 mL) were taken from each participant, both the smoking group (n = 30) and the non-smoker group (n = 31) to obtain peripheral blood mononuclear cells (PBMNC). PBMNC was isolated using ficoll-based gradient centrifugation. The flow cytometry assay method used to measure the E-selectin, PMPs and hematopoietic stem cells. Results: The mean of circulating E-selectin in smokers was higher than that of non-smokers. On the other hand, the average number of PMPs and HSCs in smokers was lower than nonsmokers. Conclusion: Smoking increases the risk of accelerated vascular block formation, as indicated by an increase in the amount of circulating E-selectin. The increase in E-selectin in the blood vessels mediates the increased adhesion of PMPs in the vascular area so that the number of circulating PMPs in smokers decreases. The decrease in circulating PMPs decreases the signal of vascular repair, which is characterized by a decline in the number of HSCs.	[Kumboyono, Kumboyono] Univ Brawijaya, Fac Med, Nursing Dept, Malang 65145, Indonesia; [Nurwidyaningtyas, Wiwit; Chomsy, Indah Nur] Univ Brawijaya, Fac Med, Doctoral Program Med Sci, Malang 65145, Indonesia; [Wihastuti, Titin Andri] Univ Brawijaya, Fac Med, Dept Biomed, Malang 65145, Indonesia		Kumboyono, K (通讯作者)，Univ Brawijaya, Fac Med, Nursing Dept, Malang 65145, Indonesia.	publikasikoe@gmail.com	Chomsy, Indah Nur/AAY-3124-2021	Chomsy, Indah Nur/0000-0002-1050-3571; Kumboyono, Kumboyono/0000-0003-2124-8673			Aicher A, 2005, HYPERTENSION, V45, P321, DOI 10.1161/01.HYP.0000154789.28695.ea; Alamanda V, 2012, BIOCHEM BIOPH RES CO, V418, P56, DOI 10.1016/j.bbrc.2011.12.127; Aleisa FA, 2020, J BIOL CHEM, V295, P3719, DOI 10.1074/jbc.RA119.010910; [Anonymous], UNPUB; Barbier V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15817-5; Blann AD, 2005, THROMB HAEMOSTASIS, V93, P228, DOI 10.1160/TH04-09-0578; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; Breen KA, 2015, THROMB RES, V135, P368, DOI 10.1016/j.thromres.2014.11.027; Balandran JC, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00666; Cherian P, 2003, STROKE, V34, P2132, DOI 10.1161/01.STR.0000086466.32421.F4; COLLINS T, 1991, J BIOL CHEM, V266, P2466; Daiber A, 2017, BRIT J PHARMACOL, V174, P1591, DOI 10.1111/bph.13517; Eikendal ALM, 2018, J CARDIOVASC MAGN R, V20, DOI 10.1186/s12968-018-0473-8; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Gargett CE, 2009, BIOL REPROD, V80, P1136, DOI 10.1095/biolreprod.108.075226; Golbidi S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/789607; Goligorsky MS, 2015, KIDNEY RES CLIN PRAC, V34, P76, DOI 10.1016/j.krcp.2015.05.003; Heiss C, 2005, J AM COLL CARDIOL, V45, P1441, DOI 10.1016/j.jacc.2004.12.074; Inami N, 2003, CLIN APPL THROMB-HEM, V9, P309, DOI 10.1177/107602960300900406; Italiano JE, 2010, CURR OPIN HEMATOL, V17, P578, DOI 10.1097/MOH.0b013e32833e77ee; Khlgatian M, 2002, INFECT IMMUN, V70, P257, DOI 10.1128/IAI.70.1.257-267.2002; Kou F, 2020, EPMA J, V11, P629, DOI 10.1007/s13167-020-00223-0; Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Liao JK, 2013, J CLIN INVEST, V123, P540, DOI 10.1172/JCI66843; Lukasik M, 2013, PLATELETS, V24, P63, DOI 10.3109/09537104.2011.654292; Mitroulis I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01540; Mobarrez F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090314; Moll NM, 2010, EXPERT REV HEMATOL, V3, P315, DOI 10.1586/EHM.10.16; Mortberg J, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1261-x; Papathanaiou G, 2014, HLTH SCI J MONOXIDE, V8; Pedersen KM, 2019, ARTERIOSCL THROM VAS, V39, P965, DOI 10.1161/ATVBAHA.118.312338; Pober JS, 2009, ANNU REV PATHOL-MECH, V4, P71, DOI 10.1146/annurev.pathol.4.110807.092155; Price DT, 1999, AM J MED, V107, P85, DOI 10.1016/S0002-9343(99)00153-9; Rabelink TJ, 2010, NAT REV NEPHROL, V6, P404, DOI 10.1038/nrneph.2010.65; Roldan V, 2003, THROMB HAEMOSTASIS, V90, P1007, DOI 10.1160/TH02-09-0083; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Siggins Robert W, 2014, Med Sci (Basel), V2, P37, DOI 10.3390/medsci2010037; Silva M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01878; Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033; Takahashi M, 2014, LEUKEMIA, V28, P1308, DOI 10.1038/leu.2013.326; Toda N, 2010, EUR J PHARMACOL, V649, P1, DOI 10.1016/j.ejphar.2010.09.042; Totani L, 2010, ARTERIOSCL THROM VAS, V30, P2357, DOI 10.1161/ATVBAHA.110.207480; Trompouki E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00660; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Versari D, 2007, CURR PHARM DESIGN, V13, P1811, DOI 10.2174/138161207780831239; Wihastuti T. A., 2018, Journal of Applied Pharmaceutical Science, V8, P64; Woywodt A, 2002, NEPHROL DIAL TRANSPL, V17, P1728, DOI 10.1093/ndt/17.10.1728; Yun SH, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9060143; Zahran AM, 2020, ACTA ONCOL, V59, P33, DOI 10.1080/0284186X.2019.1657940	51	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						103	109		10.2147/VHRM.S296293			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RK0UL	WOS:000638020300001	33790567	Green Published, gold			2022-04-27	
J	Kirsten, N; Mohr, N; Gensel, F; Alhumam, A; Bruning, G; Augustin, M				Kirsten, Natalia; Mohr, Nicole; Gensel, Franziska; Alhumam, Aminah; Bruning, Guido; Augustin, Matthias			Population-Based Epidemiologic Study in Venous Diseases in Germany - Prevalence, Comorbidity, and Medical Needs in a Cohort of 19,104 Workers	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						venous insufficiency; epidemiology; prevalence	VARICOSE-VEINS; RISK-FACTORS; GENERAL-POPULATION; LOWER-LIMBS; DISORDERS; INSUFFICIENCY; LIFE; WOMEN	Introduction: Data on the prevalence of chronic venous disorders (CVD) at the national level in Germany are scarce. Methods: We performed a population-based observational study based on clinical examinations, personal history, and technical examinations. Data were collected from 2006 to 2015. Descriptive data analysis was done to determine CVD and chronic venous insufficiency (CVI) prevalence and occurrence of potential risk factors. Chi-squared tests were performed to estimate the influence of risk factors on the prevalence of CVD. Results: In total, 19,104 employees from different branches were included. The majority of the examined people were doing office work (n = 8157; 80.2%). A total of 4038 persons (21.1%) show at least one sign of CVD. At least one sign of CVI could be found in 679 persons (3.6%). Being female was found to be protective with an odds ratio of 0.66 (95% CI 0.59-0.73). Conclusion: There is clear indication for active venous treatment in 22.3% of the adult working population in Germany.	[Kirsten, Natalia; Mohr, Nicole; Gensel, Franziska; Alhumam, Aminah; Augustin, Matthias] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Martinistr 52, D-20246 Hamburg, Germany; [Alhumam, Aminah] King Faisal Univ, Coll Med, Dept Dermatol, Al Hasa, Saudi Arabia; [Bruning, Guido] Tabea Hosp GmbH & Co KG, Dept Vein & Dermatosurg, Hamburg, Germany		Kirsten, N (通讯作者)，Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Martinistr 52, D-20246 Hamburg, Germany.	n.kirsten@uke.de			BSN medical GmbH, Hamburg, Germany	This work was supported by an unrestricted research grant from BSN medical GmbH, Hamburg, Germany. The fun-ders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMSON JH, 1981, J EPIDEMIOL COMMUN H, V35, P213, DOI 10.1136/jech.35.3.213; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; Bergan JJ, 2006, NEW ENGL J MED, V355, P488, DOI 10.1056/NEJMra055289; BRAND FN, 1988, AM J PREV MED, V4, P96, DOI 10.1016/S0749-3797(18)31203-0; Carpentier PH, 2004, J VASC SURG, V40, P650, DOI 10.1016/j.jvs.2004.07.025; Cesarone MR, 2002, ANGIOLOGY, V53, P119, DOI 10.1177/000331970205300201; Cunha Nelia, 2017, Br J Community Nurs, V22, pS30, DOI 10.12968/bjcn.2017.22.Sup9.S30; EBERTHWILLERSHAUSEN W, 1984, HAUTARZT, V35, P68; Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027; Evans CJ, 1999, J EPIDEMIOL COMMUN H, V53, P149, DOI 10.1136/jech.53.3.149; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Fiebig A, 2010, HUM GENET, V127, P669, DOI 10.1007/s00439-010-0812-9; Fowkes FGR, 2001, INT J EPIDEMIOL, V30, P846, DOI 10.1093/ije/30.4.846; Garcia-Honduvilla N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3974026; Homs-Romero E, 2021, J NURS SCHOLARSHIP, V53, P296, DOI 10.1111/jnu.12639; Huang Y, 2016, PHLEBOLOGY, V31, P88, DOI 10.1177/0268355516630868; Krijnen RMA, 1997, DERMATOLOGY, V194, P111, DOI 10.1159/000246077; Lake M, 1942, J AMER MED ASSOC, V119, P696, DOI 10.1001/jama.1942.02830260010004; Lee AJ, 2003, J CLIN EPIDEMIOL, V56, P171, DOI 10.1016/S0895-4356(02)00518-8; Mashiah A, 1999, CARDIOVASC SURG, V7, P327, DOI 10.1016/S0967-2109(98)00132-X; Novak CJ, 2019, CURR PAIN HEADACHE R, V23, DOI 10.1007/s11916-019-0759-z; Prochaska JH, 2021, EUR HEART J, V42, P4157, DOI 10.1093/eurheartj/ehab495; Belczak CEQ, 2014, PHLEBOLOGY, V29, P500, DOI 10.1177/0268355513492510; Rabe E, 2012, INT ANGIOL, V31, P105; Rabe E, 2003, PHLEBOLOGIE, V32, P1; Rabe E, 2018, PHLEBOLOGY, V33, P163, DOI 10.1177/0268355516689631; Robertson L, 2013, J VASC SURG-VENOUS L, V1, P59, DOI 10.1016/j.jvsv.2012.05.006; Statistisches Bundesamt, 2013, BEV MIGR ERG MIKR; STVRTINOVA V, 1991, INT ANGIOL, V10, P2; VANDENBERG E, 1983, PHLEBOL PROKTOL, V12, P91; WIDMER LK, 1978, PERIPHERAL VENOUS DI	31	0	0	4	4	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						679	687		10.2147/VHRM.S323084			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WR8RY	WOS:000714763400002	34744435	gold, Green Published			2022-04-27	
J	Nagayama, D; Saiki, A; Shirai, K				Nagayama, Daiji; Saiki, Atsuhito; Shirai, Kohji			The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Editorial Material						pitavastatin; anti-cancer effect; TOHO-LIP	CANCER-CELLS; IN-VITRO; ATORVASTATIN; PREVENTION; EXPRESSION; CORONARY; ASPIRIN; MTOR	The significance of statin treatment for the reduction of cardiovascular (CV) disease has been reported, whereas other reports have also described anti-cancer properties associated with the class effect of statins. However, the differences in anti-cancer effect of various types of statins have rarely been examined. Pitavastatin is a statin with a different chemical structure and pharmacokinetics from other statins, and the mechanism of the specific anti-cancer effect of pitavastatin has been reported in in vivo therapeutic models. We previously revealed that pitavastatin therapy was superior to atorvastatin therapy in the prevention of CV events, despite similar LDL-cholesterol-lowering effect in the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP). Furthermore, in subgroup analysis of the TOHO-LIP study, cumulative 240-week incidence of new cancer cases tended to be lower in the pitavastatin group compared to the atorvastatin group [0.32% (1/312) vs 1.94% (6/310), log-rank P=0.051]. This finding might reveal the superiority of pitavastatin to prevent carcinogenesis. The molecular mechanism by which pitavastatin suppresses the incidence of any-organ cancer is gradually elucidated, and new combination of cancer treatments with pitavastatin will be developed in the future to further enhance the anti-cancer activity and reduce the side effects.	[Nagayama, Daiji] Nagayama Clin, Dept Internal Med, 2-12-22 Tenjin Cho, Oyama City, Tochigi 3230032, Japan; [Nagayama, Daiji; Saiki, Atsuhito] Toho Univ, Sakura Med Ctr, Ctr Diabet Endocrine & Metab, Chiba, Japan; [Shirai, Kohji] Mihama Hosp, Dept Internal Med, Chiba, Japan		Nagayama, D (通讯作者)，Nagayama Clin, Dept Internal Med, 2-12-22 Tenjin Cho, Oyama City, Tochigi 3230032, Japan.	deverlast96071@gmail.com		yong shan, da er/0000-0001-6119-8012			Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135; Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163-7258(99)00045-5; de Wolf E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05595-4; Di Bello E, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00516; Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050; Fujino M, 2006, ATHEROSCLEROSIS, V187, P301, DOI 10.1016/j.atherosclerosis.2005.10.008; Jiang P, 2014, BRIT J CANCER, V111, P1562, DOI 10.1038/bjc.2014.431; Jiao ZH, 2020, P NATL ACAD SCI USA, V117, P4158, DOI 10.1073/pnas.1917938117; Lee N, 2020, J CELL MOL MED, V24, P7055, DOI 10.1111/jcmm.15389; Moroi M, 2020, INT J CARDIOL, V305, P139, DOI 10.1016/j.ijcard.2020.01.006; Nagayama D, 2022, J ATHEROSCLER THROMB, V29, P451, DOI 10.5551/jat.62141; Nakamura H, 2006, LANCET, V368, P1155, DOI 10.1016/S0140-6736(06)69472-5; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; Ohira M, 2012, METABOLISM, V61, P1452, DOI 10.1016/j.metabol.2012.03.010; Okazaki S, 2004, CIRCULATION, V110, P1061, DOI 10.1161/01.CIR.0000140261.58966.A4; Okubo K, 2020, CANCER SCI, V111, P112, DOI 10.1111/cas.14225; Otahal A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57707-2; Saito Y, 2011, ATHEROSCLEROSIS SUPP, V12, P271, DOI 10.1016/S1567-5688(11)70886-8; Saito Y, 2009, VASC HEALTH RISK MAN, V5, P921; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Tsubaki M, 2017, CLIN EXP PHARMACOL P, V44, P222, DOI 10.1111/1440-1681.12690; Villarino N, 2017, ONCOTARGET, V8, P53154, DOI 10.18632/oncotarget.18587; Wang LQ, 2019, FASEB J, V33, P13710, DOI 10.1096/fj.201901388R; Xu B, 2021, MOL CANCER RES, V19, P585, DOI 10.1158/1541-7786.MCR-20-0688; Yokomichi H, 2017, J EPIDEMIOL, V27, pS84, DOI 10.1016/j.je.2016.12.011; You HY, 2016, ONCOTARGETS THER, V9, P5383, DOI 10.2147/OTT.S106906; Yue W, 2014, CANCER PREV RES, V7, P388, DOI 10.1158/1940-6207.CAPR-13-0337; Zhang ZY, 2017, EUR REV MED PHARMACO, V21, P1226	28	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						169	173		10.2147/VHRM.S306540			5	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RU0QD	WOS:000644856100001	33953560	Green Published, gold			2022-04-27	
J	Cazaubon, M; Benigni, JP; Steinbruch, M; Jabbour, V; Gouhier-Kodas, C				Cazaubon, Michele; Benigni, Jean-Patrick; Steinbruch, Marcio; Jabbour, Violaine; Gouhier-Kodas, Christelle			Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						chronic venous disorders; venoactive drugs; flavonoids; randomized clinical trials; literature review	LOWER-LIMBS GUIDELINES; QUALITY-OF-LIFE; CEAP CLASSIFICATION; DISEASE; MANAGEMENT; PLACEBO; INSUFFICIENCY; METAANALYSIS; SYMPTOMS; TRIAL	Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders (CVD). Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources; it can also be obtained after conversion of hesperidin extracted from citrus rinds. Micronized purified flavonoid fraction (MPFF) is a preparation that contains mainly diosmin and a small fraction of hesperidin. We performed a state-of-the-art literature review to collect and analyze well-conducted randomized clinical studies comparing diosmin - also called non-micronized or hemisynthetic diosmin - 600 mg a day and MPFF, 1000 mg a day. Three clinical studies met the criteria and were included for this literature review. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six-month treatment with diosmin or MPFF, without statistical differences between these two forms of diosmin. Both treatments were well tolerated with few mild adverse drug reactions reported. Overall, based on this literature review, there is no clinical benefit to increase the dose of diosmin beyond 600 mg per day, to use the micronized form, or to add hesperidin, since clinical efficacy on venous symptomatology is achieved with 600 mg per day of pure non-micronized diosmin. This challenges the status of diosmin - 600 mg a day - in guidelines for the management of CVD, which is currently categorized 2C (weak recommendations for use and poor quality of evidence), while the most widely used and assessed preparation MPFF is rated 1B (strong recommendation for use and moderate quality of evidence).	[Benigni, Jean-Patrick] Sorbonne Univ, Fac Med Pitie Salpetriere, Pedag Support Off, Paris, France; [Steinbruch, Marcio] Hosp Albert Einstein, Sao Paulo, Brazil; [Jabbour, Violaine; Gouhier-Kodas, Christelle] Lab Innotech Int, Arcueil, France		Gouhier-Kodas, C (通讯作者)，Lab Innotech Int, Arcueil, France.	christelle.gouhier-kodas@innothera.com					Allaert FA, 2012, INT ANGIOL, V31, P310; Bodinier M, 1994, ARTERES VEINES, VXIII, P124; Bogachev VY, 2018, INT ANGIOL, V37, P71, DOI 10.23736/S0392-9590.17.03868-8; BOUDET C, 1986, ARCH INT PHARMACOD T, V283, P312; Carpentier PH, 1998, J MAL VASCUL, V23, P106; Cazaubon M, 2011, ANGEIOLOGIE, V63, P69; COSPITE M, 1989, INT ANGIOL, V8, P61; Danielsson G, 2002, EUR J VASC ENDOVASC, V23, P73, DOI 10.1053/ejvs.2001.1531; Delecluse M, 1991, ARTERES VEINES, V10, P498; Eberhardt RT, 2014, CIRCULATION, V130, P333, DOI 10.1161/CIRCULATIONAHA.113.006898; Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027; Feldo M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2561705; Garner RC, 2002, J PHARM SCI, V91, P32, DOI 10.1002/jps.1168; Henriet J.-P, 1995, Phlebologie, V48, P285; Martinez-Zapata MJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003229.pub3; Kakkos SK, 2018, INT ANGIOL, V37, P143, DOI 10.23736/S0392-9590.18.03975-5; Labropoulos N, 2019, ADV THER, V36, P13, DOI 10.1007/s12325-019-0885-3; Lurie F, 2020, J VASC SURG-VENOUS L, V8, P342, DOI 10.1016/j.jvsv.2019.12.075; Mansilha A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061669; Martinez MJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003229.pub2; Martinez-Zapata Maria Jose, 2020, Cochrane Database Syst Rev, V11, pCD003229, DOI 10.1002/14651858.CD003229.pub4; Maruszynski A., 2004, PRZEGLAD FLEBOLOGICZ, V13, P89; Nicolaides A, 2014, INT ANGIOL, V33, P275; Nicolaides AN, 2008, INT ANGIOL, V27, P1; Nicolaides A, 2018, INT ANGIOL, V37, P181, DOI 10.23736/S0392-9590.18.03999-8; Perrin M, 2011, EUR J VASC ENDOVASC, V41, P117, DOI 10.1016/j.ejvs.2010.09.025; PORTER JM, 1995, J VASC SURG, V21, P635, DOI 10.1016/S0741-5214(95)70195-8; Rabe E, 2015, INT ANGIOL, V34, P428; Rabe E, 2013, PHLEBOLOGY, V28, P308, DOI 10.1177/0268355512471929; Raffetto JD, 2021, VESSEL PLUS, V5, P36; Ramelet AA, 2005, CLIN HEMORHEOL MICRO, V33, P309; Santler B, 2017, J DTSCH DERMATOL GES, V15, P538, DOI 10.1111/ddg.13242; SAVINEAU JP, 1994, BRIT J PHARMACOL, V111, P978, DOI 10.1111/j.1476-5381.1994.tb14838.x; Serra R, 2017, PHLEBOLOGY, V32, P588, DOI 10.1177/0268355516686451; Shami SK, 1997, INT J ANGIOL, V6, P30, DOI [10.1007/BF01616230, DOI 10.1007/BF01616230]; Steinbruch M, 2020, INT J VASC MED, V2020, DOI 10.1155/2020/4237204	36	0	0	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						591	600		10.2147/VHRM.S324112			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	US2IY	WOS:000697259000001	34556990	Green Published, gold			2022-04-27	
J	Harnarayan, P; Islam, S; Harnanan, D; Bheem, V; Budhooram, S				Harnarayan, Patrick; Islam, Shariful; Harnanan, Dave; Bheem, Vinoo; Budhooram, Steve			Acute Upper Limb Ischemia: Prompt Surgery and Long-Term Anticoagulation Prevent Limb Loss and Debilitation	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						acute-ischemia; prompt-surgery; anticoagulation; limb-salvage	UPPER EXTREMITY; THROMBEMBOLECTOMY; OCCLUSION; EMBOLI	Background: Acute upper limb ischemia is an uncommon clinical manifestation of thromboembolism seen predominantly in patients with atrial fibrillation. Treatment can be by conservative or surgical means but the consensus is that after conservative treatment, symptoms still persist. In this series, an attempt was made at limb preservation and return to functional capacity by early surgery in all patients diagnosed with acute limb ischemia. Methods: Patients referred with upper limb ischemia (22) were stratified into non-acute (6) treated with anticoagulation alone and those with acute ischemia. Sixteen (16) patients, age range 30-92 years (median 62.4 years) comprising mainly females (13), had clinical evidence of severe ischemia and underwent immediate brachial embolectomy with postoperative anticoagulation. Results: Sixteen patients underwent 20 embolectomies with immediate reperfusion of limbs and relief of symptoms. Two patients had two re-operations each due to recurrent symptoms but both recovered with good outcome, one going on to have an axillary-radial bypass. There was no limb disability nor limb loss, but one postoperative mortality. All other patients were seen at their 1-year review and at 5 years, eleven out of 15 patients were still alive with most resuming an active lifestyle and some returning to work. Conclusion: Good outcomes were obtained in this series in both the short and long term. Despite one mortality, there was no limb loss nor disability in a mainly elderly population. Prompt surgery and meticulous long-term anticoagulation reduced complications and improved limb salvage rates ensuring that patients had a good quality of life after surgery.	[Harnarayan, Patrick; Harnanan, Dave] Univ West Indies, Dept Clin Surg Sci, St Augustine, Trinidad Tobago; [Islam, Shariful; Bheem, Vinoo] San Fernando Gen & Teaching Hosp, Dept Surg, San Fernando, Trinidad Tobago; [Budhooram, Steve] Surgi Med Clin, San Fernando, Trinidad Tobago		Harnarayan, P (通讯作者)，Univ West Indies, Dept Clin Surg Sci, St Augustine, Trinidad Tobago.	patrick_harnarayan@hotmil.com					Andersen LV, 2013, J THROMB HAEMOST, V11, P836, DOI 10.1111/jth.12181; Andersen LV, 2011, J THROMB HAEMOST, V9, P1738, DOI 10.1111/j.1538-7836.2011.04435.x; Andersen LV, 2010, EUR J VASC ENDOVASC, V40, P628, DOI 10.1016/j.ejvs.2010.06.009; Bae Miju, 2015, Korean J Thorac Cardiovasc Surg, V48, P246, DOI 10.5090/kjtcs.2015.48.4.246; BAIRD RJ, 1964, ANN SURG, V160, P905, DOI 10.1097/00000658-196411000-00020; Bang SL, 2009, ANN ACAD MED SINGAP, V38, P891; Cupka I, 2003, Rozhl Chir, V82, P157; Davies M G, 1991, Ann Vasc Surg, V5, P85, DOI 10.1007/BF02021785; Deguara J, 2005, VASCULAR, V13, P84, DOI 10.1258/rsmvasc.13.2.84; Eyers P, 1998, BRIT J SURG, V85, P1340; Fan Long-hua, 2003, Zhonghua Wai Ke Za Zhi, V41, P50; Hernandez-Richter T, 2001, LANGENBECK ARCH SURG, V386, P261, DOI 10.1007/s004230100224; Jane E., 2010, VASCULAR DIS MANAG, V7, pE219; KAAR G, 1989, J CARDIOVASC SURG, V30, P165; Kofoed H, 1976, Acta Chir Scand Suppl, V472, P113; KRETZ JG, 1984, J CARDIOVASC SURG, V25, P233; Licht PB, 2004, EUR J VASC ENDOVASC, V28, P508, DOI 10.1016/j.ejvs.2004.08.007; Lin G., 1994, HAREFUAH, V126, P304; Magishi K, 2010, ANN THORAC CARDIOVAS, V16, P31; MICHAELS JA, 1993, EUR J VASCULAR SURG, V7, P744, DOI 10.1016/S0950-821X(05)80731-5; Quraishy MS., J R SOC MED, V85; RAPP JH, 1986, AM J SURG, V152, P122, DOI 10.1016/0002-9610(86)90161-3; Rudarakanchana N., 2016, OXFORD TXB VASCULAR; STAUDACHER M, 1991, VASA-J VASCULAR DIS, V20, P358; Sultan S, 2001, Vasc Surg, V35, P181, DOI 10.1177/153857440103500305; Tenenbaum A, 1998, CARDIOLOGY, V89, P246, DOI 10.1159/000006795; VOHRA R, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P83; Vrtik L, 2001, Rozhl Chir, V80, P465; WARREN R, 1948, NEW ENGL J MED, V238, P421, DOI 10.1056/NEJM194803252381301; WELLING RE, 1981, ARCH SURG-CHICAGO, V116, P1593; WIRSING P, 1983, J CARDIOVASC SURG, V24, P40; Wong Victor W, 2016, Hand (N Y), V11, P131, DOI 10.1177/1558944716628499	32	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						489	495		10.2147/VHRM.S321953			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UB0JU	WOS:000685540200003	34429609	gold, Green Published			2022-04-27	
J	Harnarayan, P; Ramdass, MJ; Islam, S; Naraynsingh, V				Harnarayan, Patrick; Ramdass, Michael J.; Islam, Shariful; Naraynsingh, Vijay			Achenbach's Syndrome Revisited: The Paroxysmal Finger Hematoma May Have a Genetic Link	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						acute pain; finger-bruising; spontaneous-resolution; negative investigations		Achenbach's syndrome describes the sudden occurrence of bruising, pain and swelling of one or more digits of the hand involving the volar aspect of the proximal and middle phalanges. Also known as the paroxysmal finger hematoma, it presents in dramatic fashion, sometimes with a prodrome of tingling, itching or numbness but despite its dramatic presentation, all investigations are normal. Routine blood investigations, as well as coagulation and thrombophilia screens are all negative as are vascular imaging and echocardiography. The diagnosis is solely clinical. Due to the nature of its presentation, almost all patients are referred for an urgent vascular consultation but the condition resolves spontaneously usually within 2-3 days, although the discoloration may persist for longer. Its appearance usually leads clinicians to start anticoagulation in the belief that it may progress but, in fact, it settles as quickly as it appears. Though there are episodic cases which recur years later, it is generally self-resolving with no complications nor residual morbidity. Although the etiology was previously unknown, there is now a recognized genetic link. Genes related to the acute phase reactive proteins and the coagulation and complement cascades appear to be linked to Achenbach's syndrome. This evidence may explain why only certain individuals seem prone to this acutely painful, bruising disorder. We review this interesting disorder and compare patients from the tropical Caribbean region with similar cases from the temperate United Kingdom and discuss whether there are climatic variations in presentations.	[Harnarayan, Patrick; Ramdass, Michael J.] Univ West Indies, Dept Clin Surg Sci, St Augustine, Trinidad Tobago; [Islam, Shariful] San Fernando Gen & Teaching Hosp, Dept Surg, San Fernando, Trinidad Tobago; [Naraynsingh, Vijay] Med Associates Hosp, Dept Surg, St Joseph, Trinidad Tobago		Harnarayan, P (通讯作者)，Univ West Indies, Dept Clin Surg Sci, St Augustine, Trinidad Tobago.	patrick_harnarayan@hotmail.com		Ramdass, Michael J/0000-0002-5687-9523			ACHENBACH W, 1958, Medizinische, V52, P2138; Ada F, 2019, WORLD J CLIN CASES, V7, P1103, DOI 10.12998/wjcc.v7.i10.1103; Ahmed Z, 2018, EJVES Short Rep, V40, P1, DOI 10.1016/j.ejvssr.2018.05.008; Ashrafzadeh Sepideh, 2020, JAAD Case Rep, V6, P1053, DOI 10.1016/j.jdcr.2020.06.045; Cowen R, 2008, ANN ROY COLL SURG, V90, P557, DOI 10.1308/003588408X318237; Frerix M, 2015, ARTHRITIS RHEUMATOL, V67, P1073, DOI 10.1002/art.39003; Godoy A, 2019, VASC MED, V24, P361, DOI 10.1177/1358863X19849627; Helm RH, 2022, J HAND SURG-EUR VOL, V47, P214, DOI 10.1177/17531934211024567; Khaira HS, 2001, ANN ROY COLL SURG, V83, P154; Kordzadeh A, 2016, EUR J TRAUMA EMERG S, V42, P439, DOI 10.1007/s00068-015-0610-0; LAYTON AM, 1993, CLIN EXP DERMATOL, V18, P60, DOI 10.1111/j.1365-2230.1993.tb00970.x; Mishra P, 2015, INDIAN J DERMATOL, V60, P632, DOI 10.4103/0019-5154.169155; Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012; Ribeiro Fani, 2019, Eur J Case Rep Intern Med, V6, P001231, DOI 10.12890/2019_001231; SINGER R, 1962, Wien Klin Wochenschr, V74, P741; Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5; STIELER W, 1990, HAUTARZT, V41, P270; Takeuchi H, 2016, BMJ CASE REP, DOI [10.1136/bcr-2016-214491, DOI 10.1136/BCR-2016-214491]; Watanabe Shin, 2019, JMA J, V2, P89, DOI 10.31662/jmaj.2018-0033; Yie Kilsoo, 2019, Vasc Specialist Int, V35, P251, DOI 10.5758/vsi.2019.35.4.251	20	1	1	2	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						809	816		10.2147/VHRM.S342847			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	YI6YG	WOS:000743991700001	34934323	Green Published			2022-04-27	
J	Haile, DG; Sharew, NT; Mekuria, AD; Abebe, AM; Mezemir, Y				Haile, Demelash Geset; Sharew, Nigussie Taddess; Mekuria, Abinet Dagnaw; Abebe, Ayele Mamo; Mezemir, Yordanos			Prevalence of Hypertension and Associated Factors Among Adults in Debre Berhan Town, North Shoa Zone, Ethiopia, 2020	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypertension; prevalence; adult; Debre Berhan	KHAT; RISK	Introduction: Hypertension is a serious medical condition that significantly increases the risks of heart, brain, kidney, and other diseases. The prevalence is highest in Africa (27%) and lowest in America (18%). Hypertension is a major reason for premature death worldwide; this is why it will become a targeted non-communicable disease by 2025. Objective: To assess the prevalence of hypertension and associated factors among adults in Debre Berhan town, Amhara region, Ethiopia. Methods: A community-based cross-sectional study was conducted among 680 participants who were selected by a systematic sampling technique. Data were checked, cleaned, and entered into Epi-data then exported to SPSS-23 for analysis. Hosmer-Lemeshow test was used to check the model fitness. Binary logistic regression analysis was used to see the association between dependent and independent variables. All variables with p <0.25 were taken into the multivariable model to minimize the possible confounders. The multi collinearity test was carried out to see the correlation between independent variables by using a variance inflation factor (VIF). The odds ratio along with 95% CI were estimated to measure the strength of association and to identify factors associated with hypertension using multivariable logistic regression. Descriptive statistics in the form of tables, figures, percent with measure of central tendency and dispersion with multivariable analysis were used to report the findings and to identify the factors associated with the outcome variable at a p<0.05. Results: Among 680 participants, the prevalence of hypertension was 27.5%. Sex, being male (AOR: 1.77, 95% CI: 1.12-2.81), alcohol consumption (AOR: 2.76: 95% CI: 1.874.05), physical exercise (AOR: 2.17, 95% CI: 1.28-3.71), being overweight (AOR: 1.99, 95% CI: 1.11-3.58), and family history of hypertension (AOR: 2.10, 95% CI: 1.43-3.08) were found to be significantly associated with hypertension. Conclusion and Recommendation: Prevalence of hypertension in Debre Berhan town was relatively high compared with other studies. So, it is necessary to emphasize intervention in the community for behavioral change, in order to minimize alcohol consumption and to encourage adoption of regular physical exercise, with the existing health system and partners working on hypertension.	[Haile, Demelash Geset; Mezemir, Yordanos] Debre Berhan Hlth Sci Coll, Dept Nursing, Debre Berhan, Ethiopia; [Sharew, Nigussie Taddess; Abebe, Ayele Mamo] Debre Berhan Univ, Dept Nursing, Hlth Sci Coll, Debre Berhan, Ethiopia; [Mekuria, Abinet Dagnaw] Debre Berhan Univ, Dept Publ Hlth, Hlth Sci Coll, Debre Berhan, Ethiopia		Mekuria, AD (通讯作者)，Debre Berhan Univ, Dept Publ Hlth, Hlth Sci Coll, Debre Berhan, Ethiopia.	abinetdagn@gmail.com	Sharew, Nigussie Tadesse/AAD-5597-2022; Abebe, Ayele/AAE-4589-2020; Mekuria, Abinet/AAV-1831-2021	Sharew, Nigussie Tadesse/0000-0002-6443-6992; Abebe, Ayele/0000-0002-1801-8167; Mekuria, Abinet/0000-0002-3892-1572	Debre Berhan University; Debre Berhan Health Science College; Debre Berhan town Health Bureau	The authors would like to thank Debre Berhan University, Debre Berhan Health Science College and, Debre Berhan town Health Bureau for providing sponsorship. All study participants are thanked for their cooperation during sample collection.	Abebe S, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4127-1; Abebe SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125210; African U., 2013, IMPACT NONCOMMUNICAB; Ahmad S., 2015, PREVALENCE RISK FACT; [Anonymous], 2011, WHO STEPWISE APPROAC; Asfaw Likawunt Samuel, 2018, BMC Res Notes, V11, P306, DOI 10.1186/s13104-018-3435-1; Asresahegn Henok, 2017, BMC Res Notes, V10, P629, DOI 10.1186/s13104-017-2966-1; Bayram A, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0201652, DOI 10.1371/JOURNAL.PONE.0201652]; Bisanzio D, 2018, GLOBAL REGIONAL NATL; Bonsa F, 2014, ETHIOP J HEALTH SCI, V24, P21, DOI 10.4314/ejhs.v24i1.3; Debre Berhan North Shoa Zone Health Department, 2018, ANN HYP REP; Demisse AG, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4646-4; Dhungana RR, 2016, INT J HYPERTENS, V2016, P1, DOI 10.1155/2016/1656938; El-Menyar Ayman, 2015, Oman Med J, V30, P77, DOI 10.5001/omj.2015.18; Federal Democratic Republic Of Ethiopia Ministry Of Health, 2018, ETH NONC DIS INJ NCD; Felman A., 2019, MED NEWS TODAY; Fuchs FD, 2001, HYPERTENSION, V37, P1242, DOI 10.1161/01.HYP.37.5.1242; Geta TG, 2019, INTEGR BLOOD PRESS C, V12, P33, DOI 10.2147/IBPC.S234671; Helelo TP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112790; Herald Ethiopian, 2019, DUE ATTENTION HYPERT; Kiber M, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4431-9; Kibret KT, 2015, PUBLIC HEALTH REV, V36, DOI 10.1186/s40985-015-0014-z; Lemieux AM, 2015, J ETHNOPHARMACOL, V160, P78, DOI 10.1016/j.jep.2014.11.002; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Mohamed SF, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6052-y; Mosha NR, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1321279; Paul PJ., 2017, INT J COMMUNITY MED, V4, P1620, DOI [10.18203/2394-6040.ijcmph20171774, DOI 10.18203/2394-6040.IJCMPH20171774]; Pyakurel P, 2019, NEPAL HEART J, V16, P19, DOI 10.3126/njh.v16i1.23894; Saka M, 2019, E MEDITERR HEALTH J, V25, P2; Sarki AM, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001959; Sawicka K., 2011, J PRECLIN CLIN RES, V5, P2; Singh S, 2017, INT J HYPERTENS, V2017, DOI 10.1155/2017/5491838; Tesfaye TD, 2019, AFR HEALTH SCI, V19, P2580, DOI 10.4314/ahs.v19i3.34; Van De Vijver S, 2013, IMPACT NONCOMMUNICAB; Veientlena S, 2018, PREVALENCE, V11; World Health Organisation, 2013, GLOBAL BRIEF HYPERTE; World Health Organization (WHO), 2019, ETH SETS IMPR HYP PR	37	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						203	210		10.2147/VHRM.S297403			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RZ2JF	WOS:000648422000001	33981144	Green Published, gold			2022-04-27	
J	Shimizu, K; Takahashi, M; Sato, S; Saiki, A; Nagayama, D; Harada, M; Miyazaki, C; Takahara, A; Shirai, K				Shimizu, Kazuhiro; Takahashi, Mao; Sato, Shuji; Saiki, Atsuhito; Nagayama, Daiji; Harada, Masashi; Miyazaki, Chikao; Takahara, Akira; Shirai, Kohji			Rapid Rise of Cardio-Ankle Vascular Index May Be a Trigger of Cerebro-Cardiovascular Events: Proposal of Smooth Muscle Cell Contraction Theory for Plaque Rupture	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						arterial stiffness; atherosclerosis; smooth muscle cell contraction; CAVI	PULSE-WAVE VELOCITY; EAST JAPAN EARTHQUAKE; ARTERIAL STIFFNESS; METABOLIC SYNDROME; CORONARY SPASM; VASA VASORUM; STRESS; HEART; WALL; ATHEROSCLEROSIS	Cardiovascular diseases have been recognized as the main cause of death all over the world. Recently, the established cardio-ankle vascular index (CAVI) has become known as an index of arterial stiffness of the arterial tree from the origin of the aorta to the ankle. CAVI reflects the progress of arteriosclerosis, and a rapid rise in CAVI indicates arterial smooth muscle cell contraction. Considering the vasculature of the atheroma where vasa vasorum penetrates the smooth muscle cell layer and supplies blood to the intimal atheromatous lesion, a rapid rise of CAVI means "choked" atheroma. Thus, we proposed a "smooth muscle cell contraction" hypothesis of plaque rupture.	[Shimizu, Kazuhiro; Takahashi, Mao; Sato, Shuji; Saiki, Atsuhito; Nagayama, Daiji; Shirai, Kohji] Toho Univ, Dept Internal Med, Sakura Med Ctr, 561-4 Shimoshizu, Sakura, Chiba 2858741, Japan; [Harada, Masashi; Miyazaki, Chikao] Toho Univ, Dept Neurosurg, Omori Med Ctr, Omori, Tokyo, Japan; [Takahara, Akira] Toho Univ, Fac Pharmaceut Sci, Dept Pharmacol & Therapeut, Funabashi, Chiba, Japan		Shirai, K (通讯作者)，Toho Univ, Dept Internal Med, Sakura Med Ctr, 561-4 Shimoshizu, Sakura, Chiba 2858741, Japan.	kshirai@kb3.so-net.ne.jp		Kazuhiro, Shimizu/0000-0001-9896-0939; yong shan, da er/0000-0001-6119-8012; Sato, Shuji/0000-0002-6386-8670			Aoki T, 2012, EUR HEART J, V33, P2796, DOI 10.1093/eurheartj/ehs288; Ben-Shlomo Y, 2014, J AM COLL CARDIOL, V63, P636, DOI 10.1016/j.jacc.2013.09.063; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Blacher J, 1999, HYPERTENSION, V33, P1111, DOI 10.1161/01.HYP.33.5.1111; Bornfeldt KE, 2014, ARTERIOSCL THROM VAS, V34, P705, DOI 10.1161/ATVBAHA.113.301928; Boyle EC, 2017, VASC PHARMACOL, V96-98, P5, DOI 10.1016/j.vph.2017.08.003; Bramwell JC, 1922, P R SOC LOND B-CONTA, V93, P298, DOI 10.1098/rspb.1922.0022; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757, DOI 10.5694/j.1326-5377.1991.tb94029.x; Doyle B, 2007, J AM COLL CARDIOL, V49, P2073, DOI 10.1016/j.jacc.2007.01.089; Fukuda S, 2000, ARCH ENVIRON HEALTH, V55, P121, DOI 10.1080/00039890009603398; Gohbara M, 2016, CIRC J, V80, P1420, DOI 10.1253/circj.CJ-15-1257; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8; Hayashi K, 2015, J HYPERTENS, V33, P1742, DOI 10.1097/HJH.0000000000000651; Kario K, 1997, J AM COLL CARDIOL, V29, P926, DOI 10.1016/S0735-1097(97)00002-8; Kario K, 2003, HYPERTENS RES, V26, P355, DOI 10.1291/hypres.26.355; Kasai T, 2011, AM J HYPERTENS, V24, P401, DOI 10.1038/ajh.2010.248; Kubota Y, 2011, ARTERY RES, V5, P91, DOI 10.1016/j.artres.2011.03.005; Kubozono T, 2011, CIRC J, V75, P698, DOI 10.1253/circj.CJ-10-0552; Kumagai T, 2009, CHEST, V136, P779, DOI 10.1378/chest.09-0178; Kusunose K, 2016, CIRC J, V80, P1034, DOI 10.1253/circj.CJ-15-1356; Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Lim J, 2015, AM J PHYSIOL-REG I, V309, pR1540, DOI 10.1152/ajpregu.00368.2015; Matsushita K, 2019, J CLIN HYPERTENS, V21, P16, DOI 10.1111/jch.13425; Michel JB, 2007, ARTERIOSCL THROM VAS, V27, P1259, DOI 10.1161/ATVBAHA.106.137851; Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655; Miyashita Y, 2009, J ATHEROSCLER THROMB, V16, P621, DOI 10.5551/jat.497; Miyashita Y, 2009, J ATHEROSCLER THROMB, V16, P539, DOI 10.5551/jat.281; Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005; Muller J E, 1992, Ann Epidemiol, V2, P393; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; Nagayama D, 2010, INT J CLIN PRACT, V64, P1796, DOI 10.1111/j.1742-1241.2010.02399.x; Nagayama D, 2017, VASC HEALTH RISK MAN, V13, P1, DOI 10.2147/VHRM.S119646; Nagayama D, 2013, OBES RES CLIN PRACT, V7, pE139, DOI 10.1016/j.orcp.2011.08.154; Nakamura K, 2008, CIRC J, V72, P598; Nakamura K, 2009, J ATHEROSCLER THROMB, V16, P371, DOI 10.5551/jat.No687; Namekata T, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-51; Noike H, 2010, J ATHEROSCLER THROMB, V17, P517, DOI 10.5551/jat.3707; Nozaki E, 2013, INT HEART J, V54, P247, DOI 10.1536/ihj.54.247; Osada H, 2013, EUR J CARDIO-THORAC, V43, pE82, DOI 10.1093/ejcts/ezs640; Otsuka K, 2014, HYPERTENS RES, V37, P1014, DOI 10.1038/hr.2014.116; RAIZNER AE, 1980, CIRCULATION, V62, P925, DOI 10.1161/01.CIR.62.5.925; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1979, ANNU REV MED, V30, P1, DOI 10.1146/annurev.me.30.020179.000245; Saji N, 2015, HYPERTENS RES, V38, P323, DOI 10.1038/hr.2015.8; Sakakura K, 2013, HEART LUNG CIRC, V22, P399, DOI 10.1016/j.hlc.2013.03.001; Sasaki JIH, 2008, DIABETES RES CLIN PR, V80, P265, DOI 10.1016/j.diabres.2007.12.016; Sato Y, 2016, J ATHEROSCLER THROMB, V23, P596, DOI 10.5551/jat.31385; Satoh-Asahara N, 2015, ATHEROSCLEROSIS, V242, P461, DOI 10.1016/j.atherosclerosis.2015.08.003; Shimizu K, 2016, INT MED CASE REP J, V9, P231, DOI 10.2147/IMCRJ.S113377; Shimizu K, 2016, VASC HEALTH RISK MAN, V12, P313, DOI 10.2147/VHRM.S106542; Shimizu K, 2013, J ATHEROSCLER THROMB, V20, P503, DOI 10.5551/jat.16097; Shimoyama T, 2012, HYPERTENS RES, V35, P975, DOI 10.1038/hr.2012.84; Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101, DOI 10.5551/jat.13.101; Shirai K, 2011, J ATHEROSCLER THROMB, V18, P49, DOI 10.5551/jat.3582; Stewart S, 2017, NAT REV CARDIOL, V14, P654, DOI 10.1038/nrcardio.2017.76; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P3384, DOI 10.1161/CIRCULATIONAHA.104.483628; Suzuki J, 2013, J STROKE CEREBROVASC, V22, P171, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.010; Topouchian J, 2018, J HYPERTENS, V36, P824, DOI 10.1097/HJH.0000000000001631; TRICHOPOULOS D, 1983, LANCET, V1, P441; von Kanel R, 2002, AM HEART J, V144, P68, DOI 10.1067/mhj.2002.123146; Wang LX, 2011, CHINESE MED J-PEKING, V124, P4071, DOI 10.3760/cma.j.issn.0366-6999.2011.23.041; Wilbert-Lampen U, 2010, J AM COLL CARDIOL, V55, P637, DOI 10.1016/j.jacc.2009.07.073; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; Yamamoto T, 2017, J ATHEROSCLER THROMB, V24, P1048, DOI 10.5551/jat.38646; Yasue H, 1997, INTERNAL MED, V36, P760, DOI 10.2169/internalmedicine.36.760; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; Yingchoncharoen T, 2012, HEART ASIA, V4, P77, DOI 10.1136/heartasia-2011-010079; Yukutake T, 2014, J ATHEROSCLER THROMB, V21, P49; Zhao XX, 2018, CLIN EXP HYPERTENS, V40, P312, DOI 10.1080/10641963.2017.1377213	72	2	2	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						37	47		10.2147/VHRM.S290841			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QM5XK	WOS:000621851800001	33603388	gold, Green Published			2022-04-27	
J	Tada, H; Takamura, M; Kawashiri, M				Tada, Hayato; Takamura, Masayuki; Kawashiri, Masa-aki			Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						familial hypercholesterolemia; cardiovascular disease; statin; children; adolescents	CHOLESTEROL; PREVALENCE; LIPOPROTEINS; MUTATIONS; EFFICACY; SAFETY; EZETIMIBE; GUIDANCE; THERAPY; DISEASE	Familial hypercholesterolemia (FH) is a relatively common inherited disorder caused by deleterious mutation(s) in the low-density lipoprotein (LDL) receptor or its associated genes. Given its nature as a heritable disease, any useful screening scheme, including universal, and cascade screening, allows for the early identification of patients with FH. Another important aspect to note is that early diagnosis associated with appropriate treatment can promote better prognosis. However, most clinical diagnostic criteria for adults have adopted clinical elements, such as physical xanthomas and family history, both of which are usually obscure and/or difficult to obtain in children and adolescents. Moreover, LDL cholesterol levels fluctuating considerably during adolescence, hindering the timely diagnosis of FH. In addition, recent advancements in human genetics have revealed several types of FH, including conventional monogenic FH, polygenic FH caused by common single nucleotide variations (SNV) accumulation associated with elevated LDL cholesterol, and oligogenic FH with multiple deleterious genetic variations leading to substantially elevated LDL cholesterol. The aforementioned findings collectively suggest the need for amassing information related to genetics and imaging, in addition to classical clinical elements, for the accurate diagnosis of FH in this era of personalized medicine. The current narrative review summarizes the current status of the clinical and genetic diagnosis of FH in children and adolescents, as well as provide useful management strategies for FH in children and adolescents based on currently available clinical evidence.	[Tada, Hayato; Takamura, Masayuki; Kawashiri, Masa-aki] Kanazawa Univ, Dept Cardiol, Grad Sch Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan		Tada, H (通讯作者)，Kanazawa Univ, Dept Cardiol, Grad Sch Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	ht240z@sa3.so-net.ne.jp					Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Anagnostis P, 2020, ENDOCRINE, V69, P249, DOI 10.1007/s12020-020-02302-8; Austin MA, 2004, AM J EPIDEMIOL, V160, P407, DOI 10.1093/aje/kwh236; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Beheshti SO, 2020, J AM COLL CARDIOL, V75, P2553, DOI 10.1016/j.jacc.2020.03.057; Bell DA, 2012, ANN CLIN BIOCHEM, V49, P534, DOI 10.1258/acb.2012.012002; Benn M, 2016, EUR HEART J, V37, P1384, DOI 10.1093/eurheartj/ehw028; Besseling J, 2015, ATHEROSCLEROSIS, V241, P597, DOI 10.1016/j.atherosclerosis.2015.06.011; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; de Ferranti SD, 2016, CIRCULATION, V133, P1067, DOI 10.1161/CIRCULATIONAHA.115.018791; Dombalis S, 2021, J PEDIATR HEALTH CAR, V35, P292, DOI 10.1016/j.pedhc.2020.11.007; Eissa MA, 2016, J PEDIATR-US, V170, P199, DOI 10.1016/j.jpeds.2015.11.018; Fagge CH, 1873, T PATHOL SOC, V24, P242; France M, 2016, PAEDIATR INT CHILD H, V36, P243, DOI 10.1080/20469047.2016.1246640; FRIEDMAN M, 1963, ARCH PATHOL, V76, P318; Gidding SS, 2015, CIRCULATION, V132, P2167, DOI 10.1161/CIR.0000000000000297; GLUECK CJ, 1986, PEDIATRICS, V78, P338; Goldberg AC, 2011, J CLIN LIPIDOL, V5, P133, DOI 10.1016/j.jacl.2011.03.001; Goldstein JL, 2001, METABOLIC MOL BASES; Groselj U, 2018, ATHEROSCLEROSIS, V277, P383, DOI 10.1016/j.atherosclerosis.2018.06.858; Harada-Shiba M, 2018, J ATHEROSCLER THROMB, V25, P539, DOI 10.5551/jat.CR002; Ibarretxe D, 2018, ATHEROSCLEROSIS, V278, P210, DOI 10.1016/j.atherosclerosis.2018.09.039; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; Kawagishi N, 2007, J ATHEROSCLER THROMB, V14, P94, DOI 10.5551/jat.14.94; Lozano P, 2016, JAMA-J AM MED ASSOC, V316, P645, DOI 10.1001/jama.2016.6176; Luirink IK, 2019, NEW ENGL J MED, V381, P1547, DOI 10.1056/NEJMoa1816454; Mabuchi H, 2017, J ATHEROSCLER THROMB, V24, P189, DOI 10.5551/jat.RV16008; Mabuchi H, 2011, ATHEROSCLEROSIS, V214, P404, DOI 10.1016/j.atherosclerosis.2010.11.005; Malhotra A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001918.pub3; Masana L, 2019, ATHEROSCLEROSIS, V287, P89, DOI 10.1016/j.atherosclerosis.2019.06.905; Mirzaee S, 2019, IJC HEART VASC, V23, DOI 10.1016/j.ijcha.2019.100354; Mlinaric M, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.567895; Okada H, 2018, J ATHEROSCLER THROMB, V25, P634, DOI 10.5551/jat.42705; Pottle A, 2019, ATHEROSCLEROSIS, V290, P44, DOI 10.1016/j.atherosclerosis.2019.09.006; Raal FJ, 2020, NEW ENGL J MED, V383, P711, DOI 10.1056/NEJMoa2004215; Raal FJ, 2018, ATHEROSCLEROSIS, V277, P483, DOI 10.1016/j.atherosclerosis.2018.06.859; Ramaswami U, 2019, ATHEROSCLEROSIS, V290, P1, DOI 10.1016/j.atherosclerosis.2019.09.005; Rodenburg J, 2007, CIRCULATION, V116, P664, DOI 10.1161/CIRCULATIONAHA.106.671016; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Santos RD, 2020, NEW ENGL J MED, V383, P1317, DOI 10.1056/NEJMoa2019910; Santos RD, 2020, J AM COLL CARDIOL, V75, P565, DOI 10.1016/j.jacc.2019.12.020; Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174; Scicali R, 2018, NUTR METAB CARDIOVAS, V28, P35, DOI 10.1016/j.numecd.2017.07.003; Tada H, 2021, J CLIN LIPIDOL, V15, P358, DOI 10.1016/j.jacl.2020.12.012; Tada H, 2020, J ATHEROSCLER THROMB, V27, P489, DOI 10.5551/jat.RV17040; Tada H, 2019, CIRC J, V83, P1917, DOI 10.1253/circj.CJ-19-0317; Tada H, 2019, CURR OPIN LIPIDOL, V30, P300, DOI [10.1097/QCO.0000000000000563, 10.1097/MOL.0000000000000609]; Tada H, 2020, J ATHEROSCLER THROMB, V27, P38, DOI 10.5551/jat.49551; Tada H, 2018, J CLIN LIPIDOL, V12, P1436, DOI 10.1016/j.jacl.2018.08.006; Tada H, 2018, J ATHEROSCLER THROMB, V25, P783, DOI 10.5551/jat.RV17024; Tada H, 2018, J CLIN LIPIDOL, V12, P397, DOI 10.1016/j.jacl.2017.12.002; Tada H, 2017, AM J CARDIOL, V120, P1955, DOI 10.1016/j.amjcard.2017.08.012; Tada H, 2017, EUR HEART J, V38, P1573, DOI 10.1093/eurheartj/ehx004; Tada H, 2015, JIMD REP, V21, P115, DOI 10.1007/8904_2014_404; Tada H, 2015, AM J CARDIOL, V115, P724, DOI 10.1016/j.amjcard.2014.12.034; Thannhauser SJ, 1938, ANN INTERN MED, V11, P1662, DOI 10.7326/0003-4819-11-9-1662; van der Graaf A, 2008, J AM COLL CARDIOL, V52, P1421, DOI 10.1016/j.jacc.2008.09.002; Vinson A, 2019, J PEDIATR NURS, V44, P50, DOI 10.1016/j.pedn.2018.09.011; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Wiegman A, 2015, EUR HEART J, V36, P2425, DOI 10.1093/eurheartj/ehv157; WILLIAMS RR, 1993, AM J CARDIOL, V72, P171, DOI 10.1016/0002-9149(93)90155-6; Wu X, 2017, CLIN CARDIOL, V40, P1169, DOI 10.1002/clc.22809	64	2	2	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						59	67		10.2147/VHRM.S266249			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QM5YA	WOS:000621853400001	33628029	gold, Green Published			2022-04-27	
J	Schurmann, J; Noack, F; Bethge, S; Heinze, V; Schlitt, A				Schuermann, Juliane; Noack, Frank; Bethge, Steffi; Heinze, Viktoria; Schlitt, Axel			Patients with Heart Failure During and After Inpatient Cardiac Rehabilitation	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						heart failure; cardiac rehabilitation; inpatient rehabilitation	DIAGNOSIS; EPIDEMIOLOGY; GUIDELINES	Background: Heart failure is the third most fatal disease in Germany and generates considerable treatment costs. The multimodal program of inpatient rehabilitation can improve the symptoms and prognosis of these patients. At the present time, however, only few data are available on the effectiveness of rehabilitation for heart failure patients. Methods: After receiving study approval from the ethics committee of the Saxony-Anhalt Medical Association, 200 patients with a primary or secondary diagnosis of heart failure were prospectively included in the study at Paracelsus-Harz-Clinic Bad Suderode, Quedlinburg, Germany. Baseline parameters such as age, gender, and HMI were documented. Outcome variables included NYHA classifications, quality of life, and mortality. For follow-up, the patients were contacted again by mail or phone after three and 12 months and, data on symptoms and serious events were recorded. Results: The proportion of patients with a highly reduced ejection fraction (HFrEF) was 13.5%, with a midrange reduced ejection fraction (HFmrEF) 33%, and with preserved ejection fraction (HFpEF) 53.5%. The mean age was 64 +/- 11.9 years, the proportion of women 24.1%. The effects of rehabilitation were documented by low overall mortality (no patient died during the stay, only 4% of the patients died in the 12-month follow-up) and an improvement in NYHA classification during and after the inpatient rehabilitation. Conclusion: This monocentric study showed effects both for symptoms (improvement in NYHA classifications) and prognosis (overall mortality) after rehabilitation. These data reflect the effectiveness of multimodal rehabilitation and underscore the need for rehabilitation in patients diagnosed with heart failure after an acute event and hospital stay or who present with chronic deterioration.	[Schuermann, Juliane] AMEOS Clin Bernburg, Dept Cardiol & Pulmonol, D-06406 Bernburg, Germany; [Noack, Frank] Univ Clin Halle Saale, Dept Emergency Med, Halle, Germany; [Noack, Frank] Univ Clin Halle Saale, Dept Med 1, Halle, Germany; [Bethge, Steffi; Heinze, Viktoria; Schlitt, Axel] Paracelsus Harz Clin Bad Suderode, Quedlinburg, Germany; [Schlitt, Axel] Martin Luther Univ Halle Wittenberg, Med Fac, Halle, Germany		Schurmann, J (通讯作者)，AMEOS Clin Bernburg, Dept Cardiol & Pulmonol, D-06406 Bernburg, Germany.	jsch.med@bernburg.ameos.de		Noack, Frank/0000-0002-6073-7800	Novartis(R), Germany	This study was supported by an unrestricted grant from Novartis (R), Germany.	[Anonymous], 2020, MEDLINE RES CLIN EVI; Christ M, 2016, EUR J HEART FAIL, V18, P1009, DOI 10.1002/ejhf.567; Freud T, 2016, HOSP REPORT 2016 STU, V2016, P229; Holstiege J, 2018, 1819 CI STAT HLTH CA, DOI [10.20364/UA-18.09, DOI 10.20364/UA-18.09]; Hunt SA, 2009, CIRCULATION, V119, pE391, DOI 10.1161/CIRCULATIONAHA.109.192065; Murad K, 2015, JACC-HEART FAIL, V3, P542, DOI 10.1016/j.jchf.2015.03.004; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Petermann F, 2011, Z PSYCHIATR PSYCH PS, V59, P251, DOI 10.1024/1661-4747/a000077; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Rademacher W, 2019, KARDIOLOGE, V13, P40, DOI 10.1007/s12181-018-0292-z; Reibis RK, 2016, REHABILITATION, V55, P115, DOI 10.1055/s-0042-103302; Schwaab B, 2018, INT J CARDIOL, V97, P117; Stork S, 2017, CLIN RES CARDIOL, V106, P913, DOI 10.1007/s00392-017-1137-7; Tiller D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059225; Whellan DJ, 2001, AM HEART J, V142, P160, DOI 10.1067/mhj.2001.115785; Wirtz MA, 2018, DIAGNOSTICA, V64, P84, DOI 10.1026/0012-1924/a000194	16	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						49	58		10.2147/VHRM.S276465			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	QM5XO	WOS:000621852200001	33623387	Green Published, gold			2022-04-27	
J	Stefanczyk, P; Nowosielecka, D; Tulecki, L; Tomkow, K; Polewczyk, A; Jachec, W; Kleinrok, A; Borzecki, W; Kutarski, A				Stefanczyk, Pawel; Nowosielecka, Dorota; Tulecki, Lukasz; Tomkow, Konrad; Polewczyk, Anna; Jachec, Wojciech; Kleinrok, Andrzej; Borzecki, Wojciech; Kutarski, Andrzej			Transvenous Lead Extraction without Procedure-Related Deaths in 1000 Consecutive Patients: A Single-Center Experience	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						lead extraction; complications of lead extraction; venue of TLE; mechanical dilatation; safety precautions	EXPERT CONSENSUS STATEMENT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; OUTCOMES; PACEMAKER; SAFETY; COMPLICATIONS; PREDICTORS; MANAGEMENT; REMOVAL; ELECTRA	Background: Transvenous lead extraction (TLE) is now a first-line technique for the treatment of complications related to cardiac implantable electronic devices. The aim of the study was to demonstrate that it is possible to safely perform difficult TLE procedures with a maximum reduction of peri-procedural major complications. Methods: A total of 1000 consecutive patients undergoing TLE in a single high-volume center from 2016 to 2019 were studied. All procedures were performed in a hybrid room or operating room by a specialized TLE team. TLE was performed under general anesthesia and monitored by transesophageal echocardiography, and the operating room was suitably equipped for immediate surgical intervention. The effectiveness and safety of the procedures were assessed, with particular emphasis on major complications. Results: In all, 1952 leads with the mean implant duration of 111.7 +/- 77.6 months had been extracted. Complete procedural success of patients was achieved in 95.9% and clinical success in 99.1%. Major complications, predominantly cardiac tamponade (63.3%), occurred in 22 patients (2.2%). Rapid diagnosis and immediate intervention were the key to a 100% survival in patients with this complication. Conclusion: Performing procedures in a hybrid operating room under general anesthesia in the presence of a cardiac surgeon and with the use of transesophageal echocardiography significantly improves the safety of transvenous lead extraction.	[Stefanczyk, Pawel; Nowosielecka, Dorota; Kleinrok, Andrzej; Borzecki, Wojciech] Pope John Paul II Prov Hosp Zamosc, Dept Cardiol, Zamosc, Poland; [Tulecki, Lukasz; Tomkow, Konrad] Pope John Paul II Prov Hosp Zamosc, Dept Cardiac Surg, Zamosc, Poland; [Polewczyk, Anna] Jan Kochanowski Univ Humanities & Sci, Coll Med, Dept Physiol Pathophysiol & Clin Immunol, 19A Aleja IX Wiekow Kielc Str, PL-25317 Kielce, Poland; [Polewczyk, Anna] Swietokrzyskie Cardiol Ctr, Dept Cardiac Surg, Kielce, Poland; [Jachec, Wojciech] Silesian Med Univ, Dept Cardiol 2, Zabrze, Poland; [Kleinrok, Andrzej] Univ Informat Technol & Management, Dept Physiotherapy, Med Coll, Rzeszow, Poland; [Kutarski, Andrzej] Med Univ, Dept Cardiol, Lublin, Poland		Polewczyk, A (通讯作者)，Jan Kochanowski Univ Humanities & Sci, Coll Med, Dept Physiol Pathophysiol & Clin Immunol, 19A Aleja IX Wiekow Kielc Str, PL-25317 Kielce, Poland.	annapolewczyk@wp.pl	Dorota, Nowosielecka/AAB-9005-2022; Nowosielecka, Dorota/ABD-2499-2021	Nowosielecka, Dorota/0000-0002-2441-3876; Jachec, Wojciech/0000-0002-1091-9788			Barakat AF, 2017, HEART RHYTHM, V14, P1807, DOI 10.1016/j.hrthm.2017.08.019; Bashir J, 2016, CIRC-ARRHYTHMIA ELEC, V9, DOI 10.1161/CIRCEP.115.003741; Bongiorni MG, 2018, EUROPACE, V20, P1217, DOI 10.1093/europace/euy050; Bongiorni MG, 2017, EUR HEART J, V38, P2995, DOI 10.1093/eurheartj/ehx080; Bongiorni MG, 2008, EUR HEART J, V29, P2886, DOI 10.1093/eurheartj/ehn461; Bontempi L, 2014, J CARDIOVASC MED, V15, P668, DOI 10.2459/JCM.0000000000000023; Brunner MP, 2014, HEART RHYTHM, V11, P799, DOI 10.1016/j.hrthm.2014.01.016; Byrd CL, 1999, PACE, V22, P1348, DOI 10.1111/j.1540-8159.1999.tb00628.x; BYRD CL, 1990, PACE, V13, P1871, DOI 10.1111/j.1540-8159.1990.tb06906.x; Deharo JC, 2012, EUROPACE, V14, P124, DOI 10.1093/europace/eur338; Di Cori A, 2019, EUROPACE, V21, P1096, DOI 10.1093/europace/euz062; El-Chami MF, 2015, HEART RHYTHM, V12, P1216, DOI 10.1016/j.hrthm.2015.02.031; Fu HX, 2015, PACE, V38, P1439, DOI 10.1111/pace.12736; Gomes S, 2017, HEART LUNG CIRC, V26, P240, DOI 10.1016/j.hlc.2016.06.1217; Gomes S, 2014, EUROPACE, V16, P1350, DOI 10.1093/europace/eut424; Gould J, 2019, PACE, V42, P1355, DOI 10.1111/pace.13791; Hussein Ayman A, 2017, JACC Clin Electrophysiol, V3, P1, DOI 10.1016/j.jacep.2016.06.009; Jachec W, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020361; Jachec W, 2019, PACE, V42, P1006, DOI 10.1111/pace.13715; Jachec W, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8796704; Kennergren C, 2009, EUROPACE, V11, P612, DOI 10.1093/europace/eup054; Kusumoto FM, 2017, HEART RHYTHM, V14, pE503, DOI 10.1016/j.hrthm.2017.09.001; Kutarski A, 2018, EUROPACE, V20, P1324, DOI 10.1093/europace/eux218; Maytin M, 2012, CIRC-ARRHYTHMIA ELEC, V5, P252, DOI 10.1161/CIRCEP.111.965277; Mazzone P, 2020, J ARRYTHM, V36, P343, DOI 10.1002/joa3.12310; Merchant FM, 2015, PACE, V38, P1297, DOI 10.1111/pace.12733; Migliore F, 2019, PACE, V42, P989, DOI 10.1111/pace.13700; Nowosielecka D, 2021, CARDIOVASC DIAGN THE, V11, P394, DOI 10.21037/cdt-20-871; Nowosielecka D, 2020, KARDIOL POL, V78, P1206, DOI 10.33963/KP.15651; Nowosielecka D, 2021, CLIN PHYSIOL FUNCT I, V41, P25, DOI 10.1111/cpf.12662; Nowosielecka D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051382; Nowosielecka D, 2020, ECHOCARDIOGR-J CARD, V37, P601, DOI 10.1111/echo.14628; Rao A, 2020, EUROPACE, V22, P1743, DOI 10.1093/europace/euaa218; Santoro MG, 2020, PACE, V43, P382, DOI 10.1111/pace.13896; Segreti L, 2020, EUROPACE, V22, P1401, DOI 10.1093/europace/euaa134; Sharma S, 2018, JACC-CLIN ELECTROPHY, V4, P212, DOI 10.1016/j.jacep.2017.12.010; Sood N, 2018, CIRC-ARRHYTHMIA ELEC, V11, DOI 10.1161/CIRCEP.116.004768; Starcke CT, 2020, EUROPACE, V22, P1103, DOI 10.1093/europace/euaa103; Tarakji KG, 2013, EXPERT REV CARDIOVAS, V11, P607, DOI [10.1586/ERC.12.190, 10.1586/erc.12.190]; Wazni O, 2010, J AM COLL CARDIOL, V55, P579, DOI 10.1016/j.jacc.2009.08.070; Wilkoff BL, 1999, J AM COLL CARDIOL, V33, P1671, DOI 10.1016/S0735-1097(99)00074-1; Wilkoff BL, 2009, HEART RHYTHM, V6, P1085, DOI 10.1016/j.hrthm.2009.05.020; Zhou X, 2020, HEART VESSELS, V35, P825, DOI 10.1007/s00380-019-01539-2; Zucchelli G, 2019, EUROPACE, V21, P771, DOI 10.1093/europace/euy300	44	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						445	459		10.2147/VHRM.S318205			15	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TX5ZX	WOS:000683169900001	34385818	gold, Green Published			2022-04-27	
J	Zemmrich, C; Bramlage, P; Hillmeister, P; Sacirovic, M; Buschmann, I				Zemmrich, Claudia; Bramlage, Peter; Hillmeister, Philipp; Sacirovic, Mesud; Buschmann, Ivo			Risk Factor Management in Non-Metropolitan Patients with Coronary and Peripheral Artery Disease - A Protocol of a Prospective, Multi-Center, Quality Improvement Strategy	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						coronary artery disease; peripheral arterial disease; atherosclerosis; rural; risk factor; quality improvement	PRIMARY-CARE PATIENTS; HIGH PREVALENCE; HEALTH-CARE; DIAGNOSIS; GERMANY; COEXISTENCE; AWARENESS; MORTALITY; TRENDS	Introduction: Coronary artery disease (CAD) and peripheral arterial disease (PAD) account for significant morbidity and mortality in Germany and are more prevalent in rural, nonmetropolitan areas. The goal of this study is to screen patients for their current atherosclerotic status, initiate treatment according to the latest scientific findings using a standardised multimodal approach and track their atherosclerotic status over one year. Methods and Analysis: This manuscript describes the study protocol of a prospective, multicentre registry of 500 sequential patients with CAD and/or PAD in rural, non-metropolitan regions of Germany. Patients, who visit the "WalkByLab" at the Brandenburg Medical School, Brandenburg, Germany, will be assessed by using our structured, multimodal risk factor management (SMART) tool to evaluate cardiovascular morbidity data, collect information on care and deliver multimodal therapy. The study's primary objective is a cross-sectional examination of the risk profile, diagnostic and therapeutic status in this patient group. Secondary objectives include the assessment of risk factor correlations as well as changes in risk-factor profile and therapy adherence. Patients will be examined at baseline and followed up at three-monthly intervals for one year. Over this time, atherosclerotic risk factors and patient adherence to defined therapeutic strategies will be evaluated. Study completion is estimated to be December 2021. An expansion of this concept into other rural, non-metropolitan neighbouring regions is planned. Ethics and Dissemination: This registry was assessed and approved by the ethics committee of the Brandenburg State Medical Association, Brandenburg, Germany, and conducted in accordance with the Declaration of Helsinki. The study findings will be disseminated through usual academic channels including meeting presentations and peer-reviewed publications.	[Zemmrich, Claudia] Deutsch Angiol CRO, Berlin, Germany; [Bramlage, Peter] Inst Pharmacol & Prevent Med, Cloppenburg, Germany; [Hillmeister, Philipp; Sacirovic, Mesud; Buschmann, Ivo] Med Univ Brandenburg, Dept Angiol, Brandenburg, Germany		Zemmrich, C (通讯作者)，Deutsch Angiol CRO DA CRO, Straubinger Str 20, D-12683 Berlin, Germany.	claudia.zemmrich@da-cro.de			Bayer Vital GmbHBayer AG	This work was supported with an unrestricted grant from Bayer Vital GmbH.	ARONOW WS, 1994, AM J CARDIOL, V74, P64, DOI 10.1016/0002-9149(94)90493-6; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Camarero L, 2019, PALGR COMMUN, V5, DOI 10.1057/s41599-019-0306-x; Cassar A, 2009, MAYO CLIN PROC, V84, P1130, DOI 10.4065/mcp.2009.0391; Diehm C, 2004, ATHEROSCLEROSIS, V172, P95, DOI 10.1016/S0021-9150(03)00204-1; Dornquast C, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00158; Dornquast C, 2016, DTSCH ARZTEBL INT, V113, P704, DOI [10.3238/arztebl.2016.0704, 10.3238/arztebl.2016.704]; Gehring S, 2018, METHOD INFORM MED, V57, pE46, DOI 10.3414/ME18-13-0001; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Hur DJ, 2012, AM J CARDIOL, V110, P736, DOI 10.1016/j.amjcard.2012.04.059; JUERGENS JL, 1960, CIRCULATION, V21, P188, DOI 10.1161/01.CIR.21.2.188; Kuhn B, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0696-z; Lampert T, 2019, J HLTH MONIT; Lange S, 2004, EXP CLIN ENDOCR DIAB, V112, P566, DOI 10.1055/s-2004-830408; Lawall H, 2017, VASA, V46, P79, DOI 10.1024/0301-1526/a000603; Muller-Nordhorn J, 2004, J EPIDEMIOL COMMUN H, V58, P481, DOI 10.1136/jech.2003.013367; Ness J, 1999, J AM GERIATR SOC, V47, P1255, DOI 10.1111/j.1532-5415.1999.tb05208.x; Olin JW, 2010, MAYO CLIN PROC, V85, P678, DOI 10.4065/mcp.2010.0133; Plass D, 2014, DTSCH ARZTEBL INT, V111, P629, DOI 10.3238/arztebl.2014.0629; Potrafke N, 2020, REG STUD, V54, P340, DOI 10.1080/00343404.2019.1623390; Regensteiner JG, 2008, VASC MED, V13, P15, DOI 10.1177/1358863X07084911; Stang A, 2014, DTSCH ARZTEBL INT, V111, P530, DOI 10.3238/arztebl.2014.0530	22	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						267	272		10.2147/VHRM.S307014			6	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7NV	WOS:000655718100001	34079274	gold, Green Published			2022-04-27	
J	Cheng, YC; Kuo, YC; Chang, PC; Li, YC; Huang, WT; Chen, W; Chou, CY				Cheng, Ya-Chi; Kuo, Yi-Chun; Chang, Pei-Chi; Li, Ya-Ching; Huang, Wan-Ting; Chen, Wei; Chou, Che-Yi			Geriatric Functional Impairment Using the Integrated Care for Older People (ICOPE) Approach in Community-Dwelling Elderly and Its Association with Dyslipidemia	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						aging; elderly; function impairment; geriatric functional impairment; ICOPE; renal function	DISEASE; TAIWAN	Background: The World Health Organization (WHO) proposed the integrated care for older people (ICOPE) screening tool to identify functional impairment. We explore the association of geriatric functional impairment and hypertension, diabetes, dyslipidemia in the community-dwelling elderly. Methods: We enrolled individuals aged at least 65 with hypertension, diabetes, or dyslipidemia; or those aged at least 75 from May to July 2019. We applied ICOPE tools to evaluate six function assessments: cognitive decline, limited mobility, malnutrition, visual impairment, hearing loss, and depressive symptoms. Factors were analyzed using stepwise multivariable linear regression for ICOPE scores and logistic regression for geriatric functional impairment. All analyses were adjusted for age and glomerular filtration rate. Results: We enrolled 457 participants including 303 (66.3%) participants with hypertension, 296 (64.8%) diabetes, and 221 (48.4%) dyslipidemia. Seventy-eight (17.1%) participants have at least one geriatric functional impairment, including 41 (25.9%) participants aged >= 75 and 37 (12.4%) aged 65-74. The ICOPE score (0.4 +/- 0.6) of participants aged at least 75 was higher than that (0.1 +/- 0.4) of the participants aged 65-74 (p < 0.001). Dyslipidemia (p = 0.002) was positively associated with ICOPE score. Dyslipidemia (odds ratio: 2.15, 95% confidence interval: 1.27-3.70, p = 0.005), not hypertension (p = 0.3) and diabetes (p = 0.9), was associated with geriatric functional impairment. Visual impairment was the most common function impairment. Female was linked to limited mobility, renal function was associated with mobility (p < 0.001) and nutrition (p = 0.02). Conclusion: Dyslipidemia but not hypertension, diabetes is linked to geriatric functional impairment in community-dwelling elderly. Lower renal function is associated with decreased mobility and nutrition. More studies are needed to determine if treatment of dyslipidemia reduces geriatric functional impairment.	[Cheng, Ya-Chi] Ditmanson Med Fdn Chiayi Christian Hosp, Div Family Med, Chiayi, Taiwan; [Kuo, Yi-Chun; Chang, Pei-Chi; Li, Ya-Ching] Ditmanson Med Fdn Chiayi Christian Hosp, Community Nursing Room, Chiayi, Taiwan; [Huang, Wan-Ting] Ditmanson Med Fdn Chiayi Christian Hosp, Clin Med Res Ctr, Chiayi, Taiwan; [Chen, Wei] Ditmanson Med Fdn Chiayi Christian Hosp, Div Pulm & Crit Care Med, Chiayi, Taiwan; [Chou, Che-Yi] Asia Univ Hosp, Div Nephrol, Taichung, Taiwan; [Chou, Che-Yi] Asia Univ, Dept Postbaccalaureate Vet Med, Taichung, Taiwan; [Chou, Che-Yi] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan		Chou, CY (通讯作者)，222 Fuxin Rd, Taichung 413, Taiwan.	cychou.chou@gmail.com	Chou, Che-Yi/N-8887-2015	Chou, Che-Yi/0000-0003-4029-9097	Asia University Hospital [AUH-10651015]	This study was partially supported by the grant from Asia University Hospital (AUH-10651015) . The funders had no role in study design, data collection, analysis, decision to publish, or manuscript preparation.	Araki A, 2009, GERIATR GERONTOL INT, V9, P105, DOI 10.1111/j.1447-0594.2008.00495.x; Cesari M, 2016, EUR J INTERN MED, V31, P11, DOI 10.1016/j.ejim.2016.03.005; Chandra A, 2015, AGING DIS, V6, P188, DOI 10.14336/AD.2014.0706; Chen IR, 2014, CLIN J AM SOC NEPHRO, V9, P1183, DOI 10.2215/CJN.09810913; Gaitonde DY, 2012, AM FAM PHYSICIAN, V86, P244; Jia HM, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.025; Koppe L, 2019, J CACHEXIA SARCOPENI, V10, P479, DOI 10.1002/jcsm.12421; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Li YH, 2017, J FORMOS MED ASSOC, V116, P217, DOI 10.1016/j.jfma.2016.11.013; Liu PT, 2013, METABOLISM, V62, P220, DOI 10.1016/j.metabol.2012.07.022; Ma LN, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576079; Mah HY, 2020, GERIATR GERONTOL INT, V20, P911, DOI 10.1111/ggi.14011; Noori H, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101415; Sabanayagam C, 2016, OPHTHALMOLOGY, V123, P2436, DOI 10.1016/j.ophtha.2016.06.036; Sabatino A, 2017, J NEPHROL, V30, P743, DOI 10.1007/s40620-017-0435-5; Seclen SN, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2015-000110; Siriwardhana DD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018195; Tseng LN, 2012, J FORMOS MED ASSOC, V111, P625, DOI 10.1016/j.jfma.2012.09.010; Valderrama Amy L., 2012, Morbidity and Mortality Weekly Report, V61, P703; Wang Q, 2019, EBIOMEDICINE, V45, P487, DOI 10.1016/j.ebiom.2019.07.007; WHO, 2017, INT CAR OLD PEOPL GU; Yamada K, 2015, CLIN EXP NEPHROL, V19, P830, DOI 10.1007/s10157-014-1070-2; Yoshida Hiroto, 2012, Nihon Ronen Igakkai Zasshi, V49, P442	23	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						389	394		10.2147/VHRM.S305490			6	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TE3EV	WOS:000669897900001	34262283	gold, Green Published			2022-04-27	
J	Mallet, RT; Burtscher, J; Richalet, JP; Millet, GP; Burtscher, M				Mallet, Robert T.; Burtscher, Johannes; Richalet, Jean-Paul; Millet, Gregoire P.; Burtscher, Martin			Impact of High Altitude on Cardiovascular Health: Current Perspectives	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypoxia; hypobaria; exercise; adaptation; acclimatization; conditioning	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CORONARY-HEART-DISEASE; ACUTE MOUNTAIN-SICKNESS; MAXIMAL OXYGEN-UPTAKE; CEREBRAL-BLOOD-FLOW; HYPOBARIC HYPOXIA; INTERMITTENT HYPOXIA; NORMOBARIC HYPOXIA; RISK-FACTORS; MODERATE ALTITUDE	Globally, about 400 million people reside at terrestrial altitudes above 1500 m, and more than 100 million lowlanders visit mountainous areas above 2500 m annually. The interactions between the low barometric pressure and partial pressure of O2, climate, individual genetic, lifestyle and socio-economic factors, as well as adaptation and acclima-tization processes at high elevations are extremely complex. It is challenging to decipher the effects of these myriad factors on the cardiovascular health in high altitude residents, and even more so in those ascending to high altitudes with or without preexisting diseases. This review aims to interpret epidemiological observations in high-altitude populations; present and discuss cardiovascular responses to acute and subacute high-altitude exposure in general and more specifically in people with preexisting cardiovascular diseases; the relations between cardiovascular pathologies and neurodegenerative diseases at altitude; the effects of high-altitude exercise; and the putative cardioprotective mechanisms of hypobaric hypoxia.	[Mallet, Robert T.] Univ North Texas, Hlth Sci Ctr, Dept Physiol & Anat, Ft Worth, TX USA; [Burtscher, Johannes; Millet, Gregoire P.] Univ Lausanne, Dept Biomed Sci, CH-1015 Lausanne, Switzerland; [Burtscher, Johannes; Millet, Gregoire P.] Univ Lausanne, Inst Sport Sci, CH-1015 Lausanne, Switzerland; [Richalet, Jean-Paul] Univ Sorbonne Paris Nord 13, INSERM, UMR U1272, Lab Hypoxie & Poumon, F-93017 Bobigny, France; [Burtscher, Martin] Univ Innsbruck, Dept Sport Sci, A-6020 Innsbruck, Austria; [Burtscher, Martin] Austrian Soc Alpine & High Altitude Med, Mieming, Austria		Burtscher, M (通讯作者)，Univ Innsbruck, Dept Sport Sci, A-6020 Innsbruck, Austria.	martin.burtscher@uibk.ac.at		Burtscher, Martin/0000-0002-5232-3632			Aghajanian A, 2021, J MOL CELL CARDIOL, V150, P1, DOI 10.1016/j.yjmcc.2020.09.015; Agostoni P, 2000, AM J MED, V109, P450, DOI 10.1016/S0002-9343(00)00532-5; Agostoni P, 2013, HIGH ALT MED BIOL, V14, P96, DOI 10.1089/ham.2012.1117; Aguilar M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020366; Alexander J K, 1995, Cardiol Clin, V13, P271; ALEXANDER JK, 1994, TEX HEART I J, V21, P261; Allemann Y, 2006, JAMA-J AM MED ASSOC, V296, P2954, DOI 10.1001/jama.296.24.2954; Almohanna AM, 2018, AM J PHYSIOL-HEART C, V315, pH756, DOI 10.1152/ajpheart.00725.2017; Aryal N, 2016, HIGH ALT MED BIOL, V17, P185, DOI 10.1089/ham.2015.0118; ASA/JPL-Caltech, ASTER GLOBAL DIGITAL; Asmaro D, 2013, AVIAT SPACE ENVIR MD, V84, P1159, DOI 10.3357/ASEM.3661.2013; Bartsch P, 2013, NEW ENGL J MED, V368, P2294, DOI 10.1056/NEJMcp1214870; Baillieul S, 2017, EXP BIOL MED, V242, P1198, DOI 10.1177/1535370217712691; Bartsch P, 2007, CIRCULATION, V116, P2191, DOI 10.1161/CIRCULATIONAHA.106.650796; Basnyat B, 2003, LANCET, V361, P1967, DOI 10.1016/S0140-6736(03)13591-X; Bayer Urike, 2017, Alzheimers Dement (N Y), V3, P114, DOI 10.1016/j.trci.2017.01.002; Beall CM, 2000, HUM BIOL, V72, P201; Belaidi E, 2016, PHARMACOL THERAPEUT, V168, P1, DOI [10.1016/j.pharmthera.2016.07.010, 10.10166/j.pharmthera.2016.07.010]; Belikova MV, 2012, INTERMITTENT HYPOXIA, P147, DOI DOI 10.1007/978-1-4471-2906-6_12; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bilo G, 2020, HYPERTENSION, V76, P1962, DOI 10.1161/HYPERTENSIONAHA.120.16010; Boero JA, 1999, J APPL PHYSIOL, V86, P1211, DOI 10.1152/jappl.1999.86.4.1211; BONNON M, 1995, AVIAT SPACE ENVIR MD, V66, P330; Boscoe FP, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-264; Broce IJ, 2019, ACTA NEUROPATHOL, V137, P209, DOI 10.1007/s00401-018-1928-6; Bunker A, 2016, EBIOMEDICINE, V6, P258, DOI 10.1016/j.ebiom.2016.02.034; Burtscher J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020582; Burtscher M, 2006, INT J SPORTS MED, V27, P629, DOI 10.1055/s-2005-872823; Burtscher M, 2001, EUR J APPL PHYSIOL, V84, P379, DOI 10.1007/s004210100393; Burtscher M, 1996, EUR J APPL PHYSIOL, V74, P558; Burtscher M., SPORTS MED HLTH SCI, V3, P59, DOI [10.1016/j.smhs.2021.04.001, DOI 10.1016/J.SMHS.2021.04.001]; Burtscher Martin, 2021, J Travel Med, DOI 10.1093/jtm/taab035; Burtscher M, 2019, HIGH ALT MED BIOL, V20, P192, DOI 10.1089/ham.2018.0143; Burtscher M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01504; Burtscher M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00572; Burtscher M, 2016, AGING-US, V8, P2603, DOI 10.18632/aging.101057; Burtscher M, 2014, AGING DIS, V5, P274, DOI 10.14336/AD.2014.0500274; Burtscher M, 2010, PROG CARDIOVASC DIS, V52, P507, DOI 10.1016/j.pcad.2010.02.008; Calbet JAL, 2003, AM J PHYSIOL-REG I, V284, pR291, DOI 10.1152/ajpregu.00155.2002; Casey DP, 2012, J PHYSIOL-LONDON, V590, P6321, DOI 10.1113/jphysiol.2012.242396; Casey DP, 2011, J APPL PHYSIOL, V110, P687, DOI 10.1152/japplphysiol.00787.2010; Casey DP, 2010, J PHYSIOL-LONDON, V588, P373, DOI 10.1113/jphysiol.2009.180489; Casillas JM, 2017, ANN PHYS REHABIL MED, V60, P43, DOI 10.1016/j.rehab.2016.01.011; Chavez JC, 2000, J APPL PHYSIOL, V89, P1937, DOI 10.1152/jappl.2000.89.5.1937; Chen SM, 2008, CORONARY ARTERY DIS, V19, P173, DOI 10.1097/MCA.0b013e3282fa4b2c; Cohen JE, 1998, P NATL ACAD SCI USA, V95, P14009, DOI 10.1073/pnas.95.24.14009; Correia SC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010461; Crawford JE, 2017, AM J HUM GENET, V101, P752, DOI 10.1016/j.ajhg.2017.09.023; CYMERMAN A, 1989, J APPL PHYSIOL, V66, P2446, DOI 10.1152/jappl.1989.66.5.2446; De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056; Deng BJ, 2012, HIGH ALT MED BIOL, V13, P13, DOI 10.1089/ham.2011.1037; Dhar P, 2018, RESP PHYSIOL NEUROBI, V254, P40, DOI 10.1016/j.resp.2018.04.002; Dhar P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084274; Donegani E, 2014, TRAVEL MED INFECT DI, V12, P237, DOI 10.1016/j.tmaid.2014.02.004; El Jamali A, 2004, FASEB J, V18, P1096, DOI 10.1096/fj.03-1054fje; Erdmann J, 1998, AM J CARDIOL, V81, P266, DOI 10.1016/S0002-9149(97)00901-6; Estrada JA, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395-016-0538-5; Ezzati M, 2012, J EPIDEMIOL COMMUN H, V66, DOI 10.1136/jech.2010.112938; Faeh D, 2009, CIRCULATION, V120, P495, DOI 10.1161/CIRCULATIONAHA.108.819250; Faulhaber M, 2007, HIGH ALT MED BIOL, V8, P245, DOI 10.1089/ham.2007.1005; Feddersen B, 2015, J CEREBR BLOOD F MET, V35, P1846, DOI 10.1038/jcbfm.2015.142; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Fiuza-Luces C, 2018, NAT REV CARDIOL, V15, P731, DOI 10.1038/s41569-018-0065-1; Fukuda T, 2010, INT HEART J, V51, P170, DOI 10.1536/ihj.51.170; Gazal S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00690; Gore CJ, 1996, J APPL PHYSIOL, V80, P2204, DOI 10.1152/jappl.1996.80.6.2204; Griva K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174277; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Guo HC, 2009, ACTA PHARMACOL SIN, V30, P947, DOI 10.1038/aps.2009.57; HACKETT PH, 1980, NEW ENGL J MED, V302, P1070, DOI 10.1056/NEJM198005083021907; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Harinck E, 1996, CIRCULATION, V93, P272, DOI 10.1161/01.CIR.93.2.272; Hautala N, 2002, PFLUG ARCH EUR J PHY, V443, P362, DOI 10.1007/s004240100699; He F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134777; Herrera EA, 2015, MAR DRUGS, V13, P838, DOI 10.3390/md13020838; Higgins JP, 2010, AM HEART J, V159, P25, DOI 10.1016/j.ahj.2009.10.028; Hill CM, 2014, NEUROPSYCHOLOGY, V28, P752, DOI 10.1037/neu0000065; HORSTMAN D, 1980, J APPL PHYSIOL, V49, P311, DOI 10.1152/jappl.1980.49.2.311; Huang YT, 2019, J CELL PHYSIOL, V234, P13557, DOI 10.1002/jcp.28034; Hur T, 2015, J NEUROL SCI, V357, pE270, DOI 10.1016/j.jns.2015.08.948; Hur TH, 2013, NEUROL ASIA, V18, P99; Imray CHE, 2005, J APPL PHYSIOL, V99, P699, DOI 10.1152/japplphysiol.00973.2004; Iwamoto E, 2020, J APPL PHYSIOL, V129, P603, DOI 10.1152/japplphysiol.00274.2020; Jain K, 2013, HIGH ALT MED BIOL, V14, P65, DOI 10.1089/ham.2012.1064; Jayaswal R, 2001, Med J Armed Forces India, V57, P322, DOI 10.1016/S0377-1237(01)80014-9; Jefferson JA, 2004, HIGH ALT MED BIOL, V5, P61, DOI 10.1089/152702904322963690; Jiang LF, 2019, ANTIOXID REDOX SIGN, V31, P227, DOI 10.1089/ars.2018.7624; KAGAMU H, 1994, BIOCHEM BIOPH RES CO, V202, P1612, DOI 10.1006/bbrc.1994.2117; Kakinuma Y, 2001, CIRCULATION, V103, P2387; Kalaria RN, 2004, RESP PHYSIOL NEUROBI, V140, P53, DOI 10.1016/j.resp.2004.01.003; Karar J, 2007, FEBS LETT, V581, P4577, DOI 10.1016/j.febslet.2007.08.044; Keyes LE, 2017, HIGH ALT MED BIOL, V18, P267, DOI 10.1089/ham.2017.0001; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556; Kleinnibbelink G, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022411; Kong ZW, 2014, SLEEP BREATH, V18, P591, DOI 10.1007/s11325-013-0922-4; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; LAMANNA JC, 1992, J APPL PHYSIOL, V72, P2238, DOI 10.1152/jappl.1992.72.6.2238; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Lemos VD, 2012, PSYCHOPHYSIOLOGY, V49, P1298, DOI 10.1111/j.1469-8986.2012.01411.x; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; LENFANT C, 1971, NEW ENGL J MED, V284, P1298, DOI 10.1056/NEJM197106102842305; Leon-Velarde F, 2005, HIGH ALT MED BIOL, V6, P147, DOI 10.1089/ham.2005.6.147; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; Levine BD, 1997, CIRCULATION, V96, P1224, DOI 10.1161/01.CIR.96.4.1224; Levine BD, 2015, HIGH ALT MED BIOL, V16, P89, DOI 10.1089/ham.2015.0043; Lhuissier FJ, 2012, J PHYSIOL-LONDON, V590, P5461, DOI 10.1113/jphysiol.2012.238527; Li XX, 2015, ASIA-PAC J PUBLIC HE, V27, pNP116, DOI 10.1177/1010539511427956; Li Yangyang, 2015, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V33, P731; Lichtblau M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00502; Litch JA, 2000, WILD ENVIRON MED, V11, P25, DOI 10.1580/1080-6032(2000)011[0025:HAGA]2.3.CO;2; Liu XL, 2017, J APPL PHYSIOL, V123, P1689, DOI 10.1152/japplphysiol.00647.2017; Lopez-Pascual A, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00658; Lourenco CF, 2017, FREE RADICAL BIO MED, V108, P668, DOI 10.1016/j.freeradbiomed.2017.04.026; Lundby AKM, 2014, EUR J APPL PHYSIOL, V114, P1107, DOI 10.1007/s00421-014-2844-7; Lyamina NP, 2011, J HYPERTENS, V29, P2265, DOI 10.1097/HJH.0b013e32834b5846; Ma HL, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1256; Magalhaes J, 2004, AVIAT SPACE ENVIR MD, V75, P16; Mairer K, 2010, HIGH ALT MED BIOL, V11, P343, DOI 10.1089/ham.2010.1039; Mallet RT, 2006, BASIC RES CARDIOL, V101, P436, DOI 10.1007/s00395-006-0599-y; Mallet RT, 2018, AM J PHYSIOL-HEART C, V315, pH216, DOI 10.1152/ajpheart.00060.2018; Manukhina E B, 2010, Neurosci Behav Physiol, V40, P737, DOI 10.1007/s11055-010-9320-6; Manukhina EB, 2016, EXP BIOL MED, V241, P1351, DOI 10.1177/1535370216649060; Marshall JM, 1998, BRAZ J MED BIOL RES, V31, P863, DOI 10.1590/S0100-879X1998000700002; MELA L, 1976, AM J PHYSIOL, V231, P1811, DOI 10.1152/ajplegacy.1976.231.6.1811; Mingji C, 2015, HEART, V101, P1054, DOI 10.1136/heartjnl-2014-307158; Monge-C C., 1987, HYPOXIA POLYCYTHEMIA; Montero D, 2016, SPORTS MED, V46, P1725, DOI 10.1007/s40279-016-0570-5; Moore LG, 2001, HIGH ALT MED BIOL, V2, P257, DOI 10.1089/152702901750265341; MOORE LG, 1982, AM REV RESPIR DIS, V126, P225; MORGANTI A, 1995, J HYPERTENS, V13, P859, DOI 10.1097/00004872-199508000-00006; Mourot L, 2019, HIGH ALT MED BIOL, V20, P94, DOI 10.1089/ham.2018.0104; Mourot L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00972; Mrakic-Sposta S, 2021, EUR J APPL PHYSIOL, V121, P297, DOI 10.1007/s00421-020-04527-x; Muller FU, 2005, J BIOL CHEM, V280, P6906, DOI 10.1074/jbc.M407864200; Naeije R, 2010, PROG CARDIOVASC DIS, V52, P456, DOI 10.1016/j.pcad.2010.03.004; Narvaez-Guerra O, 2018, HYPERTENSION, V72, P567, DOI 10.1161/HYPERTENSIONAHA.118.11140; Nation DA, 2017, J INT NEUROPSYCH SOC, V23, P1, DOI 10.1017/S1355617716000965; Navarrete-Opazo A, 2014, AM J PHYSIOL-REG I, V307, pR1181, DOI 10.1152/ajpregu.00208.2014; NELSON M, 1982, AVIAT SPACE ENVIR MD, V53, P122; Netzer N, 2013, J TRAVEL MED, V20, P247, DOI 10.1111/jtm.12017; Netzer NC, 2008, SLEEP BREATH, V12, P129, DOI 10.1007/s11325-007-0149-3; Nilsson PM, 2012, CURR VASC PHARMACOL, V10, P700; Okumiya K, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009728; Pagani M, 1998, CORTEX, V34, P243, DOI 10.1016/S0010-9452(08)70751-2; Parati G, 2018, EUR HEART J, V39, P1546, DOI 10.1093/eurheartj/ehx720; Parati G, 2014, EUR HEART J, V35, P3113, DOI 10.1093/eurheartj/ehu275; Pelamatti G, 2003, CORTEX, V39, P97, DOI 10.1016/S0010-9452(08)70077-7; Piperno A, 2011, BLOOD, V117, P2953, DOI 10.1182/blood-2010-08-299859; Piuhola J, 2008, CLIN SCI, V114, P293, DOI 10.1042/CS20070229; Rabin JS, 2018, JAMA NEUROL, V75, P1124, DOI 10.1001/jamaneurol.2018.1123; Ren AJ, 2008, CAN J PHYSIOL PHARM, V86, P536, DOI 10.1139/Y08-051; Richalet JP, 2008, HIGH ALT MED BIOL, V9, P179, DOI 10.1089/ham.2007.1062; Richalet JP, 2015, HIGH ALT MED BIOL, V16, P117, DOI 10.1089/ham.2015.0030; Richalet JP, 2012, AM J RESP CRIT CARE, V185, P192, DOI 10.1164/rccm.201108-1396OC; RICHALET JP, 1992, INT J SPORTS MED, V13, pS22, DOI 10.1055/s-2007-1024582; Richardson C, 2011, CLIN NEUROPHYSIOL, V122, P1726, DOI 10.1016/j.clinph.2011.02.001; Rimoldi SF, 2010, PROG CARDIOVASC DIS, V52, P512, DOI 10.1016/j.pcad.2010.03.005; Ruhlr FJ, 2008, SWISS MED WKLY, V138, P286, DOI 2008/19/smw-11971; Ryou MG, 2012, STROKE, V43, P1101, DOI 10.1161/STROKEAHA.111.620088; Ryou MG, 2009, AM J PHYSIOL-HEART C, V297, pH1914, DOI 10.1152/ajpheart.01213.2008; Sanborn MR, 2015, WILD ENVIRON MED, V26, P133, DOI 10.1016/j.wem.2014.10.001; Sartori C, 1999, LANCET, V353, P2205, DOI 10.1016/S0140-6736(98)08352-4; Sasaki H, 2002, J MOL CELL CARDIOL, V34, P335, DOI 10.1006/jmcc.2001.1516; Saugy JJ, 2016, MED SCI SPORT EXER, V48, P680, DOI 10.1249/MSS.0000000000000810; SAVONITTO S, 1992, AM J CARDIOL, V70, P1493, DOI 10.1016/0002-9149(92)90308-L; Schega L, 2016, J SCI MED SPORT, V19, P941, DOI 10.1016/j.jsams.2016.02.012; Schega L, 2013, GERONTOLOGY, V59, P316, DOI 10.1159/000350927; Schmid JP, 2006, HEART, V92, P921, DOI 10.1136/hrt.2005.072520; Schobersberger W, 2003, EUR J APPL PHYSIOL, V88, P506, DOI 10.1007/s00421-002-0736-8; Schulte JS, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395-016-0532-y; Seherrer U, 2010, PROG CARDIOVASC DIS, V52, P451, DOI 10.1016/j.pcad.2010.02.002; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza Gregg L, 2007, Sci STKE, V2007, pcm8, DOI 10.1126/stke.4072007cm8; Serebrovska ZO, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215405; Serebrovskaya TV, 2008, EXP BIOL MED, V233, P627, DOI 10.3181/0710-MR-267; Shanmugam G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00268; Sherpa LY, 2011, HIGH ALT MED BIOL, V12, P57, DOI 10.1089/ham.2010.1050; Singh M, 2013, APPL BIOCHEM BIOTECH, V169, P2405, DOI 10.1007/s12010-013-0141-2; Song C, 2020, J INT MED RES, V48, DOI [10.11770/300060520903645, DOI 10.11770/300060520903645]; Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Suzuki YJ, 2003, ANTIOXID REDOX SIGN, V5, P741, DOI 10.1089/152308603770380043; Swaminath PV, 2006, MOVEMENT DISORD, V21, P1296, DOI 10.1002/mds.20941; Swenson ER, 2014, SUBCELL BIOCHEM, V75, P361, DOI 10.1007/978-94-007-7359-2_18; Takanashi M, 2004, J CARDIOVASC PHARM, V44, pS268, DOI 10.1097/01.fjc.0000166282.01034.8f; Teppema LJ, 2010, PHYSIOL REV, V90, P675, DOI 10.1152/physrev.00012.2009; Thielke S, 2015, JAMA PSYCHIAT, V72, P1253, DOI 10.1001/jamapsychiatry.2015.1852; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; Toth P, 2017, AM J PHYSIOL-HEART C, V312, pH1, DOI 10.1152/ajpheart.00581.2016; Verma S, 2004, J SURG RES, V119, P66, DOI 10.1016/j.jss.2003.10.011; Villafuerte FC, 2016, HIGH ALT MED BIOL, V17, P61, DOI 10.1089/ham.2016.0031; Virues-Ortega J, 2009, J AM GERIATR SOC, V57, P1955, DOI 10.1111/j.1532-5415.2009.02468.x; Wang H, 2020, AM J ALZHEIMERS DIS, V35, DOI 10.1177/1533317519896725; Wehrlin JP, 2006, EUR J APPL PHYSIOL, V96, P404, DOI 10.1007/s00421-005-0081-9; WEST JB, 1993, J WILDERNESS MED, V4, P17, DOI 10.1580/0953-9859-4.1.17; WEST JB, 1984, AM REV RESPIR DIS, V130, P917; WEST JB, 1986, NATURE, V324, P517, DOI 10.1038/324517a0; Whitmer RA, 2005, NEUROLOGY, V64, P277, DOI 10.1212/01.WNL.0000149519.47454.F2; Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6; Winkler L, 2017, J HYPERTENS, V35, P2402, DOI 10.1097/HJH.0000000000001479; Woolcott OO, 2016, OBESITY, V24, P929, DOI 10.1002/oby.21401; Woolcott OO, 2014, OBESITY, V22, P2080, DOI 10.1002/oby.20800; Wu L, 2015, J MOL CELL CARDIOL, V81, P150, DOI 10.1016/j.yjmcc.2015.02.015; Wu TY, 2007, HIGH ALT MED BIOL, V8, P88, DOI 10.1089/ham.2007.1015; Zhou QQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031097; Zhuang JG, 1999, BIOL SIGNAL RECEPT, V8, P316; Zouboules SM, 2018, J PHYSIOL-LONDON, V596, P6191, DOI 10.1113/JP276973	210	5	6	2	5	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						317	335		10.2147/VHRM.S294121			19	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD7KS	WOS:000669501600001	34135590	gold, Green Published			2022-04-27	
J	Polychronopoulou, E; Wuerzner, G; Burnier, M				Polychronopoulou, Erietta; Wuerzner, Gregoire; Burnier, Michel			How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						hypertension; chronic kidney disease; CKD stage 3b-4; blockers of the renin-angiotensin; diuretics; calcium antagonists; SGLT2 inhibitors	DIETARY-SODIUM RESTRICTION; BLOOD-PRESSURE; RENAL DENERVATION; RESISTANT HYPERTENSION; PRACTICE GUIDELINE; RANDOMIZED-TRIAL; OUTCOMES; POPULATION; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE	In the general population, the prevalence of moderate and severe chronic kidney disease (CKD) is usually below 5% but this figure is often higher in specific groups of patients such as those with type 2 diabetes. Patients with advanced CKD (CKD stage 3b and 4) are at high or very high cardiovascular risk, and their risk of progressing towards end-stage kidney disease (CKD stage 5) and the need of renal replacement therapy are elevated. Hypertension is a major cause of poor cardiovascular and renal outcomes in severe CKD. Therefore, an adequate control of blood pressure (BP) is mandatory. However, normalizing BP is often challenging in these patients because the clinical management of hypertension in advanced CKD is not well defined and rarely supported by large randomized controlled trials. In the present review, we discuss the characteristics of hypertension in advanced CKD, excluding dialysis, and its management integrating data from recent clinical studies and a pragmatic approach enriched by a long-standing clinical experience.	[Polychronopoulou, Erietta; Wuerzner, Gregoire; Burnier, Michel] Univ Hosp, Serv Nephrol & Hypertens, Rue Bugnon 17, CH-1011 Lausanne, Switzerland; [Wuerzner, Gregoire; Burnier, Michel] Hypertens Res Fdn, St Legier, Switzerland		Burnier, M (通讯作者)，Univ Hosp, Serv Nephrol & Hypertens, Rue Bugnon 17, CH-1011 Lausanne, Switzerland.	michel.burnier@chuv.ch		Wuerzner, Gregoire/0000-0002-6424-7630	Hypertension Research Foundation in St-Legier, Switzerland	The Hypertension Research Foundation in St-Legier, Switzerland has supported the publication of this review.	Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1378; Agarwal R, 2005, HYPERTENSION, V46, P514, DOI 10.1161/01.HYP.0000178102.85718.66; Agarwal R, 2016, J AM SOC NEPHROL, V27, P924, DOI 10.1681/ASN.2015030243; Ahmed A, 2016, NEPHRON, V133, P147, DOI 10.1159/000447068; [Anonymous], 2019, CKD GEN POPULATION; Bakris GL, 2020, NEW ENGL J MED, V383, P2219, DOI 10.1056/NEJMoa2025845; Bakris GL, 2010, LANCET, V375, P1173, DOI 10.1016/S0140-6736(09)62100-0; Barzilay Joshua, 2007, J Clin Hypertens (Greenwich), V9, P591, DOI 10.1111/j.1524-6175.2007.07229.x; BOFFA RJ, 2019, BMJ-BRIT MED J, V367, DOI DOI 10.1136/BMJ.15310; Bohm M, 2020, LANCET, V395, P1444, DOI 10.1016/S0140-6736(20)30554-7; Bovee DM, 2020, J AM SOC NEPHROL, V31, P650, DOI 10.1681/ASN.2019090905; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Briet M, 2010, NAT REV NEPHROL, V6, P261, DOI 10.1038/nrneph.2010.30; Bruck K, 2016, J AM SOC NEPHROL, V27, P2135, DOI 10.1681/ASN.2015050542; Burnier M, 2007, SEMIN NEPHROL, V27, P565, DOI 10.1016/j.semnephrol.2007.07.007; Burnier M, 2021, NEPHROL DIAL TRANSPL, V36, P381, DOI 10.1093/ndt/gfaa120; Burnier M, 2020, KIDNEY MED, V2, P231, DOI 10.1016/j.xkme.2020.04.002; Burnier M, 2019, NEPHROL DIAL TRANSPL, V34, P184, DOI 10.1093/ndt/gfx340; Burnier M, 2015, NEPHROL DIAL TRANSPL, V30, P39, DOI 10.1093/ndt/gfu015; Burnier M, 2013, CURR MED RES OPIN, V29, P1727, DOI 10.1185/03007995.2013.842891; Carmena R, 2020, J HYPERTENS, V38, P2110, DOI 10.1097/HJH.0000000000002506; Cheung AK, 2019, KIDNEY INT, V95, P1027, DOI 10.1016/j.kint.2018.12.025; Chung EYM, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007004.pub4; Cohen DL, 2013, CURR HYPERTENS REP, V15, P160, DOI 10.1007/s11906-013-0339-2; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; Currie G, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0337-0; Dekkers CCJ, 2018, NEPHROL DIAL TRANSPL, V33, P2005, DOI 10.1093/ndt/gfx350; Drawz PE, 2016, CLIN J AM SOC NEPHRO, V11, P642, DOI 10.2215/CJN.08530815; Dussol B, 2012, J CLIN HYPERTENS, V14, P32, DOI 10.1111/j.1751-7176.2011.00564.x; Epstein M, 2015, AM J MANAG CARE, V21, pS212; Fernandez-Fernandez B, 2020, CLIN KIDNEY J, V13, P728, DOI 10.1093/ckj/sfaa198; Flack JM, 2010, HYPERTENSION, V56, P780, DOI 10.1161/HYPERTENSIONAHA.110.152892; Fukuda M, 2004, KIDNEY INT, V65, P621, DOI 10.1111/j.1523-1755.2004.00419.x; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Garofalo C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060732; Georgianos PI, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-01081-x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Heerspink HJL, 2020, NEW ENGL J MED, V383, P1436, DOI 10.1056/NEJMoa2024816; Heerspink HJL, 2020, NEPHROL DIAL TRANSPL, V35, P274, DOI 10.1093/ndt/gfz290; HEERSPINK HJL, 2012, KIDNEY INT, V82, P330, DOI DOI 10.1038/KI.2012.74; Hering D, 2012, J AM SOC NEPHROL, V23, P1250, DOI 10.1681/ASN.2011111062; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Hirst JA, 2020, BRIT J GEN PRACT, V70, pE285, DOI 10.3399/bjgp20X708245; Hou FF, 2006, NEW ENGL J MED, V354, P131, DOI 10.1056/NEJMoa053107; Jamerson K, 2008, NEW ENGL J MED, V359, P2417, DOI 10.1056/NEJMoa0806182; Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659; Krieger EM, 2018, HYPERTENSION, V71, P681, DOI 10.1161/HYPERTENSIONAHA.117.10662; Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9; Lamine F, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14282; Levey AS, 2011, KIDNEY INT, V80, P17, DOI 10.1038/ki.2010.483; Levin A, 2014, KIDNEY INT, V85, P49, DOI 10.1038/ki.2013.444; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lin CH, 2020, CHEST, V157, P673, DOI 10.1016/j.chest.2019.09.004; Mancia G, 2016, HYPERTENSION, V68, P1355, DOI 10.1161/HYPERTENSIONAHA.116.07703; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; McMahon EJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010070.pub2; McMahon EJ, 2013, J AM SOC NEPHROL, V24, P2096, DOI 10.1681/ASN.2013030285; Ogna A, 2016, SLEEP, V39, P945, DOI 10.5665/sleep.5660; Ogna VF, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14313; Ojji DB, 2019, NEW ENGL J MED, V380, P2429, DOI 10.1056/NEJMoa1901113; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Penne EL, 2009, J NEPHROL, V22, P208; Peralta CA, 2012, ARCH INTERN MED, V172, P41, DOI 10.1001/archinternmed.2011.619; Pogue V, 2009, HYPERTENSION, V53, P20, DOI 10.1161/HYPERTENSIONAHA.108.115154; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Rabi DM, 2020, CAN J CARDIOL, V36, P596, DOI 10.1016/j.cjca.2020.02.086; Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis-2019-215920; Sarafidis PA, 2018, J HYPERTENS, V36, P1076, DOI 10.1097/HJH.0000000000001670; Schmidt M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j791; Schmitt KE, 2010, AM J NEPHROL, V32, P541, DOI 10.1159/000321688; Siddiqui M, 2020, AM J HYPERTENS, V33, P741, DOI 10.1093/ajh/hpaa042; Singh RR, 2018, HYPERTENSION, V72, P528, DOI 10.1161/HYPERTENSIONAHA.118.10265; Sinha AD, 2016, J AM SOC HYPERTENS, V10, P288, DOI 10.1016/j.jash.2016.02.006; Stavropoulos K, 2020, J CLIN HYPERTENS, V22, P572, DOI 10.1111/jch.13827; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Taler SJ, 2013, AM J KIDNEY DIS, V62, P201, DOI 10.1053/j.ajkd.2013.03.018; Veelken R, 2014, NAT REV NEPHROL, V10, P305, DOI 10.1038/nrneph.2014.59; Vonend O, 2003, J HYPERTENS, V21, P1709, DOI 10.1097/00004872-200309000-00021; Weir MR, 2015, NEW ENGL J MED, V372, P211, DOI 10.1056/NEJMoa1410853; Wheeler DC, 2013, KIDNEY INT, V83, P377, DOI 10.1038/ki.2012.425; Whelton PK, 2017, JAMA-J AM MED ASSOC, V318, P2073, DOI 10.1001/jama.2017.18209; Williams B, 2018, J HYPERTENS, V36, P1953, DOI [10.1097/HJH.0000000000001940, 10.1714/3026.30245]; Williams B, 2015, LANCET, V386, P2059, DOI 10.1016/S0140-6736(15)00257-3; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Zanchi A, 1995, J HYPERTENS, V13, P1463; Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X	87	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						1	11		10.2147/VHRM.S292522			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	PS9SU	WOS:000608264200001	33442257	gold, Green Published			2022-04-27	
J	Rupoli, S; Fiorentini, A; Morsia, E; Svegliati-Baroni, G; Micucci, G; Maroni, L; Garvey, KB; Snr, AF; Riva, A; Da Lio, L; Benedetti, A; Offidani, M; Olivieri, A; Giuseppe, T				Rupoli, Serena; Fiorentini, Alessandro; Morsia, Erika; Svegliati-Baroni, Gianluca; Micucci, Giorgia; Maroni, Luca; Garvey, Kimberly Blaine; Snr, Alessandro Fiorentini, Sr.; Riva, Alessandra, Sr.; Da Lio, Lidia; Benedetti, Antonio; Offidani, Massimo; Olivieri, Attilio; Giuseppe, Tarantino			Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						splanchnic vein thrombosis; cirrhosis; anticoagulant therapy; vessel recanalization; multidisciplinary approach	DIRECT ORAL ANTICOAGULANTS; VASCULAR DISORDERS; MULTICENTER; OUTCOMES; SAFETY	Background and Aim: Splanchnic vein thrombosis (SVT) is a potentially life-threatening complication of liver cirrhosis. This study aimed to evaluate the impact of a multidisciplinary approach and early anticoagulation therapy (AT) on bleeding/thrombotic events, recanalization rates and outcome of cirrhotic patients with SVT. Methods: This is a single-center, registry-based cohort study. Over 17 years, 149 SVT patients were enrolled and prospectively evaluated. Regarding cirrhotic-SVT, a pre-specified algorithm, guiding initial posology of AT and follow-up visits schedule, was performed. Major bleeding (MB), thrombotic events, functional liver scores and all cause-mortality were investigated. Efficacy of AT was evaluated by radiological imaging. Results: In cirrhotic-SVT, the incidence rate of MB was 8.4 per 100 patient-year (95% CI, 3.83-15.97), while the incidence rate of thrombosis was 5.6 per 100 patient-year (95% CI, 2.05-12.2). In incidental SVT treated with AT, MB incidence was 6.5 per 100 patient-year (95% CI: 2.8-12.82), while in symptomatic SVT was 2.2 per 100 patient-year (95% CI: 0.25-8.02). All thrombotic recurrences occurred in incidental SVT (7.7 per 100 patient years; 95% CI, 3.71-14.26). Overall survival was significantly higher in patients who had at least a partial recanalization (p < 0.01) and partial/total recanalization was independently associated with improved MELD score at multivariate analysis (HR 2.62, 95% CI 1.1-6.47, p = 0.03). Conclusion: In cirrhotic SVT patients, partial or total resolution of thrombosis ameliorates liver function and is associated with higher overall survival. A multidisciplinary approach together with radiological follow-up at pre-fixed time improves patient selection and monitoring.	[Rupoli, Serena; Fiorentini, Alessandro; Morsia, Erika; Micucci, Giorgia; Garvey, Kimberly Blaine; Offidani, Massimo; Olivieri, Attilio] Clin Ematol, Dipartimento Med Interna, Ancona, Italy; [Svegliati-Baroni, Gianluca; Maroni, Luca; Benedetti, Antonio; Giuseppe, Tarantino] SOD Clin Gastroenterol Epatol & Endoscopia Digest, Ancona, Italy; [Snr, Alessandro Fiorentini, Sr.] Osped Riuniti Ancona, Sod Malattie Infett Emergenti & Immunodepressi, Ancona, Italy; [Riva, Alessandra, Sr.] SOD Clin Malattie Infett Tropicali, Parassitol, Epatiti Cron, Ancona, Italy; [Da Lio, Lidia] Osped Riuniti Ancona, SOD Med Lab, Ancona, Italy		Morsia, E (通讯作者)，Osped Riuniti Ancona, Clin Ematol, Via Conca 71, I-60126 Ancona, Italy.	erika.morsia@ospedaliriuniti.marche.it					Ageno W, 2012, J THROMB HAEMOST, V10, P158, DOI 10.1111/j.1538-7836.2011.04565.x; Ageno W, 2015, JAMA INTERN MED, V175, P1474, DOI 10.1001/jamainternmed.2015.3184; Ageno W, 2014, BLOOD, V124, P3685, DOI 10.1182/blood-2014-07-551515; Basili S, 2018, THER ADV GASTROENTER, V11, DOI 10.1177/1756284818793561; de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022; DeLeve LD, 2009, HEPATOLOGY, V49, P1729, DOI 10.1002/hep.22772; Flores Brisas, 2017, J Transl Sci, V3, DOI 10.15761/JTS.1000182; Garcia-Pagan JC, 2016, J HEPATOL, V64, P179, DOI 10.1016/j.jhep.2015.07.040; Hanafy AS, 2019, VASC PHARMACOL, V113, P86, DOI 10.1016/j.vph.2018.05.002; Intagliata NM, 2016, DIGEST DIS SCI, V61, P1721, DOI 10.1007/s10620-015-4012-2; Janczak DT, 2018, MAYO CLIN PROC, V93, P40, DOI 10.1016/j.mayocp.2017.10.007; Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301; Le W, 2020, ADV THER, V38, P495; Lisman T, 2010, BLOOD, V116, P878, DOI 10.1182/blood-2010-02-261891; Luca A, 2012, RADIOLOGY, V265, P124, DOI 10.1148/radiol.12112236; Myers K, 2018, MANUAL VENOUS LYMPHA, P13; Nagaoki Y, 2018, HEPATOL RES, V48, P51, DOI 10.1111/hepr.12895; Naymagon L, 2021, DIGEST DIS SCI, V66, P3619, DOI 10.1007/s10620-020-06695-4; Naymagon L, 2020, BLOOD ADV, V4, P655, DOI 10.1182/bloodadvances.2019001310; Nery F, 2015, HEPATOLOGY, V61, P660, DOI 10.1002/hep.27546; Qi XS, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1069-8; Riva N, 2015, J THROMB HAEMOST, V13, P1019, DOI 10.1111/jth.12930; Riva N, 2017, VASC MED, V22, P529, DOI 10.1177/1358863X17734057; Riva N, 2016, LANCET HAEMATOL, V3, pE267, DOI 10.1016/S2352-3026(16)30020-5; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Senzolo M, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0043-2; Senzolo M, 2011, DIGEST LIVER DIS, V43, P503, DOI 10.1016/j.dld.2010.11.006; Thatipelli MR, 2010, CLIN GASTROENTEROL H, V8, P200, DOI 10.1016/j.cgh.2009.09.019; Tripodi A, 2009, GASTROENTEROLOGY, V137, P2105, DOI 10.1053/j.gastro.2009.08.045; Tufano A, 2018, THROMB RES, V164, P69, DOI 10.1016/j.thromres.2018.02.143; Turco Laura, 2018, Curr Hepatol Rep, V17, P200, DOI 10.1007/s11901-018-0406-x; Valeriani E, 2019, VASC HEALTH RISK MAN, V15, P449, DOI 10.2147/VHRM.S197732; Villa E, 2012, GASTROENTEROLOGY, V143, P1253, DOI 10.1053/j.gastro.2012.07.018; Werner KT, 2013, DIGEST DIS SCI, V58, P1776, DOI 10.1007/s10620-012-2548-y; Xu SX, 2021, EUR J GASTROEN HEPAT, V33, pE423, DOI 10.1097/MEG.0000000000002123	35	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						619	629		10.2147/VHRM.S310615			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WK4QQ	WOS:000709712300001	34594107	Green Published, gold			2022-04-27	
J	Haile, K; Haile, A; Timerga, A				Haile, Kassahun; Haile, Admasu; Timerga, Abebe			Predictors of Lipid Profile Abnormalities Among Patients with Metabolic Syndrome in Southwest Ethiopia: A Cross-Sectional Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						metabolic syndrome; lipid profile abnormalities; Ethiopia	RISK-FACTORS; PREVALENCE; DYSLIPIDEMIA; PATHOPHYSIOLOGY	Background: Lipid profile abnormalities are an integral part of metabolic syndrome (MetS) and major underlying causes of cardiovascular disease (CVD) and type-2 diabetes mellitus (T2DM). Lipid profile abnormalities in a patient with MetS are resulted due to the presence of central obesity and insulin resistance. In Ethiopia, the burden and predictors of lipid profile abnormalities in a patient with MetS are not well known. Thus, this study aimed to determine the prevalence of lipid profile abnormalities and predictors among patients with MetS in southwest Ethiopia. Methods and Materials: A cross-sectional study was conducted among 381 patients with MetS from September to December 2019 with a response rate of 100%. A structured questionnaire was used to collect data on socio-demographic and behavioral factors. Waist circumference, height, weight, and blood pressures were measured. The venous blood sample was collected for glucose and lipid profile determination. Data were entered and analyzed by using SPSS version 21. Binary logistic regression and Pearson's correlation analyses were performed. A p-value was set at a <0.05 for statistical significance. Results: In this study, about 58% of participants were at least one or more lipid profile abnormalities with the 95% CI (52.8-62.7). About 67.2%, 44.6%,18.4%, and 14.2% of study participants were low HDL, high TG, LDL, and TC, respectively. Central obesity (adjusted odds ratio (AOR): 1.89, 95% CI: 1.14-3.14), increasing age (AOR: 2.08, 95% CI: 1.27-3.4), higher BMI (AOR: 2.06, 95% CI: 1.23-3.4), being hypertensive (AOR: 3.48, 95% CI: 2.125.7) and increasing blood glucose level (AOR: 2.34, 95% CI: 1.36-4.03) were independent predictors of lipid profile abnormalities (dyslipidemia). Conclusion: In this study area, a high (58%) prevalence of dyslipidemia was observed in study participants, and increasing age, higher BMI, central obesity, hypertension, and high blood glucose level were identified as independent predictors of dyslipidemia among patients with MetS. Prevention and control of dyslipidemia and its predictors among patients with MetS were recommended.	[Haile, Kassahun; Haile, Admasu] Wolkite Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, POB 07, Wolkite, Ethiopia; [Timerga, Abebe] Wolkite Univ, Coll Med & Hlth Sci, Dept Biomed Sci, Wolkite, Ethiopia		Haile, K (通讯作者)，Wolkite Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, POB 07, Wolkite, Ethiopia.	kassahaile07@gmail.com		Haile, Kassahun/0000-0002-2520-9244; HAILE, ADMASU/0000-0003-3445-0336			Alipour N, 2012, CLIN LIPIDOL, V7, P223, DOI 10.2217/CLP.12.13; Anwar A, 2018, PROF MED J, V25, P277; Bekel GE, 2020, INT J PUBLIC HLTH SC, V9, P46; Bekele S, 2017, DIABETES METAB SYNDR, V10, P265, DOI 10.2147/DMSO.S135064; Bello-Ovosi BO, 2019, PAN AFR MED J, V34, DOI 10.11604/pamj.2019.34.123.18717; Biadgo B, 2018, ETHIOP J HEALTH SCI, V28, P645, DOI 10.4314/ejhs.v28i5.16; Blaton VH, 2008, BIOCHEM MEDICA, V18, P14; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Devi SA, 2017, INT J CARD LIPID RES, V4, P6, DOI 10.15379/2410-2822.2017.04.01.02; dos Santos CM, 2013, REV PORT CARDIOL, V32, P35, DOI 10.1016/j.repc.2012.05.017; Elizabeth H, 2019, BMC PUBLIC HEALTH, V19, P1; Fiorentino M, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100650; Gebremichael GB, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4502-y; Gebreyes YF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194819; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Halpern A, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-55; Henry N, 2010, J Cardiometab Syndr, V4, P113; Jahangiry L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44486-8; Kiplagat SV., 2017, J ENDOCRINOL DIAB, V4, P1, DOI [10.15226/2374-6890/4/5/00190, DOI 10.15226/2374-6890/4/5/00190]; Kolovou GD, 2005, POSTGRAD MED J, V81, P358, DOI 10.1136/pgmj.2004.025601; Lee MK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59203-z; de Farias CRL, 2018, REV BRAS ENFERM, V71, P1013, DOI 10.1590/0034-7167-2016-0564; Mani P, 2018, DIABET METAB SYND OB, V11, P1; McCracken E, 2018, CLIN DERMATOL, V36, P14, DOI 10.1016/j.clindermatol.2017.09.004; Mohammadbeigi A, 2018, WORLD J MENS HEALTH, V36, P50, DOI 10.5534/wjmh.17014; Narindrarangkura P, 2019, BMC LIPIDS HLTH DIS, V3, P1; Natah TM, 2014, ADV NAT APPL SCI, V8, P25; Nolan Paul B, 2017, Prev Med Rep, V7, P211, DOI 10.1016/j.pmedr.2017.07.004; Osei-Yeboah James, 2017, Int J Chronic Dis, V2017, P8765804, DOI 10.1155/2017/8765804; Pokharel Daya Ram, 2017, BMC Res Notes, V10, P146, DOI 10.1186/s13104-017-2465-4; Qi L, 2015, INT J ENV RES PUB HE, V12, P13455, DOI 10.3390/ijerph121013455; Rochlani Y, 2017, THER ADV CARDIO DIS, V11, P215, DOI 10.1177/1753944717711379; Ruotolo Giacomo, 2002, Curr Cardiol Rep, V4, P494, DOI 10.1007/s11886-002-0113-6; Saklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-z; Samrawit SWM, 2019, BMC CARDIOVASC DISOR, V19, P1; Sergio LF, 2016, PLOS ONE, V11, P1; Singh O, 2015, NATL J PHYSL PHARM P, V5, P134, DOI [10.5455/njppp.2015.5.051120141, DOI 10.5455/NJPPP.2015.5.051120141]; Sison O, 2019, J ASEAN FED ENDOCR S, V34, P171, DOI 10.15605/jafes.034.02.08; Tadewos A, 2017, HLTH SCI J, V11, P1; Tamiru S, 2010, ETHIOP J HEALTH SCI, V20, P121; Thapa SD, 2017, J PATHOL NEPAL, V7, P1149, DOI DOI 10.3126/JPN.V7I2.17978; Tran A, 2011, INT J HYPERTENS, V2011, DOI 10.4061/2011/193719; Mohamud WNW, 2012, DIABETES RES CLIN PR, V96, P90, DOI [10.1016/j.diabres.2011.12.023, 10.1016/j.diabres.2011.11.020]; Wong-McClure RA, 2015, REV PANAM SALUD PUBL, V38, P202; World Health Organization, 2000, INT GUID MON ALC CON; Wube TB, 2020, J DIABETES ENDOCRINO, V11, P10, DOI [10.5897/JDE2019.0132, DOI 10.5897/JDE2019.0132]; Yang Z, 2017, PLOS ONE, V12, P1	47	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						461	469		10.2147/VHRM.S319161			9	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TX5ZX	WOS:000683169900002	34393487	Green Published, gold			2022-04-27	
J	Souza, HCD; Philbois, SV; Veiga, AC; Aguilar, BA				Souza, Hugo Celso Dutra; Philbois, Stella Vieira; Veiga, Ana Catarine; Aguilar, Bruno Augusto			Heart Rate Variability and Cardiovascular Fitness: What We Know so Far	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						heart rate variability; cardiovascular fitness	AUTONOMIC NERVOUS-SYSTEM; BLOOD-PRESSURE VARIABILITY; ROSTRAL VENTROLATERAL MEDULLA; NITRIC-OXIDE INHIBITION; ALL-CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; PHYSICAL-ACTIVITY; PARAVENTRICULAR NUCLEUS; SPECTRAL-ANALYSIS; VAGAL MODULATION	Fluctuation analysis in intervals between heartbeats provides important indices related to autonomic modulation of heart rate variability (HRV). These indices are considered predictors of morbidity and mortality as they are frequently altered in patients with chronic degenerative diseases, especially in those with cardiovascular and metabolic diseases. Similarly, a reduction in HRV is common with aging. In all cases, cardiovascular fitness is often reduced to below the predicted values. In turn, increases in cardiovascular fitness through regular physical exercise, especially aerobic exercise, represent an important ther-apeutic tool capable of promoting positive adjustments in cardiac autonomic modulation. These adjustments are characterized by reduced sympathetic modulatory influence and/or increased vagal modulatory influence on the heart, increasing the HRV. Therefore, several methodological tools have been used to assess the degree of impairment of autonomic modulation and the therapeutic effects of physical exercise. In contrast, establishment of strict protocols in experimental design is a main challenge in establishing HRV analysis as a robust parameter for evaluating cardiovascular homeostasis. Thus, this review aimed to contribute to the understanding of autonomic modulation of HRV and its relationship with cardiovascular fitness, highlighting the advances made thus far, the applicability of analysis tools, and the confounding factors observed frequently.	[Souza, Hugo Celso Dutra; Philbois, Stella Vieira; Veiga, Ana Catarine; Aguilar, Bruno Augusto] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Sao Paulo, Brazil		Souza, HCD (通讯作者)，Univ Sao Paulo, Ribeirao Preto Med Sch, Lab Exercise Physiol & Cardiovasc Physiotherapy, Ave Bandeirantes,3900 Vila Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.	hugocds@fmrp.usp.br	Philbois, Stella/AAZ-6110-2020; Veiga, Ana Catarine/AAA-2450-2022; Aguilar, Bruno/AAA-8126-2022; Souza, Hugo/C-5818-2012	Philbois, Stella/0000-0002-8276-1035; Veiga, Ana Catarine/0000-0003-2988-1393; Aguilar, Bruno Augusto/0000-0001-7292-733X; Souza, Hugo/0000-0002-0009-0005			Abhishekh HA, 2013, J CLIN MONIT COMPUT, V27, P259, DOI 10.1007/s10877-012-9424-3; Acanfora D, 2016, INT J CARDIOL, V225, P313, DOI 10.1016/j.ijcard.2016.10.026; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Albinet CT, 2010, EUR J APPL PHYSIOL, V109, P617, DOI 10.1007/s00421-010-1393-y; Allen J, 2011, CLIN GERIATR MED, V27, P661, DOI 10.1016/j.cger.2011.07.010; Antila K, 1979, Scand J Clin Lab Invest Suppl, P3; Arnold AC, 2014, AM J PHYSIOL-HEART C, V307, pH1539, DOI 10.1152/ajpheart.00282.2014; Baumert M, 2006, CLIN J SPORT MED, V16, P412, DOI 10.1097/01.jsm.0000244610.34594.07; Beckers F., 2001, CARDIOVASC ENG, V1, P177, DOI DOI 10.1023/A:1015212328405; Benichou T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195166; Besnier F, 2017, ANN PHYS REHABIL MED, V60, P27, DOI 10.1016/j.rehab.2016.07.002; Bhati P, 2019, CLIN AUTON RES, V29, P75, DOI 10.1007/s10286-018-0558-3; Bhati P, 2018, DIABETES METAB SYND, V12, P69, DOI 10.1016/j.dsx.2017.08.015; Bosquet L, 2007, EUR J APPL PHYSIOL, V100, P363, DOI 10.1007/s00421-007-0438-3; Brunner EJ, 2002, CIRCULATION, V106, P2659, DOI 10.1161/01.CIR.0000038364.26310.BD; Buchheit M, 2004, MED SCI SPORT EXER, V36, P601, DOI 10.1249/01.MSS.0000121956.76237.B5; Camm AJ, 1996, EUR HEART J, V17, P354; Carnethon MR, 2005, JAMA-J AM MED ASSOC, V294, P2981, DOI 10.1001/jama.294.23.2981; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Carthy ER, 2014, ANN MED SURG, V3, P2, DOI 10.1016/j.amsu.2013.11.002; Cha SA, 2018, DIABETES RES CLIN PR, V143, P159, DOI 10.1016/j.diabres.2018.07.001; Chen YF, 2018, J INT MED RES, V46, P3729, DOI 10.1177/0300060518778416; Cozza IC, 2012, HYPERTENS RES, V35, P82, DOI 10.1038/hr.2011.162; Dantas EM, 2018, PSYCHOPHYSIOLOGY, V55, DOI 10.1111/psyp.13052; Dart AM, 2002, CARDIOVASC RES, V53, P678, DOI 10.1016/S0008-6363(01)00508-9; Davy KP, 1998, CLIN SCI, V94, P579, DOI 10.1042/cs0940579; de Abreu SB, 2009, AUTON NEUROSCI-BASIC, V148, P28, DOI 10.1016/j.autneu.2009.02.007; de Almeida SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115970; De Meersman RE, 2007, BIOL PSYCHOL, V74, P165, DOI 10.1016/j.biopsycho.2006.04.008; Dorey TW, 2019, AUTON NEUROSCI-BASIC, V217, P66, DOI 10.1016/j.autneu.2019.01.004; Dupuy O, 2018, BRAIN COGNITION, V125, P127, DOI 10.1016/j.bandc.2018.06.003; Dutra SGV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077092; Earnest CP, 2012, J WOMENS HEALTH, V21, P334, DOI 10.1089/jwh.2011.2932; Eggenberger P, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00197; ESLER MD, 1995, AM J PHYSIOL-REG I, V268, pR278, DOI 10.1152/ajpregu.1995.268.1.R278; Facioli TP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83071-w; Facioli TP, 2018, BLOOD PRESS MONIT, V23, P260, DOI 10.1097/MBP.0000000000000338; Fang SC, 2020, BIOL RES NURS, V22, P45, DOI 10.1177/1099800419877442; Felix ACS, 2015, J APPL PHYSIOL, V118, P1276, DOI 10.1152/japplphysiol.00483.2014; Ferrari AU, 2003, J APPL PHYSIOL, V95, P2591, DOI 10.1152/japplphysiol.00601.2003; Floras JS, 2009, J AM COLL CARDIOL, V54, P375, DOI 10.1016/j.jacc.2009.03.061; Florea VG, 2014, CIRC RES, V114, P1815, DOI 10.1161/CIRCRESAHA.114.302589; Franz R, 2013, CLIMACTERIC, V16, P576, DOI 10.3109/13697137.2012.745123; Garet M, 2004, MED SCI SPORT EXER, V36, P2112, DOI 10.1249/01.MSS.0000147588.28955.48; Goit RK, 2018, INDIAN HEART J, V70, P486, DOI 10.1016/j.ihj.2017.10.003; Hautala AJ, 2003, AM J PHYSIOL-HEART C, V285, pH1747, DOI 10.1152/ajpheart.00202.2003; Hoffman JR, 2005, MED SCI SPORT EXER, V37, P1237, DOI 10.1249/01.mss.0000170068.97498.26; HON EH, 1963, AM J OBSTET GYNECOL, V87, P814; Huikuri HV, 1996, AM J CARDIOL, V77, P1073, DOI 10.1016/S0002-9149(96)00135-X; IWASE S, 1991, J GERONTOL, V46, pM1, DOI 10.1093/geronj/46.1.M1; Jabbour G, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.654695; Jarczok MN, 2013, INT J CARDIOL, V167, P855, DOI 10.1016/j.ijcard.2012.02.002; Jia LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085481; Kaikkonen KM, 2014, J PHYS ACT HEALTH, V11, P1614, DOI 10.1123/jpah.2012-0405; Kam KWL, 2004, J PHARMACOL EXP THER, V309, P8, DOI 10.1124/jpet.103.058339; Kaminsky LA, 2019, PROG CARDIOVASC DIS, V62, P86, DOI 10.1016/j.pcad.2019.01.002; Kangas P, 2019, CLIN PHYSIOL FUNCT I, V39, P160, DOI 10.1111/cpf.12551; Kingsley JD, 2016, CLIN PHYSIOL FUNCT I, V36, P179, DOI 10.1111/cpf.12223; Kingwell BA, 2000, CLIN EXP PHARMACOL P, V27, P239, DOI 10.1046/j.1440-1681.2000.03232.x; Kirwan JP, 2017, CLEV CLIN J MED, V84, pS15, DOI 10.3949/ccjm.84.s1.03; Kishi T, 2012, CLIN EXP HYPERTENS, V34, P278, DOI 10.3109/10641963.2012.681084; Kiviniemi AM, 2006, EUR J APPL PHYSIOL, V96, P686, DOI 10.1007/s00421-005-0130-4; Kiviniemi AM, 2007, EUR J APPL PHYSIOL, V101, P743, DOI 10.1007/s00421-007-0552-2; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; Koba S, 2018, YONAGO ACTA MED, V61, P103, DOI 10.33160/yam.2018.06.002; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Koenig J, 2015, J NUTR HEALTH AGING, V19, P879, DOI 10.1007/s12603-015-0508-x; Kramer KM, 2000, BRAIN RES BULL, V53, P77; Kurajoh M, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0280-6; Lambert EA, 2015, AM J PHYSIOL-HEART C, V309, pH244, DOI 10.1152/ajpheart.00096.2015; Lavi S, 2007, AM J PHYSIOL-REG I, V292, pR788, DOI 10.1152/ajpregu.00352.2006; Lee DC, 2011, BRIT J SPORT MED, V45, P504, DOI 10.1136/bjsm.2009.066209; Leosco D, 2008, CARDIOVASC RES, V78, P385, DOI 10.1093/cvr/cvm109; MacDonnell SM, 2005, CIRCULATION, V111, P3420, DOI 10.1161/CIRCULATIONAHA.104.505784; Maida KD, 2017, AUTON NEUROSCI-BASIC, V203, P33, DOI 10.1016/j.autneu.2016.12.002; MALIK M, 1989, EUR HEART J, V10, P1060, DOI 10.1093/oxfordjournals.eurheartj.a059428; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; MALPAS SC, 1992, J AUTONOM NERV SYST, V40, P189, DOI 10.1016/0165-1838(92)90200-Z; Mancia G, 2014, CIRC RES, V114, P1804, DOI 10.1161/CIRCRESAHA.114.302524; Martins-Pinge MC, 2005, AUTON NEUROSCI-BASIC, V122, P21, DOI 10.1016/j.autneu.2005.07.007; Masson GS, 2015, AM J PHYSIOL-HEART C, V309, pH1115, DOI 10.1152/ajpheart.00349.2015; Mastelari RB, 2011, BRAIN RES, V1375, P68, DOI 10.1016/j.brainres.2010.12.049; Matos FD, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00051; Mazon J, 2013, SCAND J MED SCI SPOR, V23, P114, DOI 10.1111/j.1600-0838.2011.01357.x; McKune AJ, 2017, ARCH GERONTOL GERIAT, V70, P130, DOI 10.1016/j.archger.2017.01.012; Melo RC, 2005, BRAZ J MED BIOL RES, V38, P1331, DOI 10.1590/S0100-879X2005000900007; Meyer M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119432; Miao CY, 2006, J HYPERTENS, V24, P1125, DOI 10.1097/01.hjh.0000226203.57818.88; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; MURRAY A, 1975, BRIT HEART J, V37, P882; Myers J, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003780; Neves VFC, 2007, BRAZ J MED BIOL RES, V40, P491, DOI 10.1590/S0100-879X2006005000080; NG AV, 1993, HYPERTENSION, V21, P498, DOI 10.1161/01.HYP.21.4.498; Nohara K, 2013, AM J PHYSIOL-ENDOC M, V304, pE1321, DOI 10.1152/ajpendo.00620.2012; Pagkalos M, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.035303; Palatini P, 2009, CURR HYPERTENS REP, V11, P199, DOI 10.1007/s11906-009-0035-4; Paneni F, 2017, J AM COLL CARDIOL, V69, P1952, DOI 10.1016/j.jacc.2017.01.064; Paolisso G, 2000, J CLIN ENDOCR METAB, V85, P1810, DOI 10.1210/jc.85.5.1810; Papaioannou V, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00174; Parati G, 1997, Blood Press Suppl, V2, P91; Parati G, 1997, HYPERTENSION, V30, P803, DOI 10.1161/01.HYP.30.4.803; Parati G, 2006, J APPL PHYSIOL, V101, P676, DOI 10.1152/japplphysiol.00446.2006; Park HY, 2020, J OBES METAB SYNDR, V29, P67, DOI 10.7570/jomes19063; Pearson MJ, 2017, INT J CARDIOL, V231, P234, DOI 10.1016/j.ijcard.2016.12.145; Perciaccante Antonio, 2006, BMC Cardiovasc Disord, V6, P19, DOI 10.1186/1471-2261-6-19; Perini R, 2002, MED SCI SPORT EXER, V34, P700, DOI 10.1097/00005768-200204000-00022; Philbois SV, 2021, BIOL SEX DIFFER, V12, DOI 10.1186/s13293-020-00355-y; Picard M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251863; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; Porta A, 2007, AM J PHYSIOL-HEART C, V293, pH702, DOI 10.1152/ajpheart.00006.2007; Radak Z, 2019, FREE RADICAL BIO MED, V132, P33, DOI 10.1016/j.freeradbiomed.2018.10.444; Raffin J, 2019, SPORTS MED, V49, P719, DOI 10.1007/s40279-019-01097-7; Reland S, 2003, J GERONTOL A-BIOL, V58, P585; Ribeiro TF, 2001, BRAZ J MED BIOL RES, V34, P871, DOI 10.1590/S0100-879X2001000700006; Routledge FS, 2010, CAN J CARDIOL, V26, P303, DOI 10.1016/S0828-282X(10)70395-0; RUBIN PC, 1982, EUR J CLIN INVEST, V12, P121, DOI 10.1111/j.1365-2362.1982.tb00948.x; Sakurai T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9410954; Saleh MC, 2000, BRAIN RES, V879, P105, DOI 10.1016/S0006-8993(00)02757-8; Santa-Rosa FA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69104-w; SHEPHERD JT, 1990, J HYPERTENS, V8, pS15; Sherwood A, 2010, MENOPAUSE, V17, P403, DOI 10.1097/gme.0b013e3181b9b061; Shin K, 1997, MED SCI SPORT EXER, V29, P1482, DOI 10.1097/00005768-199711000-00015; Smart Neil A, 2011, Congest Heart Fail, V17, P110, DOI 10.1111/j.1751-7133.2011.00217.x; Soares-Miranda L, 2014, CIRCULATION, V129, P2100, DOI 10.1161/CIRCULATIONAHA.113.005361; Soares-Miranda L, 2009, EUR J CARDIOV PREV R, V16, P705, DOI 10.1097/HJR.0b013e3283316cd1; Sollers John J. III, 2005, V41, P43; Souza HCD, 2013, AGING DIS, V4, P320, DOI 10.14336/AD.2013.0400320; Sridhar B, 2010, TOHOKU J EXP MED, V220, P107, DOI 10.1620/tjem.220.107; Stauss HM, 2007, CLIN EXP PHARMACOL P, V34, P362, DOI 10.1111/j.1440-1681.2007.04588.x; Sugawara J, 2007, AM J PHYSIOL-HEART C, V293, pH1466, DOI 10.1152/ajpheart.00273.2007; Sverrisdottir YB, 2008, AM J PHYSIOL-ENDOC M, V294, pE576, DOI 10.1152/ajpendo.00725.2007; Tanaka H, 2000, CIRCULATION, V102, P1270, DOI 10.1161/01.CIR.102.11.1270; Tezini GCSV, 2013, EXP GERONTOL, V48, P147, DOI 10.1016/j.exger.2012.11.009; Thawornkaiwong A, 2003, LIFE SCI, V72, P1813, DOI 10.1016/S0024-3205(02)02473-6; Thayer JF, 2010, INT J CARDIOL, V141, P122, DOI 10.1016/j.ijcard.2009.09.543; Tian Y, 2015, PHYSIOL BEHAV, V151, P308, DOI 10.1016/j.physbeh.2015.07.038; TOWNEND JN, 1995, HYPERTENSION, V25, P1270, DOI 10.1161/01.HYP.25.6.1270; TSUJI H, 1994, CIRCULATION, V90, P878, DOI 10.1161/01.CIR.90.2.878; Tulppo MP, 2003, J APPL PHYSIOL, V95, P364, DOI 10.1152/japplphysiol.00751.2002; Ueno LM, 2002, J GERONTOL A-BIOL, V57, pM605, DOI 10.1093/gerona/57.9.M605; VEERMAN DP, 1994, HYPERTENSION, V24, P120, DOI 10.1161/01.HYP.24.1.120; Verheyden B, 2006, J SPORT SCI, V24, P1137, DOI 10.1080/02640410500497634; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Wegeberg AML, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3590389; WIELING W, 1982, DIABETOLOGIA, V22, P163, DOI 10.1007/BF00283745; WOLF MM, 1978, MED J AUSTRALIA, V2, P52, DOI 10.5694/j.1326-5377.1978.tb131339.x; Wu HT, 2018, BIOMED ENG ONLINE, V17, DOI 10.1186/s12938-018-0490-8; Yataco AR, 1997, AM J CARDIOL, V80, P1389, DOI 10.1016/S0002-9149(97)00697-8; Yperzeele L, 2015, INT J STROKE, V10, P796, DOI 10.1111/ijs.12573; Zanchi NE, 2008, EUR J APPL PHYSIOL, V104, P1045, DOI 10.1007/s00421-008-0861-0; Zekios KC, 2021, J CARDIOVASC DEV DIS, V8, DOI 10.3390/jcdd8050057; Zheng H, 2005, AM J PHYSIOL-HEART C, V288, pH2332, DOI 10.1152/ajpheart.00473.2004; Zucker IH, 2015, AM J PHYSIOL-HEART C, V308, pH781, DOI 10.1152/ajpheart.00026.2015	153	0	0	5	5	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						701	711		10.2147/VHRM.S279322			11	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WY9DD	WOS:000719576700001	34803382	gold, Green Published			2022-04-27	
J	Balanis, T; Sanner, B				Balanis, Thomas; Sanner, Bernd			Detection of Atrial Fibrillation Using a Home Blood Pressure Monitor	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						atrial fibrillation detection; blood pressure measurement; Omron BP785N	RISK-FACTORS; HYPERTENSION; ACCURACY; HEART; ELECTROCARDIOGRAM; SPHYGMOMANOMETER; POPULATION; PREVENTION; SOCIETY; WATCH	Purpose: Atrial fibrillation (AF) is the most common arrhythmia and is associated with an increased risk of complications. A screening test has the potential to prevent AF-related complications. This study investigated the diagnostic accuracy of an automated device for home blood pressure (BP) monitoring, which implements an algorithm for AF detection. Patients and Methods: A modified, automated oscillometric device for home BP monitoring (Omron BP785N (HEM-7321-Z), Omron Healthcare) with an AF detector was used to measure the BP in patients. During each BP measurements, the electrocardiogram (ECG) was recorded simultaneously. Simultaneous BP measurements and ECG recordings were obtained from 99 subjects. Results: Twenty out of 20 patients with atrial fibrillation were correctly recognized by the device and the device correctly identified 67 patients with sinus rhythm as "Not-AF". On the other hand, 12 patients with basic rhythm: sinus rhythm were incorrectly referred to as "atrial fibrillation". In summary, the device has a diagnostic accuracy of 87.88% with a sensitivity of 100% and a specificity of 84.8%. On the other hand, in 23 patients, the raw data of the device showed that a body movement occurred during the measurement of the blood pressure. If these subjects were excluded of the analysis, then the diagnostic accuracy of the device would be even better, namely 90.79%. The sensitivity would be 100% and the specificity 89.5%. Conclusion: These data suggest that an automated device for home blood pressure has an excellent diagnostic accuracy for detecting an AF and could be used as a reliable screening test for early diagnosis of atrial fibrillation. Body movements have an impact of the accuracy and specificity of a blood pressure monitor.	[Balanis, Thomas; Sanner, Bernd] Agaples Bethesda Hosp, Internal Med, Wuppertal, Germany		Balanis, T (通讯作者)，Agaples Bethesda Hosp, Internal Med, Wuppertal, Germany.	thomasmpalanis@gmail.com					Alves-Cabratosa L, 2015, HYPERTENSION, V65, P1180, DOI 10.1161/HYPERTENSIONAHA.115.05198; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Benjamin EJ, 2009, CIRCULATION, V119, P606, DOI 10.1161/CIRCULATIONAHA.108.825380; Carpenter A, 2016, EUROPACE, V18, P791, DOI 10.1093/europace/euv427; Dorr M, 2019, JACC-CLIN ELECTROPHY, V5, P199, DOI 10.1016/j.jacep.2018.10.006; Fitzmaurice DA, 2007, BRIT MED J, V335, P383, DOI 10.1136/bmj.39280.660567.55; Gladstone DJ, 2014, NEW ENGL J MED, V370, P2467, DOI 10.1056/NEJMoa1311376; Huxley RR, 2011, CIRCULATION, V123, P1501, DOI [10.1161/CIRCULATIONAHA.110.009035, 10.1161/circulationaha.110.009035]; Jani B, 2006, J HUM HYPERTENS, V20, P543, DOI 10.1038/sj.jhh.1002016; Kirchhof P, 2016, EUR J CARDIO-THORAC, V50, pE1, DOI 10.1093/ejcts/ezw313; Lau YF, 2012, J HUM HYPERTENS, V26, P563, DOI 10.1038/jhh.2011.105; Mairesse GH, 2017, EUROPACE, V19, P1589, DOI 10.1093/europace/eux177; Manolis AJ, 2012, J HYPERTENS, V30, P239, DOI 10.1097/HJH.0b013e32834f03bf; Mant J, 2007, BMJ-BRIT MED J, V335, P380, DOI 10.1136/bmj.39227.551713.AE; Munschauer Frederick E 3rd, 2004, J Stroke Cerebrovasc Dis, V13, P208, DOI 10.1016/j.jstrokecerebrovasdis.2004.08.001; Nabauer M, 2009, EUROPACE, V11, P423, DOI 10.1093/europace/eun369; Rabkin SW, 2015, CAN J CARDIOL, V31, P576, DOI 10.1016/j.cjca.2015.03.022; Seshadri DR, 2020, CIRCULATION, V141, P702, DOI 10.1161/CIRCULATIONAHA.119.044126; Stergiou GS, 2009, J HUM HYPERTENS, V23, P654, DOI 10.1038/jhh.2009.5; Verdecchia P, 2012, HYPERTENSION, V59, P184, DOI 10.1161/HYPERTENSIONAHA.111.187260; Wachter R, 2017, LANCET NEUROL, V16, P282, DOI 10.1016/S1474-4422(17)30002-9; Watson T, 2006, J HUM HYPERTENS, V20, P638, DOI 10.1038/sj.jhh.1002031; Wiesel J, 2004, PACE, V27, P639, DOI 10.1111/j.1540-8159.2004.00499.x; Wiesel J, 2008, J CLIN HYPERTENS, V10, pA84; Zheng D, 2012, J HUM HYPERTENS, V26, P458, DOI 10.1038/jhh.2011.53	25	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						407	414		10.2147/VHRM.S317859			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TH8NT	WOS:000672341100001	34285495	gold, Green Published			2022-04-27	
J	Charoensri, S; Turnsaket, S; Pongchaiyakul, C				Charoensri, Suranut; Turnsaket, Supatida; Pongchaiyakul, Chatlert			Hypertriglyceridemia as an Independent Predictor for Ten-Year Incidence of Diabetes in Thais	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypertriglyceridemia; predictor; diabetes; incidence	RISK; TRIGLYCERIDES; MANAGEMENT	Background: Fasting hypertriglyceridemia commonly associates with insulin resistance and is frequently prevalent in type 2 diabetes mellitus (DM). However, hypertriglyceridemia has not been investigated as an independent predictor of incidence of DM, especially in Thais. Methods: A 10-year hospital-based retrospective cohort study was conducted in a tertiary care setting in Thailand. Health check-up data in 2007 from healthy participants without underlying disease were extracted as baseline data. In 2017, 10 years following an initial examination, the diagnosis of DM and other laboratory data were identified. Hypertriglyceridemia was defined as fasting triglyceride level >= 150 mg/dL. A generalized additive model (GAM) was applied to demonstrate a relationship between fasting TG level and probability of incident DM in 10 years. An association between hypertriglyceridemia and 10-year incidence of DM was evaluated using univariable and multivariable logistic regression analysis. Results: A total of 1342 non-diabetic adults with complete both baseline and 10-year follow-up data were included in the analysis. The incidence of DM in the study period was 10.3%. Baseline fasting triglyceride level is significantly higher in participants with incidence of DM, with a median difference of 45 mg/dL (P < 0.01). Univariable logistic regression showed that hypertriglyceridemia was associated with 10-year incidence of DM (odds ratio (OR) 3.03, 95% CI 2.12-4.35). After adjusting for potential confounders, hypertriglyceridemia remained significantly associated with incidence of DM (OR 2.33, 95% CI 1.61-3.39). Conclusion: Fasting triglyceride level is an independent risk factor for the development of new-onset DM. Testing for hypertriglyceridemia in people without diabetes may be an alternative screening tool to identify populations at risk of developing future DM, as well as providing triglyceride as a new target for DM risk reduction.	[Charoensri, Suranut; Pongchaiyakul, Chatlert] Khon Kaen Univ, Div Endocrinol & Metab, Dept Med, Fac Med, Khon Kaen 40002, Thailand; [Turnsaket, Supatida] Khon Kaen Univ, Dept Med, Fac Med, Khon Kaen, Thailand		Pongchaiyakul, C (通讯作者)，Khon Kaen Univ, Div Endocrinol & Metab, Dept Med, Fac Med, Khon Kaen 40002, Thailand.	pchatl@kku.ac.th					Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s011, 10.2337/dc12-s004]; Armstrong C, 2013, AM FAM PHYSICIAN, V88, P142; Berglund L, 2012, J CLIN ENDOCR METAB, V97, P2969, DOI 10.1210/jc.2011-3213; Carretero OA, 2000, CIRCULATION, V101, P329, DOI 10.1161/01.CIR.101.3.329; Chen CL, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.610322; Cui J, 2017, ONCOTARGET, V8, P103477, DOI 10.18632/oncotarget.21969; Dotevall A, 2004, DIABETIC MED, V21, P615, DOI 10.1111/j.1464-5491.2004.01189.x; Grundy SM, 1999, AM J CARDIOL, V83, p25F; Hjellvik Vidar, 2012, Clin Epidemiol, V4, P213, DOI 10.2147/CLEP.S31830; International Diabetes Federation, 2015, IDF DIABETES ATLAS, V7th; Kametani T, 2002, INTERNAL MED, V41, P516, DOI 10.2169/internalmedicine.41.516; Kwon YH, 2018, ENDOCRINOL METAB, V33, P55, DOI 10.3803/EnM.2018.33.1.55; Leon BM, 2015, WORLD J DIABETES, V6, P1246, DOI 10.4239/wjd.v6.i13.1246; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lin CF, 2018, INT J GERONTOL, V12, P2, DOI 10.1016/j.ijge.2018.02.010; Ma ML, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-01303-w; McLaughlin T, 2003, ANN INTERN MED, V139, P802, DOI 10.7326/0003-4819-139-10-200311180-00007; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843; Stevens PE, 2013, ANN INTERN MED, V158, P825, DOI 10.7326/0003-4819-158-11-201306040-00007; Suwannaphant K, 2017, J CLIN DIAGN RES, V11, pLC18, DOI 10.7860/JCDR/2017/28221.10286; Thai National Health Examination Survey V Study Group, 2016, THAI NATL HLTH EXAMI; Tirosh A, 2008, DIABETES CARE, V31, P2032, DOI 10.2337/dc08-0825; Zhao J, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02156-3	26	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						519	525		10.2147/VHRM.S326500			7	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UK0LS	WOS:000691667600001	34511921	gold, Green Published			2022-04-27	
J	Korosoglou, G; Giusca, S; Andre, F; Siepen, FAD; Nunninger, P; Kristen, AV; Frey, N				Korosoglou, Grigorios; Giusca, Sorin; Andre, Florian; Siepen, Fabian Aus Dem; Nunninger, Peter; Kristen, Arnt, V; Frey, Norbert			Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						cardiac amyloidosis; ATTR amyloidosis; AL amyloidosis; echocardiography; cardiac magnetic resonance; bone scintigraphy; myocardial biopsy; specific therapy	LATE GADOLINIUM ENHANCEMENT; LIGHT-CHAIN AMYLOIDOSIS; SPECKLE-TRACKING ECHOCARDIOGRAPHY; MAGNETIC-RESONANCE; VENTRICULAR-FUNCTION; PREDICTING SURVIVAL; PROGNOSTIC UTILITY; MYOCARDIAL TISSUE; NATURAL-HISTORY; AORTIC-STENOSIS	Among non-ischemic cardiomyopathies, cardiac amyloidosis is one of the most common, being caused by extracellular depositions of amyloid fibrils in the myocardium. Two main forms of cardiac amyloidosis are known so far, including 1) light-chain (AL) amyloidosis caused by monoclonal production of light-chains, and 2) transthyretin (ATTR) amyloidosis, caused by dissociation of the transthyretin tetramer into monomers. Both AL and ATTR amyloidosis are progressive diseases with median survival from diagnosis of less than 6 months and 3 to 5 years, respectively, if untreated. In this regard, death occurs in most patients due to cardiac causes, mainly congestive heart failure, which can be prevented due to the presence of effective, life-saving treatment regimens. Therefore, early diagnosis of cardiac amyloidosis is crucial more than ever. However, diagnosis of cardiac amyloidosis may be challenging due to variable clinical manifestations and the perceived rarity of the disease. In this regard, clinical and laboratory reg flags are available, which may help clinicians to raise suspicion of cardiac amyloidosis. In addition, advances in cardiovascular imaging have already revealed a higher prevalence of cardiac amyloidosis in specific populations, so that the diagnosis especially of ATTR amyloidosis has experienced a >30-fold increase during the past ten years. The goal of our review article is to summarize these findings and provide a practical approach for clinicians on how to use cardiovascular imaging techniques, such as echocardiography, cardiac magnetic resonance, bone scintigraphy and, if required, organ biopsy within predefined diagnostic algorithms for the diagnostic work-up of patients with suspected cardiac amyloidosis. In addition, two clinical cases and practical tips are provided in this context.	[Korosoglou, Grigorios; Giusca, Sorin] GRN Hosp Weinheim, Dept Cardiol Vasc Med & Pneumol, Roentgenstr 1, D-69469 Weinheim, Germany; [Giusca, Sorin] Hector Fdn, Cardiac Imaging Ctr Weinheim, Weinheim, Germany; [Andre, Florian; Siepen, Fabian Aus Dem; Kristen, Arnt, V; Frey, Norbert] Univ Hosp Heidelberg, Dept Cardiol Pneumol & Angiol, Heidelberg, Germany; [Andre, Florian; Siepen, Fabian Aus Dem; Frey, Norbert] German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg, Heidelberg, Germany; [Nunninger, Peter] Radiol & Nucl Med Weinheim, Weinheim, Germany; [Kristen, Arnt, V] Cardiovasc Ctr Darmstadt, Darmstadt, Germany		Korosoglou, G (通讯作者)，GRN Hosp Weinheim, Dept Cardiol Vasc Med & Pneumol, Roentgenstr 1, D-69469 Weinheim, Germany.	gkorosoglou@hotmail.com	Frey, Norbert/M-7749-2019	Frey, Norbert/0000-0001-7611-378X; Korosoglou, Grigorios/0000-0002-6038-2253			AlJaroudi WA, 2014, J NUCL CARDIOL, V21, P271, DOI 10.1007/s12350-013-9800-5; Austin BA, 2009, JACC-CARDIOVASC IMAG, V2, P1369, DOI 10.1016/j.jcmg.2009.08.008; Banypersad SM, 2013, CIRC-CARDIOVASC IMAG, V6, P34, DOI 10.1161/CIRCIMAGING.112.978627; Barros-Gomes S, 2017, JACC-CARDIOVASC IMAG, V10, P398, DOI 10.1016/j.jcmg.2016.04.008; Bhatti S, 2016, EUR HEART J-CARD IMG, V17, P970, DOI 10.1093/ehjci/jew101; Bokhari S, 2013, CIRC-CARDIOVASC IMAG, V6, P195, DOI 10.1161/CIRCIMAGING.112.000132; Boynton SJ, 2016, JACC-CARDIOVASC IMAG, V9, P680, DOI 10.1016/j.jcmg.2015.10.027; Brahmanandam V, 2014, CIRCULATION, V129, P2326, DOI 10.1161/CIRCULATIONAHA.114.009135; Bravo PE, 2019, JACC-CARDIOVASC IMAG, V12, P1165, DOI 10.1016/j.jcmg.2018.06.016; Brownrigg J, 2019, ESC HEART FAIL, V6, P1041, DOI 10.1002/ehf2.12511; Buss SJ, 2012, J AM COLL CARDIOL, V60, P1067, DOI 10.1016/j.jacc.2012.04.043; Cacciapuoti F, 2015, J ECHOCARDIOGR, V13, P84, DOI 10.1007/s12574-015-0249-1; Castano A, 2017, EUR HEART J, V38, P2879, DOI 10.1093/eurheartj/ehx350; Castano A, 2016, JAMA CARDIOL, V1, P880, DOI 10.1001/jamacardio.2016.2839; Castano A, 2015, HEART FAIL REV, V20, P163, DOI 10.1007/s10741-014-9462-7; Chang ICY, 2018, CIRC-CARDIOVASC IMAG, V11, DOI 10.1161/CIRCIMAGING.117.007059; Chatzantonis G, 2021, CLIN RES CARDIOL, V110, P555, DOI 10.1007/s00392-020-01771-1; Coelho T, 2016, NEUROL THER, V5, P1, DOI 10.1007/s40120-016-0040-x; Damy T, 2016, EUR HEART J, V37, P1826, DOI 10.1093/eurheartj/ehv583; Dass S, 2012, CIRC-CARDIOVASC IMAG, V5, P726, DOI 10.1161/CIRCIMAGING.112.976738; Dorbala S, 2014, EUR J NUCL MED MOL I, V41, P1652, DOI 10.1007/s00259-014-2787-6; Duca F, 2018, JACC-CARDIOVASC IMAG, V11, P1924, DOI 10.1016/j.jcmg.2018.06.010; Dungu JN, 2014, JACC-CARDIOVASC IMAG, V7, P133, DOI 10.1016/j.jcmg.2013.08.015; Fontana M, 2021, JACC-CARDIOVASC IMAG, V14, P189, DOI 10.1016/j.jcmg.2020.07.043; Fontana M, 2015, CIRCULATION, V132, P1570, DOI 10.1161/CIRCULATIONAHA.115.016567; Fontana M, 2014, JACC-CARDIOVASC IMAG, V7, P157, DOI 10.1016/j.jcmg.2013.10.008; Gertz MA, 2005, AM J HEMATOL, V79, P319, DOI 10.1002/ajh.20381; Gillmore JD, 2018, EUR HEART J, V39, P2799, DOI 10.1093/eurheartj/ehx589; Gillmore JD, 2016, CIRCULATION, V133, P2404, DOI 10.1161/CIRCULATIONAHA.116.021612; Giusca S, 2021, J CARDIOVASC MAGN R, V23, DOI 10.1186/s12968-021-00775-8; GLENNER GG, 1971, SCIENCE, V172, P1150, DOI 10.1126/science.172.3988.1150; Gonzalez-Lopez E, 2015, EUR HEART J, V36, P2585, DOI 10.1093/eurheartj/ehv338; Grogan M, 2016, J AM COLL CARDIOL, V68, P1014, DOI 10.1016/j.jacc.2016.06.033; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hosch W, 2007, INVEST RADIOL, V42, P636, DOI 10.1097/RLI.0b013e318059e021; Karamitsos TD, 2013, JACC-CARDIOVASC IMAG, V6, P488, DOI 10.1016/j.jcmg.2012.11.013; KLEIN AL, 1990, J AM COLL CARDIOL, V16, P1135, DOI 10.1016/0735-1097(90)90545-Z; Korosoglou G, 2021, JACC-CARDIOVASC IMAG, V14, P1177, DOI 10.1016/j.jcmg.2020.10.024; Korosoglou G, 2019, ESC HEART FAIL, V6, P584, DOI 10.1002/ehf2.12442; Korosoglou G, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00291; Korosoglou G, 2010, J AM COLL CARDIOL, V56, P1225, DOI 10.1016/j.jacc.2010.06.020; Kristen AV, 2015, AMYLOID, V22, P132, DOI 10.3109/13506129.2015.1020153; Kristen AV, 2010, CARDIOVASC PATHOL, V19, P228, DOI 10.1016/j.carpath.2009.04.005; Lee SP, 2015, JACC-CARDIOVASC IMAG, V8, P50, DOI 10.1016/j.jcmg.2014.09.018; Liu D, 2013, CIRC-CARDIOVASC IMAG, V6, P1066, DOI 10.1161/CIRCIMAGING.113.000683; Liu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056923; Maceira AM, 2005, CIRCULATION, V111, P186, DOI 10.1161/01.CIR.0000152819.97857.9D; Maron BJ, 2006, CIRCULATION, V113, P1807, DOI 10.1161/CIRCULATIONAHA.106.174287; Martinez-Naharro A, 2019, JACC-CARDIOVASC IMAG, V12, P810, DOI 10.1016/j.jcmg.2018.02.006; Martinez-Naharro A, 2017, J AM COLL CARDIOL, V70, P466, DOI 10.1016/j.jacc.2017.05.053; Maurer MS, 2018, NEW ENGL J MED, V379, P1007, DOI 10.1056/NEJMoa1805689; Maurer MS, 2016, J AM COLL CARDIOL, V68, P161, DOI 10.1016/j.jacc.2016.03.596; Maurizi N, 2020, INT J CARDIOL, V300, P191, DOI 10.1016/j.ijcard.2019.07.051; McKenna WJ, 2017, CIRC RES, V121, P722, DOI 10.1161/CIRCRESAHA.117.309711; Merlini G, 2013, HAEMATOLOGICA, V98, P1492, DOI 10.3324/haematol.2013.094482; Mesquita ET, 2017, ARQ BRAS CARDIOL, V109, P71, DOI 10.5935/abc.20170079; Messroghli DR, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0389-8; Minutoli F, 2013, AM J ROENTGENOL, V200, pW256, DOI 10.2214/AJR.12.8737; Mohty D, 2013, ARCH CARDIOVASC DIS, V106, P528, DOI 10.1016/j.acvd.2013.06.051; Mongeon FP, 2012, JACC-CARDIOVASC IMAG, V5, P897, DOI 10.1016/j.jcmg.2012.04.006; Musumeci MB, 2020, JACC-CARDIOVASC IMAG, V13, P1314, DOI 10.1016/j.jcmg.2019.10.015; Nijst Petra, 2021, Fac Rev, V10, P31, DOI 10.12703/r/10-31; Oda S, 2017, CIRC J, V81, P1014, DOI 10.1253/circj.CJ-16-1259; Oghina Silvia, 2021, JACC Heart Fail, V9, P169, DOI 10.1016/j.jchf.2020.12.005; Pan JA, 2020, JACC-CARDIOVASC IMAG, V13, P1299, DOI 10.1016/j.jcmg.2020.03.010; Perugini E, 2005, J AM COLL CARDIOL, V46, P1076, DOI 10.1016/j.jacc.2005.05.073; Phelan D, 2012, HEART, V98, P1442, DOI 10.1136/heartjnl-2012-302353; PICANO E, 1991, ECHOCARDIOGR-J CARD, V8, P253, DOI 10.1111/j.1540-8175.1991.tb01395.x; Pilebro B, 2016, UPSALA J MED SCI, V121, P17, DOI 10.3109/03009734.2015.1122687; Poterucha TJ, 2021, JACC-CARDIOVASC IMAG, V14, P2042, DOI 10.1016/j.jcmg.2021.04.006; Quarta CC, 2017, EUR HEART J, V38, P1905, DOI 10.1093/eurheartj/ehx047; Rapezzi C, 2011, JACC-CARDIOVASC IMAG, V4, P659, DOI 10.1016/j.jcmg.2011.03.016; Rapezzi C, 2011, EUR J NUCL MED MOL I, V38, P470, DOI 10.1007/s00259-010-1642-7; Rapezzi C, 2009, CIRCULATION, V120, P1203, DOI 10.1161/CIRCULATIONAHA.108.843334; Ruberg FL, 2012, CIRCULATION, V126, P1286, DOI 10.1161/CIRCULATIONAHA.111.078915; Rubin J, 2018, J CARD FAIL, V24, P504, DOI 10.1016/j.cardfail.2018.07.001; Rubinshtein R, 2009, AM J CARDIOL, V103, P718, DOI 10.1016/j.amjcard.2008.10.039; Sado DM, 2013, CIRC-CARDIOVASC IMAG, V6, P392, DOI 10.1161/CIRCIMAGING.112.000070; Salinaro F, 2017, EUR HEART J-CARD IMG, V18, P1057, DOI 10.1093/ehjci/jew298; Scully PR, 2020, JACC-CARDIOVASC IMAG, V13, P2177, DOI 10.1016/j.jcmg.2020.05.029; Selvanayagam JB, 2007, J AM COLL CARDIOL, V50, P2101, DOI 10.1016/j.jacc.2007.08.028; Siddiqi OK, 2018, TRENDS CARDIOVAS MED, V28, P10, DOI 10.1016/j.tcm.2017.07.004; SIQUEIRAFILHO AG, 1981, CIRCULATION, V63, P188, DOI 10.1161/01.CIR.63.1.188; Sperry BW, 2018, JACC-CARDIOVASC IMAG, V11, P234, DOI 10.1016/j.jcmg.2017.06.020; Sperry B, 2016, INT J CARDIOL, V214, P478, DOI 10.1016/j.ijcard.2016.04.030; SWANTON RH, 1977, AM J CARDIOL, V39, P658, DOI 10.1016/S0002-9149(77)80125-2; Syed IS, 2010, JACC-CARDIOVASC IMAG, V3, P155, DOI 10.1016/j.jcmg.2009.09.023; Tendler A, 2015, AMYLOID, V22, P61, DOI 10.3109/13506129.2014.994202; Tuzovic M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0607-4; Van Der Gucht A, 2018, J NUCL CARDIOL, V25, P2072, DOI 10.1007/s12350-017-0894-z; Vo HQ, 2020, INT J CARDIOVAS IMAG, V36, P325, DOI 10.1007/s10554-019-01717-3; Wang TKM, 2021, J MAGN RESON IMAGING, V53, P1458, DOI 10.1002/jmri.27459; Williams LK, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0376-0; Yanagisawa A, 2015, MODERN PATHOL, V28, P201, DOI 10.1038/modpathol.2014.102	94	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						661	673		10.2147/VHRM.S295376			13	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	WM8NB	WOS:000711334700002	34720583	Green Published			2022-04-27	
J	Takeshima, M; Ishikawa, H; Ogasawara, M; Komatsu, M; Fujiwara, D; Itoh, Y; Wada, Y; Omori, Y; Ohta, H; Mishima, K				Takeshima, Masahiro; Ishikawa, Hiroyasu; Ogasawara, Masaya; Komatsu, Munehiro; Fujiwara, Dai; Itoh, Yu; Wada, Yuki; Omori, Yuki; Ohta, Hidenobu; Mishima, Kazuo			The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						computed tomography; D-dimer; psychiatric patients; soluble fibrin monomer complex; venous thromboembolism	DEEP-VEIN THROMBOSIS; LIATEST D-DIMER; PULMONARY-EMBOLISM; EXCLUSION; RISK; PERFORMANCE	Purpose: D-dimer has the advantage of excluding venous thromboembolism (VTE) due to its high sensitivity but is disadvantageous for diagnosing VTE due to its low specificity. A method to increase the usefulness of D-dimer in the diagnosis of VTE is warranted. This study aimed to investigate the usefulness of the combination of D-dimer and soluble fibrin monomer complex (SFMC), which has been suggested as a new candidate marker for VTE, in VTE diagnosis. Patients and Methods: This prospective study in 109 subjects was performed at a psychiatric department between August 1, 2017 and December 31, 2019. Subjects' levels of D-dimer and SFMC were measured simultaneously. Plasma levels of D-dimer and SFMC were measured using NANOPIA (R) D-dimer and NANOPIA (R) SF. Subjects with positive D-dimer (>= 1.0 mu g/mL) results underwent contrast computed tomography for confirmation of VTE within 12 hours of D-dimer measurement. A receiver operating characteristic curve analysis was performed to examine the usefulness of SFMC for the diagnosis of VTE. Results: Only 109 of the 783 subjects without symptoms suggestive of VTE participated in the study. Out of 41 subjects with positive D-dimer results, 17 subjects were diagnosed with VTE. A receiver operating characteristic curve analysis was performed to determine cutoff values. The area under the curves was 0.848 for SFMC (p<0.001, 95% CI 0.722 to 0.974), and the optimal cutoff value was 10.0 mu g/mL (sensitivity 58.8%, specificity 100%, positive predictive value 100%, negative predictive value 77.4%). Conclusion: SFMC was useful for diagnosing VTE in the psychiatric patients with positive D-dimer results.	[Takeshima, Masahiro; Ishikawa, Hiroyasu; Ogasawara, Masaya; Fujiwara, Dai; Ohta, Hidenobu; Mishima, Kazuo] Akita Univ, Dept Neuropsychiat, Grad Sch Med, 1-1-1 Hondo, Akita, Akita 0108543, Japan; [Komatsu, Munehiro; Itoh, Yu] Akita City Hosp, Dept Neuropsychiat, Akita, Japan; [Wada, Yuki] Akita Univ, Dept Radiol, Grad Sch Med, Akita, Japan; [Omori, Yuki] Tokyo Metropolitan, Dept Neuropsychiat, Geriatr Hosp, Tokyo, Japan		Takeshima, M (通讯作者)，Akita Univ, Dept Neuropsychiat, Grad Sch Med, 1-1-1 Hondo, Akita, Akita 0108543, Japan.	m.takeshima@med.akita-u.ac.jp		Omori, Yuki/0000-0003-2843-820X			Barbui C, 2014, DRUG SAFETY, V37, P79, DOI 10.1007/s40264-013-0127-6; Di Nisio M, 2007, J THROMB HAEMOST, V5, P296, DOI 10.1111/j.1538-7836.2007.02328.x; Fronas SG, 2018, J THROMB HAEMOST, V16, P2471, DOI 10.1111/jth.14314; Ghanima W, 2006, BRIT J HAEMATOL, V132, P210, DOI 10.1111/j.1365-2141.2005.05859.x; Hasegawa M, 2013, CLIN CHIM ACTA, V425, P109, DOI 10.1016/j.cca.2013.07.009; Hsu WY, 2015, SCHIZOPHR RES, V162, P248, DOI 10.1016/j.schres.2015.01.012; Inada T, 2015, PSYCHIAT CLIN NEUROS, V69, P440, DOI 10.1111/pcn.12275; Ishida T, 2016, PSYCHIAT RES, V241, P61, DOI 10.1016/j.psychres.2016.04.105; Ishida T, 2014, PSYCHOSOMATICS, V55, P69, DOI 10.1016/j.psym.2013.04.001; Konstantinides SV, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01647-2019; Kunutsor SK, 2018, ANN MED, V50, P529, DOI 10.1080/07853890.2018.1500703; Lin CE, 2019, GEN HOSP PSYCHIAT, V61, P34, DOI 10.1016/j.genhosppsych.2019.10.003; Manu P, 2011, J CLIN PSYCHIAT, V72, P936, DOI 10.4088/JCP.10m06244gry; Notsu Y., 2019, VASC FAIL, V3, P26, DOI 10.30548/ vascfail.3.1_26; Parkin L, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005316; Stein PD, 2004, ANN INTERN MED, V140, P589, DOI 10.7326/0003-4819-140-8-200404200-00005; Suzuki A, 2007, THROMB RES, V121, P377, DOI 10.1016/j.thromres.2007.05.008; Takeshima M, 2020, NEUROPSYCH DIS TREAT, V16, P579, DOI 10.2147/NDT.S243308; Takeshima M, 2018, NEUROPSYCH DIS TREAT, V14, P1363, DOI 10.2147/NDT.S162760; Tsuji A, 2008, INT J HEMATOL, V88, P448, DOI 10.1007/s12185-008-0173-5; Vermeer HJ, 2005, THROMB RES, V115, P381, DOI 10.1016/j.thromres.2004.09.005; Waser G, 2005, THROMB RES, V116, P165, DOI 10.1016/j.thromres.2004.12.003; Wells PS, 2006, JAMA-J AM MED ASSOC, V295, P199, DOI 10.1001/jama.295.2.199; Wu CS, 2013, J CLIN PSYCHIAT, V74, P918, DOI 10.4088/JCP.12m08117; Yamaki T, 2009, J VASC SURG, V50, P1099, DOI 10.1016/j.jvs.2009.06.059; Zhang R, 2011, PHARMACOPSYCHIATRY, V44, P183, DOI 10.1055/s-0031-1280814	26	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						239	246		10.2147/VHRM.S307689			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7MT	WOS:000655715300001	34054298	Green Published, gold			2022-04-27	
J	Alshaikh, MK; Alotair, H; Alnajjar, F; Sharaf, H; Alhafi, B; Alashgar, L; Aljuaid, M				Alshaikh, Mashael K.; Alotair, Hadil; Alnajjar, Farrah; Sharaf, Hanaa; Alhafi, Bader; Alashgar, Lolwah; Aljuaid, Mohammed			Cardiovascular Risk Factors Among Patients Infected with COVID-19 in Saudi Arabia	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						Framingham risk score FRS; COVID-19; cardiovascular risk factors; Saudi Arabia	RESPIRATORY SYNDROME CORONAVIRUS; CLINICAL CHARACTERISTICS; MERS-COV; DISEASE; KINGDOM; SCORE	Background: Coronavirus disease (COVID-19) is a global pandemic with more than 60 million cases worldwide and over 1.5 million deaths by March 2021. Its outbreak has caused a huge burden on healthcare systems all over the world. Several studies in the medical literature have suggested that patients with underlying cardiovascular disease (CVD) are at higher risk for developing severe symptoms, poor prognosis, and high mortality rates. The aim of this study was to assess the prevalence of CVD risk factors among COVID-19 patients based on the Framingham risk score (FRS), and to evaluate the association of CVD risk factors with clinical outcomes. Patients and Methods: In this retrospective cross-sectional study, we identified 264 confirmed cases with COVID-19 at King Saud University Medical City in Riyadh, Saudi Arabia. Patients aged 18-80 years were included, and their electronic records were reviewed. They were classified into low, intermediate, and high risk of CVD according to FRS classification. Results: Two-hundred-six patients (67% male) were included in this study. The mean age was 55.3 +/- 15.1 years. Most patients had comorbidities: the most common were hypertension (48.1%), diabetes (45.1%), and ischemic heart disease (11.2%). More than half required intensive care admission, and 58 (28.2%) patients died. Pneumonia was the most frequently observed complication (85%), followed by mechanical ventilation (28.3%) and acute kidney injury (27.7%). Age, male gender, hypertension, and diabetes mellitus showed significant differences between FRS categories, and were associated with intermediate and high-risk groups of FRS (p < 0.05). Pneumonia and length of stay were associated with the Intermediate risk group of FRS. Conclusion: Cardiovascular disease risk factors are prevalent in Saudi patients infected with COVID-19. FRS could be a useful tool to identify CVD risk factors among COVID-19 patients and predict a complicated course.	[Alshaikh, Mashael K.] King Saud Univ Med City, Dept Pharm Serv, Riyadh, Saudi Arabia; [Alotair, Hadil; Alashgar, Lolwah] King Saud Univ, Dept Med, King Saud Univ Med City, Riyadh, Saudi Arabia; [Alnajjar, Farrah] Minist Hlth, Yanbu Gen Hosp, Riyadh, Saudi Arabia; [Sharaf, Hanaa] Minist Hlth, Dept Cytogenet Lab, Riyadh, Saudi Arabia; [Alhafi, Bader] King Saud Univ, Dept Agr Extens & Rural Soc, Riyadh, Saudi Arabia; [Aljuaid, Mohammed] King Saud Univ, Coll Business Adm, Dept Hlth Adm, POB 7115, Riyadh 11451, Saudi Arabia		Aljuaid, M (通讯作者)，King Saud Univ, Coll Business Adm, Dept Hlth Adm, POB 7115, Riyadh 11451, Saudi Arabia.	maljuaid@ksu.edu.sa	Alotaibi, Bader Alahfi/ABG-1067-2021; Alnajjar, Farrah/ABA-1667-2021	Alnajjar, Farrah/0000-0001-6738-5425; Alhafi-Alotaibi, Bader/0000-0002-9633-4341	Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia [IFKSURP-274]	This research was funded by the Deputyship for Research & Innovation, Ministry of Education, Saudi Arabia, through project number IFKSURP-274.	Algaissi AA, 2020, J INFECT PUBLIC HEAL, V13, P834, DOI 10.1016/j.jiph.2020.04.016; AlQuaiz AM, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/s12872-019-1048-9; Alsahafi AJ, 2016, INT J INFECT DIS, V45, P1, DOI 10.1016/j.ijid.2016.02.004; Alsofayan YM, 2020, J INFECT PUBLIC HEAL, V13, P920, DOI 10.1016/j.jiph.2020.05.026; Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015; Barry M, 2020, J EPIDEMIOL GLOB HEA, V10, P1, DOI 10.2991/jegh.k.200218.003; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Erener S, 2020, MOL METAB, V39, DOI 10.1016/j.molmet.2020.101044; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Hariyanto TI, 2021, AM J EMERG MED, V41, P110, DOI 10.1016/j.ajem.2020.12.076; Hariyanto TI, 2020, DIABETES METAB SYND, V14, P1613, DOI 10.1016/j.dsx.2020.08.023; Hariyanto Timotius Ivan, 2020, Obes Med, V19, P100290, DOI 10.1016/j.obmed.2020.100290; Hariyanto TI, 2020, DIABETES METAB SYND, V14, P1463, DOI 10.1016/j.dsx.2020.07.054; Hodgson K, 2015, IMMUNOLOGY, V144, P171, DOI 10.1111/imm.12394; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; Jahangiry L, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0114-0; Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152; Koh J, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00295; Kurmani Sameer, 2017, Curr Heart Fail Rep, V14, P385, DOI 10.1007/s11897-017-0351-y; Kwenandar F, 2020, IJC HEART VASC, V29, DOI 10.1016/j.ijcha.2020.100557; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Lloyd-Jones DM, 2004, AM J CARDIOL, V94, P20, DOI 10.1016/j.amjcard.2004.03.023; Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286; Mauvais-Jarvis F, 2020, DIABETES, V69, P1857, DOI 10.2337/dbi19-0023; McCormack V, 2017, BJA EDUC, V17, P161, DOI 10.1093/bjaed/mkx002; Mercado MG, 2019, AM FAM PHYSICIAN, V100, P687; Momtazmanesh S, 2020, EGYPT HEART J, V72, DOI 10.1186/s43044-020-00075-z; PALAIODIMOS L, 2020, METABOLISM, V108, DOI [10.1016/j.metabol.2020.154262, DOI 10.1016/J.METAB0L.2020.154262]; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510; Statistics GAo, 2018, HOUS HLTH SURV; Weqaya-Saudi Center for Disease Control and Prevention, 2020, COVID 19 DAIL UPD CA; World Health Organization, 2020, WEEKL OP UPD COVID 1; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5	38	0	0	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						161	168		10.2147/VHRM.S300635			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RQ0FY	WOS:000642096900001	33907410	Green Published, gold			2022-04-27	
J	Chahine, J; Kreykes, S; Vant Hof, JR; Duprez, D; Nijjar, P				Chahine, Johnny; Kreykes, Sarah; Vant Hof, Jeremy R.; Duprez, Daniel; Nijjar, Prabhjot			Variable and Severe Phenotypic Expression of the "Lebanese Allele" in Two Sisters with Familial Hypercholesterolemia	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						familial hypercholesterolemia; familial hyperlipidemia; heterozygous; Lebanese allele	PREVALENCE; MANAGEMENT; MUTATIONS; LDLR	The "Lebanese allele" {LDLR c.2043 C>A (p.cys681X)} is a nonsense mutation in the low-density lipoprotein receptor (LDLR) gene that results in a truncated non-functioning LDLR protein. We report two sisters of Lebanese descent who presented with familial hypercholesterolemia (FH) and were both heterozygous for the Lebanese allele, but had very distinct LDL-C levels and clinical phenotypes. Whereas one of the sisters had LDL-C in the expected range of Heterozygous FH (HeFH) with the Lebanese allele (LDL-C of 292 mg/dl), the other sister had a more severe LDL-C phenotype in the Homozygous FH (HoFH) range (LDL-C of 520 mg/dl) along with manifest atherosclerosis. Surprisingly, she did not demonstrate a compound heterozygote or double heterozygote status. We discuss different mechanisms that are purported to play a role in modifying the phenotype of FH, including different variants and polygenic modifiers. HeFH patients with the Lebanese allele can have a wide spectrum of LDL-C levels that range from the typical heterozygous to homozygous phenotypes.	[Chahine, Johnny; Kreykes, Sarah; Vant Hof, Jeremy R.; Duprez, Daniel; Nijjar, Prabhjot] Univ Minnesota, Div Cardiovasc, Dept Med, Sch Med, Minneapolis, MN 55455 USA		Nijjar, P (通讯作者)，Univ Minnesota, Sch Med, 420 Delaware St SE,MMC 508, Minneapolis, MN 55455 USA.	nijja003@umn.edu		Van't Hof, Jeremy/0000-0002-9982-3685; Nijjar, Prabhjot/0000-0001-8681-1397			Abifadel M, 2009, HUM MUTAT, V30, pE682, DOI 10.1002/humu.21002; Benn M, 2016, EUR HEART J, V37, P1384, DOI 10.1093/eurheartj/ehw028; Berberich AJ, 2019, NAT REV CARDIOL, V16, P9, DOI 10.1038/s41569-018-0052-6; Catapano AL, 2016, EUR HEART J, V37, P2999, DOI 10.1093/eurheartj/ehw272; de Ferranti SD, 2016, CIRCULATION, V133, P1067, DOI 10.1161/CIRCULATIONAHA.115.018791; Fahed AC, 2012, ENDOCRINE, V42, P445, DOI 10.1007/s12020-012-9669-0; Foody JM, 2016, J CLIN LIPIDOL, V10, P970, DOI 10.1016/j.jacl.2016.04.009; Jansen ACM, 2002, CURR OPIN LIPIDOL, V13, P165, DOI 10.1097/00041433-200204000-00008; Khera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; McGowan MP, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013225; Santos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9; Sturm AC, 2018, J AM COLL CARDIOL, V72, P662, DOI 10.1016/j.jacc.2018.05.044; Trinder M, 2019, J AM COLL CARDIOL, V74, P512, DOI 10.1016/j.jacc.2019.05.043; Wang J, 2016, ARTERIOSCL THROM VAS, V36, P2439, DOI 10.1161/ATVBAHA.116.308027; Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797	16	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						415	419		10.2147/VHRM.S314704			5	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TQ6OO	WOS:000678398500001	34321884	Green Published, gold			2022-04-27	
J	Ismail, HM; Algrafi, AS; Amoudi, O; Ahmed, S; Al-Thagfan, SS; Shora, H; Aljohani, M; Almutairi, M; Alharbi, F; Alhejaili, A; Alamri, M; Muhawish, A; Abdallah, A				Ismail, Hussein M.; Algrafi, Abeer S.; Amoudi, Osama; Ahmed, Sameh; Al-Thagfan, Sultan S.; Shora, Hassan; Aljohani, Mohammed; Almutairi, Mohammed; Alharbi, Fahad; Alhejaili, Abdullah; Alamri, Majed; Muhawish, Abdullah; Abdallah, Ayat			Vitamin D and Its Metabolites Deficiency in Acute Coronary Syndrome Patients Undergoing Coronary Angiography: A Case-Control Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						vitamin D-3; vitamin D-2; 25-hydroxyvitamin D; 1,25-dihydroxyvitamin D3; acute coronary syndrome; coronary artery disease	ACUTE MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; 25-HYDROXYVITAMIN D; AMERICAN-COLLEGE; ARTERY-DISEASE; ALL-CAUSE; SERUM; RISK; PREVALENCE; MANAGEMENT	Background: Vitamin D deficiency is considered an emerging health problem that affects at least one billion patients worldwide. Calcitriol 1,25(OH)(2)D-3 has several systemic effects, including anti-inflammatory, anti-thrombotic and anti-atherosclerotic impacts that explain its cardioprotective effects. The precise association between vitamin D and its metabolites and the value of supplements in acute coronary syndrome (ACS) is still controversial. This study aims to search the association between vitamin D-2, D-3, and metabolites and ACS in patients undergoing coronary angiography. Materials and Methods: This was a case-control study on 73 consecutive adult patients with ACS undergoing coronary angiography compared to 50 controls without coronary artery disease and matched for age and sex from June 2019 till July 2019. Echocardiography and coronary angiography were done for all cases. Plasma vitamin D and its metabolites were measured at admission for all participants along with chemistry profiles. Results: Vitamin D and its metabolites were statistically significantly lower in ACS patients than the controls. Multivariate regression analysis revealed that low levels of 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)(2)D) significantly predicted ACS occurrence; the other significant predictors were high systolic blood pressure (BP), high total cholesterol, and low high-density lipoprotein-cholesterol. Interestingly, vitamin D-2 and D-3 did not significantly predict ACS (p>0.05). We did not find a statistically significant association between the number of affected coronary vessels and vitamin D metabolites. Moreover, there was no statistically significant correlation between vitamin D and its metabolites and left ventricular ejection fraction measured by echocardiography. Conclusion: There was a strong association between vitamin D and all its metabolites with ACS. Significantly, low 25(OH)D and 1,25(OH)(2)D predicted ACS, but vitamin D-2 and D-3 did not. Large randomized controlled trials are needed to verify the beneficial values of vitamin D supplementation in ACS patients.	[Ismail, Hussein M.] Suez Canal Univ, Coll Med, Dept Cardiol, Ismailia, Egypt; [Ismail, Hussein M.; Algrafi, Abeer S.] Taibah Univ, Coll Med, Dept Med, Al Madinah Al Munawara, Saudi Arabia; [Amoudi, Osama] Madinah Cardiac Ctr, Adult Cardiol, Al Madinah Al Munawara, Saudi Arabia; [Ahmed, Sameh] Taibah Univ, Coll Pharm, Dept Pharmacognosy & Pharmaceut Chem, Al Madinah Al Munawara, Saudi Arabia; [Al-Thagfan, Sultan S.] Taibah Univ, Dept Clin & Hosp Pharm, Coll Pharm, Al Madinah Al Munawara, Saudi Arabia; [Shora, Hassan] Port Said Univ, Dept Mol Biol Biochem, Port Said, Egypt; [Aljohani, Mohammed; Almutairi, Mohammed; Alharbi, Fahad; Alhejaili, Abdullah; Alamri, Majed; Muhawish, Abdullah] Taibah Univ, Al Madinah Al Munawara, Saudi Arabia; [Abdallah, Ayat] Natl Liver Inst, Epidemiol & Prevent Med Dept, Shibin Al Kawm, Egypt; [Abdallah, Ayat] Taibah Univ, Dept Family & Community Med, Al Madinah Al Munawara, Saudi Arabia		Ismail, HM (通讯作者)，Suez Canal Univ, Coll Med, Dept Cardiol, Ismailia, Egypt.	husseinismail@med.suez.edu.eg	Shora, Hassan Abdelwahed abdalla/E-5816-2018; ahmed, sameh/AAV-9940-2021; Shora Hassan, Hassan Abdelwahed AbdAlla/E-5816-2018	Shora, Hassan Abdelwahed abdalla/0000-0002-1958-8145; ahmed, sameh/0000-0001-9624-6846; Ismail, Hussein/0000-0001-9377-0749; Algrafi, Abeer/0000-0002-3511-3924; Shora Hassan, Hassan Abdelwahed AbdAlla/0000-0002-0615-8015			Al-Daghri NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131315; Aleksova A, 2015, INT J VITAM NUTR RES, V85, P23, DOI 10.1024/0300-9831/a000220; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Anderson JL, 2011, CIRCULATION, V123, pE426, DOI 10.1161/CIR.0b013e318212bb8b; Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004-0360; Bahulikar Arun, 2018, J Assoc Physicians India, V66, P22; Bijaya M, 2018, INTEGR J GLOB HLTH, V2, P1; Birmpili E, 2012, OPEN CARDIOVASC MED, V6, P15, DOI 10.2174/1874192401206010015; Borji S, 2016, J PARATHYR DIS, V4, P20; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Cashman KD, 2016, AM J CLIN NUTR, V103, P1033, DOI 10.3945/ajcn.115.120873; Chen SC, 2016, ARTERIOSCL THROM VAS, V36, P1651, DOI 10.1161/ATVBAHA.116.307586; Chew DS, 2018, JACC-CLIN ELECTROPHY, V4, P672, DOI 10.1016/j.jacep.2017.12.015; Christakos S, 2010, ENDOCRIN METAB CLIN, V39, P243, DOI 10.1016/j.ecl.2010.02.002; Christodoulidis G, 2014, CARDIOL REV, V22, P279, DOI 10.1097/CRD.0000000000000006; Chun RF, 2016, ENDOCRINOLOGY, V157, P3420, DOI 10.1210/en.2016-1139; Correia LCL, 2013, AM J CARDIOL, V111, P324, DOI 10.1016/j.amjcard.2012.10.006; de Boer IH, 2009, J AM SOC NEPHROL, V20, P1805, DOI 10.1681/ASN.2008111157; De Metrio M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000857; Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340; Ganji V, 2012, J NUTR, V142, P498, DOI 10.3945/jn.111.151977; Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174; Gonzalez-Parra E, 2012, NEPHROL DIAL TRANSPL, V27, piv17, DOI 10.1093/ndt/gfs534; Greene-Finestone LS, 2011, OSTEOPOROSIS INT, V22, P1389, DOI 10.1007/s00198-010-1362-7; Grundy SM, 2019, ANN INTERN MED, V170, P779, DOI 10.7326/M19-0365; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154-017-9424-1; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Holmes MV, 2015, EUR HEART J, V36, P539, DOI 10.1093/eurheartj/eht571; Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011; Iqbal MP, 2013, CLIN CHIM ACTA, V425, P192, DOI 10.1016/j.cca.2013.08.009; Jia X, 2007, BRIT J NUTR, V98, P593, DOI 10.1017/S0007114507725163; Khalili H, 2012, CLIN RES CARDIOL, V101, P321, DOI 10.1007/s00392-011-0394-0; Kovesdy CP, 2008, ARCH INTERN MED, V168, P397, DOI 10.1001/archinternmed.2007.110; Lee JH, 2011, AM J CARDIOL, V107, P1636, DOI 10.1016/j.amjcard.2011.01.048; Lee JH, 2008, J AM COLL CARDIOL, V52, P1949, DOI 10.1016/j.jacc.2008.08.050; Lee TL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.604700; Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]; Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]; Martins D, 2007, ARCH INTERN MED, V167, P1159, DOI 10.1001/archinte.167.11.1159; Messenger W, 2012, NUTR METAB CARDIOVAS, V22, P856, DOI 10.1016/j.numecd.2010.10.019; Milazzo V, 2017, WORLD J CARDIOL, V9, P14, DOI 10.4330/wjc.v9.i1.14; Mohammad AM, 2018, CARDIOVASC ENDOCR ME, V7, P93, DOI 10.1097/XCE.0000000000000160; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Ng LL, 2013, INT J CARDIOL, V168, P2341, DOI 10.1016/j.ijcard.2013.01.030; Ordonez-Moran P, 2008, J CELL BIOL, V183, P697, DOI 10.1083/jcb.200803020; Palacios C, 2014, J STEROID BIOCHEM, V144, P138, DOI 10.1016/j.jsbmb.2013.11.003; Pandit A, 2014, OPEN HEART, V1, DOI 10.1136/openhrt-2013-000011; Pilz S, 2008, J CLIN ENDOCR METAB, V93, P3927, DOI 10.1210/jc.2008-0784; Rajasree S, 2001, EUR J EPIDEMIOL, V17, P567, DOI 10.1023/A:1014559600042; Ramalho M.J., 2017, CRITICAL EVALUATION, P11; Roy Ambuj, 2015, Indian Heart J, V67, P27, DOI 10.1016/j.ihj.2015.02.002; Santoro D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/145828; Sharif-Askari FS, 2020, DIABET METAB SYND OB, V13, P1599, DOI 10.2147/DMSO.S245742; Sung KC, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0432-3; Syal SK, 2012, J INVASIVE CARDIOL, V24, P385; Tuffaha M, 2015, N AM J MED SCI, V7, P467, DOI 10.4103/1947-2714.168675; Verdoia M, 2017, THROMB RES, V150, P90, DOI 10.1016/j.thromres.2016.12.019; Wang HM, 2017, AGING DIS, V8, P346, DOI 10.14336/AD.2016.1021; Wang ZC, 2011, ANAL BIOCHEM, V418, P126, DOI 10.1016/j.ab.2011.06.043; Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006	61	0	0	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						471	480		10.2147/VHRM.S312376			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UB0JU	WOS:000685540200001	34408425	Green Published, gold			2022-04-27	
J	Qi, LT; Zhang, QL; Zheng, ZQ; Pei, ZH; Mao, H; Jiang, TB; Kazei, D; Kahler, E; Huo, Y				Qi, Litong; Zhang, Qiuling; Zheng, Zeqi; Pei, Zhaohui; Mao, Hong; Jiang, Tingbo; Kazei, Dmitri; Kahler, Elke; Huo, Yong			Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						omega-3 PUFAs; hypertriglyceridemia; triglycerides; clinical trial; China; statin	CARDIOVASCULAR-DISEASE; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; EVENTS; ADULTS; RISK	Introduction: The lipid-modifying potential of omega-3 polyunsaturated fatty acids in Chinese patients is under-researched. We conducted a multicenter, randomized, placebo-controlled, double-blind, parallel-group study of twice-daily treatment with OMACOR (OM3EE), a prescription-only formulation of highly purified ethyl esters of omega-3 polyunsaturated fatty acids in Chinese adult patients (>= 18 years) who had elevated baseline fasting serum triglycerides (TG). Methods: Patients were stratified according to the severity of their hypertriglyceridemia (severe HTG, with baseline TG >= 500 and <1000 mg/dL or moderate HTG, with baseline TG >200 and <500 mg/dL) or use of statins. Patients randomized to OM3EE therapy received 2 g/day for 4 weeks, then 4 g/day for 8 weeks. The primary efficacy endpoint was the percentage change in fasting serum TG between baseline and the end of treatment in patients with severe HTG. The study was concluded after a planned interim analysis demonstrated a significant TG-lowering effect of OM3EE in that contingent (p=0.0019). Results: The mean TG end-of-treatment effect of OM3EE was -29.46% (standard deviation 40.60%) in the severe HTG contingent compared with +0.26% (standard deviation 54.68%) in the placebo group. Corresponding changes were -12.12% and -23.25% in the moderate HTG and combination cohorts (vs +55.45% and +6.24% in relevant placebo groups). A dose-dependent reduction in TG was evident in all patient contingents. Safety and tolerability of OM3EE were in line with previous experience. Discussion: These data indicate that OMACOR therapy at a dose of 2-4 g/day is an effective treatment for Chinese patients with raised TG levels and is well tolerated.	[Qi, Litong; Huo, Yong] Peking Univ First Hosp, Beijing 100034, Peoples R China; [Zhang, Qiuling] Hangzhou Normal Univ, Affiliated Hosp, Hangzhou 310015, Zhejiang, Peoples R China; [Zheng, Zeqi] Nanchang Univ, Affiliated Hosp 1, Nanchang 330000, Jiangxi, Peoples R China; [Pei, Zhaohui] Third Hosp Nanchang, Nanchang 330000, Jiangxi, Peoples R China; [Mao, Hong] Cent Hosp Wuhan, Wuhan 430014, Hubei, Peoples R China; [Jiang, Tingbo] Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China; [Kazei, Dmitri] Abbott Healthcare Prod BV, NL-1381 CT Weesp, Netherlands; [Kahler, Elke] Abbott Labs GmbH, D-30173 Hannover, Germany		Huo, Y (通讯作者)，Peking Univ First Hosp, Dept Cardiol, 8 Xishiku St, Beijing 100034, Peoples R China.	huoyong@263.net.cn			Abbott Products Operations AG, Allschwil, SwitzerlandAbbott Laboratories	The investigators express their appreciation to the patients who agreed to participate in this study, which was supported by Abbott Products Operations AG, Allschwil, Switzerland. Hughes associates, Oxford, UK, provided editorial assistance in the preparation of this report.	Anonymous, 2007, Zhonghua Xinxueguanbing Zazhi, V35, P390; Asztalos IB, 2016, METABOLISM, V65, P1636, DOI 10.1016/j.metabol.2016.07.010; Backes J, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0286-4; Bays HE, 2010, MAYO CLIN PROC, V85, P122, DOI 10.4065/mcp.2009.0397; China Cholesterol Education Program, 2017, Zhonghua Xin Xue Guan Bing Za Zhi, V45, P108, DOI 10.3760/cma.j.issn.0253-3758.2017.02.008; Deng LH, 2008, WORLD J GASTROENTERO, V14, P4558, DOI 10.3748/wjg.14.4558; Hu Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013543; Jiang BR, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0747-z; Kim CH, 2018, CLIN THER, V40, P83, DOI 10.1016/j.clinthera.2017.11.007; Kris-Etherton Penny M, 2019, Methodist Debakey Cardiovasc J, V15, P171, DOI 10.14797/mdcj-15-3-171; Li XJ, 2019, J DIABETES, V11, P593, DOI 10.1111/1753-0407.12887; Lu JL, 2017, J CLIN ENDOCR METAB, V102, P507, DOI 10.1210/jc.2016-2477; Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]; Pan L, 2016, ATHEROSCLEROSIS, V248, P2, DOI 10.1016/j.atherosclerosis.2016.02.006; Schwartz GG, 2015, J AM COLL CARDIOL, V65, P2267, DOI 10.1016/j.jacc.2015.03.544; Shen CX, 2018, CIRCULATION, V138, P342, DOI 10.1161/CIRCULATIONAHA.118.033484; Skulas-Ray AC, 2019, CIRCULATION, V140, pE673, DOI 10.1161/CIR.0000000000000709; Wang JP, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3163; Wei MY, 2011, CURR ATHEROSCLER REP, V13, P474, DOI 10.1007/s11883-011-0210-3; Xia SJ, 2020, CIRCULATION, V141, P530, DOI 10.1161/CIRCULATIONAHA.119.043731; Zhang XL, 2015, CHINESE MED J-PEKING, V128, P2045, DOI 10.4103/0366-6999.161361	21	0	0	1	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						571	580		10.2147/VHRM.S325217			10	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	UX7PW	WOS:000701033600001	34552329	Green Published, gold			2022-04-27	
J	Chaulin, A				Chaulin, Aleksey			Cardiac Troponins: Contemporary Biological Data and New Methods of Determination	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						laboratory diagnostics; cardiovascular diseases; acute myocardial infarction; biomarkers; cardiac troponins; cTnI; cTnT highly sensitive methods; hs-cTnI; hs-cTnT; analytical characteristics; 99th percentile; limit of detection; coefficient of variation	ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; EARLY-DIAGNOSIS; RULE-OUT; 99TH PERCENTILE; I ASSAY; DIURNAL RHYTHM; T ISOFORMS; RAPID RULE; SKELETAL	Laboratory diagnosis plays one of the key roles in the diagnosis of many diseases, including cardiovascular diseases (CVD). The methods underlying the in vitro study of many CVD biomarkers, including cardiac troponins (cTnI and cTnT), are imperfect and are continually being improved to enhance their analytical performance, with sensitivity and specificity being the most important. Recently developed improved cTnI and cTnT detection methods, referred to as highly sensitive methods (hs-cTnI, hs-cTnT), have changed many of our ideas about the biology of cardiac troponins and opened up a number of additional diagnostic capabilities for practical healthcare. This article systematizes some relevant data on the biology of cardiac troponins as well as on methods for determining cTnI and cTnT with an analysis of the diagnostic value of their analytical characteristics (limit of blank, limit of detection, 99th percentile, coefficient of variation, and others). Data on extracardiac expression of cTnI and cTnT, mechanisms of formation and potential clinical significance of gender, age, and circadian characteristics of hs-cTnI and hs-cTnT content in serum are discussed. Considerable attention is paid to the discussion of new diagnostic capabilities of hs-cTnI, hs-cTnT, including consideration of promising possibilities for their study in biological fluids that can be obtained by non-invasive methods. Also, some possibilities of using hs-cTnI and hs-cTnT as prognostic laboratory biomarkers in healthy people (for example, to assess the risk of developing CVD) and in patients suffering from a number of pathological conditions that cause damage to cardiomyocytes are examined, and the potential mechanisms underlying the increase in hs-cTnI and hs-cTnT are discussed.	[Chaulin, Aleksey] Samara State Med Univ, Dept Cardiol & Cardiovasc Surg, 89 Chapaevskaya St, Samara 443099, Samara Region, Russia; [Chaulin, Aleksey] Samara State Med Univ, Dept Histol & Embryol, Samara 443099, Russia		Chaulin, A (通讯作者)，Samara State Med Univ, Dept Cardiol & Cardiovasc Surg, 89 Chapaevskaya St, Samara 443099, Samara Region, Russia.	alekseymichailovich22976@gmail.com	Chaulin, Aleksey M./F-1229-2019	Chaulin, Aleksey M./0000-0002-2712-0227			Aakre KM, 2014, CLIN CHEM, V60, P838, DOI 10.1373/clinchem.2013.216978; Adamczyk M, 2009, ANN NY ACAD SCI, V1173, P67, DOI 10.1111/j.1749-6632.2009.04617.x; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Anand A, 2019, CLIN CHEM, V65, P484, DOI 10.1373/clinchem.2018.298059; Apple FS, 2015, CLIN BIOCHEM, V48, P201, DOI 10.1016/j.clinbiochem.2014.08.021; Apple FS, 2012, CLIN CHEM, V58, P169, DOI 10.1373/clinchem.2011.166165; Apple FS, 2009, CLIN CHEM, V55, P1303, DOI 10.1373/clinchem.2009.128363; Apple FS, 1999, CLIN CHIM ACTA, V284, P151, DOI 10.1016/S0009-8981(99)00077-7; Apple FS, 1999, CLIN CHEM LAB MED, V37, P1085, DOI 10.1515/CCLM.1999.158; Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49; Bessiere F, 2013, INTENS CARE MED, V39, P1181, DOI 10.1007/s00134-013-2902-3; Boeddinghaus J, 2020, J AM COLL CARDIOL, V75, P1111, DOI 10.1016/j.jacc.2019.12.065; Boeddinghaus J, 2016, CLIN CHEM, V62, P494, DOI 10.1373/clinchem.2015.249508; Bukkapatnam RN, 2010, AM J CARDIOL, V106, P374, DOI 10.1016/j.amjcard.2010.03.035; Cavalcanti J S, 2001, Arq Bras Cardiol, V77, P229; Cediel G, 2021, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.617705; Cervellin G, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.05.16; Chaudary Nauman, 2014, J Miss State Med Assoc, V55, P40; [Чаулин А.М. Chaulin A.M.], 2021, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V20, P82, DOI 10.15829/1728-8800-2021-2639; [Чаулин А.М. Chaulin A.M.], 2019, [Комплексные проблемы сердечно-сосудистых заболеваний, Kompleksnye problemy serdechno-sosudistykh zabolevanii], V8, P103, DOI 10.17802/2306-1278-2019-8-4-103-115; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P17, DOI 10.15829/1560-4071-2020-3814; [Чаулин А.М. Chaulin A.M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology, Rossiiskii kardiologicheskii zhurnal], V25, P62, DOI 10.15829/1560-4071-2020-4061; [Чаулин А. М. Chaulin A. M.], 2020, [Российский кардиологический журнал, Russian Journal of Cardiology], V25, P55, DOI 10.15829/1560-4071-2020-4140; Chaulin AM, 2019, KARDIOLOGIYA, V59, P66, DOI 10.18087/cardio.2019.11.n414; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2020, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V11, P70, DOI 10.17816/clinpract48893; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2019, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V10, P81, DOI 10.17816/clinpract16309; [Чаулин Алексей Михайлович Chaulin Aleksey M.], 2020, [Клиническая практика, Journal of Clinical Practice, Klinicheskaya praktika], V11, P75, DOI 10.17816/clinpract34284; Chaulin AM, 2020, RUSS OPEN MED J, V9, DOI 10.15275/rusomj.2020.0305; Chaulin AM, 2020, INT J BIOMED, V10, P198, DOI 10.21103/Article10(3)_RA3; Chaulin AM, 2021, SIGNA VITAE, V17, P79, DOI 10.22514/sv.2021.050; Chaulin AM, 2019, KARDIOLOGIYA NOVOSTI, V7, P13, DOI [10.24411/2309-1908-2019-12002.(inRussian), 10.24411/2309-1908-2019-12002, DOI 10.24411/2309-1908-2019-12002]; Chaulin AM, 2019, SIBERIAN MED REV, V6, P5, DOI [10.20333/2500136-2019-6-5-14, DOI 10.20333/2500136-2019-6-5-14]; Chaulin AM, 2019, KARDIOLOGIYA, V7, P24, DOI [10.24411/2309-1908-2019-12003, DOI 10.24411/2309-1908-2019-12003, 10.24411/2309-1908-2019-12003.(inRussian)]; Chaulin AM, 2020, MODERN PROBLEMS SCI, V6, DOI [10.17513/spno.30302, DOI 10.17513/SPNO.30302]; Chesnaye NC, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013091; Clerico A, 2021, CLIN CHEM LAB MED, V59, P641, DOI 10.1515/cclm-2020-1433; Collinson PO, 2012, CLIN CHEM, V58, P219, DOI 10.1373/clinchem.2011.171082; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; DHOOT GK, 1979, NATURE, V278, P714, DOI 10.1038/278714a0; DHOOT GK, 1978, EXP CELL RES, V117, P357, DOI 10.1016/0014-4827(78)90149-0; Dubin RF, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-229; Duplyakov DV, 2019, CARDIOLOGY NEWS OPIN, V7, P8, DOI 10.24411/2309-1908-2019-13001; Eggers KM, 2016, CLIN BIOCHEM, V49, P1109, DOI 10.1016/j.clinbiochem.2016.08.012; Ellis K, 2001, SOUTHERN MED J, V94, P993; Feng J, 2001, CIRCULATION, V103, P2035; Ferencik M, 2017, CLIN CHEM, V63, P1724, DOI 10.1373/clinchem.2017.275552; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Garcia-Osuna A, 2018, CLIN CHIM ACTA, V486, P224, DOI 10.1016/j.cca.2018.08.015; Gaze DC, 2020, ANN CLIN BIOCHEM, V57, P202, DOI 10.1177/0004563220921888; Gore MO, 2014, J AM COLL CARDIOL, V63, P1441, DOI 10.1016/j.jacc.2013.12.032; Greenslade J, 2018, CLIN CHEM, V64, P820, DOI 10.1373/clinchem.2017.283887; Greenslade JH, 2018, ANN EMERG MED, V71, P439, DOI 10.1016/j.annemergmed.2017.10.030; Hammerer-Lercher A, 2001, CLIN CHEM, V47, P451; Hermsen D, 2007, CLIN LAB, V53, P1; Jaeger C, 2016, AM HEART J, V171, P92, DOI 10.1016/j.ahj.2015.07.022; Katruha IA, 2013, ADV BIOL CHEM, V53, P149; Katrukha IA, 2018, CLIN CHEM, V64, P1104, DOI 10.1373/clinchem.2017.286211; Katrukha IA, 2017, CLIN CHEM, V63, P1094, DOI 10.1373/clinchem.2016.266635; KATUS HA, 1992, CLIN CHEM, V38, P386; Keller T, 2011, JAMA-J AM MED ASSOC, V306, P2684, DOI 10.1001/jama.2011.1896; Kelley WE, 2009, CLIN CHEM, V55, P2098, DOI 10.1373/clinchem.2009.130799; Klinkenberg LJJ, 2016, CLIN CHEM, V62, P1602, DOI 10.1373/clinchem.2016.257485; Kumar A, 2007, CRIT CARE MED, V35, P358, DOI 10.1097/01.CCM.0000254341.87098.A4; Lauer B, 1997, J AM COLL CARDIOL, V30, P1354, DOI 10.1016/S0735-1097(97)00317-3; Lazzarino AI, 2013, J AM COLL CARDIOL, V62, P1694, DOI 10.1016/j.jacc.2013.05.070; Lippi G, 2017, ANN RES HOSP, V1, P44, DOI [10.21037/arh.2017.09.02, DOI 10.21037/ARH.2017.09.02]; Lippi G, 2013, CLIN CHIM ACTA, V426, P79, DOI 10.1016/j.cca.2013.09.004; Long B, 2020, AM J EMERG MED, V38, P998, DOI 10.1016/j.ajem.2019.12.007; Lum G, 2006, LABMEDICINE, V37, P546, DOI 10.1309/T94UUXTJ3TX5Y9W2; Luo J, 2021, DNA CELL BIOL, V40, P184, DOI 10.1089/dna.2020.5828; Maekawa A, 2003, J MOL CELL CARDIOL, V35, P1277, DOI 10.1016/S0022-2828(03)00238-4; Manjunath L, 2018, CARDIOL THER, V7, P197, DOI 10.1007/s40119-018-0120-3; Marinheiro R, 2018, OPEN CARDIOVASC MED, V12, P55, DOI 10.2174/1874192401812010055; McLaurin MD, 1997, CLIN CHEM, V43, P976; Messner B, 2000, AM J CLIN PATHOL, V114, P544, DOI 10.1309/8KCL-UQRF-6EEL-36XK; Mingels A, 2009, CLIN CHEM, V55, P101, DOI 10.1373/clinchem.2008.106427; Mirzaii-Dizgah I, 2013, ORAL DIS, V19, P180, DOI 10.1111/j.1601-0825.2012.01968.x; Mogensen J, 2007, ADV EXP MED BIOL, V592, P201; Morimoto S, 2007, ADV EXP MED BIOL, V592, P227; Nestelberger T, 2019, CLIN CHEM, V65, P1437, DOI 10.1373/clinchem.2019.305193; Nestelberger T, 2016, INT J CARDIOL, V207, P238, DOI 10.1016/j.ijcard.2016.01.112; NOWAKOWSKI JF, 1986, ANN EMERG MED, V15, P354, DOI 10.1016/S0196-0644(86)80584-4; O'Hanlon R, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-38; Ohtsuki I, 2008, BIOCHEM BIOPH RES CO, V369, P62, DOI 10.1016/j.bbrc.2007.11.187; Ohtsuki I, 2007, ADV EXP MED BIOL, V592, P21; Pasquale F, 2012, CIRC-CARDIOVASC GENE, V5, P10, DOI 10.1161/CIRCGENETICS.111.959973; Pervan P., 2017, Signa Vitae, V13, P62; Pettit MA, 2014, PEDIATR EMERG CARE, V30, P832, DOI 10.1097/PEC.0000000000000272; Pickering JW, 2017, ANN INTERN MED, V166, P715, DOI 10.7326/M16-2562; Potkonjak AM, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110252; Reichlin T, 2012, ARCH INTERN MED, V172, P1211, DOI 10.1001/archinternmed.2012.3698; Reichlin T, 2009, J AM COLL CARDIOL, V54, P60, DOI 10.1016/j.jacc.2009.01.076; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; Ricchiuti V, 1998, CLIN CHEM, V44, P1919; Richardson AJ, 2018, J SCI MED SPORT, V21, P880, DOI 10.1016/j.jsams.2018.02.005; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Rosjo H, 2011, INTENS CARE MED, V37, P77, DOI 10.1007/s00134-010-2051-x; Rusakov DY, 2015, J ANAT HISTOPATHOL, V4, P105, DOI [10.18499/2225-7357-2015-4-3-105-105, DOI 10.18499/2225-7357-2015-4-3-105-105]; Schmid J, 2018, J AM COLL CARDIOL, V71, P1540, DOI 10.1016/j.jacc.2018.01.070; Seneviratna A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128526; Shah ASV, 2018, LANCET, V392, P919, DOI 10.1016/S0140-6736(18)31923-8; Shah ASV, 2015, LANCET, V386, P2481, DOI 10.1016/S0140-6736(15)00391-8; Shah ASV, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7873; Sigurdardottir FD, 2018, AM J CARDIOL, V121, P949, DOI 10.1016/j.amjcard.2018.01.004; Sorensen NA, 2017, INT J CARDIOL, V232, P289, DOI 10.1016/j.ijcard.2016.12.167; Somaya Z, 2018, J APPL LAB MED, V3, P450, DOI 10.1373/jalm.2017.025254; Suarez-Barrientos A, 2011, HEART, V97, P970, DOI 10.1136/hrt.2010.212621; Tang GS, 2012, CLIN EXP MED, V12, P47, DOI 10.1007/s10238-011-0141-x; Thygesen K, 2018, GLOB HEART, V13, P305, DOI [10.1093/eurheartj/ehy462, 10.1161/CIR.0000000000000617, 10.1016/j.recesp.2018.11.011, 10.1016/j.jacc.2018.08.1038]; Tobacman LS, 2021, J GEN PHYSIOL, V153, DOI 10.1085/jgp.202012815; Trupp RJ, 2018, CLIN BIOCHEM, V52, P173, DOI 10.1016/j.clinbiochem.2017.11.003; Twerenbold R, 2019, J AM COLL CARDIOL, V74, P483, DOI 10.1016/j.jacc.2019.05.046; Twerenbold R, 2018, J AM COLL CARDIOL, V72, P620, DOI 10.1016/j.jacc.2018.05.040; Ukena C, 2014, CLIN RES CARDIOL, V103, P743, DOI 10.1007/s00392-014-0709-z; Vafaie M, 2016, DIAGNOSIS, V3, P137, DOI 10.1515/dx-2016-0024; van der Linden N, 2016, INT J CARDIOL, V221, P287, DOI 10.1016/j.ijcard.2016.06.268; Velkov V V, 2014, Klin Lab Diagn, P43; Venge P, 2013, CLIN CHEM, V59, P976, DOI 10.1373/clinchem.2012.194928; Wens SCA, 2016, CIRC-CARDIOVASC GENE, V9, P6, DOI 10.1161/CIRCGENETICS.115.001322; Wilhelm J, 2014, CLIN RES CARDIOL, V103, P561, DOI 10.1007/s00392-014-0684-4; Xue Feng, 2014, BMC Res Notes, V7, P136, DOI 10.1186/1756-0500-7-136; Zellweger MF, 2003, SWISS MED WKLY, V133, P439; Ziebig R, 2003, CLIN CHEM, V49, P1191, DOI 10.1373/49.7.1191; Zumrutdal AO, 2000, NEPHRON, V86, P522, DOI 10.1159/000045852	125	13	13	1	4	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						299	316		10.2147/VHRM.S300002			18	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD7TO	WOS:000669524600001	34113117	Green Published, gold			2022-04-27	
J	Pathak, A; Mrabeti, S				Pathak, Atul; Mrabeti, Sanaa			beta-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						beta blockade; hypertension; congestive heart failure; ischemic heart disease; bisoprolol	CARDIAC-INSUFFICIENCY BISOPROLOL; ASSOCIATION TASK-FORCE; ACUTE MYOCARDIAL-INFARCTION; 2013 ACCF/AHA GUIDELINE; AMERICAN-COLLEGE; ATRIAL-FIBRILLATION; BLOOD-PRESSURE; DIABETES-MELLITUS; EJECTION FRACTION; BURDEN BISOPROLOL	(3-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for (31 vs (32 receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through (32 stimulation, alpha receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of (3-blockade in these conditions arises from blockade of the (31 receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of (3-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective (3-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective (31-adrenoceptor blocker, bisoprolol.	[Pathak, Atul] Ctr Hosp Princesse Grace, Dept Cardiovasc Med, 1 Ave Pasteur,BP 489 MC, MC-98012 Monaco, Monaco; [Mrabeti, Sanaa] Merck Serono Middle East FZ LLC, Med Affairs EMEA, Dubai, U Arab Emirates		Pathak, A (通讯作者)，Ctr Hosp Princesse Grace, Dept Cardiovasc Med, 1 Ave Pasteur,BP 489 MC, MC-98012 Monaco, Monaco.	Atul.PATHAK@chpg.mc			Merck Serono Middle East FZ-LLC)	A medical writer (Dr Mike Gwilt, GT Communications) funded by Merck Serono Middle East FZ-LLC) provided editorial assistance in the development of the manuscript. The authors retained full control over the content of the manuscript.	Adderley NJ, 2019, HEART, V105, P27, DOI 10.1136/heartjnl-2018-312977; Agesen FN, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.496; Albouaini Khaled, 2007, Int J Chron Obstruct Pulmon Dis, V2, P535; Amsterdam EA, 2014, CIRCULATION, V130, pE344, DOI [10.1161/CIR.0000000000000134, 10.1161/CIR.0000000000000151]; Andell P, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001611; Andersson C, 2014, J AM COLL CARDIOL, V64, P247, DOI 10.1016/j.jacc.2014.04.042; Andreasen C, 2018, TRENDS CARDIOVAS MED, V28, P382, DOI 10.1016/j.tcm.2017.12.014; Baker JG, 2005, BRIT J PHARMACOL, V144, P317, DOI 10.1038/sj.bjp.0706048; Banach M, 2006, CIRC J, V70, P438, DOI 10.1253/circj.70.438; Barron AJ, 2013, INT J CARDIOL, V168, P3572, DOI 10.1016/j.ijcard.2013.05.068; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Bloom HL, 2014, HEART INT, V9, P15, DOI 10.5301/HEART.2014.12496; Bond RA, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00124; Bonet S, 2000, ARCH INTERN MED, V160, P621, DOI 10.1001/archinte.160.5.621; Brugts JJ, 2017, CARDIOVASC DRUG THER, V31, P391, DOI 10.1007/s10557-017-6747-9; Chatterjee S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f55; Cleland JGF, 2018, EUR HEART J, V39, P26, DOI 10.1093/eurheartj/ehx564; Cruickshank JM, 2007, INT J CARDIOL, V120, P10, DOI 10.1016/j.ijcard.2007.01.069; Cruickshank JM., 2009, BMJ-BRIT MED J, P338; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Farzam K., BETA BLOCKERS; Fihn SD, 2012, J AM COLL CARDIOL, V60, pE44, DOI 10.1016/j.jacc.2012.07.013; Flather MD, 2005, EUR HEART J, V26, P215, DOI 10.1093/eurheartj/ehi118; Fonseca VA, 2010, CURR MED RES OPIN, V26, P615, DOI 10.1185/03007990903533681; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Goldberger JJ, 2015, J AM COLL CARDIOL, V66, P1431, DOI 10.1016/j.jacc.2015.07.047; Grassi, 2015, EUR SOC CARDIOL, V13, P6; Grossman E, 2001, Curr Hypertens Rep, V3, P381, DOI 10.1007/s11906-001-0054-2; Hirst JA, 2015, BRIT J CLIN PHARMACO, V79, P733, DOI 10.1111/bcp.12543; Hjalmarson A, 1999, LANCET, V353, P2001; Hoes AW, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2074; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Isted A, 2018, BRIT J GEN PRACT, V68, P151, DOI 10.3399/bjgp18X695261; January CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011; Khan N, 2006, CAN MED ASSOC J, V174, P1737, DOI 10.1503/cmaj.060110; Khan N, 2007, CAN FAM PHYSICIAN, V53, P614; Khilnani G, 2011, INDIAN J PHARMACOL, V43, P492, DOI 10.4103/0253-7613.84947; Kirchhof P, 2016, EUROPACE, V18, DOI [10.5603/KP.2016.0172, 10.1093/europace/euw295]; Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425; Kotecha D, 2016, BMJ-BRIT MED J, V353, pi1855, DOI DOI 10.1136/BMJ.I1855; Kotecha D, 2017, J AM COLL CARDIOL, V69, P2885, DOI 10.1016/j.jacc.2017.04.001; Kubota Y, 2015, INT J CHRONIC OBSTR, V10, P515, DOI 10.2147/COPD.S79942; Lainscak M, 2011, RESP MED, V105, pS44, DOI 10.1016/S0954-6111(11)70010-5; Lam PH, 2018, AM J MED, V131, P1473, DOI 10.1016/j.amjmed.2018.07.008; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; LEHTONEN A, 1985, AM HEART J, V109, P1192, DOI 10.1016/0002-8703(85)90707-0; Lim KP, 2017, INT J CHRONIC OBSTR, V12, P3041, DOI 10.2147/COPD.S144333; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; Megens MR, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007558; Metra M, 2005, EUR HEART J, V26, P2259, DOI 10.1093/eurheartj/ehi386; National Institute for Health and Care Excellence, BIS FUM; National institute for Health and Care Excellence, 2014, ATRIAL FIBRILLATION; O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI [10.1016/j.jacc.2012.11.019, 10.1161/CIR.0b013e3182742cf6]; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PERSSON H, 1995, BRIT HEART J, V74, P140; Peyracchia M, 2018, J CARDIOVASC MED, V19, P337, DOI 10.2459/JCM.0000000000000662; Poirier L, 2014, CAN J CARDIOL, V30, pS9, DOI 10.1016/j.cjca.2013.12.001; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Rozec B, 2009, J AM COLL CARDIOL, V53, P1532, DOI 10.1016/j.jacc.2008.11.057; Santilli F, 2016, HYPERTENS RES, V39, P404, DOI 10.1038/hr.2016.27; Seo GW, 2015, AM J CARDIOL, V116, P1502, DOI 10.1016/j.amjcard.2015.08.013; Shen L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6745; Sorbets E, 2019, EUR HEART J, V40, P1399, DOI 10.1093/eurheartj/ehy811; Thomopoulos C, 2015, J HYPERTENS, V33, P1321, DOI 10.1097/HJH.0000000000000614; TRAPJENSEN J, 1979, EUR J CLIN INVEST, V9, P181, DOI 10.1111/j.1365-2362.1979.tb00920.x; Tsujimoto T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27799-y; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; VONARNIM T, 1995, J AM COLL CARDIOL, V25, P231, DOI 10.1016/0735-1097(94)00345-Q; vonArnim T, 1996, J AM COLL CARDIOL, V28, P20, DOI 10.1016/0735-1097(96)00122-2; Wai B, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-14; Whelton PK, 2018, J AM COLL CARDIOL, V71, P2275, DOI 10.1016/j.jacc.2018.03.016; Willenheimer R, 2005, CIRCULATION, V112, P2426, DOI 10.1161/CIRCULATIONAHA.105.582320; Williams B, 2018, J HYPERTENS, V36, P1953, DOI [10.1097/HJH.0000000000001940, 10.1714/3026.30245]; Wiysonge CS, 2017, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002003.PUB5; Yancy CW, 2018, J AM COLL CARDIOL, V71, P201, DOI 10.1016/j.jacc.2017.11.025; Yancy CW, 2017, CIRCULATION, V136, pE137, DOI 10.1161/CIR.0000000000000509; Zhang XJ, 2016, EXP THER MED, V12, P2489, DOI 10.3892/etm.2016.3657; Zheng SL, 2018, HEART, V104, P407, DOI 10.1136/heartjnl-2017-311652; Zulkifly H, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13070	83	2	2	2	5	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						337	348		10.2147/VHRM.S285907			12	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	TD7NC	WOS:000669507800001	34135591	gold, Green Published			2022-04-27	
J	Pengpid, S; Peltzer, K				Pengpid, Supa; Peltzer, Karl			Prevalence and Correlates of Self-Reported Cardiovascular Diseases Among a Nationally Representative Population-Based Sample of Adults in Ecuador in 2018	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						chronic conditions; lifestyle factors; cardiovascular disease; adults; Ecuador	COMMUNITY-DWELLING ADULTS; CORONARY-HEART-DISEASE; RISK-FACTORS; STROKE; DETERMINANTS; MORTALITY; BRAZIL; WOMEN	Background: This study aimed to determine the prevalence and correlates of self-reported cardiovascular diseases (SRCVDs) among adults in Ecuador. Methods: National cross-sectional survey data of 4638 persons aged 18-69 years in Ecuador were analysed. Research data were collected with an interview-administered questionnaire, physical and biochemical measurements. Results: The prevalence of SRCVDs was 8.7%, 8.5% among men and 8.9% among women. In adjusted logistic regression analysis, being Montubio (adjusted odds ratio-AOR: 1.66, 95% confidence interval-CI: 1.10-2.50), family alcohol problems (AOR: 1.78, 95% CI: 1.19-2.65), past smoking tobacco (AOR: 1.36, 95% CI: 1.02-1.81), and poor oral health status (AOR: 1.74, 95% CI: 1.19-2.54) were associated with SRCVD. In addition, in unadjusted analysis, older age, alcohol dependence, obesity, and having hypertension were associated with SRCVD. Conclusion: Almost one in ten persons aged 18-69 years had SRCVD in Ecuador. Several associated factors, including Montubio by ethnicity, family alcohol problems, past smoking, and poor oral health status, were identified, which can be targeted in public health interventions.	[Pengpid, Supa] Mahidol Univ, ASEAN Inst Hlth Dev, Salaya, Nakhon Pathom, Thailand; [Pengpid, Supa] Univ Limpopo, Dept Res Adm & Dev, Turfloop, South Africa; [Peltzer, Karl] Univ Free State, Dept Psychol, Bloemfontein, South Africa		Peltzer, K (通讯作者)，Univ Free State, Dept Psychol, Bloemfontein, South Africa.	kfpeltzer@gmail.com	Peltzer, Karl/Q-7334-2019	Peltzer, Karl/0000-0002-5980-0876			Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Abbasi M, 2018, GLOB HEART, V13, P73, DOI 10.1016/j.gheart.2018.01.001; Abdalla SM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18150; Aniza I., 2016, J PUBLIC HEALTH MED, V16, P53; Armstrong T, 2006, J PUBLIC HEALTH-HEID, V14, P66, DOI 10.1007/s10389-006-0024-x; Atlantis E, 2012, GEN HOSP PSYCHIAT, V34, P345, DOI 10.1016/j.genhosppsych.2012.02.006; Australian government, ALC SCREEN AUDIT; Balda-Canizares JA, 2018, CARDIOVASC DIAGN THE, V8, P493, DOI 10.21037/cdt.2018.07.03; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Del Brutto OH, 2019, J NEUROL SCI, V398, P98, DOI 10.1016/j.jns.2019.01.037; Del Brutto OH, 2018, AGING CLIN EXP RES, V30, P539, DOI 10.1007/s40520-017-0810-z; Del Brutto OH, 2017, INT J STROKE, V12, P201, DOI 10.1177/1747493016676621; Fuchs SC, 2008, CAD SAUDE PUBLICA, V24, pS285, DOI 10.1590/S0102-311X2008001400013; Ghaemian A, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01526-w; Gikas A, 2016, OPEN CARDIOVASC MED, V10, P69, DOI 10.2174/1874192401610010069; Gongora Rivera F., 2015, MED U, V17, P184; Guevara PE, 2015, REV PANAM SALUD PUBL, V38, P226; He J, 2004, ETHNIC DIS, V14, P260; Hennis A., 2006, PREVENTION CONTROL, V2, P175, DOI [10.1016/j.precon.2007.04.003, DOI 10.1016/J.PRECON.2007.04.003]; Jamrozik E, 2014, CEREBROVASC DIS, V37, P256, DOI 10.1159/000358583; Kotlega D, 2016, NEUROL NEUROCHIR POL, V50, P265, DOI 10.1016/j.pjnns.2016.03.006; Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127; Murphy A, 2018, LANCET GLOB HEALTH, V6, pE292, DOI 10.1016/S2214-109X(18)30031-7; Nazir Muhammad Ashraf, 2017, Int J Health Sci (Qassim), V11, P72; Nepali S, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01710-y; Nunez-Gonzalez S, 2018, REV MED CHILE, V146, P850, DOI 10.4067/s0034-98872018000800850; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Pengpid S, 2019, AFR HEALTH SCI, V19, P3146, DOI 10.4314/ahs.v19i4.37; Peters SAE, 2013, STROKE, V44, P2821, DOI 10.1161/STROKEAHA.113.002342; Poggio R, 2015, PUBLIC HEALTH NUTR, V18, P695, DOI 10.1017/S1368980014000949; Ribeiro IJS, 2018, J STROKE CEREBROVASC, V27, P1616, DOI 10.1016/j.jstrokecerebrovasdis.2018.01.013; Ruan Y, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5653-9; Sánchez V Laura, 2014, Rev. Fac. Nac. Salud Pública, V32, P80; Sisa I, 2019, J INVEST MED, V67, P736, DOI 10.1136/jim-2018-000789; Subsecretaria Nacional de Vigilancia de la Salud Publica Subsecretaria Nacional de Promocion de la Salud e Igualdad Direccion Nacional de Estrategias de Prevencion y Control Direccion Nacional de Promocion de la Salud (MSP INEC OPS/ OMS), 2018, ENS STEPS EC; Teh WL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020285; Wasay M, 2014, NAT REV NEUROL, V10, P135, DOI 10.1038/nrneurol.2014.13; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; World Health Organization, WHO STEPS SURV MAN; World Health Organization, BODY MASS INDEX; World Health Organization (WHO), 2018, STEPWISE APPR SURV S; Zaw Ko Ko, 2017, BMC Res Notes, V10, P99, DOI 10.1186/s13104-017-2422-2	42	1	1	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						195	202		10.2147/VHRM.S299272			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	RZ2JE	WOS:000648421900001	33976550	gold, Green Published			2022-04-27	
J	Cocora, M; Nechifor, D; Lazar, MA; Mornos, A				Cocora, Mioara; Nechifor, Dan; Lazar, Mihai-Andrei; Mornos, Aniko			Impending Aortic Rupture in a Patient with Syphilitic Aortitis	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						tertiary syphilis; giant aortic aneurysm; aortic rupture; Bentall procedure	ANEURYSM	We report the case of a 48-year-old man, admitted for atrial fibrillation with rapid heart rate and intense chest pain. A quick evaluation revealed a giant aortic aneurysm with severe aortic regurgitation and pericardial fluid without a trace of aortic dissection. Because of high suspicion of aortic rupture, an emergency surgery was planned, and a Bentall procedure was performed. On examination of the aortic wall revealing vertical wrinkling with a tree bark aspect, suspicion of syphilitic aortitis arose. The diagnosis was confirmed through postoperative serologic testing and histological examination. Histopathologic differential diagnosis, special treatment and follow-up are presented.	[Cocora, Mioara; Nechifor, Dan] Inst Cardiovasc Dis, Dept Cardiovasc Surg, Timisoara, Romania; [Lazar, Mihai-Andrei; Mornos, Aniko] Inst Cardiovasc Dis, Dept Cardiol, Timisoara, Romania		Cocora, M (通讯作者)，Inst Cardiovasc Dis, Dept Cardiovasc Surg, Timisoara, Romania.	mcocora@cardiologie.ro					Asano M, 2007, J THORAC CARDIOV SUR, V133, P1085, DOI 10.1016/j.jtcvs.2006.11.042; de Araujo Daniel Brito, 2017, Reumatologia (Warsaw), V55, P151, DOI 10.5114/reum.2017.68916; Graciaa DS, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx198; HOFMANNWELLENHOF R, 1993, THORAX, V48, P568, DOI 10.1136/thx.48.5.568; Hsu RB, 2008, J VASC SURG, V47, P270, DOI 10.1016/j.jvs.2007.10.017; Jain D, 2011, CARDIOVASC PATHOL, V20, P15, DOI 10.1016/j.carpath.2009.09.008; Paulo N, 2012, INTERACT CARDIOV TH, V14, P223, DOI 10.1093/icvts/ivr067; Sorelius K, 2019, EUR J VASC ENDOVASC, V57, P239, DOI 10.1016/j.ejvs.2018.08.052; Sorelius K, 2014, CIRCULATION, V130, P2136, DOI 10.1161/CIRCULATIONAHA.114.009481; Tanaka Mutsuo, 2016, Surg Case Rep, V2, P138; Tsokos M, 2012, FORENSIC SCI MED PAT, V8, P325, DOI 10.1007/s12024-011-9266-1	11	1	2	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						255	258		10.2147/VHRM.S289455			4	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7NJ	WOS:000655716900001	34079272	gold, Green Published			2022-04-27	
J	Migora, B; Geleso, MG; Girum, T; Bireda, M; Gebru, M; Dessu, S				Migora, Biru; Geleso, Mulugeta Geremew; Girum, Tadele; Bireda, Meskele; Gebru, Mehari; Dessu, Samuel			Survival Time to Development of Hypertension and Its Predictors among a Cohort of Diabetic Patients in Health Facilities of Gurage Zone: A Retrospective Follow-Up Study	VASCULAR HEALTH AND RISK MANAGEMENT			English	Article						hypertension; incidence; diabetes mellitus; survival	PREVALENCE; ETHIOPIA; MELLITUS; DISEASES; ADULTS	Background: It is expected that around 50% of individuals with diabetes mellitus will develop hypertension in the course of medical follow-up. However, with strict medical follow-up and adherence to medical advice the incidence of hypertension can be highly reduced and the time to occurrence can be delayed. Therefore, this paper aimed to measure the time to development of hypertension and identify its predictors among a 10-year cohort of diabetic patients who have medical follow-up in health facilities of Gurage Zone. Methods: An institution-based retrospective cohort study was conducted in diabetic follow-up clinics of Gurage Zone by reviewing 540 consecutively selected records among the records enrolled from January 1, 2010 to December 31, 2019. The outcome variable was incidence rate and survival time to the occurrences of hypertension (a systolic blood pressure at or above 140 mmHg and/or a diastolic blood pressure at or above 90 mm Hg and known hypertensive cases taken from adults' age >= 18 years) among admitted diabetic patients (fasting blood sugar >= 126 mg/dL or random blood sugar >= 200 mg/dL). Data were collected using a standardized checklist by trained professionals by reviewing records of all clients ever enrolled. Data were cleaned and entered by Epi info version 7 and analyzed by STATA. A Cox-proportional hazard regression model was built to identify predictors of development of hypertension. Results: A total of 540 clients were followed for different periods with a median follow-up period of 2.3 years which gives 3,200 person-years of observation. Two hundred and seventy-six (51.1%) participants were males and the mean age of was 52.2 (+11.7) years. Three hundred (55.6%) participants were urban dwellers. The overall incidence density rate (IDR) of hypertension in the cohort was 48.6 cases per 1,000 persons-year. Older ages adjusted hazard ratio (AHR)=4.0 (95% CI=2.26-7.82), body mass index (BMI) >25 kg/m(2) AHR=2.3 (95% CI=1.06-3.68), Type II diabetes mellitus (DM) AHR=2.0 (95% CI=1.16-3.04), presence of comorbidity AHR=2.9 (95% CI=1.74-4.58), and poor drug adherence AHR=2.5 (95% CI=1.45-4.65) predicted the development of hypertension. Conclusion: The risk of occurrences of hypertension among diabetic patients was high at the early periods and the risk was less at the late diabetic periods and the incidence density rate of hypertension among diabetic patients was high. In addition, age, BMI, type of DM, comorbidity, and drug adherence were independent predictors of occurrences of hypertension. Therefore, intervention to further reduce its occurrence has to focus on drug adherence and prevention of infection.	[Migora, Biru; Geleso, Mulugeta Geremew] Wolkite Univ, Coll Nat & Computat Sci, Dept Stat, Wolkite, Ethiopia; [Girum, Tadele; Gebru, Mehari; Dessu, Samuel] Wolkite Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Wolkite, Ethiopia; [Bireda, Meskele] Wolkite Univ, Coll Med & Hlth Sci, Dept Med, Wolkite, Ethiopia		Migora, B (通讯作者)，Wolkite Univ, Wolkite 07, Ethiopia.	merratse@gmail.com		Geleso, Mulugeta/0000-0002-3157-8353			Abdissa D, 2020, DIABET METAB SYND OB, V13, P2317, DOI 10.2147/DMSO.S255695; Abebe SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125210; Akalu Y, 2020, DIABET METAB SYND OB, V13, P1621, DOI 10.2147/DMSO.S254537; Angaw K, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0062-9; Baynest HW, 2015, J DIABETES METAB, V6, DOI 10.4172/2155-6156.1000541; Central Statistical Agency, 2007, POPULATION HOUSING C; Delamater AM, 2006, CLIN DIABETES, V24, P71, DOI DOI 10.2337/DIACLIN.24.2.71; Giday Araya, 2011, Ethiop Med J, V49, P139; Gurage Zone health department, 2010, ANN HLTH REP 2010 EF; Helelo TP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112790; Hendriks ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032638; Initiative NO, 1998, OBES RES, V6, p51S; International Diabetes Federation (IDF), 2017, IDF DIABETES ATLAS 6; Janghorbani M, 2017, INT J HYPERTENS, V2017, DOI 10.1155/2017/3132729; Kiber M, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4431-9; Libby P, 2005, CIRCULATION, V111, P3489, DOI 10.1161/CIRCULATIONAHA.104.529651; Lloyd-Sherlock P, 2014, INT J EPIDEMIOL, V43, P116, DOI 10.1093/ije/dyt215; Muluneh AT, 2012, ETHIOP J HEALTH SCI, V22, P7; Roba HS, 2019, INT J HYPERTENS, V2019, DOI 10.1155/2019/9878437; Sachithananthan Vedavalli LE, 2013, INT STD RES REV, P1, DOI DOI 10.9734/ISRR/2013/1897; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Sowers JR, 2000, POSTGRAD MED, V107, P47, DOI 10.3810/pgm.2000.04.990; Tesfaye S, 2005, NEW ENGL J MED, V352, P341, DOI 10.1056/NEJMoa032782; Unadike BC, 2011, NIGER J CLIN PRACT, V14, P300, DOI 10.4103/1119-3077.86772; World Health Organization, 2016, GLOBAL REPORT DIABET, DOI DOI 10.1093/eurheartj/ehy420; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	26	0	0	0	0	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						259	266		10.2147/VHRM.S297968			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7NQ	WOS:000655717600001	34079273	Green Published, gold			2022-04-27	
J	Napoli, C; Bontempo, P; Palmieri, V; Coscioni, E; Maiello, C; Donatelli, F; Benincasa, G				Napoli, Claudio; Bontempo, Paola; Palmieri, Vittorio; Coscioni, Enrico; Maiello, Ciro; Donatelli, Francesco; Benincasa, Giuditta			Epigenetic Therapies for Heart Failure: Current Insights and Future Potential	VASCULAR HEALTH AND RISK MANAGEMENT			English	Review						heart failure; personalized therapy; epidrugs	PRESERVED EJECTION FRACTION; ATTENUATES CARDIAC FIBROSIS; POLYUNSATURATED FATTY-ACIDS; GISSI-HF TRIAL; HISTONE DEACETYLASES; CLINICAL EPIGENETICS; NETWORK MEDICINE; DNA METHYLATION; DOUBLE-BLIND; EMPAGLIFLOZIN	Despite the current reductionist approach providing an optimal indication for diagnosis and treatment of patients with heart failure with reduced ejection fraction (HFrEF), there are no standard pharmacological therapies for heart failure with preserved ejection fraction (HFpEF). Although in its infancy in cardiovascular diseases, the epigenetic-based therapy ("epidrugs") is capturing the interest of physician community. In fact, an increasing number of controlled clinical trials is evaluating the putative beneficial effects of: 1) direct epigenetic-oriented drugs, eg, apabetalone, and 2) repurposed drugs with a possible indirect epigenetic interference, eg, metformin, statins, sodium glucose transporter inhibitors 2 (SGLT2i), and omega 3 polyunsaturated fatty acids (PUFAs) in both HFrEF and HFpEF, separately. Apabetalone is the first and unique direct epidrug tested in cardiovascular patients to date, and the BETonMACE trial has reported a reduction in first HF hospitalization (any EF value) and cardiovascular death in patients with type 2 diabetes and recent acute coronary syndrome, suggesting a possible role in secondary prevention. Patients with HFpEF seem to benefit from supplementation to the standard therapy with statins, metformin, and SGLT2i owing to their ability in reducing mortality. In contrast, the vasodilator hydralazine, with or without isosorbide dinitrate, did not provide beneficial effects. In HFrEF, metformin and SGLT2i could reduce the risk of incident HF and mortality in affected patients whereas clinical trials based on statins provided mixed results. Furthermore, PUFAs diet supplementation was significantly associated with reduced cardiovascular risk in both HFpEF and HFrEF. Future large trials will reveal whether direct and indirect epitherapy will remain a work in progress or become a useful way to customize the therapy in the real-world management of HFpEF and HFrEF. Our goal is to discuss the recent advancement in the epitherapy as a possible way to improve personalized therapy of HF.	[Napoli, Claudio; Benincasa, Giuditta] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci DAMSS, I-80138 Naples, Italy; [Bontempo, Paola] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy; [Palmieri, Vittorio] Heart Transplantat Unit Adults Osped CoIli Monald, Dept Cardiac Surg & Transplantat, Naples, Italy; [Coscioni, Enrico] Azienda Osped Univ San Giovanni di Dio & Ruggi dA, Salerno, Italy; [Maiello, Ciro] Monaldi Hosp, Dept Cardiovasc Surg & Transplants, Naples, Italy; [Donatelli, Francesco] Univ Milan, Dept Cardiothorac Ctr, Ist Clin St Ambrogio, Chair Cardiac Surg, Milan, Italy		Benincasa, G (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci DAMSS, I-80138 Naples, Italy.	giuditta.benincasa@unicampania.it	Benincasa, Giuditta/AAB-3951-2021; Donatelli, Francesco/G-9311-2012	Benincasa, Giuditta/0000-0002-7552-3522; Donatelli, Francesco/0000-0003-2839-0373	Italian Ministry of University and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [PRIN2017F8ZB89]; Italian Ministry of HealthMinistry of Health, Italy	This work was supported by PRIN2017F8ZB89 from "Italian Ministry of University and Research (MIUR)" (PI Prof Napoli) and Ricerca Corrente (RC) 2019 from "Italian Ministry of Health" (PI Prof. Napoli).	Alehagen U, 2015, CIRC-HEART FAIL, V8, P252, DOI 10.1161/CIRCHEARTFAILURE.114.001730; Anand P, 2013, CELL, V154, P569, DOI 10.1016/j.cell.2013.07.013; Arow M, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-019-0980-4; Bailey D, 2010, J AM COLL CARDIOL, V55, P2580, DOI 10.1016/j.jacc.2010.02.035; Benincasa G, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03406-2020; Benincasa G, 2020, ANN MED SURG, V60, P218, DOI 10.1016/j.amsu.2020.10.016; Benincasa G, 2021, EUR J GASTROEN HEPAT, V33, P1247, DOI 10.1097/MEG.0000000000001867; Benincasa G, 2020, CIRC J, V84, P144, DOI 10.1253/circj.CJ-19-0879; Berezin A, 2016, DIABETES METAB SYND, V10, pS176, DOI 10.1016/j.dsx.2016.03.016; Block RC, 2019, JACC-HEART FAIL, V7, P651, DOI 10.1016/j.jchf.2019.03.008; Borck PC, 2020, CIRC RES, V126, P1190, DOI 10.1161/CIRCRESAHA.120.315929; Bridgeman SC, 2018, DIABETES OBES METAB, V20, P1553, DOI 10.1111/dom.13262; Burdge GC, 2014, CURR OPIN CLIN NUTR, V17, P156, DOI 10.1097/MCO.0000000000000023; Cacciatore F, 2020, ESC HEART FAIL, V7, P757, DOI 10.1002/ehf2.12610; Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x; Chen YF, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0262-8; Clark KAA, 2020, JAMA-J AM MED ASSOC, V324, P1506, DOI 10.1001/jama.2020.15566; de la Rocha C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25867; de Nigris F, 2018, JAMA CARDIOL, V3, P1184, DOI 10.1001/jamacardio.2018.3546; Dey A, 2019, EMBO J, V38, DOI 10.15252/embj.2018100293; Ferguson BS, 2015, J MOL CELL CARDIOL, V83, P14, DOI 10.1016/j.yjmcc.2015.03.010; Gaucher J, 2012, EMBO J, V31, P3809, DOI 10.1038/emboj.2012.233; Grimaldi V, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0476-3; Gronda E, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018889; Gronda E, 2019, J CARDIOVASC MED, V20, P640, DOI 10.2459/JCM.0000000000000834; Gronda E, 2020, HEART FAIL REV, V25, P295, DOI 10.1007/s10741-019-09823-z; Gu J, 2020, INT J CARDIOL, V306, P140, DOI 10.1016/j.ijcard.2019.11.087; Halabi A, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01100-w; Heydari B, 2016, CIRCULATION, V134, P378, DOI 10.1161/CIRCULATIONAHA.115.019949; Infante T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210909; Kao YH, 2011, LAB INVEST, V91, P1291, DOI 10.1038/labinvest.2011.92; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Lam CSP, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013389; Lee HC, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0849-6; Lee MS, 2018, AM J CARDIOL, V122, P405, DOI 10.1016/j.amjcard.2018.04.027; Li CG, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0816-2; Marfella R, 2020, J AM COLL CARDIOL, V75, P1249, DOI 10.1016/j.jacc.2020.01.018; Marume K, 2019, CIRC J, V83, P357, DOI 10.1253/circj.CJ-18-0639; McLure KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083190; Mohammadzadeh N, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13388; Mohebi-Nejad Azin, 2014, Tanaffos, V13, P6; Napoli C, 2021, CURR OPIN CARDIOL, V36, P295, DOI 10.1097/HCO.0000000000000843; Napoli C, 2020, AM HEART J, V224, P113, DOI 10.1016/j.ahj.2020.03.007; Napoli C, 2020, EUR HEART J-CARD PHA, V6, P239, DOI 10.1093/ehjcvp/pvz062; Nicholls SJ, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933-020-01199-x; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nikolic M, 2021, HEART FAIL REV, DOI 10.1007/s10741-021-10079-9; Nishitani S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27181-y; Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; Ooi JYY, 2015, EPIGENETICS-US, V10, P418, DOI 10.1080/15592294.2015.1024406; Pantalone KM, 2009, ACTA DIABETOL, V46, P145, DOI 10.1007/s00592-008-0090-3; Papanas N, 2012, EXPERT OPIN PHARMACO, V13, P1, DOI 10.1517/14656566.2012.638283; Picaud S, 2013, P NATL ACAD SCI USA, V110, P19754, DOI 10.1073/pnas.1310658110; Ray KK, 2020, JAMA-J AM MED ASSOC, V323, P1565, DOI 10.1001/jama.2020.3308; Russell-Hallinan A, 2021, J CARDIOVASC PHARM T, V26, P375, DOI 10.1177/1074248420979235; Sabia C, 2017, TRANSPLANT REV-ORLAN, V31, P249, DOI 10.1016/j.trre.2017.08.004; Sarno F, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01047-z; Schiano C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236951; Schiano C, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107514; Sokos GG, 2020, VASC HEALTH RISK MAN, V16, P41, DOI 10.2147/VHRM.S197291; Sommese L, 2018, J DIABETES COMPLICAT, V32, P1076, DOI 10.1016/j.jdiacomp.2018.08.012; Song S, 2019, J MOL CELL CARDIOL, V127, P83, DOI 10.1016/j.yjmcc.2018.12.002; Spiltoir JI, 2013, J MOL CELL CARDIOL, V63, P175, DOI 10.1016/j.yjmcc.2013.07.017; Steven S, 2017, REDOX BIOL, V13, P370, DOI 10.1016/j.redox.2017.06.009; Sun F, 2015, BRIT J PHARMACOL, V172, P3779, DOI 10.1111/bph.13166; Tavazzi L, 2008, LANCET, V372, P1231, DOI 10.1016/S0140-6736(08)61240-4; Tavazzi L, 2008, LANCET, V372, P1223, DOI 10.1016/S0140-6736(08)61239-8; Tonini C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041297; Trum M, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165729; Vasco M, 2021, TRANSPLANT REV-ORLAN, V35, DOI 10.1016/j.trre.2021.100609; Wong AKF, 2008, CARDIOVASC THER, V26, P203, DOI 10.1111/j.1755-5922.2008.00053.x; Xiao H, 2010, CARDIOVASC RES, V87, P504, DOI 10.1093/cvr/cvq066; Zamani P, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004262; Zannad F, 2020, LANCET, V396, P819, DOI 10.1016/S0140-6736(20)31824-9; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhao QS, 2021, CURR RES TRANSL MED, V69, DOI 10.1016/j.retram.2020.103270; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	77	2	2	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1176-6344	1178-2048		VASC HEALTH RISK MAN	Vasc. Health Risk Manag.		2021	17						247	254		10.2147/VHRM.S287082			8	Peripheral Vascular Disease	Emerging Sources Citation Index (ESCI)	Cardiovascular System & Cardiology	SJ7NC	WOS:000655716200001	34079271	gold, Green Published			2022-04-27	
